,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,82653,3385,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,82653,3385,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,147,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad52 strain,Other,,
61,149,1,1,,82653,3385,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt1 strain,Other,,
62,151,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50EPP+ strain,Other,,
63,153,1,1,,82653,3385,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain,Other,,
64,155,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
65,157,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
66,159,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad14 strain,Other,,
67,161,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
68,163,1,1,,82653,3385,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain,Other,,
69,165,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
70,167,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
71,169,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt2 strain,Other,,
72,171,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain,Other,,
73,173,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain,Other,,
74,175,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
75,177,1,1,,82653,3385,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,Other,,
76,180,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
77,182,1,1,,82653,3385,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 06 and 41 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
78,184,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,Other,,
79,186,1,1,,82653,3385,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
80,188,1,1,,82653,3385,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
81,190,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma AKR (Transplanted) (intraperitoneal) in AKR/Lw mice,Other,,
82,192,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
83,194,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
84,196,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
85,198,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in C57BL/6 mice,Other,,
86,204,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia resistant to methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
87,206,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
88,208,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
89,210,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
90,212,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
91,214,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6C3F1 mice,Other,,
92,216,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
93,218,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in C57BL/6 mice,Other,,
94,220,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
95,222,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
96,224,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P335 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
97,226,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
98,228,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
99,230,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice,Other,,
100,232,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
101,236,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  AK4 Lymphoid Leukemia (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
102,238,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Leiomyosarcoma (No. 2) (intraperitoneal) in CAF1 mice,Other,,
103,240,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 4 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
104,242,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
105,244,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
106,246,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1081 Chloroleukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
107,248,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
108,250,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
109,252,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in B6D2F1 (BDF1) mice,Other,,
110,254,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intravenous) in B6D2F1 (BDF1) mice,Other,,
111,256,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
112,258,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,Other,,
113,260,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
114,262,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
115,264,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
116,270,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
117,272,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intramuscular) in B6D2F1 (BDF1) mice,Other,,
118,274,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
119,276,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
120,278,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  A549 Human Adenocarcinoma of Lung with characteristics of Type II Alveolar Epithelial cells (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
121,280,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
122,282,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
123,284,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
124,286,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
125,288,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
126,290,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in unknown mice,Other,,
127,292,1,1,,82653,3385,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
128,296,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
129,298,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
130,300,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in unknown mice,Other,,
131,304,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Mecca (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
132,306,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
133,312,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  C1498 Myeloid Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
134,318,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P815 Mast Cell Leukemia (Ascitic) (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
135,320,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P329 Reticulum Cell Sarcoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
136,322,1,1,,82653,3385,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 08 (intraperitoneal) in CD2F1 (CDF1) mice",Other,,
137,324,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
138,326,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Dihydroxy Anthracenedione; NSC 299195 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
139,328,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
140,330,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
141,332,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-20 Plasma Cell (subcutaneous) in unknown mice,Other,,
142,336,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
143,338,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
144,342,1,1,,82653,3385,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
145,344,1,1,,82653,3385,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lieberman Plasma Cell No. 1 (LPC-1) (intraperitoneal) in unknown mice,Other,,
146,357,2,1,,11111190,3385,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
147,410,1,5,,11111190,3385,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
148,411,2,1,,11111190,3385,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
149,421,1,3,,17389875,3385,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
150,422,1,5,,17405099,3385,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
151,426,1,2,,17389875,3385,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
152,427,1,1,,17389875,3385,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
153,429,1,5,,17405099,3385,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
154,429,1,5,,17405099,3385,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
155,433,1,1,,17389875,3385,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
156,434,1,2,,17389875,3385,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
157,435,1,2,,17389875,3385,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
158,436,2,1,,17405099,3385,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
159,444,1,1,,11111190,3385,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
160,445,3,1,,11111190,3385,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
161,445,3,1,,17389875,3385,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
162,446,1,1,,11111190,3385,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
163,447,1,1,,11111190,3385,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
164,448,1,2,,11111190,3385,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
165,450,1,2,,11111190,3385,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
166,451,1,2,,11111190,3385,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
167,485,1,8,,8139872,3385,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
168,526,1,1,,11111190,3385,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
169,530,1,1,,11111190,3385,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
170,530,1,1,,17389875,3385,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
171,540,1,1,,17389875,3385,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
172,541,1,1,,17389875,3385,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
173,542,1,1,,17389875,3385,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
174,543,1,1,,17389875,3385,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
175,544,2,1,,17389875,3385,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
176,545,1,1,,17389875,3385,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
177,546,1,1,,17389875,3385,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
178,547,1,4,,17405099,3385,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
179,568,1,7,,8139872,3385,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
180,568,1,7,,8139872,3385,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
181,583,2,6,,8139872,3385,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
182,584,1,3,,11111190,3385,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
183,584,1,3,,17389875,3385,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
184,585,1,4,,11111190,3385,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
185,585,1,4,,17389875,3385,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
186,587,1,5,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
187,588,1,4,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
188,589,1,3,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
189,590,1,3,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
190,591,1,4,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
191,592,1,6,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
192,593,1,4,,11111190,3385,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
193,594,1,4,,11111190,3385,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
194,595,1,3,,11111190,3385,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
195,595,1,3,,17389875,3385,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
196,596,1,2,,11111190,3385,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
197,596,1,2,,17389875,3385,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
198,597,1,3,,11111190,3385,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
199,598,1,4,,8139872,3385,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
200,602,1,4,,8139872,3385,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
201,603,1,2,,11111190,3385,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
202,603,1,2,,17389875,3385,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
203,605,1,2,,11111190,3385,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
204,605,1,2,,17389875,3385,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
205,606,1,3,,8139872,3385,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
206,606,1,3,,8139872,3385,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
207,607,1,3,,11111190,3385,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
208,618,2,6,,8139872,3385,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
209,620,2,5,,8139872,3385,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
210,629,1,3,,8139872,3385,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
211,630,1,1,,8139872,3385,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
212,631,1,4,,8139872,3385,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
213,631,1,4,,8139872,3385,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
214,633,1,3,,8139872,3385,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
215,639,1,2,,8139872,3385,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
216,648,1,3,,8139872,3385,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
217,654,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
218,655,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
219,656,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
220,657,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
221,658,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
222,659,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
223,660,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
224,661,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
225,662,1,1,,11111190,3385,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
226,662,1,1,,17389875,3385,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
227,663,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
228,664,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
229,665,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
230,666,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
231,667,1,1,,17389875,3385,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
232,687,1,17,,8139872,3385,Inactive,180352.0,,,,Factor XIa Single Well HTS,Screening,,
233,694,1,1,,17405099,3385,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
234,701,1,17,,8139872,3385,Inactive,317373446.0,2161.0,,,Factor XIIa Single Well HTS,Screening,,
235,719,1,3,,8139872,3385,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
236,731,1,5,,8139872,3385,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
237,731,1,5,,8139872,3385,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
238,732,1,2,,17405099,3385,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
239,750,1,3,,8139872,3385,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
240,757,1,4,,8139872,3385,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
241,758,1,4,,8139872,3385,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
242,759,1,4,,8139872,3385,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
243,760,1,4,,8139872,3385,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
244,761,1,4,,8139872,3385,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
245,764,1,4,,8139872,3385,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
246,775,1,3,,8139872,3385,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
247,781,1,1,,8139872,3385,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
248,782,1,2,,8139872,3385,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
249,782,1,2,,8139872,3385,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
250,793,1,2,,8139872,3385,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
251,797,1,1,,8139872,3385,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
252,798,2,12,,8139872,3385,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
253,799,1,5,,8139872,3385,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
254,800,2,11,,8139872,3385,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
255,803,1,4,,8139872,3385,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
256,804,1,3,,8139872,3385,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
257,817,1,1,,8139872,3385,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
258,818,1,2,,8139872,3385,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
259,827,1,2,,8139872,3385,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
260,828,1,5,,8139872,3385,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
261,834,1,3,,8139872,3385,Inactive,,,,,C. albicans biofilm killing,Screening,,
262,841,1,1,,8139872,3385,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
263,861,1,1,,8139872,3385,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
264,862,1,2,,8139872,3385,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
265,868,1,3,,8139872,3385,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
266,871,1,2,,8139872,3385,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
267,873,1,13,,8139872,3385,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
268,875,1,2,,17389875,3385,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
269,878,1,2,,8139872,3385,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
270,879,1,2,,17389875,3385,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
271,879,1,2,,17389875,3385,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
272,880,2,1,,8139872,3385,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
273,880,2,1,,8139872,3385,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
274,880,2,1,,17389875,3385,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
275,880,2,1,,17389875,3385,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
276,880,2,1,,26747342,3385,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
277,880,2,1,,26747342,3385,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
278,880,2,1,,26752979,3385,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
279,880,2,1,,26752979,3385,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
280,880,2,1,,50105574,3385,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
281,880,2,1,,50105574,3385,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
282,881,2,2,,17389875,3385,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
283,881,2,2,,26752979,3385,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
284,883,1,3,,11111190,3385,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
285,884,1,2,,17389875,3385,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
286,885,1,2,,17389875,3385,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
287,886,1,2,,11111190,3385,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
288,886,1,2,,11111190,3385,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
289,886,1,2,,17389875,3385,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
290,886,1,2,,17389875,3385,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
291,887,1,2,,17389875,3385,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
292,889,1,3,,17389875,3385,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
293,891,1,2,,11111190,3385,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
294,892,1,2,,17389875,3385,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
295,893,1,2,,17389875,3385,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
296,893,1,2,,17389875,3385,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
297,894,2,1,,8139872,3385,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
298,894,2,1,,17389875,3385,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
299,894,2,1,,26747342,3385,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
300,894,2,1,,26752979,3385,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
301,894,2,1,,50105574,3385,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
302,895,1,2,,17389875,3385,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
303,898,1,1,,8139872,3385,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
304,899,1,2,,11111190,3385,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
305,900,1,3,,17389875,3385,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
306,901,1,2,,17389875,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
307,902,1,2,,17389875,3385,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
308,910,1,2,,17389875,3385,Inconclusive,4504349.0,3043.0,25.1189,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
309,912,1,2,,11111190,3385,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
310,912,1,2,,17389875,3385,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
311,914,1,3,,11111190,3385,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
312,915,1,3,,11111190,3385,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
313,917,1,3,,17389875,3385,Inconclusive,120660324.0,7066.0,0.0126,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
314,918,1,3,,17389875,3385,Inconclusive,120660324.0,7066.0,0.0126,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
315,920,1,2,,8139872,3385,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
316,921,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
317,923,1,2,,17389875,3385,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
318,924,1,2,,17389875,3385,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
319,925,1,2,,11111190,3385,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
320,925,1,2,,17389875,3385,Inconclusive,4504349.0,3043.0,31.6228,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
321,926,1,2,,11111190,3385,Inconclusive,38016895.0,7253.0,0.7943,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
322,926,1,2,,17389875,3385,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
323,927,1,3,,17389875,3385,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
324,928,1,2,,17389875,3385,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
325,930,1,2,,17389875,3385,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
326,931,1,2,,17389875,3385,Active,4504349.0,3043.0,12.5893,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus: Cytotoxicity,Confirmatory,,
327,932,1,4,,8139872,3385,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
328,938,1,2,,11111190,3385,Inconclusive,38016895.0,7253.0,0.7943,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
329,938,1,2,,17389875,3385,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
330,940,1,2,,8139872,3385,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
331,940,1,2,,17405099,3385,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
332,940,1,2,,26611750,3385,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
333,943,1,2,,17389875,3385,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
334,944,1,2,,17389875,3385,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
335,945,1,4,,17389875,3385,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
336,946,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
337,947,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
338,948,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
339,950,1,1,,8139872,3385,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
340,951,1,1,,8139872,3385,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
341,952,1,1,,8139872,3385,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
342,954,1,2,,17389875,3385,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
343,955,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
344,957,1,2,,17389875,3385,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
345,958,1,2,,17389875,3385,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
346,959,1,4,,17389875,3385,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
347,960,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
348,961,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
349,962,1,2,,17389875,3385,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
350,963,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
351,964,1,2,,17389875,3385,Inconclusive,,,1.2589,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
352,965,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
353,966,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
354,967,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
355,968,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
356,969,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
357,970,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
358,971,1,2,,17389875,3385,Inconclusive,,,19.9526,Potency,Cell Viability - LYMP2-015,Confirmatory,,
359,972,1,2,,17389875,3385,Inconclusive,,,19.9526,Potency,Cell Viability - LYMP2-017,Confirmatory,,
360,973,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
361,974,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
362,975,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
363,976,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
364,977,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
365,978,1,2,,17389875,3385,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-006,Confirmatory,,
366,979,1,2,,17389875,3385,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-007,Confirmatory,,
367,980,1,2,,17389875,3385,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-008,Confirmatory,,
368,981,1,2,,17389875,3385,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-010,Confirmatory,,
369,982,1,2,,17389875,3385,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-012,Confirmatory,,
370,983,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
371,984,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
372,985,1,2,,17389875,3385,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-018,Confirmatory,,
373,986,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
374,987,1,2,,17389875,3385,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-022,Confirmatory,,
375,988,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
376,989,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
377,992,1,3,,17389875,3385,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
378,993,1,2,,17389875,3385,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
379,994,1,2,,17389875,3385,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
380,995,1,2,,17389875,3385,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
381,997,1,2,,17389875,3385,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
382,998,1,2,,17389875,3385,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
383,999,1,1,,46487912,3385,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
384,1001,2,2,,8139872,3385,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
385,1004,1,1,,46487912,3385,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
386,1006,1,6,,8139872,3385,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
387,1007,1,1,,8139872,3385,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
388,1008,1,2,,8139872,3385,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
389,1009,1,2,,8139872,3385,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
390,1012,1,4,,8139872,3385,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
391,1016,1,4,,8139872,3385,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
392,1018,2,5,,8139872,3385,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
393,1019,1,4,,8139872,3385,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
394,1020,1,5,,8139872,3385,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
395,1021,1,1,,8139872,3385,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
396,1022,1,1,,8139872,3385,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
397,1027,1,3,,8139872,3385,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
398,1030,2,1,,8139872,3385,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
399,1030,2,1,,17389875,3385,Inconclusive,30582681.0,216.0,37.6505,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
400,1030,2,1,,26747342,3385,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
401,1030,2,1,,26752979,3385,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
402,1030,2,1,,50105574,3385,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
403,1032,1,2,,8139872,3385,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
404,1032,1,2,,8139872,3385,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
405,1040,1,2,,8139872,3385,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
406,1046,1,6,,8139872,3385,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
407,1048,1,1,,8139872,3385,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
408,1048,1,1,,8139872,3385,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
409,1049,1,1,,8139872,3385,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
410,1049,1,1,,8139872,3385,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
411,1051,1,1,,8139872,3385,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
412,1051,1,1,,8139872,3385,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
413,1063,1,1,,8139872,3385,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
414,1066,1,2,,8139872,3385,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
415,1085,1,1,,8139872,3385,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
416,1135,1,3,,8139872,3385,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
417,1136,1,3,,8139872,3385,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
418,1189,1,5,,48413789,3385,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
419,1194,1,3,,48413789,3385,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
420,1195,1,2,,48416025,3385,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
421,1199,1,3,,48413789,3385,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
422,1203,1,3,,8139872,3385,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
423,1205,1,4,,48413789,3385,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
424,1208,1,3,,48413789,3385,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
425,1209,2,2,,8139872,3385,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
426,1214,1,4,,8139872,3385,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
427,1216,1,5,,8139872,3385,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
428,1217,1,4,,8139872,3385,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
429,1220,2,2,,8139872,3385,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
430,1222,1,6,,8139872,3385,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
431,1229,1,3,,8139872,3385,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
432,1236,1,1,,8139872,3385,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
433,1239,1,3,,8139872,3385,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
434,1239,1,3,,8139872,3385,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
435,1242,1,1,,8139872,3385,Inactive,11094021.0,,,,C. albicans biofilm killing---Mixture HTS,Screening,,
436,1251,1,1,,8139872,3385,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
437,1273,1,1,,8139872,3385,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
438,1274,1,2,,8139872,3385,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
439,1276,1,1,,8139872,3385,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
440,1285,1,1,,8139872,3385,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
441,1296,1,1,,8139872,3385,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
442,1304,1,2,,8139872,3385,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
443,1321,1,2,,8139872,3385,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
444,1325,1,2,,8139872,3385,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
445,1326,1,4,,8139872,3385,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
446,1359,1,4,,8139872,3385,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
447,1362,1,2,,8139872,3385,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
448,1376,1,2,,8139872,3385,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
449,1377,1,1,,8139872,3385,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
450,1379,1,2,,8139872,3385,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
451,1379,1,2,,26747342,3385,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
452,1379,1,2,,26752979,3385,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
453,1379,1,2,,50105574,3385,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
454,1381,1,1,,8139872,3385,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
455,1385,2,2,,8139872,3385,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
456,1415,1,2,,8139872,3385,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
457,1415,1,2,,8139872,3385,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
458,1416,1,2,,8139872,3385,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
459,1422,1,1,,8139872,3385,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
460,1422,1,1,,17405099,3385,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
461,1422,1,1,,26611750,3385,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
462,1423,1,2,,8139872,3385,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
463,1423,1,2,,8139872,3385,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
464,1424,1,1,,8139872,3385,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
465,1430,1,1,,8139872,3385,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
466,1434,2,3,,8139872,3385,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
467,1434,2,3,,8139872,3385,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
468,1439,1,1,,8139872,3385,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
469,1439,1,1,,8139872,3385,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
470,1440,1,1,,8139872,3385,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
471,1440,1,1,,8139872,3385,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
472,1441,1,1,,8139872,3385,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
473,1441,1,1,,8139872,3385,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
474,1443,1,3,,8139872,3385,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
475,1445,1,1,,8139872,3385,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
476,1446,1,3,,8139872,3385,Active,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
477,1448,1,3,,8139872,3385,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
478,1452,1,1,,8139872,3385,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
479,1452,1,1,,17389875,3385,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
480,1452,1,1,,26752979,3385,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
481,1454,1,1,,26747342,3385,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
482,1454,1,1,,50105574,3385,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
483,1456,1,1,,8139872,3385,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
484,1457,1,1,,8139872,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
485,1457,1,1,,17389875,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
486,1457,1,1,,26747342,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
487,1457,1,1,,26752979,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
488,1457,1,1,,50105574,3385,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
489,1458,1,1,,8139872,3385,Inactive,10937869.0,6607.0,0.631,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
490,1458,1,1,,17389875,3385,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
491,1458,1,1,,26747342,3385,Inactive,10937869.0,6607.0,5.0119,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
492,1458,1,1,,50105574,3385,Inactive,10937869.0,6607.0,11.2202,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
493,1459,1,1,,50105574,3385,Inconclusive,27436948.0,4000.0,0.1585,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
494,1460,1,3,,8139872,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
495,1460,1,3,,26747342,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
496,1460,1,3,,26752979,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
497,1460,1,3,,50105574,3385,Inconclusive,92096784.0,4137.0,5.6234,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
498,1461,1,2,,8139872,3385,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
499,1461,1,2,,50105574,3385,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
500,1463,1,1,,8139872,3385,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
501,1463,1,1,,26747342,3385,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
502,1463,1,1,,26752979,3385,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
503,1463,1,1,,50105574,3385,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
504,1465,1,1,,8139872,3385,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
505,1466,1,2,,8139872,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
506,1467,1,3,,26747342,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
507,1467,1,3,,26752979,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
508,1467,1,3,,50105574,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
509,1468,1,1,,8139872,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
510,1468,1,1,,26747342,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
511,1468,1,1,,26752979,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
512,1468,1,1,,50105574,3385,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
513,1469,1,1,,8139872,3385,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
514,1469,1,1,,17389875,3385,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
515,1469,1,1,,26747342,3385,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
516,1469,1,1,,26752979,3385,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
517,1469,1,1,,50105574,3385,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
518,1471,2,1,,11111190,3385,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
519,1471,2,1,,17389875,3385,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
520,1471,2,1,,26747342,3385,Unspecified,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
521,1471,2,1,,26752979,3385,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
522,1476,2,1,,8139872,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
523,1476,2,1,,17389875,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
524,1476,2,1,,26747342,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
525,1476,2,1,,26752979,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
526,1476,2,1,,50105574,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
527,1477,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
528,1477,1,1,,17389875,3385,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
529,1477,1,1,,26747342,3385,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
530,1477,1,1,,26752979,3385,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
531,1477,1,1,,50105574,3385,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
532,1478,2,1,,8139872,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
533,1478,2,1,,17389875,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
534,1478,2,1,,26747342,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
535,1478,2,1,,26752979,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
536,1478,2,1,,50105574,3385,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
537,1479,1,2,,8139872,3385,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
538,1479,1,2,,17389875,3385,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
539,1479,1,2,,26747342,3385,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
540,1479,1,2,,26752979,3385,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
541,1479,1,2,,50105574,3385,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
542,1481,1,2,,8139872,3385,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
543,1486,1,3,,8139872,3385,Active,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
544,1487,1,1,,8139872,3385,Inconclusive,27436948.0,4000.0,1.2589,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
545,1487,1,1,,17389875,3385,Inconclusive,27436948.0,4000.0,0.0112,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
546,1487,1,1,,50105574,3385,Inconclusive,27436948.0,4000.0,0.1259,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
547,1490,2,1,,8139872,3385,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
548,1490,2,1,,17389875,3385,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
549,1490,2,1,,26747342,3385,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
550,1490,2,1,,26752979,3385,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
551,1496,1,4,,8139872,3385,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
552,1496,1,4,,8139872,3385,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
553,1509,1,2,,8139872,3385,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
554,1510,1,3,,8139872,3385,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
555,1511,1,3,,8139872,3385,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
556,1515,1,2,,8139872,3385,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
557,1519,1,3,,26747342,3385,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
558,1519,1,3,,50105574,3385,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
559,1527,1,3,,8139872,3385,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
560,1529,1,1,,8139872,3385,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
561,1530,1,1,,8139872,3385,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
562,1531,1,1,,8139872,3385,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
563,1532,1,1,,8139872,3385,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
564,1554,1,1,,8139872,3385,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
565,1556,1,4,,8139872,3385,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
566,1565,2,2,,8139872,3385,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
567,1566,2,3,,8139872,3385,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
568,1578,3,2,,8139872,3385,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
569,1580,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
570,1581,1,1,,8149350,3385,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
571,1582,1,1,,8149350,3385,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
572,1583,1,1,,8149350,3385,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
573,1584,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
574,1585,1,1,,8149350,3385,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
575,1586,1,1,,8149350,3385,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
576,1587,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
577,1588,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
578,1589,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
579,1590,1,1,,8149350,3385,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
580,1593,1,1,,8149350,3385,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
581,1594,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
582,1595,1,1,,8149350,3385,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
583,1596,1,1,,8149350,3385,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
584,1597,1,1,,8149350,3385,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
585,1598,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
586,1599,1,1,,8149350,3385,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
587,1600,1,1,,8149350,3385,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
588,1601,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
589,1602,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
590,1603,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
591,1604,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
592,1605,1,1,,8149350,3385,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
593,1606,1,1,,8149350,3385,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
594,1607,1,1,,8149350,3385,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
595,1608,1,1,,8149350,3385,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
596,1609,1,1,,8149350,3385,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
597,1610,1,1,,8149350,3385,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
598,1611,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
599,1612,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
600,1613,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
601,1614,1,1,,8149350,3385,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
602,1616,1,1,,8149350,3385,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
603,1619,1,2,,8139872,3385,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
604,1621,1,2,,8139872,3385,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
605,1626,1,2,,8139872,3385,Inconclusive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
606,1631,3,1,,8139872,3385,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
607,1634,3,1,,8139872,3385,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
608,1654,2,2,,8139872,3385,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
609,1656,2,2,,8139872,3385,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
610,1662,1,2,,8139872,3385,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
611,1663,1,2,,8139872,3385,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
612,1672,1,3,,8139872,3385,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
613,1688,1,1,,8139872,3385,Inconclusive,90903231.0,3064.0,1.9953,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
614,1688,1,1,,17389875,3385,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
615,1700,1,2,,8139872,3385,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
616,1705,1,2,,50105574,3385,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
617,1706,1,2,,8139872,3385,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
618,1707,1,3,,50105574,3385,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
619,1708,1,3,,50105574,3385,Inconclusive,405898.0,,8.9125,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
620,1721,1,2,,8139872,3385,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
621,1722,1,2,,8139872,3385,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
622,1766,1,1,,8139872,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
623,1766,1,1,,8139872,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
624,1766,1,1,,17389875,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
625,1766,1,1,,17389875,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
626,1766,1,1,,26747342,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
627,1766,1,1,,26747342,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
628,1766,1,1,,26752979,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
629,1766,1,1,,26752979,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
630,1766,1,1,,50105574,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
631,1766,1,1,,50105574,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
632,1768,1,1,,8139872,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
633,1768,1,1,,8139872,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
634,1768,1,1,,17389875,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
635,1768,1,1,,17389875,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
636,1768,1,1,,26747342,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
637,1768,1,1,,26747342,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
638,1768,1,1,,26752979,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
639,1768,1,1,,26752979,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
640,1768,1,1,,50105574,3385,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
641,1768,1,1,,50105574,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
642,1775,1,2,,8139872,3385,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
643,1776,1,2,,8139872,3385,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
644,1777,3,2,,8139872,3385,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
645,1778,3,3,,8139872,3385,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
646,1779,2,2,,8139872,3385,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
647,1789,1,2,,8139872,3385,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
648,1800,1,2,,8139872,3385,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
649,1811,3,2,,46393324,3385,Active,5542496.0,,,,Experimentally measured binding affinity data derived from PDB,Other,9628859.0,
650,1813,1,2,,8139872,3385,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
651,1814,1,2,,8139872,3385,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
652,1815,1,1,,50105574,3385,Active,,,7.0795,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
653,1816,1,1,,50105574,3385,Active,,,7.9433,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
654,1817,2,2,,8139872,3385,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
655,1822,1,3,,8139872,3385,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
656,1825,1,1,,8139872,3385,Active,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
657,1828,2,1,,50105574,3385,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
658,1832,2,1,,8139872,3385,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
659,1845,1,2,,8139872,3385,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
660,1850,2,1,,8139872,3385,Active,,,2.99,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
661,1861,2,1,,8139872,3385,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
662,1862,1,4,,8139872,3385,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
663,1863,2,1,,8139872,3385,Active,,,9.78,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
664,1865,1,1,,8139872,3385,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
665,1865,1,1,,26747342,3385,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
666,1865,1,1,,26752979,3385,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
667,1865,1,1,,50105574,3385,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
668,1867,1,4,,8139872,3385,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
669,1868,1,4,,8139872,3385,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
670,1870,1,4,,8139872,3385,Active,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
671,1873,1,4,,8139872,3385,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
672,1875,2,1,,8139872,3385,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
673,1876,1,1,,50105574,3385,Active,,,4.4668,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
674,1877,1,1,,50105574,3385,Active,,,4.4668,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
675,1882,1,1,,50105574,3385,Inconclusive,,,14.1254,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
676,1883,1,1,,50105574,3385,Active,,,7.9433,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
677,1885,2,1,,8139872,3385,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
678,1886,1,1,,50105574,3385,Active,,,5.0119,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
679,1887,1,4,,8139872,3385,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
680,1899,1,3,,8139872,3385,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
681,1903,2,3,,8139872,3385,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
682,1906,1,3,,8139872,3385,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
683,1910,1,2,,8139872,3385,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
684,1947,1,2,,8139872,3385,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
685,1948,1,1,,17389875,3385,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
686,1948,1,1,,26747342,3385,Inactive,,,3.9811,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
687,1948,1,1,,26752979,3385,Inactive,,,1.2589,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
688,1948,1,1,,50105574,3385,Inactive,,,1.5849,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
689,1950,1,3,,8139872,3385,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
690,1956,1,1,,8139872,3385,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
691,1961,2,2,,8139872,3385,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
692,1962,1,2,,8139872,3385,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
693,1967,1,1,,85231050,3385,Inconclusive,4505907.0,5376.0,4.7755,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
694,1974,1,2,,8139872,3385,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
695,1981,2,1,,8139872,3385,Active,,,4.17,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,Confirmatory,,
696,1984,1,3,,8139872,3385,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
697,1985,2,1,,8139872,3385,Active,,,0.37799999999999995,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,Confirmatory,,
698,1986,1,2,,8139872,3385,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
699,1987,1,2,,8139872,3385,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
700,2006,3,2,,8139872,3385,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
701,2006,3,2,,8139872,3385,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
702,2006,3,2,,8139872,3385,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
703,2012,3,2,,8139872,3385,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
704,2013,2,2,,8139872,3385,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
705,2014,3,2,,8139872,3385,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
706,2016,1,3,,8139872,3385,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
707,2023,1,3,,8139872,3385,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
708,2025,1,3,,8139872,3385,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
709,2029,1,3,,8139872,3385,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
710,2052,2,1,,8139872,3385,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
711,2057,1,2,,8139872,3385,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
712,2058,3,2,,8139872,3385,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
713,2066,1,4,,8139872,3385,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
714,2071,2,2,,8139872,3385,Active,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
715,2073,2,3,,8139872,3385,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
716,2073,2,3,,8139872,3385,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
717,2094,1,2,,8139872,3385,Active,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
718,2094,1,2,,8139872,3385,Active,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
719,2094,1,2,,8139872,3385,Active,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
720,2097,1,2,,8139872,3385,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
721,2098,1,1,,8139872,3385,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
722,2099,1,1,,8139872,3385,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
723,2100,1,1,,8139872,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
724,2101,1,1,,8139872,3385,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
725,2101,1,1,,17389875,3385,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
726,2101,1,1,,26747342,3385,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
727,2101,1,1,,26752979,3385,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
728,2101,1,1,,50105574,3385,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
729,2107,1,1,,8139872,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
730,2107,1,1,,17389875,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
731,2107,1,1,,26747342,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
732,2107,1,1,,26752979,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
733,2107,1,1,,50105574,3385,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
734,2112,1,1,,8139872,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
735,2112,1,1,,17389875,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
736,2112,1,1,,26747342,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
737,2112,1,1,,26752979,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
738,2112,1,1,,50105574,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
739,2120,1,1,,17389875,3385,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
740,2129,1,2,,8139872,3385,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
741,2130,1,3,,8139872,3385,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
742,2147,1,1,,8139872,3385,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
743,2147,1,1,,26747342,3385,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
744,2147,1,1,,50105574,3385,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
745,2156,2,2,,8139872,3385,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
746,2174,1,3,,8139872,3385,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
747,2177,1,3,,8139872,3385,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
748,2205,1,1,,8139872,3385,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
749,2216,1,3,,8139872,3385,Inconclusive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
750,2221,1,2,,8139872,3385,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
751,2227,1,2,,8139872,3385,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
752,2234,1,2,,8139872,3385,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
753,2235,1,2,,8139872,3385,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
754,2237,1,2,,8139872,3385,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
755,2239,1,2,,8139872,3385,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
756,2242,1,1,,8139872,3385,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
757,2247,1,2,,8139872,3385,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
758,2252,1,1,,8139872,3385,Active,,,6.24,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,Confirmatory,,
759,2253,1,1,,8139872,3385,Active,,,4.25,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,Confirmatory,,
760,2270,1,3,,8139872,3385,Inactive,536029.0,,,,"Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae, specifically RPL19A Cherry Pick Compounds",Screening,,
761,2271,1,3,,8139872,3385,Inactive,486173.0,,,,"Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae, specifically LAP4 Cherry Pick Compounds",Screening,,
762,2272,1,3,,8139872,3385,Inactive,1302091.0,,,,"Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae, specifically MEP2 Cherry Pick Compounds",Screening,,
763,2273,1,4,,8139872,3385,Inactive,85666113.0,850333.0,,,"Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae, specifically AGP1 Cherry Pick Compounds",Screening,,
764,2274,1,3,,8139872,3385,Inactive,171229.0,,,,"Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae, specifically CIT2 Cherry Pick Compounds",Screening,,
765,2280,2,3,,8139872,3385,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
766,2288,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
767,2289,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
768,2300,1,3,,8139872,3385,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
769,2314,1,2,,8139872,3385,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
770,2314,1,2,,8139872,3385,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
771,2315,1,2,,8139872,3385,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
772,2315,1,2,,8139872,3385,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
773,2323,1,1,,50105574,3385,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
774,2326,1,1,,8139872,3385,Inactive,194352380.0,,1.0,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
775,2326,1,1,,50105574,3385,Inactive,194352380.0,,3.1623,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
776,2353,1,3,,50105574,3385,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
777,2364,1,2,,50105574,3385,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
778,2384,1,1,,8139872,3385,Active,,,2.53,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
779,2391,1,1,,8139872,3385,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
780,2401,1,2,,8139872,3385,Active,,,20.47,IC50,A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
781,2417,1,1,,8139872,3385,Active,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
782,2435,1,2,,8139872,3385,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
783,2445,1,2,,8139872,3385,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
784,2451,1,2,,8139872,3385,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
785,2451,1,2,,26747342,3385,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
786,2451,1,2,,26752979,3385,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
787,2451,1,2,,50105574,3385,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
788,2462,1,1,,8139872,3385,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
789,2462,1,1,,8139872,3385,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
790,2472,1,2,,8139872,3385,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
791,2472,1,2,,26747342,3385,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
792,2472,1,2,,26752979,3385,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
793,2517,2,1,,8139872,3385,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
794,2517,2,1,,17389875,3385,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
795,2517,2,1,,26747342,3385,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
796,2517,2,1,,26752979,3385,Inactive,6980812.0,,0.0009,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
797,2517,2,1,,50105574,3385,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
798,2523,1,1,,8139872,3385,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
799,2528,1,2,,8139872,3385,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
800,2528,1,2,,17389875,3385,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
801,2528,1,2,,26747342,3385,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
802,2528,1,2,,26752979,3385,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
803,2528,1,2,,50105574,3385,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
804,2546,1,1,,8139872,3385,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
805,2546,1,1,,17389875,3385,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
806,2546,1,1,,26747342,3385,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
807,2546,1,1,,26752979,3385,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
808,2549,1,1,,8139872,3385,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
809,2549,1,1,,17389875,3385,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
810,2549,1,1,,26747342,3385,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
811,2549,1,1,,26752979,3385,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
812,2549,1,1,,50105574,3385,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
813,2550,1,3,,8139872,3385,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
814,2551,1,1,,8139872,3385,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
815,2551,1,1,,17389875,3385,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
816,2551,1,1,,26747342,3385,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
817,2551,1,1,,26752979,3385,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
818,2553,1,2,,8139872,3385,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
819,2557,1,3,,8139872,3385,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
820,2563,1,1,,8139872,3385,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
821,2606,1,2,,8139872,3385,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
822,2629,1,1,,8139872,3385,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
823,2629,1,1,,85148656,3385,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
824,2642,1,2,,8139872,3385,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
825,2648,1,2,,8139872,3385,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
826,2650,2,1,,8139872,3385,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
827,2660,1,1,,90341469,3385,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
828,2661,1,1,,8139872,3385,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
829,2662,2,1,,8139872,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
830,2662,2,1,,85231050,3385,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
831,2666,1,1,,90341469,3385,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
832,2667,1,1,,90341469,3385,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
833,2668,1,1,,90341469,3385,Inconclusive,4826730.0,2475.0,23.2809,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
834,2674,1,1,,8139872,3385,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
835,2675,1,1,,8139872,3385,Inconclusive,41281591.0,4154.0,158.489,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
836,2675,1,1,,50105574,3385,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
837,2676,1,2,,8139872,3385,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
838,2685,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
839,2690,1,2,,8139872,3385,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
840,2706,1,1,,8139872,3385,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
841,2716,1,1,,8139872,3385,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
842,2716,1,1,,85148656,3385,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
843,2717,1,2,,8139872,3385,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
844,2718,1,1,,8139872,3385,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
845,2732,1,1,,8139872,3385,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
846,2732,1,1,,17405099,3385,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
847,2751,2,2,,8139872,3385,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
848,2774,1,3,,92303943,3385,Inactive,,,,,LOPAC Circadian Assay,Screening,,
849,2796,1,4,,8139872,3385,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
850,2797,1,2,,8139872,3385,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
851,8090,6,2,,103507642,3385,Unspecified,,,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Other,11814824.0,
852,8233,9,1,,103507642,3385,Unspecified,,,,IC50,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Confirmatory,8496926.0,
853,8448,6,2,,103507642,3385,Active,,,1.0,IC50,Tested in vitro for anticancer activity against 9L cells,Confirmatory,10072683.0,
854,9024,6,3,,103507642,3385,Active,,,1.7,IC50,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Confirmatory,,
855,22293,4,4,,103507642,3385,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
856,23271,4,4,,103507642,3385,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
857,23734,3,3,,103507642,3385,Unspecified,,,,,Micelle/water partition coefficient (Pmic) of the compound was determined,Other,8691461.0,
858,26304,4,4,,103507642,3385,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
859,26811,3,3,,103507642,3385,Unspecified,,,,,Partition coefficient (logP),Other,7392035.0,
860,29359,3,3,,103507642,3385,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
861,29811,4,3,,103507642,3385,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
862,32546,6,3,,103507642,3385,Active,,,3.9,IC50,Compound was tested for its inhibitory effect on the growth of AZ-521 tumor cell line from stomach.,Confirmatory,,
863,32549,3,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of AZ-521 tumor cell line from stomach at an iv dose of 2 mh/kg x10.,Other,,
864,39130,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Mouse melanoma (B16) cell line.,Other,1995905.0,
865,39418,7,1,,103507642,3385,Unspecified,,,,,In vitro cytotoxicity (LC99) was measured against B16 Melanoma cells,Other,7629806.0,
866,40606,5,1,,103507642,3385,Unspecified,,,,,Tested in vitro inhibitory activity against murine B16 melanoma cells line,Other,8258836.0,
867,42689,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion assay of the activity against Candida albicans B-311 at 1.5 ug/disk,Other,6387121.0,
868,42690,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion assay of the activity against Candida albicans B-311 at 12.5 ug/disk,Other,6387121.0,
869,42691,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion assay of the activity against Candida albicans B-311 at 25.0 ug/disk,Other,6387121.0,
870,42692,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion assay of the activity against Candida albicans B-311 at 3.0 ug/disk,Other,6387121.0,
871,42693,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion assay of the activity against Candida albicans B-311 at 6.0 ug/disk,Other,6387121.0,
872,42694,4,2,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion analysis of activity in complex media for C. albicans;,Other,6387121.0,
873,42696,4,2,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion analysis of activity in defined media for Candida albicans;,Other,6387121.0,
874,42699,7,2,,103507642,3385,Unspecified,,,,,Compound is evaluated for minimum inhibitory concentrations against Candida albicans strain 3153A,Other,6387121.0,
875,42700,7,2,,103507642,3385,Unspecified,,,,,Compound is evaluated for minimum inhibitory concentrations against Candida albicans strain B311,Other,6387121.0,
876,42701,7,2,,103507642,3385,Unspecified,,,,,Compound is evaluated for minimum inhibitory concentrations against Candida albicans strain BC759,Other,6387121.0,
877,43026,9,1,,103507642,3385,Unspecified,,,,IC50,"Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro",Confirmatory,8496926.0,
878,43232,5,3,,103507642,3385,Unspecified,,,,,Concentration at 50 percent inhibition of cell growth against human leukemia CCRF CEM cell line in vitro,Other,,
879,43233,5,3,,103507642,3385,Unspecified,,,,,The compound was evaluated for antitumoral activity against human leukemia cell line CCRF CEM after 72 hr of incubation,Other,,
880,43234,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.,Other,1992123.0,
881,43682,6,3,,103507642,3385,Active,,,2.0,IC50,In vitro cytotoxic activity against CCRF-CEM human lymphoblastoid cells in culture.,Confirmatory,,
882,43697,6,2,,103507642,3385,Active,,,5.0,IC50,Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture,Confirmatory,7120290.0,
883,43716,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.,Other,1995905.0,
884,43717,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human acute lymphocytic leukemia (CCRF-CEM) cells,Other,1995901.0,
885,44210,6,2,,103507642,3385,Active,,,2.0,IC50,Effect on CCRF-CEM cells in culture,Confirmatory,2362278.0,
886,44376,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.,Other,3373480.0,
887,44586,2,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of BxPC-3 tumor cell line from colon at an iv dose of 15 mg/kg x14.,Other,,
888,44892,6,2,,103507642,3385,Active,,,5.0,IC50,Growth inhibitory activity against CHO cells in culture.,Confirmatory,7853342.0,
889,45400,3,4,,103507642,3385,Unspecified,,,,,Effect on cross resistance of CHO cells resistant to colchicine (CHRC5),Other,2362268.0,
890,45594,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Growth inhibitory activity against CHO/FU cells in culture.,Confirmatory,7853342.0,
891,46264,3,6,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of CO-3 tumor cell line from colon at an iv dose of 15 mg/kg x14.,Other,,
892,46287,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human colon adenocarcinoma (COLO 205) cells.,Other,1995901.0,
893,46639,6,2,,103507642,3385,Unspecified,,,,,Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0),Other,11123990.0,
894,46731,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human epidermoid carcinoma (Calu-1) cells,Other,1995901.0,
895,46737,3,3,,103507642,3385,Unspecified,,,,,Calu3 lung tumor cell proliferation inhibition by the compound in vitro at a concentration of 0.7 uM.,Other,1495008.0,
896,46741,3,3,,103507642,3385,Unspecified,,,,,Calu3 lung tumor cell proliferation inhibition by the compound in vitro at a concentration of 7.0 uM.,Other,1495008.0,
897,46742,3,3,,103507642,3385,Unspecified,,,,,Calu3 lung tumor cell proliferation inhibition by the compound in vitro at a concentration of 70 uM.,Other,1495008.0,
898,47449,6,2,,103507642,3385,Unspecified,,,90.5,IC50,Tested in vitro for anticancer activity against CEM cells,Confirmatory,10072683.0,
899,47647,6,2,,103507642,3385,Active,,,8.9,IC50,Concentration required to inhibit 50% of cell growth on CEM lymphocytes.,Confirmatory,11052798.0,
900,50735,7,1,,103507642,3385,Active,,,,,Mean graph mid point was measured on colon cancer cells.,Other,11052798.0,
901,52508,3,4,,103507642,3385,Unspecified,,,,,COLO 320DM colon tumor cell proliferation inhibition by the compound in vitro at a concentration of 0.7 uM.,Other,1495008.0,
902,52512,3,4,,103507642,3385,Unspecified,,,,,COLO 320DM colon tumor cell proliferation inhibition by the compound in vitro at a concentration of 7.0 uM.,Other,1495008.0,
903,52513,3,4,,103507642,3385,Unspecified,,,,,COLO 320DM colon tumor cell proliferation inhibition by the compound in vitro at a concentration of 70 uM.,Other,1495008.0,
904,52650,6,3,,103507642,3385,Active,,,1.1,IC50,Compound was tested for its inhibitory effect on the growth of COLO 320DM tumor cell line from colon.,Confirmatory,,
905,53784,6,3,,103507642,3385,Active,,,6.0,IC50,Compound was tested for its inhibitory effect on the growth of DLD-1 tumor cell line from colon.,Confirmatory,,
906,53913,2,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of DLD-1 tumor cell line from colon at an iv dose of 15 mg/kg x14.,Other,,
907,64716,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion analysis of activity in complex media for E. coli;,Other,6387121.0,
908,64718,4,3,,103507642,3385,Unspecified,,,,,Compound is evaluated for disk diffusion analysis of activity in defined media for E. coli;,Other,6387121.0,
909,64719,3,4,,103507642,3385,Unspecified,,,,,"2 mg/disk of dialanine was codisked on the compound and evaluated for antagonistic activity against Escherichia coli M2626,at 1.5 ug/disk",Other,6387121.0,
910,64720,3,4,,103507642,3385,Unspecified,,,,,"2 mg/disk of dialanine was codisked on the compound and evaluated for antagonistic activity against Escherichia coli M2626,at 12.5 ug/disk",Other,6387121.0,
911,64722,5,3,,103507642,3385,Inconclusive,,,,,"2 mg/disk of dialanine was codisked on the compound and evaluated for antagonistic activity against Escherichia coli M2626,at 25.0 ug/disk; ND=No data",Other,6387121.0,
912,64723,3,4,,103507642,3385,Unspecified,,,,,"2 mg/disk of dialanine was codisked on the compound and evaluated for antagonistic activity against Escherichia coli M2626,at 3.0 ug/disk",Other,6387121.0,
913,64724,3,4,,103507642,3385,Unspecified,,,,,"2 mg/disk of dialanine was codisked on the compound and evaluated for antagonistic activity against Escherichia coli M2626,at 6.0 ug/disk",Other,6387121.0,
914,64725,3,4,,103507642,3385,Unspecified,,,,,Compound is evaluated for antagonistic activity against Escherichia coli M2626 at 1.5 ug/disk,Other,6387121.0,
915,64727,3,4,,103507642,3385,Unspecified,,,,,Compound is evaluated for antagonistic activity against Escherichia coli M2626 at 25.0 ug/disk,Other,6387121.0,
916,64728,3,4,,103507642,3385,Unspecified,,,,,Compound is evaluated for antagonistic activity against Escherichia coli M2626 at 3.0 ug/disk,Other,6387121.0,
917,64729,3,4,,103507642,3385,Unspecified,,,,,Compound is evaluated for antagonistic activity against Escherichia coli M2626 at 6.0 ug/disk,Other,6387121.0,
918,64730,3,4,,103507642,3385,Unspecified,,,,,Compound is evaluated for antagonistic activity against Escherichia coli M2626 at 12.5 ug/disk,Other,6387121.0,
919,66141,3,4,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor at the dose of 20 mg/kg,Other,2362278.0,
920,68602,4,3,,103507642,3385,Unspecified,,,,,Drug evaluation at the dose of 50 mg/kg by calculating fluid weight; fluid could not be drawn,Other,2362278.0,
921,68603,4,3,,103507642,3385,Unspecified,,,,,Drug evaluation at the dose of 50 mg/kg by counting the average ascites cells number; Completely dry,Other,2362278.0,
922,68605,3,5,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor in percent controls at the dose of 140 mg/kg,Other,2362278.0,
923,68606,3,5,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor in percent controls at the dose of 20 mg/kg,Other,2362278.0,
924,68611,3,4,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor in extremes treated at the dose of 140 mg/kg,Other,2362278.0,
925,68612,3,4,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor in extremes treated at the dose of 20 mg/kg,Other,2362278.0,
926,68618,6,3,,103507642,3385,Unspecified,,,,,Percent inhibition of ascites cell at the dose of 50 mg/kg; Completely dry,Other,2362278.0,
927,68621,6,3,,103507642,3385,Unspecified,,,,,Percent inhibition of ascitic fluid at the dose of 50 mg/kg; fluid could not be drawn,Other,2362278.0,
928,68624,3,4,,103507642,3385,Unspecified,,,,,Effect on the survival of mice bearing ascites tumor at the dose of 140 mg/kg,Other,2362278.0,
929,72041,6,2,,103507642,3385,Unspecified,,,,,Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0),Other,11123990.0,
930,72411,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human osteogenic sarcoma (G-292) cells,Other,1995901.0,
931,78624,6,3,,103507642,3385,Active,,,5.7,IC50,Compound was tested for its inhibitory effect on the growth of HCT-15 tumor cell line from colon.,Confirmatory,,
932,78631,6,2,,103507642,3385,Unspecified,,,,,Inhibitory concentration of compound for cytotoxicity against HCT15 human colon cells was determined,Other,11814824.0,
933,79229,3,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of H-81 tumor cell line from stomach at an iv dose of 15 mg/kg x14.,Other,,
934,80953,6,2,,103507642,3385,Active,,,1.0,IC50,Inhibitory concentration against Human leukemia cancer cell (HL-60)lines was determined.,Confirmatory,11229742.0,
935,81470,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.,Other,1995905.0,
936,81471,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human promyelocytic leukemia (HL-60) cells,Other,1995901.0,
937,82529,3,5,,103507642,3385,Unspecified,,,,,Evaluated for cytotoxic concentration required to reduce normal human embryonic lung (fibroblast) (HEL) cell growth by 50%; No data,Other,11123990.0,
938,82530,3,5,,103507642,3385,Unspecified,,,,,Evaluated for minimum cytotoxic concentration that causes a microscopically detectable alteration of normal HEL cell morphology; No data,Other,11123990.0,
939,82976,8,1,,103507642,3385,Active,,,6.5,AC50,In vitro concentration required to induce apoptosis in HL60 cells,Confirmatory,12877593.0,
940,82982,6,2,,103507642,3385,Active,,,1.5,IC50,In vitro inhibitory concentration against proliferation of HL60 cells,Confirmatory,12877593.0,
941,83533,4,3,,103507642,3385,Inconclusive,,,,,In vitro inhibitory concentration for antiviral activity was tested against HEL cells; No data,Other,,
942,83891,4,3,,103507642,3385,Inconclusive,,,,,In vitro minimum inhibitory concentration for antiviral activity was tested against Herpes simplex virus type 1(HSV-1); No data,Other,,
943,83946,6,2,,103507642,3385,Active,,,0.15,IC50,Antitumor activity against colon carcinoma cell line (HT-29),Confirmatory,2547068.0,
944,84372,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human osteogenic sarcoma (HOS) cells,Other,1995901.0,
945,85597,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human bladder carcinoma (HT1376) cells,Other,1995901.0,
946,86391,6,3,,103507642,3385,Unspecified,,,85.0,IC50,"Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).",Confirmatory,,
947,86403,7,1,,103507642,3385,Unspecified,,,,,"Compound was evaluated for the cytotoxicity against human hepatocellular carcinoma, HepG2 (ATCC HB8065)",Other,,
948,86522,7,1,,103507642,3385,Active,,,,,"Compound was evaluated for the cytotoxicity against human cervix epithelioid carcinoma, HeLa (ATCC CCL2).",Other,,
949,86696,6,2,,103507642,3385,Active,,,37.9,IC50,Tested in vitro for anticancer activity against HepG2 cells,Confirmatory,10072683.0,
950,86984,6,3,,103507642,3385,Unspecified,,,,,In vitro inhibitory concentration for cytotoxic activity was tested against HeLa cells,Other,,
951,87460,3,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 0.1 micro g/mL of the compound,Other,2666666.0,
952,87461,4,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 10 micro g/mL of the compound,Other,2666666.0,
953,87462,3,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 1 micro g/mL of the compound,Other,2666666.0,
954,87463,3,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 25 micro g/mL of the compound,Other,2666666.0,
955,87464,3,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 50 micro g/mL of the compound,Other,2666666.0,
956,87465,3,4,,103507642,3385,Unspecified,,,,,Percent inhibition of growth of human cervical carcinoma (HeLa) cells in culture at 5 micro g/mL of the compound,Other,2666666.0,
957,87474,8,1,,103507642,3385,Active,,,0.8,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 144 hr,Confirmatory,3625714.0,
958,87475,8,1,,103507642,3385,Active,,,6.1,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 72 hr,Confirmatory,3625714.0,
959,88256,6,2,,103507642,3385,Active,,,1.6,IC50,Inhibitory concentration against Hella cancer cell lines was determined.,Confirmatory,11229742.0,
960,88526,4,3,,103507642,3385,Unspecified,,,,,Compound was tested in vitro for cytotoxicity against HeLa cells.,Other,8709115.0,
961,88943,6,2,,103507642,3385,Unspecified,,,68.0,IC50,Inhibitory concentration against Human Gastric cancer cell (BGC) lines was determined.,Confirmatory,11229742.0,
962,91371,6,2,,103507642,3385,Unspecified,,,,,In vitro antitumor activity in IM-9 cell lines,Other,8648611.0,
963,91673,7,1,,103507642,3385,Active,,,,,Mean graph mid point was measured on all cell lines.,Other,11052798.0,
964,93849,8,1,,103507642,3385,Active,,,2.0,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against KB human cell lines after 144 hr,Confirmatory,3625714.0,
965,93850,8,1,,103507642,3385,Active,,,13.8,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against KB human cell lines after 72 hr,Confirmatory,3625714.0,
966,94108,4,4,,103507642,3385,Active,,,0.22,IC50,Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 24 hr,Confirmatory,11063625.0,
967,94109,4,4,,103507642,3385,Active,,,2.2,IC50,Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 2 hr,Confirmatory,11063625.0,
968,94110,4,4,,103507642,3385,Active,,,0.125,IC50,Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 48 hr,Confirmatory,11063625.0,
969,94111,4,4,,103507642,3385,Active,,,0.63,IC50,Growth inhibition in L1210 mouse Leukemia cells for a treatment time of 8 hr,Confirmatory,11063625.0,
970,94555,5,1,,103507642,3385,Unspecified,,,,,Tested in vitro inhibitory activity against murine L 1210 leukemia cells line,Other,8258836.0,
971,94680,6,3,,103507642,3385,Active,,,6.2,IC50,Compound was tested for its inhibitory effect on the growth of KKLS tumor cell line from stomach.,Confirmatory,,
972,94813,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human chronic myelogenous leukemia (K562 cells,Other,1995901.0,
973,94833,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.,Other,3373480.0,
974,94866,2,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of KM12C tumor cell line from colon at an iv dose of 15 mg/kg x14.,Other,,
975,95010,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human renal-cell carcinoma (KU-2) cells,Other,1995901.0,
976,95139,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.,Other,1992123.0,
977,95309,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human gastric carcinoma (KATO III) cell line.,Other,1995905.0,
978,95313,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma KATO III solid cell lines.,Other,1992123.0,
979,95480,6,2,,103507642,3385,Active,,,3.5,IC50,Inhibitory concentration against KB cancer cell lines was determined.,Confirmatory,11229742.0,
980,95696,5,3,,103507642,3385,Unspecified,,,,,Concentration at 50 percent inhibition of cell growth against human cancer KB cell line in vitro,Other,,
981,95850,6,3,,103507642,3385,Active,,,2.3,IC50,In vitro cytotoxicity against human oral epidermoid carcinoma KB cells.,Confirmatory,10229634.0,
982,95852,6,3,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.,Other,1995905.0,
983,96153,6,2,,103507642,3385,Unspecified,,,,,In vitro antitumor activity in K-562 cell lines,Other,8648611.0,
984,96176,8,1,,103507642,3385,Unspecified,,,,,In vitro antitumor activity against human erythroleukemia K-562 cells,Other,7086837.0,
985,96471,4,5,,103507642,3385,Active,,,2.5,IC50,Growth inhibition in L1210 mouse leukemia cells after 2 hr treatment,Confirmatory,11728193.0,
986,96472,4,4,,103507642,3385,Active,,,0.36,IC50,Growth inhibition in L1210 mouse leukemia cells after 24 h treatment,Confirmatory,11728193.0,
987,96473,4,5,,103507642,3385,Active,,,0.2,IC50,Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment,Confirmatory,11728193.0,
988,96474,4,4,,103507642,3385,Active,,,1.01,IC50,Growth inhibition in L1210 mouse leukemia cells after 8 h treatment,Confirmatory,11728193.0,
989,96642,5,1,,103507642,3385,Unspecified,,,,,Cytostatic activity against proliferation of L1210/0 cells (murine leukemia L1210 cells),Other,3007759.0,
990,96643,5,1,,103507642,3385,Unspecified,,,,,Cytostatic activity against proliferation of L1210/BdU cells (deoxythymidine kinase deficient L1210 cells),Other,3007759.0,
991,96713,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.,Other,3373480.0,
992,96794,8,1,,103507642,3385,Unspecified,,,,,In vitro antitumor activity against mouse myeloid leukemia L1210,Other,7086837.0,
993,96823,8,1,,103507642,3385,Active,,,1.0,ID50,Inhibition against L1210 mouse leukemia cells,Confirmatory,7328578.0,
994,97731,3,4,,103507642,3385,Unspecified,,,,,Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 1 uM Maximum cell kill in a 72-h period,Other,3918171.0,
995,97732,3,4,,103507642,3385,Unspecified,,,,,Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 10 uM Maximum cell kill in a 72-h period,Other,3918171.0,
996,97733,3,4,,103507642,3385,Unspecified,,,,,Evaluated in vitro for the Cytotoxic activity in the L1210 cell culture screen at 100 uM Maximum cell kill in a 72-h period,Other,3918171.0,
997,98340,6,2,,103507642,3385,Active,,,0.3,IC50,Inhibition of cell growth of L1210 mouse Leukemia cells,Confirmatory,2967375.0,
998,98541,5,3,,103507642,3385,Unspecified,,,,,Concentration at 50 percent inhibition of cell growth against mouse leukemia 1210 cell line in vitro,Other,,
999,98552,6,2,,103507642,3385,Active,,,0.5,IC50,Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture,Confirmatory,7120290.0,
1000,98673,8,1,,103507642,3385,Active,,,1.0,ID50,Evaluated for cytotoxicity against L1210 mouse leukemia cells,Confirmatory,7131481.0,
1001,98740,6,2,,103507642,3385,Active,,,0.62,IC50,In vitro cytotoxicity against murine Leukemia L1210 cells.,Confirmatory,10229634.0,
1002,98745,6,2,,103507642,3385,Active,,,2.2,IC50,In vitro growth inhibition of L1210 cells 2 hours after administration of compound,Confirmatory,7629806.0,
1003,98746,6,2,,103507642,3385,Active,,,0.22,IC50,In vitro growth inhibition of L1210 cells 24 hours after administration of compound,Confirmatory,7629806.0,
1004,98747,6,2,,103507642,3385,Active,,,0.12,IC50,In vitro growth inhibition of L1210 cells 48 hours after administration of compound,Confirmatory,7629806.0,
1005,98748,6,2,,103507642,3385,Active,,,0.63,IC50,In vitro growth inhibition of L1210 cells 8 hours after administration of compound,Confirmatory,7629806.0,
1006,99152,6,2,,103507642,3385,Unspecified,,,,,Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0),Other,11123990.0,
1007,99159,6,2,,103507642,3385,Active,,,0.3,IC50,Effect on L1210/0 cells in culture,Confirmatory,2362278.0,
1008,99173,3,4,,103507642,3385,Unspecified,,,,,Cross resistance profile versus L1210/R71 cells.,Other,2362268.0,
1009,99188,6,3,,103507642,3385,Unspecified,,,,,The compound was evaluated for antitumoral activity against mouse leukemia cell line L1210/c after 72 hr of incubation,Other,,
1010,99422,7,1,,103507642,3385,Active,,,,,Mean graph mid point was measured on leukemic cells.,Other,11052798.0,
1011,99488,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.,Other,1992123.0,
1012,100091,6,3,,103507642,3385,Active,,,28.5,IC50,In vitro cytotoxic activity against LFCl2A cell line derived from an hepatocarcinoma induced in the commentary rat by dimethylaminoazobenzene,Confirmatory,,
1013,100092,6,3,,103507642,3385,Active,,,28.5,IC50,In vitro cytotoxicity against LFCl2A (rat hepatocarcinoma) cells.,Confirmatory,,
1014,100403,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Tested in vitro for anticancer activity against LNCaP cells,Confirmatory,10072683.0,
1015,100509,8,1,,103507642,3385,Active,,,0.4,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the L1210 murine cell lines after 72 hours,Confirmatory,3625714.0,
1016,101616,7,1,,103507642,3385,Active,,,,,Inhibition of human breast cancer cell line MCF-7,Other,6827533.0,
1017,101747,8,1,,103507642,3385,Active,,,0.3,ID50,Inhibition of human breast cancer cell line MCF-7,Confirmatory,6827533.0,
1018,102615,6,2,,103507642,3385,Active,,,41.0,IC50,Tested in vitro for anticancer activity against MCF-7 cells,Confirmatory,10072683.0,
1019,103245,3,4,,103507642,3385,Unspecified,,,,,MC-7M breast tumor cell proliferation inhibition by the compound in vitro at a concentration 7.0 of uM,Other,1495008.0,
1020,103246,3,4,,103507642,3385,Unspecified,,,,,MC-7M breast tumor cell proliferation inhibition by the compound in vitro at a concentration 70 of uM,Other,1495008.0,
1021,103250,3,4,,103507642,3385,Unspecified,,,,,MC-7M breast tumor cell proliferation inhibition by the compound in vitro at a concentration of 0.7 uM.,Other,1495008.0,
1022,105082,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.,Other,3373480.0,
1023,105087,6,2,,103507642,3385,Unspecified,,,,,In vitro antitumor activity in MOLT-3 cell lines,Other,8648611.0,
1024,105312,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.,Other,1995905.0,
1025,105451,8,1,,103507642,3385,Unspecified,,,,,In vitro antitumor activity (tumor cell growth inhibition) against MDAY-D2 cells,Other,7086837.0,
1026,105661,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.,Other,1992123.0,
1027,106146,5,1,,103507642,3385,Unspecified,,,,,Evaluated for cytotoxicity against murine embryo fibroblasts (MEF),Other,11123990.0,
1028,106845,6,3,,103507642,3385,Active,,,2.5,IC50,Compound was tested for its inhibitory effect on the growth of MKN-28 tumor cell line from stomach.,Confirmatory,,
1029,106851,6,3,,103507642,3385,Active,,,3.0,IC50,Compound was tested for its inhibitory effect on the growth of MKN-45 tumor cell line from stomach.,Confirmatory,,
1030,108225,3,3,,103507642,3385,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 100 mg/kg dose 2-4 days after tumor challenge,Other,2002471.0,
1031,108226,3,3,,103507642,3385,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 100 mg/kg dose 3-6 days after tumor challenge,Other,2002471.0,
1032,108231,3,3,,103507642,3385,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 200 mg/kg dose 2-4 days after tumor challenge,Other,2002471.0,
1033,108233,3,3,,103507642,3385,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 25 mg/kg dose 2-4 days after tumor challenge,Other,2002471.0,
1034,108239,4,3,,103507642,3385,Unspecified,,,,,Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 50 mg/kg dose 2-4 days after tumor challenge,Other,2002471.0,
1035,108373,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 100 mg/kg dose, dosing on days 2-4 after tumor challenge",Other,2002471.0,
1036,108375,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 100 mg/kg dose, dosing on days 3-6 after tumor challenge",Other,2002471.0,
1037,108379,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 200 mg/kg dose, dosing on days 2-4 after tumor challenge",Other,2002471.0,
1038,108381,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 25 mg/kg dose, dosing on days 2-4 after tumor challenge",Other,2002471.0,
1039,108384,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 50 mg/kg dose, dosing on days 2-4 after tumor challenge",Other,2002471.0,
1040,108386,3,3,,103507642,3385,Unspecified,,,,,"In vivo activity measured against 3LL metastasis in BDF1 mice after ip administration at 50 mg/kg dose, dosing on days 3-6 after tumor challenge",Other,2002471.0,
1041,110405,7,1,,103507642,3385,Unspecified,,,,,"Antileukemic activity of compound against the P-388 lymphocytic leukemic BDF1 male mice at 25(mg/kg)/day, administered intraperitoneally; 18.0/9.66 (Treated/control)",Other,7328595.0,
1042,110713,7,1,,103507642,3385,Unspecified,,,,,Average survival days was measured by administrating the compound to Ehrlich ascites carcinoma (EAC) in swiss mice at 25 mg/kg dose,Other,3701777.0,
1043,111276,3,4,,103507642,3385,Unspecified,,,,,Effect of compound on P-388 lymphocytic leukemia growth at a given dose 25 mg/kg per day ip expressed as average survival days of treated mice,Other,7277393.0,
1044,112076,3,4,,103507642,3385,Unspecified,,,,,Compound was tested for the effect on the survival time of the mice bearing P388 leukemia at dose 20 mg/kg,Other,3941417.0,
1045,112084,3,4,,103507642,3385,Unspecified,,,,,Compound was tested for the effect on the survival time of the mice bearing Sarcoma 180 ascites at dose of 20 mg/kg,Other,3941417.0,
1046,115005,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia sensitive cells compared with controls at a dose of 20 mg/kg.,Other,7853342.0,
1047,115006,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia sensitive cells compared with controls at a dose of 30 mg/kg.,Other,7853342.0,
1048,115017,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span when the compound was administered intraperitoneally at dose of 200 mg/Kg in P388 leukemia in CDF1 mice was determined,Other,3806574.0,
1049,115360,5,2,,103507642,3385,Unspecified,,,,,Therapeutic effect of compound (25 mkdx3) on mice with L1210/5-FU leukemia; No effect,Other,2704026.0,
1050,115426,6,1,,103507642,3385,Unspecified,,,,,Mean corpuscular hemoglobin concentration (MCHC),Other,10780911.0,
1051,116432,3,4,,103507642,3385,Unspecified,,,,,Percent increase in life span (ILS) was measured on P388 cells which were inoculated intraperitoneally in CD2F1 mice,Other,2821258.0,
1052,116606,4,3,,103507642,3385,Unspecified,,,,,Percent increase in life span of L1210 leukemic BDF1 mice when compound (0.15 nmol/kg/day) was administered intravenously,Other,11814824.0,
1053,116752,7,1,,103507642,3385,Unspecified,,,,,In vivo mean survival time of L1210 leukemic BDF1 mice when compound (0.23 nmol/kg/day) was administered intravenously,Other,11814824.0,
1054,116800,3,3,,103507642,3385,Unspecified,,,,,"Percent increase in life span of leukemic mice administered, with compound at 25 mkdx3, on days 1,3,6",Other,2704026.0,
1055,116801,3,3,,103507642,3385,Unspecified,,,,,"Percent increase in life span of leukemic mice administered, with compound at 5 mkdx3, on days 1,3,6",Other,2704026.0,
1056,116943,6,1,,103507642,3385,Unspecified,,,,,Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 20 mg/kg.,Other,7853342.0,
1057,116944,6,1,,103507642,3385,Unspecified,,,,,Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 30 mg/kg.,Other,7853342.0,
1058,116945,6,1,,103507642,3385,Unspecified,,,,,Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 40 mg/kg.,Other,7853342.0,
1059,116957,6,1,,103507642,3385,Unspecified,,,,,Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 20 mg/kg.,Other,7853342.0,
1060,116958,6,1,,103507642,3385,Unspecified,,,,,Median survival time of 15 mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 30 mg/kg.,Other,7853342.0,
1061,117349,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 20 mg/kg.,Other,7853342.0,
1062,117350,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 30 mg/kg.,Other,7853342.0,
1063,117351,3,3,,103507642,3385,Unspecified,,,,,Percentage increase in life span of treated mice implanted intraperitoneally with P-388 leukemia resistant cells compared with controls at a dose of 40 mg/kg.,Other,7853342.0,
1064,117642,3,4,,103507642,3385,Inactive,,,,,In vivo activity against transplanted Mam-16/C/ Taxol tumors of mice; Not active,Other,11356111.0,
1065,119060,9,1,,103507642,3385,Unspecified,,,,,"Hematological effects in female CDF1 mice at the dose of 30mg, in red blood cells",Other,10780911.0,
1066,119110,3,4,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was evaluated on L1210 leukemia model and median survival day was determined at 20 mg/kg dosage concentration,Other,3625709.0,
1067,120681,4,3,,103507642,3385,Unspecified,,,,,Compound was evaluated for the anticancer activity against P388 leukemia in CD2F1 male mice at a dose of 200 mg/kg/day.,Other,3806574.0,
1068,121008,3,3,,103507642,3385,Unspecified,,,,,Compound was tested for the effect on the survival time of the mice bearing P388 leukemia at dose 20 mg/kg; ratio of survival time of treated and control,Other,3941417.0,
1069,121016,3,3,,103507642,3385,Unspecified,,,,,Compound was tested for the effect on the survival time of the mice bearing Sarcoma 180 ascites at dose of 20 mg/kg; ratio of survival time of treated and control,Other,3941417.0,
1070,121019,3,3,,103507642,3385,Unspecified,,,,,Compound was tested in vivo antitumor activity against Ehrlich ascites in mice at 100 mg/kg ip,Other,8709115.0,
1071,121025,3,3,,103507642,3385,Unspecified,,,,,Compound was tested in vivo for antitumor activity at 25 mg/kg dose,Other,3701777.0,
1072,121166,3,4,,103507642,3385,Unspecified,,,,,Effect of compound on P-388 lymphocytic leukemia growth at a given dose 25 mg/kg per day ip expressed as ratio of treated / control (T/C>125 is required for significant activity),Other,7277393.0,
1073,121647,3,3,,103507642,3385,Unspecified,,,,,In vivo antileukemic activity against P-388 lymphocytic leukemia in BDF1 male mice at 60 mg/kg/day intraperitoneal dose expressed as T/C,Other,7328595.0,
1074,121875,3,4,,103507642,3385,Unspecified,,,,,Anticancer activity against P388 leukemia in CD2F1 male mice. Number of survivors vs number of treated animals after 30 days were reported at a dose of 200 mg/kg/day; 0/6,Other,3806574.0,
1075,122127,3,4,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was determined against P388 leukemia cells expressed as treated/control at the dose of 20 mg/kg,Other,3625709.0,
1076,122144,3,4,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was evaluated on L1210 leukemia model and percent of treated/control of tumor cells was determined at 20 mg/kg dosage concentration,Other,3625709.0,
1077,122351,3,5,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was determined against P388 leukemia cells expressed as number of animals survived,Other,3625709.0,
1078,122362,3,4,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was evaluated on L1210 leukemia model and number of survivors (animals) was determined at 20 mg/kg dosage concentration,Other,3625709.0,
1079,122619,3,4,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 20 mg/kg.,Other,7853342.0,
1080,122620,3,4,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia sensitive cells at a dose of 30 mg/kg.,Other,7853342.0,
1081,122777,3,4,,103507642,3385,Unspecified,,,,,Anticancer activity against P388 leukemia in CD2F1 male mice expressed as Average % weight change on day 5 as a measure of toxicity was reported at a dose of 200 mg/kg/day.,Other,3806574.0,
1082,122789,3,3,,103507642,3385,Unspecified,,,,,Weight loss in mice treated with compound at 100 mkdx5,Other,2704026.0,
1083,122790,3,3,,103507642,3385,Unspecified,,,,,Weight loss in mice treated with compound at 200 mkdx5,Other,2704026.0,
1084,122791,3,3,,103507642,3385,Unspecified,,,,,Weight loss in mice treated with compound at 50 mkdx5,Other,2704026.0,
1085,123389,8,1,,103507642,3385,Unspecified,,,,,"Hematological effects in female CDF1 mice at the dose of 30 mg, in platelet cells",Other,10780911.0,
1086,123633,3,4,,103507642,3385,Unspecified,,,,,In vivo inhibitory activity against BxPC-3 tumor xenograft of pancreas in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1087,123648,3,4,,103507642,3385,Unspecified,,,,,In vivo inhibitory activity against PAN-12 tumor xenograft of pancreas in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1088,123759,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity of CO-3 tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1089,123761,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity of H-81 tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1090,123763,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against AZ-521 tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1091,123765,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against DLD-1 tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1092,123766,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against H-31 cells tumor xenograft of breast in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1093,123767,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against Hucc-T1 cells tumor xenograft of bile duct in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1094,123768,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against JRC-11 cells tumor xenograft of renal in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1095,123770,3,4,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against KM12C tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1096,123772,5,2,,103507642,3385,Unspecified,,,,,In vivo tumor cell growth inhibitory activity against NUGC-3 tumor xenograft of stomach in nude mice at a concentration of 15 mg/kg for 15 days,Other,8960561.0,
1097,124034,8,1,,103507642,3385,Unspecified,,,,,"Hematological effects in female CDF1 mice at the dose of 30 mg, in white blood cells",Other,10780911.0,
1098,124253,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against iv transplanted AML Leukemia 1498 tumors of mice,Other,11356111.0,
1099,124254,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against iv transplanted Leukemia L1210 tumors of mice,Other,11356111.0,
1100,124255,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Mam-16/C tumors of mice,Other,11356111.0,
1101,124257,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Mam-16/C/Adr tumors of mice,Other,11356111.0,
1102,124259,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Mam-17 tumors of mice,Other,11356111.0,
1103,124260,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Mam-17/Adr tumors of mice,Other,11356111.0,
1104,124261,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Mel-B16 tumors of mice,Other,11356111.0,
1105,124262,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Panc-02 tumors of mice,Other,11356111.0,
1106,124263,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Panc-03 tumors of mice,Other,11356111.0,
1107,124264,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted Squam lung-LC12 tumors of mice,Other,11356111.0,
1108,124265,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted colon-26 tumors of mice,Other,11356111.0,
1109,124266,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted colon-38 tumors of mice,Other,11356111.0,
1110,124267,3,3,,103507642,3385,Unspecified,,,,,In vivo activity against transplanted colon-51 tumors of mice,Other,11356111.0,
1111,124826,3,4,,103507642,3385,Unspecified,,,,,In vivo antitumor activity was evaluated on L1210 leukemia model and weight change in tumors was determined at 20 mg/kg dosage concentration,Other,3625709.0,
1112,124995,3,4,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 20 mg/kg.,Other,7853342.0,
1113,124996,3,4,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 30 mg/kg.,Other,7853342.0,
1114,124997,3,4,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 5 in mice implanted intraperitoneally with P-388 leukemia resistant cells at a dose of 40 mg/kg.,Other,7853342.0,
1115,125495,6,2,,103507642,3385,Unspecified,,,,,Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (Molt4/C8),Other,11123990.0,
1116,127576,2,5,,103507642,3385,Unspecified,,,,,Antitumor activity was evaluated by the change in body weight against IMC carcinoma in mice at a dose of 30.0 mg/kg,Other,,
1117,130337,3,3,,103507642,3385,Unspecified,,,,,The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 20 mg/kg,Other,7966151.0,
1118,130340,3,3,,103507642,3385,Unspecified,,,,,The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 30 mg/kg,Other,7966151.0,
1119,130480,3,3,,103507642,3385,Unspecified,,,,,The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 20 mg/kg,Other,7966151.0,
1120,130483,3,3,,103507642,3385,Unspecified,,,,,The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 30 mg/kg,Other,7966151.0,
1121,130486,3,3,,103507642,3385,Unspecified,,,,,The compound was tested for increase in life span for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 40 mg/kg,Other,7966151.0,
1122,130990,2,4,,103507642,3385,Unspecified,,,,,Antitumor activity was evaluated by the increase in life span (I.L.S) against IMC carcinoma in mice at a dose of 30.0 mg/kg,Other,,
1123,133614,6,1,,103507642,3385,Unspecified,,,,,The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/0 Leukemia cell line at 20 mg/kg,Other,7966151.0,
1124,133640,3,3,,103507642,3385,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity against colon adenocarcinoma after injecting the compound intraperitoneally for optimal dose,Other,1992140.0,
1125,133739,6,1,,103507642,3385,Unspecified,,,,,The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/0 Leukemia cell line at 30 mg/kg,Other,7966151.0,
1126,133747,6,1,,103507642,3385,Unspecified,,,,,The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 20 mg/kg,Other,7966151.0,
1127,133750,6,1,,103507642,3385,Unspecified,,,,,The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 30 mg/kg,Other,7966151.0,
1128,133753,6,1,,103507642,3385,Unspecified,,,,,The compound was tested for mean survival time for 15 mice implanted Intraperitoneally with P-388/FU Leukemia cell line at 40 mg/kg,Other,7966151.0,
1129,135564,3,3,,103507642,3385,Unspecified,,,,,Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 10 mg/kg orally on day 20,Other,8277499.0,
1130,135567,3,3,,103507642,3385,Unspecified,,,,,Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 20 mg/kg orally on day 20,Other,8277499.0,
1131,135570,3,3,,103507642,3385,Unspecified,,,,,Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 30 mg/kg orally on day 20,Other,8277499.0,
1132,135572,3,3,,103507642,3385,Unspecified,,,,,Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 40 mg/kg orally on day 20,Other,8277499.0,
1133,135574,3,3,,103507642,3385,Unspecified,,,,,Percent inhibition against M5076 mouse reticulum cell sarcoma after administration at 50 mg/kg orally on day 20,Other,8277499.0,
1134,135592,5,1,,103507642,3385,Unspecified,,,,,Antitumor activity was evaluated by the change in life span (day) against IMC carcinoma in mice at a dose of 30.0 mg/kg,Other,,
1135,135880,3,3,,103507642,3385,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity against colon adenocarcinoma after injecting the compound intraperitoneally for percent T/C,Other,1992140.0,
1136,136201,3,4,,103507642,3385,Unspecified,,,,,Tested for 60-day survivors after administration at 10 mg/kg orally in M5076 mouse reticulum cell sarcoma,Other,8277499.0,
1137,136204,3,4,,103507642,3385,Unspecified,,,,,Tested for 60-day survivors after administration at 20 mg/kg orally in M5076 mouse reticulum cell sarcoma,Other,8277499.0,
1138,136207,3,4,,103507642,3385,Unspecified,,,,,Tested for 60-day survivors after administration at 30 mg/kg orally in M5076 mouse reticulum cell sarcoma,Other,8277499.0,
1139,136346,3,4,,103507642,3385,Unspecified,,,,,Tested for 60-day survivors after administration at 40 mg/kg orally in M5076 mouse reticulum cell sarcoma,Other,8277499.0,
1140,136348,3,4,,103507642,3385,Unspecified,,,,,Tested for 60-day survivors after administration at 50 mg/kg orally in M5076 mouse reticulum cell sarcoma,Other,8277499.0,
1141,137194,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against P-388 Leukemia in female BDF1 mice expressed as percent T/C at dose 12.5 mg/kg,Other,7452684.0,
1142,137196,3,5,,103507642,3385,Unspecified,,,,,Percentage change in median survival time of P388 (leukemia) inoculated female mice following 25 mg/kg i.p.,Other,7452684.0,
1143,137197,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against P-388 Leukemia in female BDF1 mice expressed as percent T/C at dose 50 mg/kg,Other,7452684.0,
1144,137339,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity in mice bearing Ehrlich ascites tumor cells at 100 mg/kg ip,Other,1469693.0,
1145,137580,3,3,,103507642,3385,Unspecified,,,,,Percent treated was determined after administration at 10 mg/kg orally,Other,8277499.0,
1146,137707,3,3,,103507642,3385,Unspecified,,,,,Percent treated was determined after administration at 20 mg/kg orally,Other,8277499.0,
1147,137710,3,3,,103507642,3385,Unspecified,,,,,Percent treated was determined after administration at 30 mg/kg orally,Other,8277499.0,
1148,137712,3,3,,103507642,3385,Unspecified,,,,,Percent treated was determined after administration at 40 mg/kg orally,Other,8277499.0,
1149,137714,3,3,,103507642,3385,Unspecified,,,,,Percent treated was determined after administration at 50 mg/kg orally,Other,8277499.0,
1150,138602,3,3,,103507642,3385,Unspecified,,,,,Percentage inhibition as antitumor activity in carcinoma CF1 male mice.,Other,7365742.0,
1151,139030,3,4,,103507642,3385,Unspecified,,,,,Weight change in M5076 mouse reticulum cell sarcoma after administration at 10 mg/kg orally,Other,8277499.0,
1152,139033,3,4,,103507642,3385,Unspecified,,,,,Weight change in M5076 mouse reticulum cell sarcoma after administration at 20 mg/kg orally,Other,8277499.0,
1153,139036,3,4,,103507642,3385,Unspecified,,,,,Weight change in M5076 mouse reticulum cell sarcoma after administration at 30 mg/kg orally,Other,8277499.0,
1154,139038,3,4,,103507642,3385,Unspecified,,,,,Weight change in M5076 mouse reticulum cell sarcoma after administration at 40 mg/kg orally,Other,8277499.0,
1155,139040,3,4,,103507642,3385,Unspecified,,,,,Weight change in M5076 mouse reticulum cell sarcoma after administration at 50 mg/kg orally,Other,8277499.0,
1156,139117,3,3,,103507642,3385,Unspecified,,,,,Volume of fluid collected 8 days after tumor transplantation in mice.,Other,7365742.0,
1157,139146,3,4,,103507642,3385,Unspecified,,,,,The compound was tested for change in weight for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 20 mg/kg,Other,7966151.0,
1158,139149,3,4,,103507642,3385,Unspecified,,,,,The compound was tested for change in weight for mice implanted intraperitoneally with P-388/0 Leukemia cell line at 30 mg/kg,Other,7966151.0,
1159,139156,3,4,,103507642,3385,Unspecified,,,,,The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 20 mg/kg,Other,7966151.0,
1160,139284,3,4,,103507642,3385,Unspecified,,,,,The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 30 mg/kg,Other,7966151.0,
1161,139287,3,4,,103507642,3385,Unspecified,,,,,The compound was tested for change in weight for mice implanted intraperitoneally with P-388/FU Leukemia cell line at 40 mg/kg,Other,7966151.0,
1162,139457,8,1,,103507642,3385,Active,,,0.1,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the P388/doxorubicin resistant murine cell lines after 72 hours,Confirmatory,3625714.0,
1163,139721,3,4,,103507642,3385,Unspecified,,,,,Screening of Ehrlich ascites carcinoma cells in mice at 20 mg/kg/day intraperitoneally.,Other,7365742.0,
1164,139857,3,3,,103507642,3385,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity against colon adenocarcinoma after injecting the compound intraperitoneally for total dose.,Other,1992140.0,
1165,140160,3,3,,103507642,3385,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity against colon adenocarcinoma after injecting the compound intraperitoneally for toxicity related death.,Other,1992140.0,
1166,140353,3,3,,103507642,3385,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity against colon adenocarcinoma after injecting the compound intraperitoneally for median tumor burden,Other,1992140.0,
1167,140766,3,4,,103507642,3385,Unspecified,,,,,Anticarcinoma activity of Diazomethyl Ketone against Ehrlich ascites Carcinoma pharmacological screens were reported; 12/12,Other,7365742.0,
1168,146713,6,3,,103507642,3385,Active,,,4.4,IC50,Compound was tested for its inhibitory effect on the growth of NUGC-3 tumor cell line from stomach.,Confirmatory,,
1169,150942,6,4,,103507642,3385,Unspecified,,,,,The compound was evaluated for antitumoral activity against human melanoma cell line P36 after 72 hr of incubation,Other,,
1170,152249,6,3,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human melanoma (P-36) cell line.,Other,1995905.0,
1171,152413,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 15 mg/kg,Other,7131481.0,
1172,152414,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for average 7-day weight change against P-388 leukemia in mice at a dose of 30 mg/kg,Other,7131481.0,
1173,152415,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 15 mg/kg,Other,7131481.0,
1174,152416,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for average weight on day 1 against P-388 leukemia in mice at a dose of 30 mg/kg,Other,7131481.0,
1175,152438,3,4,,103507642,3385,Unspecified,,,,,Percent increase in life span against P-388 leukemia in mice was determined at a dose of 15 mg/kg,Other,7131481.0,
1176,152439,3,4,,103507642,3385,Unspecified,,,,,Percent increase in life span against P-388 leukemia in mice was determined at a dose of 30 mg/kg,Other,7131481.0,
1177,152440,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 15 mg/kg,Other,7131481.0,
1178,152441,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for median survival of mice against P-388 leukemia in mice at a dose of 30 mg/kg,Other,7131481.0,
1179,152442,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 15 mg/kg,Other,7131481.0,
1180,152443,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for survival range of mice against P-388 leukemia in mice at a dose of 30 mg/kg,Other,7131481.0,
1181,152444,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 15 mg/kg,Other,7131481.0,
1182,152445,3,5,,103507642,3385,Unspecified,,,,,Antitumor activity was determined for 7-day average percent weight change against P-388 leukemia in mice at a dose of 30 mg/kg,Other,7131481.0,
1183,152593,8,1,,103507642,3385,Active,,,0.3,ID50,The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the P388 murine cell lines after 72 hours,Confirmatory,3625714.0,
1184,152793,8,3,,103507642,3385,Inconclusive,,,,,The compound was tested in vitro for anti HIV-1 activity against PBM cells; Not determined,Other,10072683.0,
1185,152794,6,3,,103507642,3385,Active,,,5.0,IC50,Tested in vitro for cytotoxicity against PBM cells,Confirmatory,10072683.0,
1186,152997,6,1,,103507642,3385,Unspecified,,,,,Survival of the mice for average number of days; expressed as average survival days,Other,7365742.0,
1187,153200,3,6,,103507642,3385,Unspecified,,,,,Antineoplastic activity against P388 leukemia in CD2F1 male mice and the percent increase in life span was measured on day 30.,Other,2431142.0,
1188,153206,3,6,,103507642,3385,Unspecified,,,,,Number of cures from P388 leukemia in CD2F1 male mice as tumor-free survivors after day 60.,Other,2431142.0,
1189,153210,3,6,,103507642,3385,Unspecified,,,,,Antineoplastic activities against P388 leukemia in CD2F1 male mice.,Other,2431142.0,
1190,153212,3,7,,103507642,3385,Unspecified,,,,,Antineoplastic activity against P388 leukemia in CD2F1 male mice and the average percentage weight change on day 5 was measured.,Other,2431142.0,
1191,153575,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia at a dose of 20 g/kg in q.d. 1-9 schedule,Other,7328578.0,
1192,153578,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia at a dose of 40 g/kg in b.i.d. x 4 schedule; Toxic,Other,7328578.0,
1193,153579,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia at a dose of 40 g/kg in q.d. 1-9 schedule; Toxic,Other,7328578.0,
1194,153584,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia for a dose of 20 g/kg in q.d. 1-4 schedule,Other,7328578.0,
1195,153586,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia for a dose of 40 g/kg in q.d. 1-4 schedule; Toxic,Other,7328578.0,
1196,153588,3,5,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia at a dose of 20 g/kg in b.i.d. x 4 schedule,Other,7328578.0,
1197,153603,3,4,,103507642,3385,Unspecified,,,,,Evaluated for the antitumor activity in the P388 lymphocytic leukemia in female CDF1 mice injected intraperitoneally with 10 E-6 tumor cells dosed for 9 days at 20 mg/kg,Other,3918171.0,
1198,153728,3,5,,103507642,3385,Unspecified,,,,,"Percentage increase in life span of murine leukemia P388 resistant to 5-FU, at a dose 15 mg/kg",Other,6308257.0,
1199,153730,3,5,,103507642,3385,Unspecified,,,,,"Percentage increase in life span of murine leukemia P388 resistant to 5-FU, at a dose 20 mg/kg",Other,6308257.0,
1200,153732,3,5,,103507642,3385,Unspecified,,,,,"Percentage increase in life span of murine leukemia P388 resistant to 5-FU, at a dose 35 mg/kg",Other,6308257.0,
1201,153737,3,5,,103507642,3385,Unspecified,,,,,"Percentage increase in life span of murine leukemia P388 sensitive to 5-FU, at a dose 20 mg/kg",Other,6308257.0,
1202,153738,3,5,,103507642,3385,Unspecified,,,,,"Percentage increase in life span of murine leukemia P388 sensitive to 5-FU, at a dose 35 mg/kg",Other,6308257.0,
1203,153904,3,4,,103507642,3385,Unspecified,,,,,"In vivo cytotoxicity was determined against P388 mouse leukemia cells, (% treated / control) at 20 mg/kg (ip) administration",Other,2299637.0,
1204,154054,3,4,,103507642,3385,Unspecified,,,,,T/C expresses antileukemic activity measured as tested over that of control,Other,7365742.0,
1205,154225,3,6,,103507642,3385,Unspecified,,,,,Compound was evaluated for the 7-day percent change in weight of mice infected with P388 leukemia at a dose of 20 g/kg in b.i.d. x 4 schedule,Other,7328578.0,
1206,154226,3,6,,103507642,3385,Unspecified,,,,,Compound was evaluated for the 7-day percent change in weight of mice infected with P388 leukemia at a dose of 20 g/kg in q.d. 1-4 schedule,Other,7328578.0,
1207,154230,3,6,,103507642,3385,Unspecified,,,,,Compound was evaluated for the 7-day percent change in weight of mice infected with P388 leukemia at a dose of 40 g/kg in b.i.d. x 4 schedule,Other,7328578.0,
1208,154352,3,6,,103507642,3385,Unspecified,,,,,Compound was evaluated for the 7-day percent change in weight of mice infected with P388 leukemia at a dose of 40 g/kg in q.d. 1-4 schedule,Other,7328578.0,
1209,154353,3,6,,103507642,3385,Unspecified,,,,,Compound was evaluated for the 7-day percent change in weight of mice infected with P388 leukemia at a dose of 40 g/kg in q.d. 1-9 schedule,Other,7328578.0,
1210,154357,3,6,,103507642,3385,Unspecified,,,,,Percent increase in life span against mice infected with P388 leukemia at a dose of 20 g/kg in q.d. 1-9 schedule,Other,7328578.0,
1211,154359,6,1,,103507642,3385,Unspecified,,,,,"Average days survival of female CDF1 mice bearing lymphocytic leukemia, when 10 E-6 tumor cells were injected intraperitoneally, dosed for 9 days at 20 mg/kg.",Other,3918171.0,
1212,154511,6,1,,103507642,3385,Unspecified,,,,,"Median survival time (MST) of murine leukemia P388 (1*10e 6 cells) resistant to 5-FU in 500 mice, dose of 35 mg/kg(ip)",Other,6308257.0,
1213,154598,3,5,,103507642,3385,Unspecified,,,,,Compound was tested for its percentage inhibitory effect on the growth of PAN-12 tumor cell line from colon at an iv dose of 15 mg/kg x14.,Other,,
1214,154604,6,3,,103507642,3385,Unspecified,,,78.0,IC50,Compound was tested for its inhibitory effect on the growth of PANC-1 tumor cell line from pancreas.,Confirmatory,,
1215,154612,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human pancreas epitheloid carcinoma (PANC-1) cells,Other,1995901.0,
1216,154646,6,1,,103507642,3385,Unspecified,,,,,"Median survival time (MST) of murine leukemia P388 (1*10e 6 cells) resistant to 5-FU in mice, dose of 15 mg/kg(ip)",Other,6308257.0,
1217,154648,6,1,,103507642,3385,Unspecified,,,,,"Median survival time (MST) of murine leukemia P388 (1*10e 6 cells) resistant to 5-FU in mice, dose of 20 mg/kg (i.p.)",Other,6308257.0,
1218,154654,6,1,,103507642,3385,Unspecified,,,,,"Median survival time (MST) of murine leukemia P388 (1*10e 6 cells) sensitive to 5-FU in mice, dose of 20 mg/kg(ip)",Other,6308257.0,
1219,154656,6,1,,103507642,3385,Unspecified,,,,,"Median survival time (MST) of murine leukemia P388 (1*10e 6 cells) sensitive to 5-FU in mice, dose of 35 mg/kg(ip)",Other,6308257.0,
1220,154821,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 20 g/kg in b.i.d. x 4 schedule,Other,7328578.0,
1221,154822,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 20 g/kg in q.d. 1-4 schedule,Other,7328578.0,
1222,154823,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 20 g/kg in q.d. 1-9 schedule,Other,7328578.0,
1223,154827,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 40 g/kg in b.i.d. x 4 schedule,Other,7328578.0,
1224,154828,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 40 g/kg in q.d. 1-4 schedule,Other,7328578.0,
1225,154829,6,1,,103507642,3385,Unspecified,,,,,Compound was evaluated for the median survival time of mice infected with P388 leukemia at a dose of 40 g/kg in q.d. 1-9 schedule,Other,7328578.0,
1226,154862,3,6,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 6 in murine leukemia P388 resistant to 5-FU at a dose of 15 mg/kg,Other,6308257.0,
1227,154863,3,6,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 6 in murine leukemia P388 resistant to 5-FU at a dose of 20 mg/Kg,Other,6308257.0,
1228,154864,3,6,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 6 in murine leukemia P388 resistant to 5-FU at a dose of 35 mg/kg,Other,6308257.0,
1229,154870,3,6,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 6 in murine leukemia P388 sensitive to 5-FU at a dose of 20 mg/kg,Other,6308257.0,
1230,154871,3,6,,103507642,3385,Unspecified,,,,,Average percentage weight change on day 6 in murine leukemia P388 sensitive to 5-FU at a dose of 35 mg/kg,Other,6308257.0,
1231,155541,6,2,,103507642,3385,Unspecified,,,,,IIn vitro antitumor activity in PHA-Ly cell lines,Other,8648611.0,
1232,155844,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.,Other,1995905.0,
1233,155865,7,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.,Other,1995905.0,
1234,155995,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.,Other,1995905.0,
1235,156334,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Tested in vitro for anticancer activity against PC-3 cells,Confirmatory,10072683.0,
1236,156355,7,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.,Other,1995905.0,
1237,156480,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human lung adenocarcinoma (PC-8) cells,Other,1995901.0,
1238,156492,6,3,,103507642,3385,Unspecified,,,,,Concentration at 50 percent inhibition of cell growth against human cancer PC10 cell line in vitro,Other,,
1239,156495,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).,Other,3373480.0,
1240,156496,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.,Other,1992123.0,
1241,156634,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.,Other,1992123.0,
1242,163140,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human lung squamous-cell carcinoma (QG-56) cells,Other,1995901.0,
1243,163144,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human lung small cell carcinoma (QG-90) cells,Other,1995901.0,
1244,165908,5,1,,103507642,3385,Unspecified,,,,,Cytostatic activity against proliferation of Raji/0 cells (human lymphoblast Raji cells),Other,3007759.0,
1245,165909,5,1,,103507642,3385,Unspecified,,,,,Cytostatic activity against proliferation of Raji/TK cells (deoxythymidine kinase deficient Raji cells),Other,3007759.0,
1246,166895,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human myeloma (RPMI 8226) cells,Other,1995901.0,
1247,189629,3,3,,103507642,3385,Unspecified,,,,,The capillary permeability of radioligand was measured in Rat brain,Other,7392035.0,
1248,200620,6,2,,103507642,3385,Active,,,5.4,IC50,Cytotoxicity against human small-cell lung cancer (SCLC),Confirmatory,8258835.0,
1249,200624,6,2,,103507642,3385,Active,,,8.4,IC50,Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP),Confirmatory,8258835.0,
1250,201194,6,3,,103507642,3385,Active,,,2.7,IC50,Compound was tested for its inhibitory effect on the growth of SUN-C2A tumor cell line from colon.,Confirmatory,,
1251,201544,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human osteogenic sarcoma (Saos-2) cells,Other,1995901.0,
1252,201681,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.,Other,1992123.0,
1253,201687,6,3,,103507642,3385,Active,,,5.7,IC50,Compound was tested for its inhibitory effect on the growth of SW-48 tumor cell line from colon.,Confirmatory,,
1254,201696,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.,Other,1995905.0,
1255,201740,3,5,,103507642,3385,Unspecified,,,,,Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 40 mg/kg,Other,6447210.0,
1256,201883,5,4,,103507642,3385,Unspecified,,,,,Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 50 mg/kg,Other,6447210.0,
1257,201898,6,1,,103507642,3385,Unspecified,,,,,"Ability of compound (65 mg/kg, q4dx3) to inhibit growth of Sc colon 38 tumor cells in mice",Other,2704025.0,
1258,201986,6,2,,103507642,3385,Active,,,4.5,IC50,Tested in vitro for anticancer activity against SK-MEL-28 cells,Confirmatory,10072683.0,
1259,202005,5,3,,103507642,3385,Unspecified,,,,,The compound was evaluated for antitumoral activity against human cancer cell line SW480 after 72 hr of incubation,Other,,
1260,202209,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).,Other,3373480.0,
1261,202326,6,2,,103507642,3385,Active,,,0.31,IC50,Antitumor activity against lung carcinoma cell line (SK-MES-1),Confirmatory,2547068.0,
1262,202327,6,2,,103507642,3385,Active,,,13.1,IC50,Tested in vitro for anticancer activity against SK-MES-1 cells,Confirmatory,10072683.0,
1263,202819,6,2,,103507642,3385,Unspecified,,,,,Inhibitory concentration of compound for cytotoxicity against SK-MEL-2 human melanoma cells was determined,Other,11814824.0,
1264,202976,6,2,,103507642,3385,Unspecified,,,,,Inhibitory concentration of compound for cytotoxicity against SK-OV-3 human ovarian cells was determined,Other,11814824.0,
1265,208520,5,3,,103507642,3385,Unspecified,,,,,The compound was evaluated for antitumoral activity against human cancer cell line T24 after 72 hr of incubation,Other,,
1266,208522,6,3,,103507642,3385,Active,,,22.0,IC50,Compound was tested for its inhibitory effect on the growth of T24 tumor cell line from bladder.,Confirmatory,,
1267,208532,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).,Other,3373480.0,
1268,208539,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.,Other,1992123.0,
1269,208863,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.,Other,1995905.0,
1270,208867,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).,Other,3373480.0,
1271,208868,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.,Other,1992123.0,
1272,209962,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.,Other,1995905.0,
1273,209964,9,1,,103507642,3385,Unspecified,,,,IC50,Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression,Confirmatory,8496926.0,
1274,212010,6,2,,103507642,3385,Unspecified,,,,,Toxicity by oral administration of single dose in mice,Other,11814824.0,
1275,214063,6,2,,103507642,3385,Unspecified,,,,,In vitro antitumor activity in U-937 cell lines,Other,8648611.0,
1276,214064,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.,Other,1995905.0,
1277,214418,6,2,,103507642,3385,Unspecified,,,,,In vitro inhibitory activity against growth of Human histocytic lymphoma (U937) cells,Other,1995901.0,
1278,214573,6,2,,103507642,3385,Unspecified,,,,,Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.,Other,1992123.0,
1279,216188,6,2,,103507642,3385,Active,,,6.81,IC50,Tested in vitro for cytotoxicity against Vero cells,Confirmatory,10072683.0,
1280,216330,5,3,,103507642,3385,Inconclusive,,,,,In vitro minimum inhibitory concentration for antiviral activity was tested against Varicella-Zoster virus(VZV); No data,Other,,
1281,217736,5,3,,103507642,3385,Inconclusive,,,,,In vitro inhibitory concentration for antiviral activity was tested against vero cells; No data,Other,,
1282,221285,7,1,,103507642,3385,Unspecified,,,,,Average days survived for treated / average days survived for control at 25 (mg/kg); 17.6/9.5,Other,6854591.0,
1283,221951,6,2,,103507642,3385,Active,,,23.0,IC50,Concentration required to inhibit 50% of cell growth on human Molt 4/C8 cells.,Confirmatory,11052798.0,
1284,222600,6,4,,103507642,3385,Active,,,8.0,IC50,Compound was evaluated for the inhibition of cell proliferation of human ocular lens epithelium (CECH).,Confirmatory,,
1285,223348,3,3,,103507642,3385,Unspecified,,,,,Anti tumor activity in mice bearing lymphocytic leukemia P-388 at 25 mg/kg,Other,6854591.0,
1286,224730,6,2,,103507642,3385,Active,,,0.28,IC50,Concentration required to inhibit 50% of cell growth on murine L1210 cells.,Confirmatory,11052798.0,
1287,224731,6,2,,103507642,3385,Active,,,0.49,IC50,Concentration required to inhibit 50% of cell growth on murine P388 D1 cells.,Confirmatory,11052798.0,
1288,228983,3,4,,103507642,3385,Unspecified,,,,,Percent reduction against sarcoma 180J tumor growth in mice when administered intraperitoneally at dose 25 mg/kg,Other,6447210.0,
1289,231421,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 25 mg/kg, ip; 22/22",Other,6447210.0,
1290,231422,3,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against sarcoma 180J infected mice was evaluated as ratio of number of survivors to the number of tested animals at dose 40 mg/kg, ip; 17/24",Other,6447210.0,
1291,232291,3,5,,103507642,3385,Unspecified,,,,,"Cytotoxicity ratio for Human hepatocellular carcinoma, HepG2 (ATCC HB 8065) cells",Other,,
1292,235488,3,3,,103507642,3385,Unspecified,,,,,Selectivity index is the ratio of MG MID value for all cell lines to that of colon cancer cells,Other,11052798.0,
1293,235489,3,3,,103507642,3385,Unspecified,,,,,Selectivity index is the ratio of MG MID value for all cell lines to that of leukemic cells,Other,11052798.0,
1294,244681,3,3,,103507642,3385,Unspecified,,,,,Average tumor weight in mouse tumor sarcoma-180 model after intraperitoneal administration of 75 mg/kg dose,Other,15808456.0,
1295,244686,3,3,,103507642,3385,Unspecified,,,,,Average tumor weight in mouse with tumor sarcoma-180 after intraperitoneal (i.p.) injection at a dose of 75 mg/Kg,Other,15913996.0,
1296,244705,3,3,,103507642,3385,Unspecified,,,,,Percent change in body-weight of mouse tumor sarcoma-180 model after intraperitoneal administration of 75 mg/kg dose,Other,15808456.0,
1297,244707,3,3,,103507642,3385,Unspecified,,,,,Percent body weight change in mouse with tumor sarcoma-180 after intraperitoneal (i.p.) injection at a dose of 75 mg/Kg,Other,15913996.0,
1298,245824,3,3,,103507642,3385,Unspecified,,,,,Percent tumor-weight inhibition in mouse with tumor sarcoma-180 after intraperitoneal (i.p.) injection at a dose of 75 mg/Kg,Other,15913996.0,
1299,245828,3,3,,103507642,3385,Unspecified,,,,,Percent tumor-weight inhibition in mouse tumor sarcoma-180 model after intraperitoneal administration of 75 mg/kg dose in comparison with control mice,Other,15808456.0,
1300,247836,6,2,,103507642,3385,Active,,,3.6,IC50,Concentration required to inhibit proliferation of TSU prostate cancer cell lines,Confirmatory,15341952.0,
1301,247857,6,2,,103507642,3385,Active,,,12.0,IC50,Concentration required to inhibit proliferation of PC-3 prostate cancer cell lines,Confirmatory,15341952.0,
1302,247884,6,2,,103507642,3385,Active,,,4.9,IC50,Concentration required to inhibit proliferation of LNCaP prostate cancer cell lines,Confirmatory,15341952.0,
1303,247885,6,2,,103507642,3385,Active,,,6.4,IC50,Concentration required to inhibit proliferation of PPC-1 prostate cancer cell lines,Confirmatory,15341952.0,
1304,247903,6,2,,103507642,3385,Active,,,11.9,IC50,Concentration required to inhibit proliferation of DU-145 prostate cancer cell lines,Confirmatory,15341952.0,
1305,248055,6,2,,103507642,3385,Active,,,4.8,IC50,Antiproliferative activity in MCF-7 human breast cancer cells,Confirmatory,15658875.0,
1306,248173,6,3,,103507642,3385,Active,,,9.6,IC50,Antiproliferative activity in MDA-MB 231 human breast cancer cells,Confirmatory,15658875.0,
1307,248189,8,1,,103507642,3385,Active,,,12.0,IC50,Antiproliferative activity against prostate cancer PC-3 cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1308,248190,6,2,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative effect against RH7777 cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1309,248208,8,2,,103507642,3385,Active,,,4.9,IC50,Antiproliferative activity against prostate cancer LNCaP Cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1310,248209,8,1,,103507642,3385,Active,,,6.4,IC50,Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1311,248236,8,1,,103507642,3385,Active,,,11.9,IC50,Antiproliferative activity against prostate cancer DU-145 cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1312,248247,8,1,,103507642,3385,Active,,,3.6,IC50,Antiproliferative activity against prostate cancer TSU-Pr1 cell line using sulforhodamine B(SRB) assay,Confirmatory,15801848.0,
1313,248510,6,2,,103507642,3385,Active,,,12.0,IC50,Antiproliferative activity against human prostate cancer PC-3 cell line by sulforhodamine B assay,Confirmatory,16005217.0,
1314,248531,6,2,,103507642,3385,Active,,,4.9,IC50,Antiproliferative activity against human prostate cancer LNCaP cell line by sulforhodamine B assay,Confirmatory,16005217.0,
1315,248532,6,2,,103507642,3385,Active,,,6.4,IC50,Antiproliferative activity against human prostate cancer PPC-1 cell line by sulforhodamine B assay,Confirmatory,16005217.0,
1316,248548,6,2,,103507642,3385,Active,,,11.9,IC50,Antiproliferative activity against human prostate cancer DU-145 cell line by sulforhodamine B assay,Confirmatory,16005217.0,
1317,248571,6,2,,103507642,3385,Active,,,3.6,IC50,Antiproliferative activity against human prostate cancer TSU-Pr1 cell line by sulforhodamine B assay,Confirmatory,16005217.0,
1318,248849,6,2,,103507642,3385,Active,,,3.6,IC50,Antiproliferative activity was evaluated against human prostate TSU cancer cell lines using the sulforhodamine B (STB) assay,Confirmatory,15454213.0,
1319,248856,6,2,,103507642,3385,Active,,,12.0,IC50,Antiproliferative activity was evaluated against human prostate PC-3 cancer cell lines using the sulforhodamine B (STB) assay,Confirmatory,15454213.0,
1320,248862,6,2,,103507642,3385,Active,,,4.9,IC50,Antiproliferative activity was evaluated against human prostate LNCaP cancer cell lines using the sulforhodamine B (STB) assay,Confirmatory,15454213.0,
1321,248863,6,2,,103507642,3385,Active,,,6.4,IC50,Antiproliferative activity was evaluated against human prostate PPC-1 cancer cell lines using the sulforhodamine B (STB) assay,Confirmatory,15454213.0,
1322,248867,6,2,,103507642,3385,Active,,,11.9,IC50,Antiproliferative activity was evaluated against human prostate DU-145 cancer cell lines using the sulforhodamine B (STB) assay,Confirmatory,15454213.0,
1323,248869,6,2,,103507642,3385,Unspecified,,,65.3,IC50,In vitro inhibitory concentration required against human leukemic HL-60 cell line was determined after 48 hrs of drug exposure using MTT method,Confirmatory,15380199.0,
1324,248915,6,2,,103507642,3385,Unspecified,,,50.5,IC50,In vitro inhibitory concentration required against human lung carcinoma A-549 cell line was determined after 72 hrs of drug exposure using SRB method,Confirmatory,15380199.0,
1325,253445,3,4,,103507642,3385,Unspecified,,,,,Lethal toxicity against mouse tumor sarcoma-180 model after intraperitoneal administration of 75 mg/kg dose expressed as number of deaths out of 20 mice,Other,15808456.0,
1326,253453,3,4,,103507642,3385,Unspecified,,,,,Lethal toxicity in mouse with tumor sarcoma-180 after intraperitoneal (i.p.) injection at a dose of 75 mg/Kg of total 10 tested,Other,15913996.0,
1327,258227,3,4,,103507642,3385,Unspecified,,,,,Cell survival against human breast cancer MCF7 cell line after 72h at 10 uM,Other,16275069.0,
1328,258228,3,4,,103507642,3385,Unspecified,,,,,Cell survival against human breast cancer MDA-MB-231 cell line after 72h at 10 uM,Other,16275069.0,
1329,270650,6,2,,103507642,3385,Active,,,6.1,IC50,Cytotoxicity against rat C6 glioma cell line,Confirmatory,16970409.0,
1330,270651,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against rat astrocytes,Confirmatory,16970409.0,
1331,275251,6,3,,103507642,3385,Active,,,37.0,IC50,Cytotoxicity against SW1116 cells by MTT colometric method,Confirmatory,17253861.0,
1332,276813,3,4,,103507642,3385,Inactive,,,,,Cytotoxicity against HT29 cell line below 2.5 uM,Other,16990003.0,
1333,276814,4,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against HT29 cell line without 4 Gy [60Co]-induced irradiation by MTT assay relative to control,Other,16990003.0,
1334,276815,4,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against 4 Gy [60Co] irradiated HT29 cell line by MTT assay relative to control,Other,16990003.0,
1335,276818,3,4,,103507642,3385,Inactive,,,,,Radiosensitizing activity in 4 Gy [60Co] irradiated HT29 cells,Other,16990003.0,
1336,276881,3,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human Bel7404 cells at 6.25 ug/ml after 18 hrs by MTT assay,Other,16997554.0,
1337,276882,3,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human MCG cells at 6.25 ug/ml after 18 hrs by MTT assay,Other,16997554.0,
1338,276883,3,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human HNE1 cells at 6.25 ug/ml after 18 hrs by MTT assay,Other,16997554.0,
1339,276933,3,3,,103507642,3385,Unspecified,,,,,Decrease in body weight of Ehrlich's ascites carcinoma xenografted Swiss albino mouse at 20 mg/kg,Other,17000104.0,
1340,276934,6,1,,103507642,3385,Unspecified,,,,,Increase in mean survival time of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1341,276935,3,3,,103507642,3385,Unspecified,,,,,Increase in life span of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1342,276936,4,4,,103507642,3385,Unspecified,,,,,Effect on TBARS levels in liver of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg measured per 100 g tissue,Other,17000104.0,
1343,276937,4,4,,103507642,3385,Unspecified,,,,,Effect on hydroperoxide levels in liver of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg measured per 100 g tissue,Other,17000104.0,
1344,276938,4,4,,103507642,3385,Unspecified,,,,,Effect on GSH content in liver of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg measured per 100 g tissue,Other,17000104.0,
1345,276939,6,1,,103507642,3385,Unspecified,,,,,Increase in liver SOD activity of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1346,276940,6,1,,103507642,3385,Unspecified,,,,,Increase in liver catalase activity of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1347,276941,6,1,,103507642,3385,Unspecified,,,,,Increase in liver GST activity of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1348,276942,6,1,,103507642,3385,Unspecified,,,,,Increase in liver glutathione peroxidase activity of Ehrlich's ascites carcinoma xenografted Swiss Albino mouse at 20 mg/kg,Other,17000104.0,
1349,278142,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0176 by checkerboard method,Other,17043122.0,
1350,278143,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 18476 by checkerboard method,Other,17043122.0,
1351,278144,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 285 by checkerboard method,Other,17043122.0,
1352,278145,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 550 by checkerboard method,Other,17043122.0,
1353,278146,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.0673 by checkerboard method,Other,17043122.0,
1354,278147,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 99.1026 by checkerboard method,Other,17043122.0,
1355,278148,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 98.1121 by checkerboard method,Other,17043122.0,
1356,278149,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 276 by checkerboard method,Other,17043122.0,
1357,278150,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 280 by checkerboard method,Other,17043122.0,
1358,278151,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against flucytosine-resistant Cryptococcus neoformans 533 by checkerboard method,Other,17043122.0,
1359,278380,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 by microdilution assay,Other,17060521.0,
1360,278381,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fcy2delta::URA3 by microdilution assay,Other,17060521.0,
1361,278382,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fcy1delta::URA3 by microdilution assay,Other,17060521.0,
1362,278383,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 URA3[D95V] derived null mutant fur1delta::URA3 by microdilution assay,Other,17060521.0,
1363,278384,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 revertant fcy2delta::[FCY2-URA3] by microdilution assay,Other,17060521.0,
1364,278385,6,2,,103507642,3385,Unspecified,,,,,Antifungal activity against Candida lusitaniae 6936 revertant fcy1delta::[FCY1-URA3] by microdilution assay,Other,17060521.0,
1365,280941,6,3,,103507642,3385,Active,,,0.31,IC50,Cytotoxicity against mouse L1210/0 cells after 48 hrs,Confirmatory,17341060.0,
1366,283688,6,2,,103507642,3385,Active,,,0.16,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,17291040.0,
1367,283689,6,3,,103507642,3385,Active,,,23.21,IC50,Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay,Confirmatory,17291040.0,
1368,283690,6,3,,103507642,3385,Active,,,31.16,IC50,Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay,Confirmatory,17291040.0,
1369,283820,6,2,,103507642,3385,Active,,,3.39,IC50,Cytotoxicity against human COLO205 cells,Confirmatory,16996657.0,
1370,283821,6,2,,103507642,3385,Active,,,2.04,IC50,Cytotoxicity against human HCT116 cells,Confirmatory,16996657.0,
1371,283822,6,2,,103507642,3385,Active,,,6.61,IC50,Cytotoxicity against human HCT15 cells,Confirmatory,16996657.0,
1372,283823,6,2,,103507642,3385,Active,,,7.94,IC50,Cytotoxicity against human KM12 cells,Confirmatory,16996657.0,
1373,283824,6,2,,103507642,3385,Active,,,18.6,IC50,Cytotoxicity against human SW620 cells,Confirmatory,16996657.0,
1374,283825,6,2,,103507642,3385,Active,,,5.75,IC50,Cytotoxicity against human HCC2998 cells,Confirmatory,16996657.0,
1375,283826,6,2,,103507642,3385,Unspecified,,,126.0,IC50,Cytotoxicity against human K562 cells,Confirmatory,16996657.0,
1376,283827,6,3,,103507642,3385,Active,,,3.55,IC50,Cytotoxicity against human RPMI8226 cells,Confirmatory,16996657.0,
1377,283828,6,3,,103507642,3385,Unspecified,,,85.1,IC50,Cytotoxicity against human HL60 (TB) cells,Confirmatory,16996657.0,
1378,283829,6,2,,103507642,3385,Unspecified,,,60.3,IC50,Cytotoxicity against human SR cells,Confirmatory,16996657.0,
1379,283831,6,2,,103507642,3385,Unspecified,,,29.5,IC50,Cytotoxicity against human NCI49 cell lines,Confirmatory,16996657.0,
1380,286399,6,2,,103507642,3385,Unspecified,,,300.0,IC50,Growth inhibition in WS1 cells assessed as inhibition of [3H]thymidine incorporation,Confirmatory,17411027.0,
1381,286400,6,2,,103507642,3385,Unspecified,,,300.0,IC50,Growth inhibition in HCT116 cells assessed as inhibition of [3H]thymidine incorporation,Confirmatory,17411027.0,
1382,286401,6,2,,103507642,3385,Unspecified,,,300.0,IC50,Growth inhibition in HCT15 cells assessed as inhibition of [3H]thymidine incorporation,Confirmatory,17411027.0,
1383,287091,6,2,,103507642,3385,Active,,,13.4,IC50,Cytotoxicity against human KB cells after 48 hrs,Confirmatory,17000031.0,
1384,287875,6,2,,103507642,3385,Unspecified,,,3843.8,CC50,Cytotoxicity against human H4 cells after 72 hrs,Confirmatory,17337193.0,
1385,287876,6,2,,103507642,3385,Unspecified,,,384.4,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,17337193.0,
1386,287877,6,2,,103507642,3385,Active,,,46.1,CC50,Cytotoxicity against human skin melanoma cells after 72 hrs,Confirmatory,17337193.0,
1387,287878,6,2,,103507642,3385,Unspecified,,,768.8,CC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,17337193.0,
1388,287879,3,4,,103507642,3385,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human H4 cells to CC50 for human Caco-2 cells",Other,17337193.0,
1389,287880,3,4,,103507642,3385,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human H4 cells to CC50 for human skin melanoma cells",Other,17337193.0,
1390,287881,3,4,,103507642,3385,Unspecified,,,,,"Selectivity index, Ratio of CC50 for human H4 cells to CC50 for human MCF7 cells",Other,17337193.0,
1391,287882,6,2,,103507642,3385,Active,,,1.5,IC50,Growth inhibition of human Caco-2 cells after 10 days,Confirmatory,17337193.0,
1392,288214,5,2,,103507642,3385,Active,,,31.6228,GI50,Antitumor activity against human CCRF-CEM cells,Confirmatory,17446077.0,
1393,288215,5,3,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human HL60 (TB) cells,Confirmatory,17446077.0,
1394,288216,5,2,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human K562 cells,Confirmatory,17446077.0,
1395,288217,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human MOLT4 cells,Confirmatory,17446077.0,
1396,288218,5,3,,103507642,3385,Active,,,5.01187,GI50,Antitumor activity against human RPMI8226 cells,Confirmatory,17446077.0,
1397,288219,5,2,,103507642,3385,Active,,,3.98107,GI50,Antitumor activity against human SR cells,Confirmatory,17446077.0,
1398,288220,5,2,,103507642,3385,Active,,,1.9952599999999998,GI50,Antitumor activity against human A549 cells,Confirmatory,17446077.0,
1399,288221,5,2,,103507642,3385,Unspecified,,,316.228,GI50,Antitumor activity against human EKVX cells,Confirmatory,17446077.0,
1400,288222,5,2,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human HOP62 cells,Confirmatory,17446077.0,
1401,288223,5,2,,103507642,3385,Unspecified,,,158.489,GI50,Antitumor activity against human HOP92 cells,Confirmatory,17446077.0,
1402,288224,5,2,,103507642,3385,Unspecified,,,251.18900000000002,GI50,Antitumor activity against human NCI-H226 cells,Confirmatory,17446077.0,
1403,288225,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human NCI-H23 cells,Confirmatory,17446077.0,
1404,288226,5,3,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human NCI-H322 cells,Confirmatory,17446077.0,
1405,288227,5,2,,103507642,3385,Active,,,1.0,GI50,Antitumor activity against human NCI-H460 cells,Confirmatory,17446077.0,
1406,288228,5,2,,103507642,3385,Active,,,39.8107,GI50,Antitumor activity against human NCI-H522 cells,Confirmatory,17446077.0,
1407,288229,5,2,,103507642,3385,Active,,,6.30957,GI50,Antitumor activity against human COLO205 cells,Confirmatory,17446077.0,
1408,288230,5,2,,103507642,3385,Active,,,1.58489,GI50,Antitumor activity against human HCC2998 cells,Confirmatory,17446077.0,
1409,288231,5,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Antitumor activity against human HCT116 cells,Confirmatory,17446077.0,
1410,288232,5,2,,103507642,3385,Active,,,6.30957,GI50,Antitumor activity against human HCT15 cells,Confirmatory,17446077.0,
1411,288233,5,2,,103507642,3385,Active,,,6.30957,GI50,Antitumor activity against human HT29 cells,Confirmatory,17446077.0,
1412,288234,5,2,,103507642,3385,Active,,,10.0,GI50,Antitumor activity against human KM12 cells,Confirmatory,17446077.0,
1413,288235,5,2,,103507642,3385,Active,,,25.1189,GI50,Antitumor activity against human SW620 cells,Confirmatory,17446077.0,
1414,288236,5,2,,103507642,3385,Unspecified,,,50.1187,GI50,Antitumor activity against human SF268 cells,Confirmatory,17446077.0,
1415,288237,5,2,,103507642,3385,Unspecified,,,50.1187,GI50,Antitumor activity against human SF295 cells,Confirmatory,17446077.0,
1416,288238,5,2,,103507642,3385,Active,,,1.2589299999999999,GI50,Antitumor activity against human SF539 cells,Confirmatory,17446077.0,
1417,288239,5,2,,103507642,3385,Unspecified,,,125.89299999999999,GI50,Antitumor activity against human SNB19 cells,Confirmatory,17446077.0,
1418,288240,5,2,,103507642,3385,Unspecified,,,199.52599999999998,GI50,Antitumor activity against human SNB75 cells,Confirmatory,17446077.0,
1419,288241,5,2,,103507642,3385,Active,,,39.8107,GI50,Antitumor activity against human U251 cells,Confirmatory,17446077.0,
1420,288242,5,2,,103507642,3385,Active,,,6.30957,GI50,Antitumor activity against human LOX IMVI cells,Confirmatory,17446077.0,
1421,288243,5,2,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human MALME-3M cells,Confirmatory,17446077.0,
1422,288244,5,2,,103507642,3385,Unspecified,,,50.1187,GI50,Antitumor activity against human SK-MEL-28 cells,Confirmatory,17446077.0,
1423,288245,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human SK-MEL-5 cells,Confirmatory,17446077.0,
1424,288246,5,2,,103507642,3385,Unspecified,,,100.0,GI50,Antitumor activity against human UACC257 cells,Confirmatory,17446077.0,
1425,288247,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human UACC62 cells,Confirmatory,17446077.0,
1426,288248,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human IGROV1 cells,Confirmatory,17446077.0,
1427,288249,5,2,,103507642,3385,Active,,,25.1189,GI50,Antitumor activity against human OVCAR-3 cells,Confirmatory,17446077.0,
1428,288250,5,2,,103507642,3385,Unspecified,,,63.0957,GI50,Antitumor activity against human OVCAR4 cells,Confirmatory,17446077.0,
1429,288251,5,2,,103507642,3385,Unspecified,,,158.489,GI50,Antitumor activity against human OVCAR5 cells,Confirmatory,17446077.0,
1430,288252,5,2,,103507642,3385,Active,,,19.9526,GI50,Antitumor activity against human OVCAR8 cells,Confirmatory,17446077.0,
1431,288253,5,2,,103507642,3385,Unspecified,,,158.489,GI50,Antitumor activity against human SK-OV-3 cells,Confirmatory,17446077.0,
1432,288254,5,2,,103507642,3385,Active,,,12.5892,GI50,Antitumor activity against human 786-0 cells,Confirmatory,17446077.0,
1433,288255,5,2,,103507642,3385,Active,,,10.0,GI50,Antitumor activity against human A498 cells,Confirmatory,17446077.0,
1434,288256,5,2,,103507642,3385,Active,,,10.0,GI50,Antitumor activity against human ACHN cells,Confirmatory,17446077.0,
1435,288257,5,2,,103507642,3385,Active,,,3.98107,GI50,Antitumor activity against human CAKI-1 cells,Confirmatory,17446077.0,
1436,288258,5,3,,103507642,3385,Unspecified,,,50.1187,GI50,Antitumor activity against human RXF393 cells,Confirmatory,17446077.0,
1437,288259,5,2,,103507642,3385,Active,,,25.1189,GI50,Antitumor activity against human SN12C cells,Confirmatory,17446077.0,
1438,288260,5,2,,103507642,3385,Unspecified,,,125.89299999999999,GI50,Antitumor activity against human TK10 cells,Confirmatory,17446077.0,
1439,288261,5,2,,103507642,3385,Active,,,5.01187,GI50,Antitumor activity against human UO31 cells,Confirmatory,17446077.0,
1440,288262,5,2,,103507642,3385,Unspecified,,,50.1187,GI50,Antitumor activity against human PC3 cells,Confirmatory,17446077.0,
1441,288263,5,2,,103507642,3385,Active,,,10.0,GI50,Antitumor activity against human DU145 cells,Confirmatory,17446077.0,
1442,288264,5,2,,103507642,3385,Active,,,1.58489,GI50,Antitumor activity against human MCF7 cells,Confirmatory,17446077.0,
1443,288265,5,2,,103507642,3385,Active,,,39.8107,GI50,Antitumor activity against human NCI/ADR-RES cells,Confirmatory,17446077.0,
1444,288266,5,2,,103507642,3385,Unspecified,,,501.18699999999995,GI50,Antitumor activity against human MDA-MB-2321/ATCC cells,Confirmatory,17446077.0,
1445,288267,5,3,,103507642,3385,Unspecified,,,251.18900000000002,GI50,Antitumor activity against human HS 578T cells,Confirmatory,17446077.0,
1446,288268,5,2,,103507642,3385,Active,,,10.0,GI50,Antitumor activity against human MDA-MB-435 cells,Confirmatory,17446077.0,
1447,288269,5,2,,103507642,3385,Unspecified,,,100.0,GI50,Antitumor activity against human BT549 cells,Confirmatory,17446077.0,
1448,292432,6,2,,103507642,3385,Active,,,9.2,IC50,Cytotoxicity against A549 cells after 48 hrs by MTT assay,Confirmatory,17604394.0,
1449,292433,6,3,,103507642,3385,Unspecified,,,51.0,IC50,Cytotoxicity against SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,17604394.0,
1450,292434,6,2,,103507642,3385,Unspecified,,,370.0,IC50,Cytotoxicity against AGS cells after 48 hrs by MTT assay,Confirmatory,17604394.0,
1451,292435,6,2,,103507642,3385,Unspecified,,,540.0,IC50,Cytotoxicity against HT29 cells after 48 hrs by MTT assay,Confirmatory,17604394.0,
1452,292954,6,2,,103507642,3385,Active,,,7.3,IC50,Antiproliferative activity against HT29 cells,Confirmatory,17110105.0,
1453,293356,3,4,,103507642,3385,Unspecified,,,,,"Toxicity in mouse implanted with S180 cells at 50 mg/kg, ip after 2 days",Other,17174089.0,
1454,293362,3,4,,103507642,3385,Unspecified,,,,,"Effect on body weight in mouse implanted with S180 cells at 50 mg/kg, ip after 2 days",Other,17174089.0,
1455,293368,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity in mouse implanted with S180 cells at 50 mg/kg, ip after 2 days",Other,17174089.0,
1456,293618,6,2,,103507642,3385,Active,,,0.2,IC50,Cytotoxicity against Vero cells,Confirmatory,17234303.0,
1457,293714,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of DLA cells at 62.5 ug/mL after 3 hrs,Other,17239491.0,
1458,293715,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of DLA cells at 31.25 ug/mL after 3 hrs,Other,17239491.0,
1459,293716,6,2,,103507642,3385,Active,,,37.36,CC50,Growth inhibition of DLA cells after 3 hrs,Confirmatory,17239491.0,
1460,293717,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of EAC cells at 500 ug/mL after 3 hrs,Other,17239491.0,
1461,293718,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of EAC cells at 250 ug/mL after 3 hrs,Other,17239491.0,
1462,293722,6,2,,103507642,3385,Unspecified,,,90.55,CC50,Growth inhibition of EAC cells after 3 hrs,Confirmatory,17239491.0,
1463,293723,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of DLA cells at 15.63 ug/mL after 3 hrs,Other,17239491.0,
1464,293724,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of DLA cells at 7.81 ug/mL after 3 hrs,Other,17239491.0,
1465,293725,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of DLA cells at 3.91 ug/mL after 3 hrs,Other,17239491.0,
1466,293726,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of EAC cells at 15.63 ug/mL after 3 hrs,Other,17239491.0,
1467,293727,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of EAC cells at 7.81 ug/mL after 3 hrs,Other,17239491.0,
1468,293728,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of EAC cells at 3.91 ug/mL after 3 hrs,Other,17239491.0,
1469,294568,6,2,,103507642,3385,Active,,,3.1,IC50,Cytotoxicity against human A549 cells by MTT microassay,Confirmatory,17320246.0,
1470,294569,6,3,,103507642,3385,Active,,,0.6,IC50,Cytotoxicity against human Hep 3B cells by MTT microassay,Confirmatory,17320246.0,
1471,294570,6,2,,103507642,3385,Active,,,0.6,IC50,Cytotoxicity against human HT29 cells by MTT microassay,Confirmatory,17320246.0,
1472,294571,6,2,,103507642,3385,Active,,,1.5,IC50,Cytotoxicity against human MCF7 cells by MTT microassay,Confirmatory,17320246.0,
1473,299973,6,3,,103507642,3385,Active,,,18.6,IC50,Antiproliferative activity against human HCCLM7 cells after 72 hrs by MTT method,Confirmatory,17524655.0,
1474,299974,6,3,,103507642,3385,Unspecified,,,128.7,IC50,Antiproliferative activity against human Hep2 cells after 72 hrs by MTT method,Confirmatory,17524655.0,
1475,299975,6,3,,103507642,3385,Active,,,14.5,IC50,Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT method,Confirmatory,17524655.0,
1476,299976,6,2,,103507642,3385,Active,,,8.1,IC50,Antiproliferative activity against human SW480 cells after 72 hrs by MTT method,Confirmatory,17524655.0,
1477,300115,6,2,,103507642,3385,Active,,,0.3,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs,Confirmatory,17548198.0,
1478,300116,6,3,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against human Mes-sa cells after 72 hrs,Confirmatory,17548198.0,
1479,300117,6,2,,103507642,3385,Active,,,2.8,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs,Confirmatory,17548198.0,
1480,300118,6,2,,103507642,3385,Active,,,5.3,IC50,Antiproliferative activity against human SW48 cells after 72 hrs,Confirmatory,17548198.0,
1481,300119,6,2,,103507642,3385,Active,,,3.5,IC50,Antiproliferative activity against human SW480 cells after 72 hrs,Confirmatory,17548198.0,
1482,300145,6,2,,103507642,3385,Active,,,4.5,IC50,Growth inhibition of human DLD1 cells,Confirmatory,17553685.0,
1483,300154,6,2,,103507642,3385,Unspecified,,,3843.8,CC50,Cytotoxicity against human H4 cells after 72 hrs,Confirmatory,17555969.0,
1484,300155,6,2,,103507642,3385,Unspecified,,,384.4,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,17555969.0,
1485,300156,6,3,,103507642,3385,Unspecified,,,230.6,CC50,Cytotoxicity against rhesus monkey MA104 cells after 72 hrs,Confirmatory,17555969.0,
1486,300157,3,4,,103507642,3385,Unspecified,,,,,"Tumor selectivity index, ratio of CC50 for human H4 cells to CC50 for human Caco-2 cells",Other,17555969.0,
1487,300158,3,4,,103507642,3385,Unspecified,,,,,"Tumor selectivity index, ratio of CC50 for human H4 cells to CC50 for rhesus monkey MA104 cells",Other,17555969.0,
1488,300159,6,2,,103507642,3385,Active,,,1.5,IC50,Growth inhibition of human Caco-2 cells after 10 days,Confirmatory,17555969.0,
1489,300178,6,3,,103507642,3385,Active,,,5.75,GI50,Cytotoxicity against human colon cancer cells,Confirmatory,17562365.0,
1490,300179,6,3,,103507642,3385,Unspecified,,,52.5,GI50,Cytotoxicity against human leukemia cells,Confirmatory,17562365.0,
1491,303280,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 50 uM after 48 hrs,Other,17950603.0,
1492,303281,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells at 50 uM after 48 hrs,Other,17950603.0,
1493,303282,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells at 50 uM after 48 hrs,Other,17950603.0,
1494,303283,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human 502713 cells at 50 uM after 48 hrs,Other,17950603.0,
1495,303284,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT29 cells at 50 uM after 48 hrs,Other,17950603.0,
1496,306342,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity in B16 cells xenografted ICR mouse assessed as tumor weight at 25 mg/kg, iv after 11 days",Other,17275295.0,
1497,306343,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity in B16 cells xenografted ICR mouse assessed as tumor growth inhibition at 25 mg/kg, iv after 11 days",Other,17275295.0,
1498,306767,6,2,,103507642,3385,Active,,,4.8,IC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,17336074.0,
1499,306768,6,2,,103507642,3385,Active,,,9.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs,Confirmatory,17336074.0,
1500,307357,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against Ehrlich ascites carcinoma cells in mouse assessed as increase in life span at 20 mg/kg relative to control,Other,17428583.0,
1501,307358,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against Ehrlich ascites carcinoma cells in mouse assessed as haemoglobin level at 20 mg/kg after 14 days,Other,17428583.0,
1502,307359,6,1,,103507642,3385,Unspecified,,,,,Antitumor activity against Ehrlich ascites carcinoma cells in mouse assessed as RBC count at 20 mg/kg after 14 days,Other,17428583.0,
1503,307360,8,1,,103507642,3385,Unspecified,,,,,Antitumor activity against Ehrlich ascites carcinoma cells in mouse assessed as WBC count at 20 mg/kg after 14 days,Other,17428583.0,
1504,307361,7,1,,103507642,3385,Unspecified,,,,,Antitumor activity against Ehrlich ascites carcinoma cells in mouse assessed as cell viability at 20 mg/kg after 5 days,Other,17428583.0,
1505,310284,6,2,,103507642,3385,Active,,,0.28,IC50,Cytostatic activity against mouse L1210 cells,Confirmatory,17931862.0,
1506,310285,6,3,,103507642,3385,Active,,,23.0,IC50,Cytostatic activity against human Molt4/C8 cells,Confirmatory,17931862.0,
1507,310286,6,2,,103507642,3385,Active,,,9.0,IC50,Cytostatic activity against human CEM cells,Confirmatory,17931862.0,
1508,311367,3,6,,103507642,3385,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
1509,313354,7,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PANC1 cells in nutrient deprived medium after 24 hrs,Other,17950610.0,
1510,321274,6,2,,103507642,3385,Active,,,4.32,IC50,Antiproliferative activity against human MCF7 cells,Confirmatory,18194866.0,
1511,328146,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,18205316.0,
1512,328147,6,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Bel 7402 cells by MTT assay,Other,18205316.0,
1513,328148,6,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human BGC 823 cells by MTT assay,Other,18205316.0,
1514,328149,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT8 cells by MTT assay,Other,18205316.0,
1515,328150,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A2780 cells by MTT assay,Other,18205316.0,
1516,332843,3,5,,103507642,3385,Unspecified,,,,,In vivo antitumor activity against mouse P388 cells at 200 mg/kg after 1 day,Other,3760882.0,
1517,332898,3,5,,103507642,3385,Unspecified,,,,,Antileukemic activity against mouse P388 cells xenografted in mouse at 200 mg/kg dosed for 1 day relative to control,Other,3572419.0,
1518,333151,6,2,,103507642,3385,Active,,,7.38,IC50,Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay,Confirmatory,15387639.0,
1519,333152,6,2,,103507642,3385,Active,,,4.93,IC50,Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay,Confirmatory,15387639.0,
1520,333277,6,3,,103507642,3385,Active,,,5.4,IC50,Cytotoxicity against human HeLaS3 cells after 72 hrs by WST1 assay,Confirmatory,15387656.0,
1521,333513,6,3,,103507642,3385,Active,,,5.4,IC50,Cytotoxicity against human HeLaS3 cells by WST1 assay,Confirmatory,15568771.0,
1522,334275,6,3,,103507642,3385,Active,,,1.23,EC50,Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay,Confirmatory,12027739.0,
1523,334276,6,2,,103507642,3385,Active,,,1.38,EC50,Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,12027739.0,
1524,334277,6,2,,103507642,3385,Active,,,3.61,EC50,Antiproliferative activity against human A549 cells after 72 hrs by MTT assay,Confirmatory,12027739.0,
1525,334278,6,2,,103507642,3385,Active,,,0.23,EC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,12027739.0,
1526,334279,6,3,,103507642,3385,Active,,,0.31,EC50,Antiproliferative activity against mouse 26-L5 cells after 72 hrs by MTT assay,Confirmatory,12027739.0,
1527,334375,2,5,,103507642,3385,Active,,,,,Cytotoxicity against mouse P388 cells at 0.1 ug,Other,,
1528,337079,4,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 cells xenografted ICR/kwl mouse assessed as increase in mouse life span at 5 mg/kg, ip relative to control",Other,12662110.0,
1529,337080,4,4,,103507642,3385,Active,,,,,"Antitumor activity against mouse S180 cells xenografted ICR/kwl mouse assessed as increase in mouse life span at 10 mg/kg, ip relative to control",Other,12662110.0,
1530,337691,3,5,,103507642,3385,Unspecified,,,,,In vivo antitumor activity against mouse P388 cells at 200 mg/kg in 1 day dosing schedule relative to control,Other,3841557.0,
1531,338340,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,3443857.0,
1532,338341,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse L1210 cells,Other,3443857.0,
1533,338641,11,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against mouse 212 cells by MTT assay,Other,11908984.0,
1534,338642,9,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human CaSKi cells by MTT assay,Other,11908984.0,
1535,338643,11,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,11908984.0,
1536,338644,11,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human SiHa cells by MTT assay,Other,11908984.0,
1537,338645,11,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,11908984.0,
1538,338646,11,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,11908984.0,
1539,338647,10,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT116 cells by MTT assay,Other,11908984.0,
1540,338648,8,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,11908984.0,
1541,338649,9,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human MCF7-ras cells by MTT assay,Other,11908984.0,
1542,338731,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1543,338732,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1544,338733,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1545,338734,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1546,338735,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1547,338736,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MB9812 cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1548,338738,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human EH118MG cells after 3 days by trypan blue exclusion technique,Other,1800632.0,
1549,341664,6,2,,103507642,3385,Active,,,1.5,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,18606546.0,
1550,341665,6,2,,103507642,3385,Active,,,3.1,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,18606546.0,
1551,341666,6,3,,103507642,3385,Active,,,0.6,IC50,Cytotoxicity against human Hep3B cells by MTT assay,Confirmatory,18606546.0,
1552,341667,6,2,,103507642,3385,Active,,,0.6,IC50,Cytotoxicity against human HT29 cells by MTT assay,Confirmatory,18606546.0,
1553,344136,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity in mouse sarcoma 180 cells transplanted in Kunming mouse assessed as inhibition of tumor weight at 20 mg/kg, ip after 7 days relative to control",Other,18539036.0,
1554,345166,3,4,,103507642,3385,Unspecified,,,,,"Antimetastatic activity in mouse EAC cells xenografted in NMRI mouse assessed as metastatic colony formation in lungs at 20 mg/kg, ip daily for 9 days relative to control",Other,18951805.0,
1555,351820,6,2,,103507642,3385,Active,,,17.7,GI50,Growth inhibition of human NCI60 cells,Confirmatory,19398334.0,
1556,352122,6,2,,103507642,3385,Active,,,4.0,IC50,Growth inhibition of human HeLa cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1557,352123,6,2,,103507642,3385,Active,,,10.0,IC50,Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1558,352124,6,2,,103507642,3385,Active,,,9.0,IC50,Growth inhibition of human SW620 cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1559,352125,6,2,,103507642,3385,Active,,,15.0,IC50,Growth inhibition of human MCF7 cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1560,352126,6,2,,103507642,3385,Active,,,2.0,IC50,Growth inhibition of human H460 cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1561,352127,6,2,,103507642,3385,Active,,,0.4,IC50,Growth inhibition of human HaCaT cells after 72 hrs by MTT assay,Confirmatory,18640746.0,
1562,352140,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry,Other,18640746.0,
1563,352141,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 10 uM after 72 hrs by flow cytometry,Other,18640746.0,
1564,352142,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 10 uM after 48 hrs by flow cytometry,Other,18640746.0,
1565,352143,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry,Other,18640746.0,
1566,352144,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 10 uM after 72 hrs by flow cytometry,Other,18640746.0,
1567,352145,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by flow cytometry,Other,18640746.0,
1568,352146,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry,Other,18640746.0,
1569,352308,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at subG1 phase at 10 uM after 72 hrs by flow cytometry,Other,18640746.0,
1570,352309,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at subG1 phase at 10 uM after 48 hrs by flow cytometry,Other,18640746.0,
1571,352310,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at subG1 phase at 10 uM after 24 hrs by flow cytometry,Other,18640746.0,
1572,352311,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by flow cytometry,Other,18640746.0,
1573,352312,3,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 10 uM after 72 hrs by flow cytometry,Other,18640746.0,
1574,353084,8,1,,103507642,3385,Active,,,0.00446,IC50,Cytotoxicity against human KB cells by MTT assay,Confirmatory,19345581.0,
1575,355578,9,1,,103507642,3385,Active,,,0.69,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
1576,355579,3,5,,103507642,3385,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1577,355580,3,5,,103507642,3385,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1578,355581,3,5,,103507642,3385,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1579,355582,3,5,,103507642,3385,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1580,355583,9,1,,103507642,3385,Active,,,0.609,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
1581,355584,3,5,,103507642,3385,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1582,355585,3,5,,103507642,3385,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1583,355586,3,5,,103507642,3385,Inactive,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1584,355631,3,5,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse L1210 cells at 1.5 ug/disk by corbett disk diffusion assay,Other,2809606.0,
1585,355637,3,6,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse C38 cells at 1.5 ug/disk by corbett disk diffusion assay,Other,2809606.0,
1586,355811,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of Xenopus laevis blastular stage cells at 10 ug/mL,Other,12762796.0,
1587,356211,5,1,,103507642,3385,Unspecified,,,,,Antimicrobial activity against Pyricularia oryzae P-2b assessed as drug concentration causing minimum morphological deformation,Other,12932123.0,
1588,356599,4,4,,103507642,3385,Active,,,3.7,IC50,Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,14640513.0,
1589,356692,8,1,,103507642,3385,Active,,,0.53,ED50,Cytotoxicity against mouse 26-L5 cells by MTT assay,Confirmatory,11430002.0,
1590,356693,8,1,,103507642,3385,Active,,,8.0,ED50,Cytotoxicity against human HT1080 cells by MTT assay,Confirmatory,11430002.0,
1591,357233,5,1,,103507642,3385,Unspecified,,,,,Growth inhibition of mouse P388 cells,Other,12502333.0,
1592,357611,6,3,,103507642,3385,Active,,,0.5,IC50,Antiproliferative activity against mouse Colon 26-L5 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,11575942.0,
1593,357612,6,2,,103507642,3385,Active,,,1.5,IC50,Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,11575942.0,
1594,357613,6,3,,103507642,3385,Active,,,0.6,IC50,Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay,Confirmatory,11575942.0,
1595,357843,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,1812210.0,
1596,358852,8,1,,103507642,3385,Active,,,0.5,ED50,Antiproliferative activity against mouse Colon 26-L5 cells by MTT assay,Confirmatory,11277741.0,
1597,358853,8,1,,103507642,3385,Active,,,8.0,ED50,Antiproliferative activity against human HT1080 cells by MTT assay,Confirmatory,11277741.0,
1598,358967,8,1,,103507642,3385,Active,,,44.0,ED50,Cytotoxicity against human A431 cells by MTT assay,Confirmatory,12027771.0,
1599,359692,8,1,,103507642,3385,Active,,,0.53,ED50,Antiproliferative activity against mouse Colon 26-L5 cells by MTT assay,Confirmatory,11325233.0,
1600,359693,8,1,,103507642,3385,Active,,,8.0,ED50,Antiproliferative activity against human HT1080 cells by MTT assay,Confirmatory,11325233.0,
1601,360002,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay,Other,11374943.0,
1602,360003,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay,Other,11374943.0,
1603,360004,7,2,,103507642,3385,Inactive,,,,,Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay,Other,11374943.0,
1604,360005,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay,Other,11374943.0,
1605,360319,5,1,,103507642,3385,Unspecified,,,,,Antiproliferative activity against mouse Colon 26-L5 cells after 4 days by MTT assay,Other,11374950.0,
1606,360320,5,1,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human HT1080 cells after 4 days by MTT assay,Other,11374950.0,
1607,360496,6,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,8594149.0,
1608,361437,6,2,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human HT1080 cells by MTT assay,Other,12444707.0,
1609,361438,6,3,,103507642,3385,Unspecified,,,,,Antiproliferative activity against mouse Colon 26-L5 cells by MTT assay,Other,12444707.0,
1610,363849,6,2,,103507642,3385,Unspecified,,,3843.8,CC50,Cytotoxicity against human H4 cells after 72 hrs,Confirmatory,18037195.0,
1611,363851,6,2,,103507642,3385,Unspecified,,,384.4,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,18037195.0,
1612,363852,6,3,,103507642,3385,Active,,,46.1,CC50,Cytotoxicity against human melanoma cells after 72 hrs,Confirmatory,18037195.0,
1613,363853,6,2,,103507642,3385,Unspecified,,,768.8,CC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,18037195.0,
1614,363854,6,2,,103507642,3385,Active,,,10.0,CC50,"Tumor selectivity index, ratio of CC50 for human H4 cells to CC50 for human Caco-2 cells",Confirmatory,18037195.0,
1615,363855,6,2,,103507642,3385,Unspecified,,,83.4,CC50,"Tumor selectivity index, ratio of CC50 for human H4 cells to CC50 for human melanoma cells",Confirmatory,18037195.0,
1616,363856,6,2,,103507642,3385,Active,,,5.0,CC50,"Tumor selectivity index, ratio of CC50 for human H4 cells to CC50 for human MCF7 cells",Confirmatory,18037195.0,
1617,363857,6,2,,103507642,3385,Active,,,1.5,IC50,Growth inhibition of human Caco-2 cells after 10 days,Confirmatory,18037195.0,
1618,365415,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1619,365419,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HOP62 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1620,365423,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1621,365427,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human COLO205 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1622,365431,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human IGROV1 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1623,365435,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SKOV3 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1624,365439,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1625,365443,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HEP2 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1626,365447,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF295 cells assessed as age growth inhibition at 20 uM after 48 hrs by sulforhodamine B assay,Other,18707881.0,
1627,366665,6,2,,103507642,3385,Active,,,10.85,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,18644718.0,
1628,366666,6,3,,103507642,3385,Active,,,16.35,IC50,Cytotoxicity against human BGC-7901 cells by MTT assay,Confirmatory,18644718.0,
1629,366667,6,2,,103507642,3385,Active,,,13.16,IC50,Cytotoxicity against human SW480 cells by MTT assay,Confirmatory,18644718.0,
1630,366668,6,2,,103507642,3385,Active,,,21.38,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,18644718.0,
1631,366669,6,3,,103507642,3385,Active,,,14.41,IC50,Cytotoxicity against human BEL-7402 cells by MTT assay,Confirmatory,18644718.0,
1632,366670,6,2,,103507642,3385,Active,,,8.73,IC50,Cytotoxicity against mouse B16 cells by MTT assay,Confirmatory,18644718.0,
1633,366673,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity in mouse B16 cell xenografted mouse at 20 mg/kg/day, iv after 4 days",Other,18644718.0,
1634,371507,6,2,,103507642,3385,Active,,,4.32,IC50,Antiproliferative activity against human MCF7 cells after 3 days by SRB assay,Confirmatory,18069093.0,
1635,375443,6,3,,103507642,3385,Unspecified,,,53.2,EC50,Cytotoxicity against human 1321N1 cells after 72 hrs to 144 hrs by MTT assay,Confirmatory,19463000.0,
1636,375444,6,3,,103507642,3385,Active,,,5.71,EC50,Cytotoxicity against human 1539 cells after 72 hrs to 144 hrs by MTT assay,Confirmatory,19463000.0,
1637,376373,6,2,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells,Other,10579858.0,
1638,376374,6,2,,103507642,3385,Unspecified,,,,,Antitumor activity against human A549 cells,Other,10579858.0,
1639,376375,6,2,,103507642,3385,Unspecified,,,,,Antitumor activity against human HT-29 cells,Other,10579858.0,
1640,376376,6,3,,103507642,3385,Unspecified,,,,,Antitumor activity against human SK MEL28 cells,Other,10579858.0,
1641,378628,10,1,,103507642,3385,Active,,,8.0,ED50,"Cytotoxicity against human HT1080 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide assay",Confirmatory,11141109.0,
1642,378805,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,17067147.0,
1643,379167,5,1,,103507642,3385,Unspecified,,,,,Antimicrobial activity against Pseudomonas oryzae,Other,17067169.0,
1644,379418,9,1,,103507642,3385,Active,,,4.2,IC50,Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay,Confirmatory,16499317.0,
1645,379419,9,2,,103507642,3385,Active,,,5.4,IC50,Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay,Confirmatory,16499317.0,
1646,379420,9,2,,103507642,3385,Active,,,4.2,IC50,Cytotoxicity against human BEL-7402 cells after 96 hrs by MTT assay,Confirmatory,16499317.0,
1647,379421,9,1,,103507642,3385,Active,,,5.0,IC50,Cytotoxicity against human A2780 cells after 96 hrs by MTT assay,Confirmatory,16499317.0,
1648,379422,9,1,,103507642,3385,Active,,,1.4,IC50,Cytotoxicity against human A549 cells after 96 hrs by MTT assay,Confirmatory,16499317.0,
1649,379770,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,16499328.0,
1650,380107,6,2,,103507642,3385,Unspecified,,,,,Growth inhibition of mouse P388 cells,Other,16562827.0,
1651,380585,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human KB cells,Other,10425135.0,
1652,380586,6,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa S3 cells,Other,10425135.0,
1653,382984,6,2,,103507642,3385,Unspecified,,,3843.8,CC50,Cytotoxicity against human H4 cells after 72 hrs,Confirmatory,17548129.0,
1654,382985,6,2,,103507642,3385,Unspecified,,,384.4,CC50,Cytotoxicity against human Caco-2 cells after 72 hrs,Confirmatory,17548129.0,
1655,382986,6,2,,103507642,3385,Unspecified,,,768.8,CC50,Cytotoxicity against human MCF7 cells after 72 hrs,Confirmatory,17548129.0,
1656,382987,6,3,,103507642,3385,Active,,,46.1,CC50,Cytotoxicity against human melanoma cells after 72 hrs,Confirmatory,17548129.0,
1657,382988,3,4,,103507642,3385,Unspecified,,,,,"Tumor selectivity index, CC50 for human H4 cells to CC50 for human Caco-2 cells",Other,17548129.0,
1658,382989,3,4,,103507642,3385,Unspecified,,,,,"Tumor selectivity index, CC50 for human H4 cells to CC50 for human melanoma cells",Other,17548129.0,
1659,382990,3,4,,103507642,3385,Unspecified,,,,,"Tumor selectivity index, CC50 for human H4 cells to CC50 for human MCF7 cells",Other,17548129.0,
1660,382991,6,2,,103507642,3385,Active,,,1.5,IC50,Growth inhibition of human Caco-2 cells,Confirmatory,17548129.0,
1661,385110,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of embryonic cells of stage 8 Xenopus laevis blastulae at 10 ug/mL,Other,18271558.0,
1662,385111,6,2,,103507642,3385,Active,,,26.8,IC50,Induction of cleavage arrest in embryonic cells of stage 8 Xenopus laevis blastulae,Confirmatory,18271558.0,
1663,385359,6,2,,103507642,3385,Active,,,18.7,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,18302336.0,
1664,386623,4,8,,103507642,3385,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1665,391017,6,3,,103507642,3385,Active,,,1.54,GI50,Cytotoxicity against BALB mouse 3T3 cells after 48 hrs,Confirmatory,18798609.0,
1666,391018,6,2,,103507642,3385,Active,,,4.1,GI50,Cytotoxicity against human H460 cells after 48 hrs,Confirmatory,18798609.0,
1667,391019,6,2,,103507642,3385,Active,,,15.4,GI50,Cytotoxicity against human DU145 cells after 48 hrs,Confirmatory,18798609.0,
1668,391020,6,2,,103507642,3385,Active,,,6.5,GI50,Cytotoxicity against human MCF7 cells after 48 hrs,Confirmatory,18798609.0,
1669,391021,6,2,,103507642,3385,Active,,,22.4,GI50,Cytotoxicity against human M14 cells after 48 hrs,Confirmatory,18798609.0,
1670,391022,6,2,,103507642,3385,Active,,,8.9,GI50,Cytotoxicity against human HT29 cells after 48 hrs,Confirmatory,18798609.0,
1671,391023,6,2,,103507642,3385,Active,,,14.6,GI50,Cytotoxicity against human PC3 cells after 48 hrs,Confirmatory,18798609.0,
1672,391024,6,2,,103507642,3385,Active,,,16.7,GI50,Cytotoxicity against human K562 cells after 48 hrs,Confirmatory,18798609.0,
1673,399063,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,16309328.0,
1674,399064,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,16309328.0,
1675,399065,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,16309328.0,
1676,399066,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,16309328.0,
1677,403011,10,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,16038565.0,
1678,403012,10,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Hep3B cells by MTT assay,Other,16038565.0,
1679,403013,9,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT-29 cells by MTT assay,Other,16038565.0,
1680,404179,6,3,,103507642,3385,Active,,,0.46,IC50,Cytotoxicity against mouse colon 26-L5 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1681,404180,6,3,,103507642,3385,Active,,,5.78,IC50,Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1682,404181,6,3,,103507642,3385,Active,,,2.59,IC50,Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1683,404182,6,2,,103507642,3385,Active,,,9.19,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1684,404183,6,2,,103507642,3385,Active,,,0.77,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1685,404184,6,2,,103507642,3385,Active,,,9.45,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,18440233.0,
1686,405760,6,2,,103507642,3385,Active,,,3.8,GI50,Antiproliferative activity against human HL60 cells after 3 days by trypan blue staining,Confirmatory,18491866.0,
1687,405982,4,2,,103507642,3385,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing colon 38 cells assessed as tumor growth inhibition at 70 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
1688,405990,3,5,,103507642,3385,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing colon 38 cells assessed as maximum weight loss at 70 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
1689,406121,3,5,,103507642,3385,Unspecified,,,,,"Antitumor activity in BDF1 mouse bearing colon 38 cells assessed as cell death at 70 mg/kg, iv daily 4 times for 3 days",Other,18508273.0,
1690,407948,6,2,,103507642,3385,Active,,,0.69,IC50,Antiproliferative activity against mouse L1210 cells after 2 days by MTT assay,Confirmatory,18424155.0,
1691,407949,6,3,,103507642,3385,Active,,,20.0,IC50,Antiproliferative activity against human Molt4/C8 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1692,407950,6,2,,103507642,3385,Active,,,9.23,IC50,Antiproliferative activity against human CEM cells after 3 days by MTT assay,Confirmatory,18424155.0,
1693,407951,6,2,,103507642,3385,Active,,,16.0,IC50,Antiproliferative activity against human HeLa cells after 3 days by MTT assay,Confirmatory,18424155.0,
1694,407952,6,2,,103507642,3385,Active,,,4.5,IC50,Antiproliferative activity against human MCF7 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1695,407953,6,2,,103507642,3385,Active,,,6.5,IC50,Antiproliferative activity against human MiaPaCa2 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1696,407954,6,2,,103507642,3385,Active,,,8.7,IC50,Antiproliferative activity against human SW620 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1697,407955,6,2,,103507642,3385,Active,,,9.2,IC50,Antiproliferative activity against human HepG2 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1698,407956,6,3,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human WI38 cells after 3 days by MTT assay,Confirmatory,18424155.0,
1699,409954,4,9,,103507642,3385,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1700,409956,4,9,,103507642,3385,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
1701,415310,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,19324555.0,
1702,415311,6,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human AGS cells after 72 hrs by SRB method,Confirmatory,19324555.0,
1703,415312,6,2,,103507642,3385,Unspecified,,,65.3,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,19324555.0,
1704,415313,6,2,,103507642,3385,Unspecified,,,50.5,IC50,Cytotoxicity against human A549 cells after 72 hrs by SRB method,Confirmatory,19324555.0,
1705,418210,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay,Other,19201604.0,
1706,418211,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay,Other,19201604.0,
1707,418212,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells after 48 hrs by SRB assay,Other,19201604.0,
1708,418216,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay,Other,19201604.0,
1709,418315,6,3,,103507642,3385,Active,,,4.3,IC50,Cytotoxicity against human Bel7402 after 72 hrs by MTT assay,Confirmatory,19233650.0,
1710,418316,6,2,,103507642,3385,Active,,,4.7,IC50,Cytotoxicity against human MCF7 after 72 hrs by MTT assay,Confirmatory,19233650.0,
1711,419796,7,2,,103507642,3385,Active,,,15.09,GI50,Growth inhibition of human leukemia cells after 48 hrs,Confirmatory,18950904.0,
1712,419797,7,2,,103507642,3385,Unspecified,,,100.0,GI50,Growth inhibition of human NSCLC cells after 48 hrs,Confirmatory,18950904.0,
1713,419798,7,2,,103507642,3385,Active,,,8.37,GI50,Growth inhibition of human Colon cancer cells after 48 hrs,Confirmatory,18950904.0,
1714,419799,7,2,,103507642,3385,Unspecified,,,72.07,GI50,Growth inhibition of human CNS cancer cells after 48 hrs,Confirmatory,18950904.0,
1715,419800,7,2,,103507642,3385,Unspecified,,,70.6,GI50,Growth inhibition of human melanoma cells after 48 hrs,Confirmatory,18950904.0,
1716,419801,7,2,,103507642,3385,Unspecified,,,61.4,GI50,Growth inhibition of human ovarian cancer cells after 48 hrs,Confirmatory,18950904.0,
1717,419802,7,2,,103507642,3385,Active,,,45.6,GI50,Growth inhibition of human renal cancer cells after 48 hrs,Confirmatory,18950904.0,
1718,419803,7,2,,103507642,3385,Active,,,22.7,GI50,Growth inhibition of human prostate cancer cells after 48 hrs,Confirmatory,18950904.0,
1719,419804,7,2,,103507642,3385,Unspecified,,,76.4,GI50,Growth inhibition of human breast cancer cells after 48 hrs,Confirmatory,18950904.0,
1720,424772,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Bel7404 after 24 hrs by MTT assay,Other,19338315.0,
1721,424773,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 after 24 hrs by MTT assay,Other,19338315.0,
1722,424774,7,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human BGC823 after 24 hrs by MTT assay,Other,19338315.0,
1723,424775,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT8 after 24 hrs by MTT assay,Other,19338315.0,
1724,424776,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A2780 after 24 hrs by MTT assay,Other,19338315.0,
1725,425200,6,2,,103507642,3385,Unspecified,,,10.0,GI50,Growth inhibition of human MIAPaCa2 cells after 72 hrs by Alamar Blue assay,Confirmatory,19406645.0,
1726,425201,6,2,,103507642,3385,Unspecified,,,10.0,GI50,Growth inhibition of human MCF7 cells after 72 hrs by Alamar Blue assay,Confirmatory,19406645.0,
1727,425652,7,2,,103507642,3385,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1728,425653,7,2,,103507642,3385,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1729,429843,6,2,,103507642,3385,Active,,,20.8,IC50,Cytotoxicity against human A549 cells by SRB method,Confirmatory,19422203.0,
1730,430984,7,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as 100% cell death after 24 hrs by WST8 assay,Other,19572611.0,
1731,430989,7,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PANC1 cells in nutrient-deprived condition assessed as 50% cell death after 24 hrs by WST8 assay,Other,19572611.0,
1732,430990,6,2,,103507642,3385,Active,,,10.0,GI50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,19572613.0,
1733,430991,6,2,,103507642,3385,Active,,,15.0,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,19572613.0,
1734,431421,6,2,,103507642,3385,Active,,,0.3,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1735,431422,6,3,,103507642,3385,Active,,,1.1,IC50,Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1736,431423,6,2,,103507642,3385,Active,,,0.6,IC50,Antiproliferative activity against human T47D cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1737,431424,6,2,,103507642,3385,Active,,,3.1,IC50,Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1738,431425,6,3,,103507642,3385,Active,,,3.2,IC50,Antiproliferative activity against human RL cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1739,431426,6,2,,103507642,3385,Unspecified,,,125.0,IC50,Antiproliferative activity against human CEM cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1740,431427,6,2,,103507642,3385,Active,,,2.6,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1741,431428,6,2,,103507642,3385,Active,,,4.4,IC50,Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1742,431429,6,2,,103507642,3385,Active,,,2.1,IC50,Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay,Confirmatory,19743863.0,
1743,434176,3,5,,103507642,3385,Active,,,,,"Antitumor activity against human LS 174T cells xenografted BALB/c nu/nu mouse assessed as inhibition of tumor growth at 25 mg/kg, ip",Other,19615903.0,
1744,434177,3,4,,103507642,3385,Unspecified,,,,,"Toxicity in human SK-RC-52 cells xenografted BALB/c nu/nu mouse assessed as effect on body weight at 25 mg/kg, ip",Other,19615903.0,
1745,434955,1,2,,8139872,3385,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1746,434962,1,2,,8139872,3385,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1747,434989,1,1,,8139872,3385,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1748,435030,1,2,,8139872,3385,Active,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1749,435030,1,2,,8139872,3385,Active,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1750,436373,5,2,,103507642,3385,Active,,,0.016,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,19423198.0,
1751,436374,5,2,,103507642,3385,Active,,,0.018000000000000002,IC50,Antiproliferative activity against human A431 cells after 48 hrs by MTT assay,Confirmatory,19423198.0,
1752,438052,4,2,,103507642,3385,Active,,,9.77237,GI50,Anticancer activity against human CCRF-CEM cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1753,438053,4,4,,103507642,3385,Active,,,2.29087,GI50,Anticancer activity against human HL-60(TB) cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1754,438054,4,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Anticancer activity against human K562 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1755,438055,4,2,,103507642,3385,Active,,,0.35481,GI50,Anticancer activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1756,438056,4,3,,103507642,3385,Active,,,0.04467,GI50,Anticancer activity against human RPMI8266 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1757,438057,4,2,,103507642,3385,Active,,,0.02399,GI50,Anticancer activity against human SR cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1758,438058,4,2,,103507642,3385,Active,,,0.19055,GI50,Anticancer activity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1759,438059,4,2,,103507642,3385,Unspecified,,,61.6595,GI50,Anticancer activity against human EKVX cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1760,438060,4,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Anticancer activity against human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1761,438061,4,2,,103507642,3385,Unspecified,,,77.6247,GI50,Anticancer activity against human HOP92 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1762,438062,4,2,,103507642,3385,Unspecified,,,54.9541,GI50,Anticancer activity against human NCI-H226 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1763,438063,4,2,,103507642,3385,Active,,,0.17783,GI50,Anticancer activity against human NCI-H322M cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1764,438064,4,2,,103507642,3385,Active,,,0.056229999999999995,GI50,Anticancer activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1765,438065,4,2,,103507642,3385,Active,,,7.24436,GI50,Anticancer activity against human NCI-H522 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1766,438066,4,2,,103507642,3385,Active,,,0.33113000000000004,GI50,Anticancer activity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1767,438067,4,2,,103507642,3385,Active,,,0.15849000000000002,GI50,Anticancer activity against human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1768,438068,4,2,,103507642,3385,Active,,,0.05248,GI50,Anticancer activity against human HCC2998 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1769,438069,4,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Anticancer activity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1770,438070,4,2,,103507642,3385,Active,,,0.10965,GI50,Anticancer activity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1771,438071,4,2,,103507642,3385,Active,,,0.17783,GI50,Anticancer activity against human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1772,438072,4,2,,103507642,3385,Active,,,0.2138,GI50,Anticancer activity against human KM12 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1773,438073,4,2,,103507642,3385,Active,,,0.93325,GI50,Anticancer activity against human SW620 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1774,438074,4,2,,103507642,3385,Active,,,1.58489,GI50,Anticancer activity against human SF268 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1775,438075,4,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Anticancer activity against human SF295 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1776,438076,4,2,,103507642,3385,Active,,,0.0631,GI50,Anticancer activity against human SF539 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1777,438077,4,2,,103507642,3385,Active,,,3.80189,GI50,Anticancer activity against human SNB19 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1778,438078,4,2,,103507642,3385,Unspecified,,,79.4328,GI50,Anticancer activity against human SNB75 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1779,438079,4,2,,103507642,3385,Active,,,0.91201,GI50,Anticancer activity against human U251 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1780,438080,4,2,,103507642,3385,Active,,,0.24547,GI50,Anticancer activity against human LOXIMVI cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1781,438081,4,2,,103507642,3385,Active,,,0.051289999999999995,GI50,Anticancer activity against human MALME-3M cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1782,438082,4,2,,103507642,3385,Active,,,0.97724,GI50,Anticancer activity against human M14 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1783,438083,4,2,,103507642,3385,Unspecified,,,56.2341,GI50,Anticancer activity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1784,438084,4,2,,103507642,3385,Active,,,1.02329,GI50,Anticancer activity against human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1785,438085,4,2,,103507642,3385,Active,,,0.46774,GI50,Anticancer activity against human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1786,438086,4,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Anticancer activity against human UACC257 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1787,438087,4,2,,103507642,3385,Active,,,0.52481,GI50,Anticancer activity against human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1788,438088,4,2,,103507642,3385,Active,,,1.23027,GI50,Anticancer activity against human IGROV1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1789,438089,4,2,,103507642,3385,Active,,,0.01585,GI50,Anticancer activity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1790,438090,4,2,,103507642,3385,Active,,,4.46684,GI50,Anticancer activity against human OVCAR4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1791,438091,4,2,,103507642,3385,Active,,,10.9648,GI50,Anticancer activity against human OVCAR5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1792,438092,4,2,,103507642,3385,Active,,,1.7378,GI50,Anticancer activity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1793,438093,4,2,,103507642,3385,Active,,,21.8776,GI50,Anticancer activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1794,438269,4,2,,103507642,3385,Active,,,0.72444,GI50,Anticancer activity against human 786-0 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1795,438270,4,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Anticancer activity against human A498 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1796,438271,4,2,,103507642,3385,Active,,,0.29512,GI50,Anticancer activity against human ACHN cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1797,438272,4,2,,103507642,3385,Active,,,0.07244,GI50,Anticancer activity against human Caki1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1798,438273,4,3,,103507642,3385,Active,,,2.63027,GI50,Anticancer activity against human RXF393 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1799,438274,4,2,,103507642,3385,Active,,,0.5011899999999999,GI50,Anticancer activity against human SN12C cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1800,438275,4,2,,103507642,3385,Active,,,1.12202,GI50,Anticancer activity against human TK10 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1801,438276,4,2,,103507642,3385,Active,,,1.41254,GI50,Anticancer activity against human UO31 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1802,438277,4,2,,103507642,3385,Active,,,2.34423,GI50,Anticancer activity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1803,438278,4,2,,103507642,3385,Active,,,0.36308,GI50,Anticancer activity against human DU145 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1804,438279,4,2,,103507642,3385,Active,,,0.07943,GI50,Anticancer activity against human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1805,438280,4,2,,103507642,3385,Active,,,0.31623,GI50,Anticancer activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1806,438281,4,2,,103507642,3385,Active,,,6.60693,GI50,Anticancer activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1807,438282,4,3,,103507642,3385,Active,,,9.77237,GI50,Anticancer activity against human Hs 578T cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1808,438283,5,1,,103507642,3385,Active,,,0.07244,GI50,Anticancer activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1809,438285,4,2,,103507642,3385,Active,,,10.7152,GI50,Anticancer activity against human BT549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1810,438286,4,2,,103507642,3385,Active,,,8.12831,GI50,Anticancer activity against human T47D cells after 48 hrs by sulforhodamine B assay,Confirmatory,19740574.0,
1811,441063,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells by SRB assay,Other,19700322.0,
1812,442340,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human MCF7 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1813,442341,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human Hep2 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1814,442342,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1815,442343,3,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human 502713 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1816,442344,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1817,442346,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human A549 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1818,442348,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human IMR32 cells at 10 uM after 48 hrs by SRB assay,Other,19926172.0,
1819,442503,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Other,19932530.0,
1820,442504,7,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Other,19932530.0,
1821,442549,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human COLO205 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
1822,442552,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human PC3 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
1823,442555,3,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR-3 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,19939522.0,
1824,442566,8,2,,103507642,3385,Active,,,21.0,IC50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19939522.0,
1825,445609,5,2,,103507642,3385,Active,,,12.5,IC50,Cytotoxicity against human KB cells after 72 hrs MTT assay,Confirmatory,19846302.0,
1826,447804,4,3,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse EAC cells tansplanted in Swiss albino mouse assessed as dead cells at 50 to 250 mg/kg/day, ip by tyrpan blue assay",Other,19527933.0,
1827,447805,8,1,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse bearing mouse EAC cells assessed as hemoglobin level at 50 to 250 mg/kg/day, po after 14 days postimplantation",Other,19527933.0,
1828,447806,3,3,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse bearing mouse EAC cells assessed as increase in body weight at 50 to 250 mg/kg/day, po",Other,19527933.0,
1829,447807,7,1,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse bearing mouse EAC cells assessed as mean survival time at 50 to 250 mg/kg/day, po",Other,19527933.0,
1830,447808,3,3,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse bearing mouse EAC cells assessed as hematocrit level at 50 to 250 mg/kg/day, po after 14 days postimplantation",Other,19527933.0,
1831,447809,3,3,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse bearing mouse EAC cells assessed as WBC count at 50 to 250 mg/kg/day, po after 14 days postimplantation",Other,19527933.0,
1832,448067,5,2,,103507642,3385,Active,,,4.3,IC50,Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,19560842.0,
1833,448068,5,3,,103507642,3385,Active,,,4.7,IC50,Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay,Confirmatory,19560842.0,
1834,449728,1,2,,8139872,3385,Active,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1835,449739,1,2,,8139872,3385,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1836,449762,1,2,,8139872,3385,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1837,449768,1,1,,8139872,3385,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1838,450979,5,2,,103507642,3385,Active,,,4.4,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1839,450980,5,3,,103507642,3385,Active,,,5.5,GI50,Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1840,450981,5,2,,103507642,3385,Active,,,19.0,GI50,Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1841,450982,5,2,,103507642,3385,Active,,,4.1,GI50,Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1842,450983,5,2,,103507642,3385,Active,,,29.0,GI50,Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1843,450984,5,2,,103507642,3385,Unspecified,,,50.0,GI50,Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay,Confirmatory,19664930.0,
1844,454911,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against human HCT15 cells at 20 uM after 48 hrs by Sulforhodamine assay,Other,19913412.0,
1845,455175,3,4,,103507642,3385,Unspecified,,,,,Antitumor activity against human SW620 cells at 20 uM after 48 hrs by Sulforhodamine assay,Other,19913412.0,
1846,463073,1,2,,8139872,3385,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1847,463075,1,1,,8139872,3385,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1848,463079,1,2,,8139872,3385,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1849,463082,1,1,,8139872,3385,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1850,463096,1,1,,50105574,3385,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1851,463097,1,1,,50105574,3385,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1852,463106,1,2,,90341469,3385,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1853,463111,1,1,,8139872,3385,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1854,463115,1,1,,8139872,3385,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1855,463141,1,2,,8139872,3385,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1856,463165,1,1,,8139872,3385,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1857,463187,1,1,,8139872,3385,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1858,463189,1,1,,53777642,3385,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1859,463193,1,1,,8139872,3385,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1860,463210,1,2,,8139872,3385,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1861,463254,1,1,,8139872,3385,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1862,464126,5,2,,103507642,3385,Unspecified,,,64.2,IC50,Antitumor activity against human HeLa cells by MTT assay,Confirmatory,20171096.0,
1863,464127,5,3,,103507642,3385,Unspecified,,,67.2,IC50,Antitumor activity against human QGY7701 cells by MTT assay,Confirmatory,20171096.0,
1864,466785,5,2,,103507642,3385,Unspecified,,,78.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by XTT method,Confirmatory,20151671.0,
1865,468195,5,2,,103507642,3385,Active,,,5.2,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,19919052.0,
1866,468210,5,2,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,19919065.0,
1867,468211,5,2,,103507642,3385,Active,,,15.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,19919065.0,
1868,468240,5,2,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,19618920.0,
1869,468241,5,2,,103507642,3385,Active,,,15.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,19618920.0,
1870,470122,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human U251 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1871,470123,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PC3 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1872,470124,4,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human K562 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1873,470415,5,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1874,470416,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1875,470417,3,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-LU-1 cells at 50 uM after 48 hrs by SRB assay,Other,19879023.0,
1876,470662,5,2,,103507642,3385,Active,,,8.58,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
1877,470663,5,2,,103507642,3385,Active,,,5.91,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
1878,470664,5,2,,103507642,3385,Active,,,0.44,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
1879,470665,5,3,,103507642,3385,Active,,,0.41,IC50,Cytotoxicity against mouse Colon 26-L5 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
1880,470666,5,3,,103507642,3385,Active,,,7.39,IC50,Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay,Confirmatory,19689125.0,
1881,471378,5,2,,103507642,3385,Active,,,15.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,19795843.0,
1882,471379,5,2,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,19795843.0,
1883,472238,3,3,,103507642,3385,Unspecified,,,,,Toxicity in mouse EAC cells transplanted Swiss albino mouse assessed as change in hematocrit content at 20 mg/kg. ip dissolved in DMSO for 14 days measured after final dose by 18 hrs fasting,Other,19447526.0,
1884,472239,3,3,,103507642,3385,Unspecified,,,,,Toxicity in mouse EAC cells transplanted Swiss albino mouse assessed as change in hemoglobin content at 20 mg/kg. ip dissolved in DMSO for 14 days measured after final dose by 18 hrs fasting,Other,19447526.0,
1885,472240,3,3,,103507642,3385,Unspecified,,,,,Toxicity in mouse EAC cells transplanted Swiss albino mouse assessed as change in total WBC content at 20 mg/kg. ip dissolved in DMSO for 14 days measured after final dose by 18 hrs fasting,Other,19447526.0,
1886,472241,3,3,,103507642,3385,Unspecified,,,,,Toxicity in mouse EAC cells transplanted Swiss albino mouse assessed as decrease in body weight at 20 mg/kg. ip dissolved in DMSO for 14 days measured after final dose by 18 hrs fasting,Other,19447526.0,
1887,472242,7,1,,103507642,3385,Unspecified,,,,,Antitumor activity in mouse EAC cell transplanted in Swiss albino mouse assessed as decrease in tumor volume at 20 mg/kg. ip dissolved in DMSO for 14 days measured after final dose by 18 hrs fasting,Other,19447526.0,
1888,472637,5,3,,103507642,3385,Active,,,15.1,GI50,Antitumor activity against human leukemia cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1889,472638,5,2,,103507642,3385,Unspecified,,,100.0,GI50,Antitumor activity against human non small cell lung cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1890,472639,5,3,,103507642,3385,Active,,,8.4,GI50,Antitumor activity against human colon cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1891,472640,5,3,,103507642,3385,Unspecified,,,72.1,GI50,Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1892,472641,5,3,,103507642,3385,Unspecified,,,70.6,GI50,Antitumor activity against human melanoma cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1893,472642,5,3,,103507642,3385,Unspecified,,,61.4,GI50,Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1894,472643,5,3,,103507642,3385,Active,,,45.6,GI50,Antitumor activity against human renal cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1895,472644,5,2,,103507642,3385,Active,,,22.7,GI50,Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1896,472645,5,3,,103507642,3385,Unspecified,,,76.4,GI50,Antitumor activity against human breast cancer cells after 48 hrs by SRB assay,Confirmatory,20350811.0,
1897,472718,5,3,,103507642,3385,Active,,,3.0,GI50,Cytotoxicity against BALB mouse 3T3 cells,Confirmatory,20356752.0,
1898,472719,6,2,,103507642,3385,Active,,,2.3,GI50,Cytotoxicity against human NCI-H460 cells,Confirmatory,20356752.0,
1899,472720,6,2,,103507642,3385,Active,,,5.3,GI50,Cytotoxicity against human DU145 cells,Confirmatory,20356752.0,
1900,472721,6,2,,103507642,3385,Active,,,4.5,GI50,Cytotoxicity against human MCF7 cells,Confirmatory,20356752.0,
1901,472722,6,2,,103507642,3385,Active,,,32.4,GI50,Cytotoxicity against human M14 cells,Confirmatory,20356752.0,
1902,472723,6,2,,103507642,3385,Active,,,14.9,GI50,Cytotoxicity against human HT-29 cells,Confirmatory,20356752.0,
1903,472724,6,2,,103507642,3385,Unspecified,,,89.9,GI50,Cytotoxicity against human K562 cells,Confirmatory,20356752.0,
1904,475907,5,2,,103507642,3385,Active,,,0.03,IC50,Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay,Confirmatory,20211564.0,
1905,475908,5,2,,103507642,3385,Active,,,4.0,IC50,Antitumor activity against human HCT116 cells after 24 hrs by MTT assay,Confirmatory,20211564.0,
1906,475909,5,2,,103507642,3385,Active,,,9.0,IC50,Antitumor activity against human SW620 cells after 24 hrs by MTT assay,Confirmatory,20211564.0,
1907,475910,5,2,,103507642,3385,Active,,,15.0,IC50,Antitumor activity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,20211564.0,
1908,475911,5,2,,103507642,3385,Active,,,2.0,IC50,Antitumor activity against human H460 cells after 24 hrs by MTT assay,Confirmatory,20211564.0,
1909,477218,5,2,,103507642,3385,Active,,,3.03,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,20163895.0,
1910,477295,3,3,,103507642,3385,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
1911,478022,3,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 cells transplanted in Kunming mouse assessed as inhibition of tumor growth at 50 mg/kg/day, iv for 2 days",Other,20353152.0,
1912,478026,3,4,,103507642,3385,Unspecified,,,,,"Toxicity in Kunming mouse bearing mouse S180 cells assessed as change in body weight at 50 mg/kg/day, ip for 2 days (Rvb = 18.1 g)",Other,20353152.0,
1913,478136,5,2,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,20405881.0,
1914,480902,5,2,,103507642,3385,Active,,,8.3,GI50,Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by SRB assay,Confirmatory,20438092.0,
1915,480903,5,2,,103507642,3385,Active,,,47.0,GI50,Antiproliferative activity against human T47D cells expressing estrogen receptor after 48 hrs by SRB assay,Confirmatory,20438092.0,
1916,480904,5,3,,103507642,3385,Active,,,6.2,GI50,Antiproliferative activity against human MCF7/BUS cells expressing estrogen receptor after 48 hrs by SRB assay,Confirmatory,20438092.0,
1917,480905,5,2,,103507642,3385,Unspecified,,,54.0,GI50,Antiproliferative activity against estrogen receptor deficient human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,20438092.0,
1918,480906,5,3,,103507642,3385,Active,,,3.0,GI50,Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 48 hrs by SRB assay,Confirmatory,20438092.0,
1919,481834,5,2,,103507642,3385,Active,,,5.4,IC50,Antiproliferative activity against human A549 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,20403701.0,
1920,481835,5,2,,103507642,3385,Active,,,2.7,IC50,Antiproliferative activity against human H460 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,20403701.0,
1921,481836,5,2,,103507642,3385,Active,,,15.2,IC50,Antiproliferative activity against human MCF7 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,20403701.0,
1922,481837,5,3,,103507642,3385,Active,,,3.5,IC50,Antiproliferative activity against human MDA231 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,20403701.0,
1923,485270,1,1,,8139872,3385,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1924,485272,1,1,,8139872,3385,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1925,485275,1,3,,8139872,3385,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1926,485281,1,1,,8139872,3385,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1927,485290,1,1,,8139872,3385,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1928,485290,1,1,,17389875,3385,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1929,485290,1,1,,26747342,3385,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1930,485290,1,1,,26752979,3385,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1931,485290,1,1,,50105574,3385,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1932,485294,1,1,,8139872,3385,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1933,485295,1,2,,90341469,3385,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1934,485297,1,1,,8139872,3385,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1935,485297,1,1,,90341469,3385,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1936,485298,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1937,485298,1,1,,90341469,3385,Active,,,2.9093,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1938,485313,1,2,,8139872,3385,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1939,485313,1,2,,90341469,3385,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1940,485314,1,1,,8139872,3385,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1941,485314,1,1,,50105574,3385,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1942,485317,1,2,,8139872,3385,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1943,485341,1,1,,8139872,3385,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1944,485342,1,2,,90341469,3385,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1945,485344,1,1,,8139872,3385,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1946,485345,1,2,,90341469,3385,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1947,485347,1,2,,8139872,3385,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1948,485349,1,1,,8139872,3385,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1949,485350,1,2,,92124222,3385,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1950,485353,2,1,,8139872,3385,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1951,485358,1,1,,8139872,3385,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1952,485360,1,1,,8139872,3385,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
1953,485364,1,1,,8139872,3385,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1954,485366,1,2,,90341469,3385,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1955,485367,1,2,,8139872,3385,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1956,485368,1,2,,90341469,3385,Inconclusive,72386991.0,3656265.0,8.4921,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1957,487439,5,2,,103507642,3385,Active,,,0.07,CC50,Cytotoxicity against human HL60 cells after 5 days by MTT assay,Confirmatory,20227144.0,
1958,487902,7,1,,103507642,3385,Active,,,4.46,IC50,Cytotoxicity against human KB cells after 3 days by MTT assay,Confirmatory,20356655.0,
1959,488745,1,4,,85231050,3385,Active,,,9.285,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1960,488752,1,4,,85231050,3385,Active,,,10.4179,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1961,488772,1,1,,90341469,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1962,488773,1,2,,90341469,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1963,488806,1,2,,8139872,3385,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1964,488816,1,1,,90341469,3385,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1965,488837,1,1,,8139872,3385,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1966,488837,1,1,,90341469,3385,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1967,488839,1,1,,8139872,3385,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1968,488839,1,1,,8139872,3385,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1969,488847,1,3,,8139872,3385,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1970,488862,1,1,,8139872,3385,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1971,488862,1,1,,85148656,3385,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1972,488890,1,2,,8139872,3385,Inconclusive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1973,488895,1,2,,8139872,3385,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1974,488895,1,2,,85148656,3385,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1975,488896,1,1,,8139872,3385,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1976,488896,1,1,,85148656,3385,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1977,488899,1,1,,8139872,3385,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1978,488922,1,2,,8139872,3385,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1979,488942,1,1,,8139872,3385,Active,15645703.0,899625.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1980,488942,1,1,,8139872,3385,Active,15646160.0,899738.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1981,488949,1,2,,85231050,3385,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1982,488949,1,2,,90341469,3385,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1983,488953,1,1,,90341469,3385,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1984,488955,1,1,,8139872,3385,Active,16130723.0,947287.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1985,488955,1,1,,8139872,3385,Active,16130724.0,947286.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1986,488955,1,1,,8139872,3385,Active,16130726.0,947294.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1987,488956,1,1,,8139872,3385,Active,,,,,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Screening,,
1988,488965,1,2,,8139872,3385,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1989,488965,1,2,,85148656,3385,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1990,488966,1,1,,8139872,3385,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1991,488975,1,2,,8139872,3385,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1992,488977,1,2,,8139872,3385,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1993,488978,1,1,,90341469,3385,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1994,488979,1,1,,50105574,3385,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1995,488980,1,1,,85231050,3385,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1996,488981,1,1,,90341469,3385,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1997,488982,1,1,,90341469,3385,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1998,488983,1,1,,90341469,3385,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1999,489404,6,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SGC7901 after 48 hrs by MTT assay,Other,20538457.0,
2000,490286,5,3,,103507642,3385,Active,,,3.2,IC50,Antiproliferative activity against mouse SFME cells after 24 hrs by MTT assay,Confirmatory,20398972.0,
2001,490287,5,3,,103507642,3385,Active,,,48.5,IC50,Antiproliferative activity against mouse r/m HM-SFME-1 cells after 24 hrs by MTT assay,Confirmatory,20398972.0,
2002,490450,5,2,,103507642,3385,Unspecified,,,52.43,EC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,20409617.0,
2003,490451,5,2,,103507642,3385,Unspecified,,,100.0,EC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,20409617.0,
2004,490452,5,3,,103507642,3385,Active,,,43.73,EC50,Cytotoxicity against human LAC cells after 72 hrs by MTT assay,Confirmatory,20409617.0,
2005,490453,5,2,,103507642,3385,Unspecified,,,79.79,EC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,20409617.0,
2006,492947,1,1,,8139872,3385,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
2007,492953,1,1,,8139872,3385,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
2008,492956,1,1,,8139872,3385,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
2009,492967,1,2,,99301142,3385,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
2010,492972,1,1,,8139872,3385,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
2011,493005,1,1,,8139872,3385,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
2012,493008,1,1,,8139872,3385,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2013,493008,1,1,,8139872,3385,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2014,493008,1,1,,8139872,3385,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2015,493008,1,1,,8139872,3385,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2016,493014,1,1,,8139872,3385,Inconclusive,,,29.0929,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
2017,493027,1,2,,8139872,3385,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2018,493027,1,2,,8139872,3385,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
2019,493033,1,2,,92124222,3385,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
2020,493035,1,2,,8139872,3385,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2021,493035,1,2,,8139872,3385,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2022,493056,1,1,,8139872,3385,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
2023,493084,1,1,,8139872,3385,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
2024,493087,1,1,,8139872,3385,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
2025,493091,1,1,,8139872,3385,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
2026,493098,1,1,,8139872,3385,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
2027,493106,1,1,,90341469,3385,Inconclusive,116283940.0,79915.0,3.2629,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2028,493107,1,1,,90341469,3385,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2029,493127,1,1,,50105574,3385,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
2030,493131,1,1,,8139872,3385,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
2031,493153,1,1,,90341469,3385,Inconclusive,,4780.0,2.5929,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2032,493153,1,1,,90341469,3385,Inconclusive,224028257.0,4780.0,2.5929,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
2033,493160,1,1,,8139872,3385,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
2034,493162,1,2,,99301142,3385,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
2035,493164,1,2,,90341469,3385,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2036,493164,1,2,,90341469,3385,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2037,493164,1,2,,90341469,3385,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
2038,493187,1,2,,8139872,3385,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
2039,493189,1,1,,50105574,3385,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
2040,493244,1,1,,8139872,3385,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2041,493244,1,1,,8139872,3385,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2042,493244,1,1,,8139872,3385,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2043,493244,1,1,,8139872,3385,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
2044,494421,4,2,,103507642,3385,Active,,,45.4,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,20494492.0,
2045,494422,4,2,,103507642,3385,Active,,,2.19,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,20494492.0,
2046,494423,4,3,,103507642,3385,Active,,,2.95,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,20494492.0,
2047,494424,4,2,,103507642,3385,Active,,,1.93,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,20494492.0,
2048,494425,4,2,,103507642,3385,Active,,,9.7,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,20494492.0,
2049,500340,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human PC3 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2050,500341,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in NHDF expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2051,501986,5,4,,103507642,3385,Unspecified,,,,,Antiviral activity against Influenza A virus H5N1 Vietnam/1203/2004H infected in MDCK cells,Other,20674371.0,
2052,501987,5,2,,103507642,3385,Unspecified,,,,,Antiviral activity against Influenza B virus Florida/4/2006 infected in MDCK cells,Other,20674371.0,
2053,501988,5,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against MDCK cells,Other,20674371.0,
2054,503795,4,2,,103507642,3385,Unspecified,,,87.96,IC50,Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs,Confirmatory,18469809.0,
2055,503796,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against p53 deficient human K562 cells after 72 hrs,Confirmatory,18469809.0,
2056,503797,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs,Confirmatory,18469809.0,
2057,503798,4,2,,103507642,3385,Active,,,26.26,IC50,Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2058,503799,4,2,,103507642,3385,Active,,,11.63,IC50,Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs,Confirmatory,18469809.0,
2059,503800,4,2,,103507642,3385,Active,,,28.91,IC50,Antiproliferative activity against p53 deficient human HCT116/E6 cells after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2060,503801,4,2,,103507642,3385,Unspecified,,,87.73,IC50,Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2061,503802,4,2,,103507642,3385,Active,,,38.67,IC50,Antiproliferative activity against p53 deficient human A2780/E6 cells after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2062,503803,4,2,,103507642,3385,Unspecified,,,96.37,IC50,Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2063,503804,4,2,,103507642,3385,Active,,,26.67,IC50,Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2064,503805,4,2,,103507642,3385,Active,,,6.36,IC50,Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2065,503806,4,2,,103507642,3385,Active,,,18.24,IC50,Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2066,503807,4,2,,103507642,3385,Unspecified,,,50.09,IC50,Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2067,503808,4,2,,103507642,3385,Active,,,13.18,IC50,Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2068,503809,4,2,,103507642,3385,Active,,,7.21,IC50,Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2069,503810,4,2,,103507642,3385,Active,,,13.77,IC50,Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2070,503811,4,2,,103507642,3385,Active,,,14.67,IC50,Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay,Confirmatory,18469809.0,
2071,504028,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human SF268 cells assessed as accumulation at subG1 phase at 100 uM after 24 hrs FACS analysis,Other,18469809.0,
2072,504029,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human K562 cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2073,504030,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human HeLa cells assessed as assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2074,504031,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human SW480 cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2075,504032,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human COLO205 cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2076,504033,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human HCT116-E6 cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2077,504034,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human Jurkat cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2078,504035,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human A2780/E6 cells as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2079,504036,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in p53 deficient human OVCAR8 cells assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2080,504037,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2081,504038,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human HCT116 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2082,504039,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human HCT15 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2083,504040,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human SF539 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2084,504041,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human U2OS cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2085,504042,2,4,,103507642,3385,Unspecified,,,,,Induction of cell cycle arrest in human A2780 cells expressing p53 gene assessed as accumulation at subG1 phase at 100 uM after 24hrs by FACS analysis,Other,18469809.0,
2086,504326,1,2,,8139872,3385,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2087,504326,1,2,,8139872,3385,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2088,504327,1,1,,8139872,3385,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2089,504327,1,1,,90341469,3385,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
2090,504329,1,1,,8139872,3385,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
2091,504332,1,1,,8139872,3385,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2092,504332,1,1,,50105574,3385,Inactive,168985070.0,,0.0224,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2093,504332,1,1,,90341469,3385,Inconclusive,168985070.0,,28.1838,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
2094,504333,1,1,,8139872,3385,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
2095,504339,1,1,,8139872,3385,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
2096,504357,1,1,,8139872,3385,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2097,504357,1,1,,8139872,3385,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
2098,504364,1,1,,85231050,3385,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
2099,504406,1,1,,8139872,3385,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
2100,504408,2,1,,8139872,3385,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
2101,504411,1,1,,8139872,3385,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
2102,504414,1,1,,8139872,3385,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2103,504414,1,1,,8139872,3385,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2104,504423,1,1,,8139872,3385,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2105,504441,1,1,,8139872,3385,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2106,504444,1,1,,8139872,3385,Inconclusive,224028257.0,4780.0,11.5821,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
2107,504454,1,3,,8139872,3385,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
2108,504459,1,3,,8139872,3385,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
2109,504462,1,1,,8139872,3385,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
2110,504466,1,1,,8139872,3385,Inconclusive,116283940.0,79915.0,12.9953,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2111,504467,1,1,,8139872,3385,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
2112,504490,1,2,,8139872,3385,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
2113,504523,1,1,,8139872,3385,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2114,504523,1,1,,8139872,3385,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2115,504536,1,1,,90341469,3385,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
2116,504541,1,1,,8139872,3385,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
2117,504547,1,1,,90341469,3385,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2118,504548,1,2,,90341469,3385,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
2119,504558,1,1,,8139872,3385,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2120,504577,2,2,,8139872,3385,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2121,504582,2,1,,8139872,3385,Active,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2122,504582,2,1,,85148656,3385,Inconclusive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2123,504594,1,1,,85148656,3385,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2124,504600,1,2,,8139872,3385,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
2125,504621,1,1,,8139872,3385,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2126,504634,1,1,,8139872,3385,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2127,504648,1,1,,8139872,3385,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
2128,504651,1,1,,8139872,3385,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
2129,504652,1,1,,8139872,3385,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
2130,504660,1,1,,8139872,3385,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
2131,504690,1,3,,8139872,3385,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
2132,504692,2,2,,8139872,3385,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2133,504700,1,1,,8139872,3385,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2134,504700,1,1,,8139872,3385,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2135,504706,1,1,,8139872,3385,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
2136,504707,1,1,,8139872,3385,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2137,504707,1,1,,8139872,3385,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2138,504720,1,1,,8139872,3385,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2139,504734,1,1,,8139872,3385,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2140,504749,1,3,,17389875,3385,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2141,504749,1,3,,104171158,3385,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2142,504749,1,3,1.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2143,504749,1,3,2.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2144,504749,1,3,3.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2145,504749,1,3,4.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2146,504749,1,3,5.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2147,504749,1,3,6.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2148,504749,1,3,7.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2149,504749,1,3,8.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2150,504749,1,3,9.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2151,504749,1,3,10.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2152,504749,1,3,11.0,17389875,3385,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2153,504749,1,3,12.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2154,504749,1,3,13.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2155,504749,1,3,14.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2156,504749,1,3,15.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2157,504749,1,3,16.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2158,504749,1,3,17.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2159,504749,1,3,18.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2160,504749,1,3,19.0,17389875,3385,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2161,504749,1,3,20.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2162,504749,1,3,21.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2163,504749,1,3,22.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2164,504749,1,3,23.0,104171158,3385,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2165,504749,1,3,24.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2166,504749,1,3,25.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2167,504749,1,3,26.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2168,504749,1,3,27.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2169,504749,1,3,28.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2170,504749,1,3,29.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2171,504749,1,3,30.0,104171158,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2172,504749,1,3,31.0,104171158,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2173,504749,1,3,32.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2174,504749,1,3,33.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2175,504749,1,3,34.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2176,504749,1,3,35.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2177,504749,1,3,36.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2178,504749,1,3,37.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2179,504749,1,3,38.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2180,504749,1,3,39.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2181,504749,1,3,40.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2182,504749,1,3,41.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2183,504749,1,3,42.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2184,504749,1,3,43.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2185,504749,1,3,44.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2186,504749,1,3,45.0,104171158,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2187,504749,1,3,46.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2188,504749,1,3,47.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2189,504749,1,3,48.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2190,504749,1,3,49.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2191,504749,1,3,50.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2192,504749,1,3,51.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2193,504749,1,3,52.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2194,504749,1,3,53.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2195,504749,1,3,54.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2196,504749,1,3,55.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2197,504749,1,3,56.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2198,504749,1,3,57.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2199,504749,1,3,58.0,17389875,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2200,504749,1,3,59.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2201,504749,1,3,60.0,104171158,3385,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2202,504749,1,3,61.0,17389875,3385,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2203,504766,2,1,,8139872,3385,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2204,504770,1,2,,92124222,3385,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2205,504775,1,1,,8139872,3385,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2206,504775,1,1,,85148656,3385,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2207,504803,1,1,,8139872,3385,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2208,504810,1,2,,8139872,3385,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2209,504810,1,2,,90341469,3385,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2210,504812,1,2,,8139872,3385,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2211,504812,1,2,,90341469,3385,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2212,504821,1,1,,85231050,3385,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2213,504832,1,1,,8139872,3385,Active,,,6.5733,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2214,504832,1,1,,104171158,3385,Active,,,6.7456,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2215,504834,1,1,,8139872,3385,Active,,,4.6535,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2216,504834,1,1,,104171158,3385,Active,,,4.2562,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2217,504836,1,2,,90341469,3385,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2218,504842,1,1,,8139872,3385,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2219,504845,1,1,,8139872,3385,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2220,504845,1,1,,90341469,3385,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2221,504847,1,1,,8139872,3385,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2222,504847,1,1,,90341469,3385,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2223,504847,1,1,,104171158,3385,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2224,504865,1,1,,90341469,3385,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2225,504865,1,1,,104171158,3385,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2226,504884,1,2,,8139872,3385,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2227,504891,1,1,,8139872,3385,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2228,504894,1,1,,8139872,3385,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2229,504937,1,2,,8139872,3385,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2230,510214,2,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of tumor growth at 10 mg/kg, ip administered every 3 days measured on day 7 relative to control",Other,20729093.0,
2231,510218,2,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of tumor growth at 10 mg/kg, ip administered every 3 days measured on day 15 relative to control",Other,20729093.0,
2232,510219,2,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as reduction of tumor weight at 10 mg/kg, ip administered every 3 days measured on day 15 relative to control",Other,20729093.0,
2233,510231,2,3,,103507642,3385,Unspecified,,,,,"Acute toxicity in BALB/C mouse assessed as reduction of body weight at up to 10 mg/kg, ip after 15 days",Other,20729093.0,
2234,513197,3,9,,103507642,3385,Inactive,269849759.0,7157.0,,,Inhibition of p53-mediated transactivation in human MCF7 cells in presence of 50 ug/ml of 5-fluorouracil after 24 hrs by beta-galactosidase reporter gene assay,Other,16862141.0,
2235,515780,5,1,,103507642,3385,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
2236,516692,5,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Other,20800480.0,
2237,516693,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Other,20800480.0,
2238,516694,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A431 cells after 48 hrs by MTT assay,Other,20800480.0,
2239,521220,3,3,,103507642,3385,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2240,524790,7,2,,103507642,3385,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2241,524791,7,2,,103507642,3385,Active,,,6.30957,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2242,524792,7,2,,103507642,3385,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2243,524793,7,2,,103507642,3385,Active,,,15.8489,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2244,524794,7,1,,103507642,3385,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2245,524795,7,2,,103507642,3385,Active,,,3.98107,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2246,524796,7,1,,103507642,3385,Active,,,7.943280000000001,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2247,526194,4,2,,103507642,3385,Active,,,14.0,IC50,Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2248,526349,4,2,,103507642,3385,Active,,,12.0,IC50,Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2249,526350,4,3,,103507642,3385,Unspecified,,,50.0,IC50,Antiproliferative activity against human HCT116-E6 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2250,526351,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2251,526352,4,2,,103507642,3385,Unspecified,,,57.0,IC50,Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2252,526353,4,2,,103507642,3385,Unspecified,,,90.0,IC50,Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2253,526354,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2254,526355,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2255,526356,4,2,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2256,526357,4,2,,103507642,3385,Active,,,48.0,IC50,Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2257,526358,4,2,,103507642,3385,Unspecified,,,87.0,IC50,Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2258,526359,4,2,,103507642,3385,Unspecified,,,64.0,IC50,Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2259,526360,4,2,,103507642,3385,Active,,,30.0,IC50,Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2260,526361,4,2,,103507642,3385,Active,,,30.0,IC50,Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2261,526362,4,2,,103507642,3385,Active,,,43.0,IC50,Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2262,526363,4,2,,103507642,3385,Active,,,16.0,IC50,Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay,Confirmatory,20873740.0,
2263,537479,1,5,,103507642,3385,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 3 uM after 96 hrs by sulforhodamine B assay relative to control,Other,20943401.0,
2264,537480,1,5,,103507642,3385,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 5 uM after 96 hrs by sulforhodamine B assay relative to control,Other,20943401.0,
2265,537600,5,3,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay,Other,20947362.0,
2266,538065,4,3,,103507642,3385,Active,,,4.6,IC50,Anticancer activity against human 502713 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2267,538066,4,2,,103507642,3385,Active,,,3.6,IC50,Anticancer activity against human HCT15 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2268,538067,4,3,,103507642,3385,Active,,,0.3,IC50,Anticancer activity against human Hep2 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2269,538068,4,3,,103507642,3385,Active,,,18.0,IC50,Anticancer activity against human IMR32 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2270,538069,4,2,,103507642,3385,Active,,,2.4,IC50,Anticancer activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2271,538070,4,2,,103507642,3385,Active,,,4.8,IC50,Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2272,538071,4,2,,103507642,3385,Active,,,12.0,IC50,Anticancer activity against human PC3 cells assessed as cell viability after 48 hrs by SRB assay,Confirmatory,21074444.0,
2273,538156,3,2,,103507642,3385,Active,,,9.77237,GI50,Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2274,538157,4,3,,103507642,3385,Active,,,2.29087,GI50,Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2275,538158,3,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2276,538159,4,2,,103507642,3385,Active,,,0.35481,GI50,Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2277,538160,4,2,,103507642,3385,Active,,,0.04467,GI50,Growth inhibition of human RPMI8266 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2278,538161,3,2,,103507642,3385,Active,,,0.02399,GI50,Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2279,538162,3,2,,103507642,3385,Active,,,0.19055,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2280,538163,4,2,,103507642,3385,Unspecified,,,61.6595,GI50,Growth inhibition of human EKVX cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2281,538164,4,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2282,538165,4,2,,103507642,3385,Unspecified,,,77.6247,GI50,Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2283,538166,3,2,,103507642,3385,Unspecified,,,54.9541,GI50,Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2284,538167,3,2,,103507642,3385,Active,,,0.17783,GI50,Growth inhibition of human NCI-H322M cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2285,538168,3,2,,103507642,3385,Active,,,0.056229999999999995,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2286,538236,3,2,,103507642,3385,Active,,,7.24436,GI50,Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2287,538237,3,2,,103507642,3385,Active,,,0.33113000000000004,GI50,Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2288,538238,4,2,,103507642,3385,Active,,,0.15849000000000002,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2289,538239,4,2,,103507642,3385,Active,,,0.05248,GI50,Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2290,538240,3,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2291,538241,3,2,,103507642,3385,Active,,,0.10965,GI50,Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2292,538242,3,2,,103507642,3385,Active,,,0.17783,GI50,Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2293,538243,3,2,,103507642,3385,Active,,,0.2138,GI50,Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2294,538244,3,2,,103507642,3385,Active,,,0.93325,GI50,Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2295,538245,4,2,,103507642,3385,Active,,,1.58489,GI50,Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2296,538246,4,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2297,538247,4,2,,103507642,3385,Active,,,0.0631,GI50,Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2298,538248,4,2,,103507642,3385,Active,,,3.80189,GI50,Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2299,538249,4,2,,103507642,3385,Unspecified,,,79.4328,GI50,Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2300,538250,4,2,,103507642,3385,Active,,,0.91201,GI50,Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2301,538251,4,2,,103507642,3385,Active,,,0.24547,GI50,Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2302,538252,3,2,,103507642,3385,Active,,,0.051289999999999995,GI50,Growth inhibition of human MALME-3M cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2303,538253,3,2,,103507642,3385,Active,,,0.97724,GI50,Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2304,538254,3,2,,103507642,3385,Unspecified,,,56.2341,GI50,Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2305,538255,3,2,,103507642,3385,Active,,,1.02329,GI50,Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2306,538256,3,2,,103507642,3385,Active,,,0.46774,GI50,Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2307,538257,4,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2308,538258,4,2,,103507642,3385,Active,,,0.52481,GI50,Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2309,538259,4,2,,103507642,3385,Active,,,1.23027,GI50,Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2310,538260,3,2,,103507642,3385,Active,,,0.01585,GI50,Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2311,538261,4,2,,103507642,3385,Active,,,4.46684,GI50,Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2312,538262,4,2,,103507642,3385,Active,,,10.9648,GI50,Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2313,538263,4,2,,103507642,3385,Active,,,1.7378,GI50,Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2314,538264,3,2,,103507642,3385,Active,,,21.8776,GI50,Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2315,538265,3,2,,103507642,3385,Active,,,0.72444,GI50,Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2316,538266,3,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Growth inhibition of human A498 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2317,538267,3,2,,103507642,3385,Active,,,0.29512,GI50,Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2318,538268,4,2,,103507642,3385,Active,,,0.07244,GI50,Growth inhibition of human Caki1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2319,538269,4,3,,103507642,3385,Active,,,2.63027,GI50,Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2320,538270,3,2,,103507642,3385,Active,,,0.5011899999999999,GI50,Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2321,538271,4,2,,103507642,3385,Active,,,1.12202,GI50,Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2322,538272,4,2,,103507642,3385,Active,,,1.41254,GI50,Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2323,538273,3,2,,103507642,3385,Active,,,2.34423,GI50,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2324,538274,3,2,,103507642,3385,Active,,,0.36308,GI50,Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2325,538275,3,2,,103507642,3385,Active,,,0.07943,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2326,538276,3,2,,103507642,3385,Active,,,0.31623,GI50,Growth inhibition of human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2327,538277,3,2,,103507642,3385,Active,,,6.60693,GI50,Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2328,538278,4,2,,103507642,3385,Active,,,9.77237,GI50,Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2329,538279,3,2,,103507642,3385,Active,,,0.07244,GI50,Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2330,538281,4,2,,103507642,3385,Active,,,10.7152,GI50,Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2331,538282,3,2,,103507642,3385,Active,,,8.12831,GI50,Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2332,538286,4,2,,103507642,3385,Active,,,0.56234,GI50,Growth inhibition of human leukemia cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2333,538287,4,2,,103507642,3385,Active,,,1.9952599999999998,GI50,Growth inhibition of human non-small lung cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2334,538288,4,2,,103507642,3385,Active,,,0.18621,GI50,Growth inhibition of human colon cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2335,538289,4,2,,103507642,3385,Active,,,1.34896,GI50,Growth inhibition of human CNS cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2336,538290,4,2,,103507642,3385,Active,,,0.93325,GI50,Growth inhibition of human melanoma cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2337,538291,4,2,,103507642,3385,Active,,,1.8197,GI50,Growth inhibition of human ovarian cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2338,538292,4,2,,103507642,3385,Active,,,0.57544,GI50,Growth inhibition of human renal cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2339,538293,4,2,,103507642,3385,Active,,,0.91201,GI50,Growth inhibition of human prostate cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2340,538294,4,2,,103507642,3385,Active,,,1.38038,GI50,Growth inhibition of human breast cancer cell after 48 hrs by sulforhodamine B assay,Confirmatory,20850204.0,
2341,540209,4,3,,103507642,3385,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2342,540210,4,3,,103507642,3385,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2343,540211,2,5,,103507642,3385,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2344,540212,4,3,,103507642,3385,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2345,540213,4,3,,103507642,3385,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2346,540253,1,1,,8139872,3385,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2347,540253,1,1,,8139872,3385,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2348,540253,1,1,,8139872,3385,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2349,540256,1,2,,8139872,3385,Inconclusive,,,1.2995,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2350,540256,1,2,,50105574,3385,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2351,540256,1,2,,90341469,3385,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2352,540263,1,1,,8139872,3385,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2353,540263,1,1,,8139872,3385,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2354,540267,1,1,,8139872,3385,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2355,540271,1,1,,8139872,3385,Active,124809271.0,811941.0,0.562,AbsAC1000_uM,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2356,540275,1,1,,8139872,3385,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2357,540276,1,2,,8139872,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2358,540276,1,2,,11111190,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2359,540276,1,2,,17389875,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2360,540276,1,2,,26747342,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2361,540276,1,2,,26747343,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2362,540276,1,2,,26747344,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2363,540276,1,2,,26752979,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2364,540276,1,2,,50105574,3385,Inconclusive,420597.0,,14.1254,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2365,540276,1,2,,50105575,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2366,540276,1,2,,85231050,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2367,540276,1,2,,90341469,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2368,540276,1,2,,104171158,3385,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2369,540277,1,1,,8139872,3385,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2370,540295,1,1,,8139872,3385,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2371,540299,1,2,,92124222,3385,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2372,540303,1,1,,8139872,3385,Inconclusive,6679377.0,18792.0,0.0141,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2373,540303,1,1,,8139872,3385,Inconclusive,7242179.0,18793.0,0.0141,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2374,540303,1,1,,8139872,3385,Inconclusive,257471003.0,18815.0,0.0141,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2375,540308,1,1,,8139872,3385,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2376,540317,1,1,,8139872,3385,Inactive,187960037.0,10951.0,100.0,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2377,540336,1,1,,8139872,3385,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2378,540336,1,1,,8139872,3385,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2379,540336,1,1,,85148656,3385,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2380,540336,1,1,,85148656,3385,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2381,540364,1,2,,8139872,3385,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2382,547650,2,4,,103507642,3385,Unspecified,,,,,"Toxicity in mouse S180 cells xenografted Kunming mouse assessed as change body weight at 25 mg/kg/day, ip for 9 days (Rvb = 57.8%)",Other,20970893.0,
2383,549998,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human U2OS cells after 36 hrs by MTT assay,Other,20961091.0,
2384,549999,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay,Other,20961091.0,
2385,551550,4,2,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Other,21109433.0,
2386,563904,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA121 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2387,563905,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA118 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2388,563906,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA113 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2389,563907,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA109 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2390,563908,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA108 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2391,563909,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA103 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2392,563910,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA107 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2393,563911,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA100 of Cd25 fingerprint group 3 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2394,563912,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg207 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2395,563913,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg202 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2396,563914,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg201 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2397,563915,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg200 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2398,563916,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate p7718 of Cd25 fingerprint group 3 and ITS genotype 4 by CLSI M27-A2 method,Other,19704126.0,
2399,563917,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate p6785 of Cd25 fingerprint group 2 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2400,563918,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate p7276 of Cd25 fingerprint group 2 and ITS genotype 3 by CLSI M27-A2 method,Other,19704126.0,
2401,563919,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg206 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2402,563920,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate Eg203 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2403,563921,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA115 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2404,563922,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA105 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2405,563923,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate SA101 of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2406,563924,5,2,,103507642,3385,Unspecified,,,,,Antibacterial activity against Candida dubliniensis isolate CD36b of Cd25 fingerprint group 1 and ITS genotype 1 by CLSI M27-A2 method,Other,19704126.0,
2407,565844,4,2,,103507642,3385,Active,,,38.0,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,21131104.0,
2408,565845,4,2,,103507642,3385,Active,,,2.16,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,21131104.0,
2409,565846,4,2,,103507642,3385,Active,,,2.78,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,21131104.0,
2410,565847,4,3,,103507642,3385,Unspecified,,,56.0,IC50,Cytotoxicity against human L02 cells after 48 hrs by MTT assay,Confirmatory,21131104.0,
2411,565861,4,2,,103507642,3385,Active,,,11.9,IC50,Cytotoxicity against human KB cells after 3 days by MTT assay,Confirmatory,21144621.0,
2412,565862,4,3,,103507642,3385,Active,,,13.1,IC50,Cytotoxicity against human CNE2 cells after 3 days by MTT assay,Confirmatory,21144621.0,
2413,565863,4,4,,103507642,3385,Active,,,12.6,IC50,Cytotoxicity against human MGC803 cells after 3 days by MTT assay,Confirmatory,21144621.0,
2414,565864,4,2,,103507642,3385,Active,,,15.2,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,21144621.0,
2415,567406,5,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay,Other,21115211.0,
2416,567545,4,2,,103507642,3385,Active,,,4.32,IC50,Cytotoxicity against human MCF7 cells expressing wild type p53 and ras mutant after 3 days by SRB assay,Confirmatory,21126804.0,
2417,567546,4,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human MDA-MB-231 cells expressing high level of p53 after 3 days by SRB assay,Confirmatory,21126804.0,
2418,567547,4,3,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human MCF10A cells after 3 days by SRB assay,Confirmatory,21126804.0,
2419,567550,2,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF10A cells assessed as accumulation at G0/G1 phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 65.70 +/- 1.14 %),Other,21126804.0,
2420,567551,2,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF10A cells assessed as accumulation at G2/M phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 12.55 +/- 0.68 %),Other,21126804.0,
2421,567552,2,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF10A cells assessed as accumulation at S phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 21.78 +/- 0.46 %),Other,21126804.0,
2422,567553,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 89.88 +/- 1.73 %),Other,21126804.0,
2423,567554,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 1.57 +/- 2.12 %),Other,21126804.0,
2424,567555,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 8.55 +/- 0.40 %),Other,21126804.0,
2425,567556,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 42.06 +/- 0.01 %),Other,21126804.0,
2426,567557,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 31.59 +/- 0.03 %),Other,21126804.0,
2427,567558,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 26.35 +/- 0.03 %),Other,21126804.0,
2428,567779,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as loss of cell monolayers after 96 hrs,Other,21130542.0,
2429,567780,5,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human WI38 cells assessed as loss of cell monolayers after 96 hrs,Other,21130542.0,
2430,567781,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells assessed as loss of cell monolayers after 96 hrs,Other,21130542.0,
2431,567782,4,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as loss of cell monolayers after 96 hrs,Other,21130542.0,
2432,567787,2,5,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse EAC assessed as dead cells at 25 ug/ml after 2 hrs using trypan blue staining by hemocytometer analysis,Other,21130542.0,
2433,568382,4,2,,103507642,3385,Active,,,15.9,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,21273072.0,
2434,569240,4,2,,103507642,3385,Active,,,0.56,IC50,Cytotoxicity against mouse L1210 cells after 2 days by coulter counter analysis,Confirmatory,21232828.0,
2435,569241,4,2,,103507642,3385,Active,,,14.0,IC50,Cytotoxicity against human CEM cells after 3 days by coulter counter analysis,Confirmatory,21232828.0,
2436,569242,4,2,,103507642,3385,Active,,,0.57,IC50,Cytotoxicity against human HeLa cells after 4 days by coulter counter analysis,Confirmatory,21232828.0,
2437,587198,4,2,,103507642,3385,Unspecified,,,120.0,IC50,Cytotoxicity against human SW1990 cells,Confirmatory,21226488.0,
2438,587689,4,2,,103507642,3385,Active,,,9.6,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs,Confirmatory,21295381.0,
2439,587690,4,2,,103507642,3385,Active,,,4.7,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs,Confirmatory,21295381.0,
2440,588209,2,3,,103507642,3385,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2441,588210,2,4,,103507642,3385,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2442,588211,2,3,,103507642,3385,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2443,588212,2,3,,103507642,3385,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2444,588213,2,3,,103507642,3385,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2445,588214,2,3,,103507642,3385,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2446,588215,2,3,,103507642,3385,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2447,588216,2,3,,103507642,3385,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2448,588217,2,3,,103507642,3385,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2449,588218,2,3,,103507642,3385,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2450,588219,2,3,,103507642,3385,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2451,588220,2,3,,103507642,3385,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2452,588334,1,1,,8139872,3385,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2453,588335,1,1,,8139872,3385,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2454,588342,1,1,,8139872,3385,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2455,588349,1,1,,90341469,3385,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2456,588352,1,2,,8139872,3385,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2457,588354,1,1,,8139872,3385,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2458,588358,1,2,,8139872,3385,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2459,588368,1,2,,8139872,3385,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2460,588378,1,1,,90341469,3385,Inconclusive,171543895.0,6311.0,35.4813,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2461,588391,1,1,,8139872,3385,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2462,588405,1,1,,8139872,3385,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2463,588413,1,2,,8139872,3385,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2464,588436,1,1,,8139872,3385,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2465,588436,1,1,,85148656,3385,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2466,588453,1,1,,8139872,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2467,588453,1,1,,85231050,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2468,588453,1,1,,90341469,3385,Inactive,8659577.0,58819.0,0.4467,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2469,588456,1,1,,8139872,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2470,588456,1,1,,90341469,3385,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2471,588458,1,1,,8139872,3385,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2472,588459,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2473,588459,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2474,588459,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2475,588460,1,2,,8139872,3385,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2476,588460,1,2,,8139872,3385,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2477,588460,1,2,,8139872,3385,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2478,588461,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2479,588461,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2480,588461,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2481,588473,1,1,,8139872,3385,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2482,588473,1,1,,8139872,3385,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2483,588475,1,2,,8139872,3385,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2484,588475,1,2,,8139872,3385,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2485,588489,1,1,,8139872,3385,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2486,588492,1,1,,8139872,3385,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2487,588493,1,2,,8139872,3385,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2488,588497,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2489,588497,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2490,588497,1,2,,8139872,3385,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2491,588499,1,3,,8139872,3385,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2492,588499,1,3,,8139872,3385,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2493,588499,1,3,,8139872,3385,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2494,588501,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2495,588501,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2496,588501,1,2,,8139872,3385,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2497,588506,1,2,,8139872,3385,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2498,588511,1,2,,8139872,3385,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2499,588513,1,1,,17389875,3385,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2500,588514,1,1,,17389875,3385,Inconclusive,348019627.0,2099.0,50.1187,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2501,588515,1,1,,17389875,3385,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2502,588516,1,1,,17389875,3385,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2503,588519,1,2,,92124222,3385,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2504,588526,1,1,,17389875,3385,Inconclusive,325495553.0,9971.0,25.1189,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2505,588527,1,1,,17389875,3385,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2506,588532,1,1,,17389875,3385,Inconclusive,311348376.0,2908.0,0.0224,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2507,588533,1,1,,17389875,3385,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2508,588534,1,1,,17389875,3385,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2509,588535,1,1,,17389875,3385,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2510,588536,1,1,,17389875,3385,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2511,588537,1,1,,17389875,3385,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2512,588541,1,1,,17389875,3385,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2513,588543,1,1,,17389875,3385,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2514,588544,1,1,,17389875,3385,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2515,588545,1,1,,17389875,3385,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2516,588546,1,1,,17389875,3385,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2517,588547,1,1,,17389875,3385,Inconclusive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2518,588549,1,1,,8139872,3385,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2519,588550,1,1,,8139872,3385,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2520,588579,1,1,,8139872,3385,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2521,588579,1,1,,90341469,3385,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2522,588579,1,1,,104171158,3385,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2523,588579,1,1,,124880118,3385,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2524,588579,1,1,,124880121,3385,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2525,588590,1,1,,8139872,3385,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2526,588590,1,1,,50105574,3385,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2527,588591,1,1,,8139872,3385,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2528,588591,1,1,,50105574,3385,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2529,588621,1,1,,8139872,3385,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2530,588627,1,1,,8139872,3385,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2531,588664,1,2,,8139872,3385,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2532,588664,1,2,,8139872,3385,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2533,588674,1,2,,8139872,3385,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2534,588674,1,2,,85148656,3385,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2535,588675,1,1,,8139872,3385,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2536,588676,1,1,,8139872,3385,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2537,588685,1,1,,8139872,3385,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2538,588689,1,1,,8139872,3385,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2539,588692,2,1,,8139872,3385,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2540,588726,1,2,,8139872,3385,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2541,588727,1,1,,8139872,3385,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2542,588792,1,1,,8139872,3385,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2543,588794,1,1,,8139872,3385,Active,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
2544,588795,1,1,,8139872,3385,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2545,588795,1,1,,90341469,3385,Inconclusive,4758356.0,2237.0,0.15,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2546,588812,1,1,,17389875,3385,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2547,588812,1,1,1.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2548,588812,1,1,2.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2549,588812,1,1,3.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2550,588812,1,1,4.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2551,588812,1,1,5.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2552,588812,1,1,6.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2553,588812,1,1,7.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2554,588812,1,1,8.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2555,588812,1,1,9.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2556,588812,1,1,10.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2557,588812,1,1,11.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2558,588812,1,1,12.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2559,588812,1,1,13.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2560,588812,1,1,14.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2561,588812,1,1,15.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2562,588812,1,1,16.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2563,588812,1,1,17.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2564,588812,1,1,18.0,17389875,3385,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2565,588812,1,1,19.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2566,588812,1,1,20.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2567,588812,1,1,21.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2568,588812,1,1,22.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2569,588812,1,1,23.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2570,588812,1,1,24.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2571,588812,1,1,25.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2572,588812,1,1,26.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2573,588812,1,1,27.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2574,588812,1,1,28.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2575,588812,1,1,29.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2576,588812,1,1,30.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2577,588812,1,1,31.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2578,588812,1,1,32.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2579,588812,1,1,33.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2580,588812,1,1,34.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2581,588812,1,1,35.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2582,588812,1,1,36.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2583,588812,1,1,37.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2584,588812,1,1,38.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2585,588812,1,1,39.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2586,588812,1,1,40.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2587,588812,1,1,41.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2588,588812,1,1,42.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2589,588812,1,1,43.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2590,588812,1,1,44.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2591,588812,1,1,45.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2592,588812,1,1,46.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2593,588812,1,1,47.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2594,588812,1,1,48.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2595,588812,1,1,49.0,17389875,3385,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2596,588812,1,1,50.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2597,588812,1,1,51.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2598,588812,1,1,52.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2599,588812,1,1,53.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2600,588812,1,1,54.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2601,588812,1,1,55.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2602,588812,1,1,56.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2603,588812,1,1,57.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2604,588812,1,1,58.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2605,588812,1,1,59.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2606,588812,1,1,60.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2607,588812,1,1,61.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2608,588812,1,1,62.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2609,588812,1,1,63.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2610,588812,1,1,64.0,17389875,3385,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2611,588812,1,1,65.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2612,588812,1,1,66.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2613,588812,1,1,67.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2614,588812,1,1,68.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2615,588812,1,1,69.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2616,588812,1,1,70.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2617,588812,1,1,71.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2618,588812,1,1,72.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2619,588812,1,1,73.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2620,588812,1,1,74.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2621,588812,1,1,75.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2622,588812,1,1,76.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2623,588812,1,1,77.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2624,588812,1,1,78.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2625,588812,1,1,79.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2626,588812,1,1,80.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2627,588812,1,1,81.0,17389875,3385,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2628,588813,1,1,,17389875,3385,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2629,588813,1,1,1.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2630,588813,1,1,2.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2631,588813,1,1,3.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2632,588813,1,1,4.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2633,588813,1,1,5.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2634,588813,1,1,6.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2635,588813,1,1,7.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2636,588813,1,1,8.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2637,588813,1,1,9.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2638,588813,1,1,10.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2639,588813,1,1,11.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2640,588813,1,1,12.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2641,588813,1,1,13.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2642,588813,1,1,14.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2643,588813,1,1,15.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2644,588813,1,1,16.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2645,588813,1,1,17.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2646,588813,1,1,18.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2647,588813,1,1,19.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2648,588813,1,1,20.0,17389875,3385,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2649,588813,1,1,21.0,17389875,3385,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2650,588813,1,1,22.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2651,588813,1,1,23.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2652,588813,1,1,24.0,17389875,3385,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2653,588813,1,1,25.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2654,588813,1,1,26.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2655,588813,1,1,27.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2656,588813,1,1,28.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2657,588813,1,1,29.0,17389875,3385,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2658,588813,1,1,30.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2659,588813,1,1,31.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2660,588813,1,1,32.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2661,588813,1,1,33.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2662,588813,1,1,34.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2663,588813,1,1,35.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2664,588813,1,1,36.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2665,588813,1,1,37.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2666,588813,1,1,38.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2667,588813,1,1,39.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2668,588813,1,1,40.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2669,588813,1,1,41.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2670,588813,1,1,42.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2671,588813,1,1,43.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2672,588813,1,1,44.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2673,588813,1,1,45.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2674,588813,1,1,46.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2675,588813,1,1,47.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2676,588813,1,1,48.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2677,588813,1,1,49.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2678,588813,1,1,50.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2679,588813,1,1,51.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2680,588813,1,1,52.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2681,588813,1,1,53.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2682,588813,1,1,54.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2683,588813,1,1,55.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2684,588813,1,1,56.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2685,588813,1,1,57.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2686,588813,1,1,58.0,17389875,3385,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2687,588813,1,1,59.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2688,588813,1,1,60.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2689,588813,1,1,61.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2690,588813,1,1,62.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2691,588813,1,1,63.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2692,588813,1,1,64.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2693,588813,1,1,65.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2694,588813,1,1,66.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2695,588813,1,1,67.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2696,588813,1,1,68.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2697,588813,1,1,69.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2698,588813,1,1,70.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2699,588813,1,1,71.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2700,588813,1,1,72.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2701,588813,1,1,73.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2702,588813,1,1,74.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2703,588813,1,1,75.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2704,588813,1,1,76.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2705,588813,1,1,77.0,17389875,3385,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2706,588813,1,1,78.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2707,588813,1,1,79.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2708,588813,1,1,80.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2709,588813,1,1,81.0,17389875,3385,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2710,588814,1,3,,8139872,3385,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2711,588819,1,4,,8139872,3385,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2712,588820,1,1,,8139872,3385,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1).,Screening,,
2713,588824,1,1,,8139872,3385,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16).,Screening,,
2714,588834,2,1,,17389875,3385,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2715,588834,2,1,,50105574,3385,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2716,588850,1,1,,8139872,3385,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2717,588852,1,3,,8139872,3385,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2718,588855,1,1,,8139872,3385,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2719,588856,1,1,,8139872,3385,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2720,589768,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Reovirus 1 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2721,589769,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Human parainfluenza virus 3 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2722,589863,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2723,589864,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2724,589865,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Herpes simplex virus type-2 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2725,589866,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Herpes simplex virus type-1 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2726,589872,3,2,,103507642,3385,Active,,,0.56,IC50,Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis,Confirmatory,21330014.0,
2727,589873,3,2,,103507642,3385,Active,,,0.18,IC50,Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis,Confirmatory,21330014.0,
2728,589874,3,2,,103507642,3385,Active,,,14.0,IC50,Cytostatic activity against human CEM cells after 3 days by coulter counting analysis,Confirmatory,21330014.0,
2729,589875,3,2,,103507642,3385,Active,,,0.45,IC50,Cytostatic activity against human HeLa cells after 3 days by coulter counting analysis,Confirmatory,21330014.0,
2730,589876,3,2,,103507642,3385,Active,,,21.0,IC50,Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine,Confirmatory,21330014.0,
2731,589877,3,2,,103507642,3385,Active,,,1.3,IC50,Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine,Confirmatory,21330014.0,
2732,589878,3,2,,103507642,3385,Active,,,0.62,IC50,Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine,Confirmatory,21330014.0,
2733,589879,3,2,,103507642,3385,Active,,,0.47,IC50,Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil,Confirmatory,21330014.0,
2734,589880,3,2,,103507642,3385,Active,,,1.5,IC50,Cytostatic activity against human HeLa cells in presence of 20 uM thymidine,Confirmatory,21330014.0,
2735,589881,3,2,,103507642,3385,Active,,,0.18,IC50,Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine,Confirmatory,21330014.0,
2736,589882,3,2,,103507642,3385,Active,,,1.1,IC50,Cytostatic activity against human HeLa cells in presence of 500 uM uridine,Confirmatory,21330014.0,
2737,589883,3,2,,103507642,3385,Active,,,1.0,IC50,Cytostatic activity against human HeLa cells in presence of 500 uM uracil,Confirmatory,21330014.0,
2738,589884,3,2,,103507642,3385,Unspecified,,,500.0,IC50,Inhibition of DNA synthesis in mouse L1210 cells assessed as [methyl-3H]thymidine incorporation in to DNA by liquid scintillation counting,Confirmatory,21330014.0,
2739,589885,3,2,,103507642,3385,Active,,,0.97,IC50,Inhibition of DNA synthesis in mouse L1210 cells assessed as [6-3H]2'-deoxyuridine incorporation in to DNA by liquid scintillation counting,Confirmatory,21330014.0,
2740,589886,3,2,,103507642,3385,Unspecified,,,51.0,IC50,Inhibition of RNA synthesis in mouse L1210 cells assessed as [5-3H]uridine incorporation in to RNA by liquid scintillation counting,Confirmatory,21330014.0,
2741,589887,3,2,,103507642,3385,Unspecified,,,500.0,IC50,Inhibition of DNA synthesis in mouse L1210 cells assessed as [methyl-3H]thymidine incorporation in to DNA preincubated for 24 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2742,589888,3,2,,103507642,3385,Active,,,0.37,IC50,Inhibition of DNA synthesis in mouse L1210 cells assessed as [6-3H]2'-deoxyuridine incorporation in to DNA preincubated for 24 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2743,589889,3,2,,103507642,3385,Active,,,4.9,IC50,Inhibition of RNA synthesis in mouse L1210 cells assessed as [5-3H]uridine incorporation in to RNA preincubated for 24 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2744,589980,6,5,,103507642,3385,Active,136614.0,22171.0,7.0,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting,Confirmatory,21330014.0,
2745,589981,6,5,,103507642,3385,Active,136614.0,22171.0,0.22,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 4 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2746,589982,6,5,,103507642,3385,Active,136614.0,22171.0,0.02,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2747,589983,6,5,,103507642,3385,Unspecified,136614.0,22171.0,10.0,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting,Confirmatory,21330014.0,
2748,589984,6,5,,103507642,3385,Active,136614.0,22171.0,0.6,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 4 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2749,589985,6,5,,103507642,3385,Active,136614.0,22171.0,0.06,IC50,Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting,Confirmatory,21330014.0,
2750,589986,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Punta Toro virus infected in Vero cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2751,589987,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2752,589988,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Respiratory syncytial virus infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2753,589989,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Sindbis virus infected in Vero cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2754,589990,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Human coxsackievirus B4 infected in Vero cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2755,589991,1,4,,103507642,3385,Inactive,,,,,Antiviral activity against Human coxsackievirus B4 infected in HeLa cells assessed as inhibition of virus-induced cytopathic effect,Other,21330014.0,
2756,591402,3,2,,103507642,3385,Active,,,9.5,IC50,Cytotoxicity in human HL60 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2757,591403,3,2,,103507642,3385,Active,,,11.3,IC50,Cytotoxicity in human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2758,591404,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity in human OVCAR3 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2759,591405,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity in human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2760,591406,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity in human DU145 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2761,591407,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity in human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2762,591408,3,3,,103507642,3385,Unspecified,,,54.1,IC50,Cytotoxicity in human PANC1 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2763,591409,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity in human CRL1579 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21250700.0,
2764,594175,4,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse EAC cells assessed as cell viability using trypan blue staining after 2 hrs by hemocytometer analysis,Other,21353349.0,
2765,594564,6,1,,103507642,3385,Active,,,20.3,IC50,Antitumor activity against human EC9706 cells after 72 hrs by MTT assay,Confirmatory,21486694.0,
2766,594565,6,1,,103507642,3385,Active,,,41.46,IC50,Antitumor activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,21486694.0,
2767,594566,6,1,,103507642,3385,Active,,,29.3,IC50,Antitumor activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,21486694.0,
2768,594567,6,1,,103507642,3385,Active,,,26.92,IC50,Antitumor activity against human SPC-A1 cells after 72 hrs by MTT assay,Confirmatory,21486694.0,
2769,594568,6,1,,103507642,3385,Active,,,7.54,IC50,Antitumor activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21486694.0,
2770,594632,3,3,,103507642,3385,Active,,,31.46,IC50,Cytotoxicity against human SGC7901 after 48 hrs by MTT assay,Confirmatory,21486698.0,
2771,594633,3,2,,103507642,3385,Active,,,18.85,IC50,Cytotoxicity against human HepG2 after 48 hrs by MTT assay,Confirmatory,21486698.0,
2772,594634,3,2,,103507642,3385,Active,,,15.69,IC50,Cytotoxicity against human PC3 after 48 hrs by MTT assay,Confirmatory,21486698.0,
2773,595609,3,3,,103507642,3385,Unspecified,,,20.0,IC50,Cytotoxicity against human AZ-521 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21381696.0,
2774,595610,3,2,,103507642,3385,Unspecified,,,20.0,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21381696.0,
2775,595611,3,2,,103507642,3385,Active,,,9.1,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21381696.0,
2776,595612,3,2,,103507642,3385,Unspecified,,,20.0,IC50,Cytotoxicity against human SK-BR-3 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21381696.0,
2777,595613,3,3,,103507642,3385,Unspecified,,,20.0,IC50,Cytotoxicity against human CRL1579 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,21381696.0,
2778,595816,3,2,,103507642,3385,Active,,,2.3,GI50,Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2779,595817,3,2,,103507642,3385,Active,,,2.8,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2780,595818,3,2,,103507642,3385,Active,,,5.2,GI50,Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2781,595819,3,2,,103507642,3385,Active,,,3.1,GI50,Growth inhibition of human Gurav cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2782,595820,3,2,,103507642,3385,Active,,,6.1,GI50,Growth inhibition of human DWD cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2783,595821,3,2,,103507642,3385,Active,,,2.8,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2784,595822,3,2,,103507642,3385,Active,,,2.4,GI50,Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2785,595823,3,2,,103507642,3385,Active,,,4.1,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2786,595824,3,2,,103507642,3385,Active,,,12.0,GI50,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2787,595825,3,2,,103507642,3385,Active,,,6.3,GI50,Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2788,595826,3,2,,103507642,3385,Active,,,3.5,GI50,Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21489802.0,
2789,596195,3,2,,103507642,3385,Active,,,8.51,IC50,Anticancer activity against human HCT116 cells,Confirmatory,21449610.0,
2790,596196,3,2,,103507642,3385,Active,,,13.5,IC50,Anticancer activity against human HCC2998 cells,Confirmatory,21449610.0,
2791,596197,3,2,,103507642,3385,Active,,,9.71,IC50,Anticancer activity against human HCT15 cells,Confirmatory,21449610.0,
2792,596198,3,2,,103507642,3385,Active,,,10.2,IC50,Anticancer activity against human HT-29 cells,Confirmatory,21449610.0,
2793,596199,3,2,,103507642,3385,Active,,,8.32,IC50,Anticancer activity against human KM12 cells,Confirmatory,21449610.0,
2794,596200,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Anticancer activity against human SW620 cells,Confirmatory,21449610.0,
2795,596201,3,2,,103507642,3385,Active,,,33.1,IC50,Anticancer activity against human CCRF-CEM cells,Confirmatory,21449610.0,
2796,596204,3,2,,103507642,3385,Active,,,4.17,IC50,Anticancer activity against human COLO205 cells,Confirmatory,21449610.0,
2797,596210,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Anticancer activity against human HL60 cells,Confirmatory,21449610.0,
2798,596211,3,2,,103507642,3385,Active,,,2.4,IC50,Anticancer activity against human K562 cells,Confirmatory,21449610.0,
2799,596549,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as cell growth inhibition at 1 uM after 48 hrs by sulforhodamine B assay,Other,21482109.0,
2800,597642,3,2,,103507642,3385,Active,,,16.1,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,21515044.0,
2801,597643,3,2,,103507642,3385,Active,,,5.6,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21515044.0,
2802,597644,3,3,,103507642,3385,Active,,,14.1,IC50,Cytotoxicity against human QGY cells by MTT assay,Confirmatory,21515044.0,
2803,600319,3,2,,103507642,3385,Active,,,30.0,IC50,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Confirmatory,21439690.0,
2804,600320,3,2,,103507642,3385,Active,,,40.0,IC50,Cytotoxicity against human CEM cells after 48 hrs by MTT assay,Confirmatory,21439690.0,
2805,600321,3,2,,103507642,3385,Active,,,15.0,IC50,Cytotoxicity against human CEM cells after 48 hrs by trypan blue assay,Confirmatory,21439690.0,
2806,600322,3,2,,103507642,3385,Active,,,8.0,IC50,Cytotoxicity against human CEM cells after 72 hrs by trypan blue assay,Confirmatory,21439690.0,
2807,602123,1,1,,8139872,3385,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2808,602141,1,1,,8139872,3385,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2809,602162,1,1,,8139872,3385,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2810,602163,1,1,,8139872,3385,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2811,602179,1,2,,8139872,3385,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2812,602229,1,1,,8139872,3385,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2813,602233,1,1,,8139872,3385,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2814,602244,1,2,,8139872,3385,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2815,602247,1,2,,8139872,3385,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2816,602248,1,2,,8139872,3385,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2817,602250,1,2,,8139872,3385,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2818,602252,1,1,,8139872,3385,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2819,602252,1,1,,8139872,3385,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2820,602261,1,1,,8139872,3385,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2821,602274,1,2,,8139872,3385,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2822,602281,1,1,,8139872,3385,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2823,602281,1,1,,8139872,3385,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2824,602310,1,2,,8139872,3385,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2825,602313,1,1,,8139872,3385,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2826,602314,1,2,,92124222,3385,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2827,602329,1,1,,8139872,3385,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2828,602329,1,1,,85148656,3385,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2829,602332,1,1,,8139872,3385,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2830,602332,1,1,,90341469,3385,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2831,602332,1,1,,104171158,3385,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2832,602332,1,1,,124880118,3385,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2833,602332,1,1,,124880121,3385,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2834,602340,1,2,,8139872,3385,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2835,602342,2,1,,8139872,3385,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2836,602346,1,1,,8139872,3385,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2837,602346,1,1,,85148656,3385,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2838,602363,1,1,,8139872,3385,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2839,602363,1,1,,85148656,3385,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2840,602393,1,1,,8139872,3385,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2841,602393,1,1,,85148656,3385,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2842,602396,1,2,,8139872,3385,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2843,602399,1,2,,8139872,3385,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2844,602405,1,1,,8139872,3385,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2845,602405,1,1,,85148656,3385,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2846,602410,1,1,,8139872,3385,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2847,602429,1,1,,8139872,3385,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2848,602438,1,1,,8139872,3385,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2849,602440,1,1,,8139872,3385,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2850,602449,1,2,,8139872,3385,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2851,602481,1,1,,8139872,3385,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2852,602481,1,1,,85148656,3385,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2853,602692,1,3,,103507642,3385,Unspecified,,,,,Binding affinity to bone mineral hydroxyapatite assessed as binding index after 0.5 hrs by UV-spectrophotometer analysis relative to 5-fluorouracil,Other,21612935.0,
2854,602693,1,3,,103507642,3385,Unspecified,,,,,Binding affinity to bone mineral hydroxyapatite assessed as binding index after 24 hrs by UV-spectrophotometer analysis relative to 5-fluorouracil,Other,21612935.0,
2855,602698,3,2,,103507642,3385,Active,,,4.0,IC50,Cytotoxicity against human HeLa cells after 3 days by MTT assay,Confirmatory,21612935.0,
2856,602699,3,3,,103507642,3385,Active,,,8.0,IC50,Cytotoxicity against human MG63 cells after 3 days by MTT assay,Confirmatory,21612935.0,
2857,602748,3,2,,103507642,3385,Unspecified,,,,,AUC in mouse,Other,21612935.0,
2858,602749,1,3,,103507642,3385,Unspecified,,,,,Half life in mouse,Other,21612935.0,
2859,602750,3,2,,103507642,3385,Unspecified,,,,,Apparent volume of distribution in mouse,Other,21612935.0,
2860,602751,3,2,,103507642,3385,Unspecified,,,,,Cmax in mouse,Other,21612935.0,
2861,602752,1,4,,103507642,3385,Active,,,,,Biodistribution in po dosed mouse femur after 1 hr,Other,21612935.0,
2862,602753,1,4,,103507642,3385,Active,,,,,Biodistribution in po dosed mouse femur after 12 hrs,Other,21612935.0,
2863,603034,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 100 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
2864,603035,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 50 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
2865,603036,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability at 25 ug/mL after 48 hrs by MTT assay,Other,21531049.0,
2866,603108,3,2,,103507642,3385,Active,,,2.7000000000000004e-06,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,21640594.0,
2867,603109,3,2,,103507642,3385,Active,,,1.7e-06,IC50,Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay,Confirmatory,21640594.0,
2868,603110,3,2,,103507642,3385,Active,,,1.1e-06,IC50,Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay,Confirmatory,21640594.0,
2869,603209,3,2,,103507642,3385,Active,,,7.699999999999999e-06,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,21640594.0,
2870,606402,3,2,,103507642,3385,Active,,,14.0,IC50,Antiproliferative activity against human MIAPaCa2 cells after 48 hrs,Confirmatory,21458113.0,
2871,606403,3,2,,103507642,3385,Active,,,7.4,IC50,Antiproliferative activity against human MIAPaCa2 cells after 72 hrs,Confirmatory,21458113.0,
2872,606473,3,3,,103507642,3385,Active,,,10.0,IC50,Antiproliferative activity against human COLO320 cells after 48 hrs,Confirmatory,21458113.0,
2873,606474,3,3,,103507642,3385,Active,,,8.7,IC50,Antiproliferative activity against human COLO320 cells after 72 hrs,Confirmatory,21458113.0,
2874,607081,3,3,,103507642,3385,Active,,,13.0,IC50,Cytotoxicity against human SMMC7721 cells,Confirmatory,21495659.0,
2875,607082,3,2,,103507642,3385,Active,,,13.7,IC50,Cytotoxicity against human A549 cells,Confirmatory,21495659.0,
2876,607083,3,3,,103507642,3385,Active,,,21.8,IC50,Cytotoxicity against human Bel7402 cells,Confirmatory,21495659.0,
2877,608215,3,3,,103507642,3385,Active,,,18.5,IC50,Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2878,608216,3,2,,103507642,3385,Active,,,11.45,IC50,Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2879,608217,3,2,,103507642,3385,Active,,,3.38,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2880,608218,3,3,,103507642,3385,Unspecified,,,100.0,IC50,Antiproliferative activity against human Hep2 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2881,608219,3,3,,103507642,3385,Active,,,38.25,IC50,Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2882,608220,3,2,,103507642,3385,Active,,,42.01,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2883,608221,3,2,,103507642,3385,Active,,,10.31,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,21524829.0,
2884,608274,1,4,,103507642,3385,Unspecified,,,,,"Toxicity in KM mouse harboring mouse S180 cells xenograft assessed as body weight change at 25 mg/kg, ip administered qd for 9 days measured on 10th day (Rvb = +39.1%)",Other,21620530.0,
2885,608278,1,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 cells xenografted in KM mouse assessed as decrease in tumor weight at 25 mg/kg, ip administered qd for 9 days measured on 10th day (Rvb = 2.07+/- 0.42g)",Other,21620530.0,
2886,608359,1,4,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 cells xenografted in KM mouse assessed as tumor weight inhibition rate at 25 mg/kg, ip administered qd for 9 days measured on 10th day",Other,21620530.0,
2887,608476,1,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse Ehrlich Ascites tumor xenografted in Swiss albino mouse assessed as decrease in tumor weight at 20 mg/kg, ip administered for 9 days (Rvb = 1708+/-51.07 mg)",Other,21620534.0,
2888,608562,1,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse Ehrlich Ascites tumor xenografted in Swiss albino mouse assessed as tumor growth inhibition at 20 mg/kg, ip administered for 9 days measured on day 13",Other,21620534.0,
2889,610634,3,2,,103507642,3385,Active,,,11.0,IC50,Antiproliferative activity against human fibroblasts after 48 hrs by resazurin reduction test,Confirmatory,21530016.0,
2890,610635,3,2,,103507642,3385,Active,,,15.0,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by resazurin reduction test,Confirmatory,21530016.0,
2891,610636,3,3,,103507642,3385,Active,,,5.0,IC50,Antiproliferative activity against human PA1 cells after 48 hrs by resazurin reduction test,Confirmatory,21530016.0,
2892,614236,1,4,,103507642,3385,Unspecified,,,,,Inhibition of RNA synthesis in Mucor mucedo IFO 7684 assessed as [8-14C]-adenine uptake into acid-insoluble fractions at 0.77 mM after 25 mins by liquid scintillation counting,Other,21885289.0,
2893,614237,1,4,,103507642,3385,Unspecified,,,,,Inhibition of DNA synthesis in Mucor mucedo IFO 7684 assessed as [8-14C]-adenine uptake into acid-insoluble fractions at 0.77 mM after 25 mins by liquid scintillation counting,Other,21885289.0,
2894,615261,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,21689869.0,
2895,615262,3,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,21689869.0,
2896,615488,3,2,,103507642,3385,Active,,,4.32,IC50,Cytotoxicity against human MCF7 cells after 6 days by SRB colorimetric assay,Confirmatory,21684047.0,
2897,615489,3,3,,103507642,3385,Active,,,0.73,IC50,Cytotoxicity against human MCF10A cells after 6 days by SRB colorimetric assay,Confirmatory,21684047.0,
2898,615490,1,4,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MCF10A cells to IC50 for human MCF7 cells",Other,21684047.0,
2899,615491,3,2,,103507642,3385,Active,,,1.08,IC50,Cytotoxicity against human HT-29 cells after 6 days by SRB colorimetric assay,Confirmatory,21684047.0,
2900,615492,3,3,,103507642,3385,Active,,,0.66,IC50,Cytotoxicity against rat IEC-6 cells after 6 days by SRB colorimetric assay,Confirmatory,21684047.0,
2901,615493,1,4,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for rat IEC-6 cells to IC50 for human HT-29 cells",Other,21684047.0,
2902,615637,1,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse EAC cells xenografted in Swiss albino mouse assessed as increase in lifespan of organism at 20 mg/kg, ip administered 24 hrs post inoculation for 9 days",Other,21705114.0,
2903,615639,1,4,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse xenografted with mouse EAC assessed as haemoglobin level at 20 mg/kg, ip (Rvb = 13.4 per g%)",Other,21705114.0,
2904,615712,1,4,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse xenografted with mouse EAC assessed as RBC level at 20 mg/kg, ip (Rvb = 5.1/10'6 mm-3)",Other,21705114.0,
2905,615714,1,4,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse xenografted with mouse EAC assessed as total WBC level at 20 mg/kg, ip (Rvb = 4.35/10'3 mm3)",Other,21705114.0,
2906,615716,1,4,,103507642,3385,Unspecified,,,,,"Toxicity in Swiss albino mouse xenografted with mouse EAC assessed as ALT level at 20 mg/kg, ip (Rvb = 3.7 u/L)",Other,21705114.0,
2907,615718,1,5,,103507642,3385,Active,,,,,"Antitumor activity against mouse EAC cells xenografted in Swiss albino mouse assessed as reduction in viable tumor cells at 20 mg/kg, ip after 5 days using giemsa staining by microscopy",Other,21705114.0,
2908,616883,3,2,,103507642,3385,Active,,,3.3,IC50,Cytotoxicity against human DU145 cells,Confirmatory,21774474.0,
2909,616884,3,2,,103507642,3385,Unspecified,,,109.0,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,21774474.0,
2910,616885,3,2,,103507642,3385,Active,,,31.0,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,21774474.0,
2911,616886,3,2,,103507642,3385,Active,,,8.5,IC50,Cytotoxicity against human NCI-H460 cells,Confirmatory,21774474.0,
2912,616887,3,2,,103507642,3385,Unspecified,,,59.0,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,21774474.0,
2913,616888,3,2,,103507642,3385,Unspecified,,,121.0,IC50,Cytotoxicity against human SW1990 cells,Confirmatory,21774474.0,
2914,616889,3,2,,103507642,3385,Unspecified,,,52.0,IC50,Cytotoxicity against human A549 cells,Confirmatory,21774474.0,
2915,620601,3,2,,103507642,3385,Active,,,12.5,IC50,Cytotoxicity against human KB cells after 3 days by MTT assay,Confirmatory,21843939.0,
2916,622358,4,2,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Other,21889345.0,
2917,622359,4,2,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Other,21889345.0,
2918,622360,4,3,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay,Other,21889345.0,
2919,622361,4,3,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay,Other,21889345.0,
2920,623870,1,1,,8139872,3385,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2921,623870,1,1,,8139872,3385,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2922,623870,1,1,,85148656,3385,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2923,623870,1,1,,85148656,3385,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2924,623877,1,1,,8139872,3385,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2925,623901,1,1,,8139872,3385,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2926,624030,1,2,,104171158,3385,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2927,624031,1,2,,104171158,3385,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2928,624032,1,2,,104171158,3385,Inconclusive,8393992.0,24660.0,14.3818,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2929,624037,1,3,,8139872,3385,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2930,624038,1,3,,8139872,3385,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2931,624040,1,3,,8139872,3385,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2932,624044,1,2,,104171158,3385,Active,8393992.0,24660.0,5.6192,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2933,624125,1,4,,8139872,3385,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2934,624126,1,3,,8139872,3385,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2935,624127,1,2,,8139872,3385,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2936,624146,1,1,,90341469,3385,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2937,624147,1,1,,90341469,3385,Inconclusive,62359610.0,,31.6228,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2938,624148,1,2,,90341469,3385,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2939,624149,1,1,,90341469,3385,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2940,624168,1,1,,8139872,3385,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2941,624169,1,1,,8139872,3385,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2942,624170,1,1,,8139872,3385,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2943,624170,1,1,,104171158,3385,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2944,624171,1,1,,8139872,3385,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2945,624172,1,1,,8139872,3385,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2946,624172,1,1,,104171158,3385,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2947,624173,1,3,,8139872,3385,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2948,624173,1,3,,104171158,3385,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2949,624178,1,1,,8139872,3385,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2950,624202,1,1,,8139872,3385,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2951,624204,1,2,,8139872,3385,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2952,624246,1,1,,8139872,3385,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2953,624256,1,2,,8139872,3385,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2954,624258,1,1,,8139872,3385,Active,458922.0,,9.32,AbsAC40_uM,In vivo-based yeast HTS counterscreen to detect compounds rescuing yeast growth/survival of Saccharomyces cerevisiae SKN7-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2955,624263,1,1,,8139872,3385,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2956,624263,1,1,,8139872,3385,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2957,624267,1,2,,8139872,3385,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2958,624267,1,2,,8139872,3385,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2959,624268,1,3,,8139872,3385,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2960,624288,1,1,,8139872,3385,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2961,624296,1,1,,8139872,3385,Inconclusive,7705682.0,51053.0,25.929000000000002,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2962,624296,1,1,,17389875,3385,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2963,624296,1,1,,104171158,3385,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2964,624297,1,1,,8139872,3385,Inactive,7705682.0,51053.0,1.2589,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2965,624297,1,1,,17389875,3385,Inactive,7705682.0,51053.0,3.505,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2966,624297,1,1,,104171158,3385,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2967,624304,1,2,,8139872,3385,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2968,624330,1,2,,8139872,3385,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2969,624349,1,2,,92124222,3385,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2970,624349,1,2,,92307309,3385,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2971,624349,1,2,,92309160,3385,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2972,624349,1,2,,121362603,3385,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2973,624352,1,1,,8139872,3385,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2974,624354,1,1,,8139872,3385,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2975,624377,1,1,,8139872,3385,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2976,624414,1,1,,8139872,3385,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2977,624415,1,2,,8139872,3385,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2978,624416,1,1,,8139872,3385,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2979,624417,1,1,,8139872,3385,Inconclusive,1724069.0,2740.0,11.2202,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2980,624418,1,1,,8139872,3385,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2981,624455,1,1,,90341469,3385,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2982,624463,1,1,,8139872,3385,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2983,624464,1,1,,8139872,3385,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2984,624465,1,1,,8139872,3385,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2985,624466,1,3,,8139872,3385,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2986,624467,1,1,,8139872,3385,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2987,624483,1,1,,8139872,3385,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2988,625144,5,5,,103507642,3385,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2989,625145,4,7,,103507642,3385,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2990,625146,5,5,,103507642,3385,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2991,625147,4,7,,103507642,3385,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2992,625148,4,7,,103507642,3385,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2993,625149,4,7,,103507642,3385,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2994,625150,5,5,,103507642,3385,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2995,625151,4,7,,103507642,3385,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2996,625152,4,7,,103507642,3385,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2997,625153,4,7,,103507642,3385,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2998,625154,4,7,,103507642,3385,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2999,625155,4,7,,103507642,3385,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
3000,625156,1,9,,103507642,3385,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
3001,625157,6,2,,103507642,3385,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
3002,625158,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
3003,625159,5,5,,103507642,3385,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
3004,625160,1,9,,103507642,3385,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
3005,625161,4,7,,103507642,3385,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
3006,625162,4,7,,103507642,3385,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3007,625163,4,7,,103507642,3385,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
3008,625164,1,6,,103507642,3385,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
3009,625165,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3010,625166,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
3011,625167,5,5,,103507642,3385,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
3012,625168,4,7,,103507642,3385,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
3013,625169,1,6,,103507642,3385,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
3014,625170,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
3015,625171,4,7,,103507642,3385,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
3016,625172,4,7,,103507642,3385,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
3017,625173,5,5,,103507642,3385,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
3018,625174,5,5,,103507642,3385,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
3019,625175,5,5,,103507642,3385,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
3020,625176,1,9,,103507642,3385,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
3021,625177,5,5,,103507642,3385,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3022,625178,5,5,,103507642,3385,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
3023,625179,1,9,,103507642,3385,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
3024,625180,5,5,,103507642,3385,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3025,625181,5,5,,103507642,3385,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3026,625182,5,5,,103507642,3385,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
3027,625183,5,5,,103507642,3385,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
3028,625184,5,5,,103507642,3385,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3029,625185,5,5,,103507642,3385,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3030,625186,5,5,,103507642,3385,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3031,625187,5,5,,103507642,3385,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
3032,625188,1,9,,103507642,3385,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
3033,625189,1,7,,103507642,3385,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
3034,625190,4,5,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
3035,625191,4,7,,103507642,3385,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3036,625192,4,7,,103507642,3385,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
3037,625193,5,5,,103507642,3385,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
3038,625194,4,7,,103507642,3385,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
3039,625195,4,7,,103507642,3385,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
3040,625196,5,6,,103507642,3385,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
3041,625197,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
3042,625198,4,7,,103507642,3385,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3043,625199,4,7,,103507642,3385,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3044,625200,4,7,,103507642,3385,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
3045,625201,4,7,,103507642,3385,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
3046,625202,4,7,,103507642,3385,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
3047,625203,4,7,,103507642,3385,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
3048,625204,4,7,,103507642,3385,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3049,625205,4,7,,103507642,3385,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
3050,625206,4,7,,103507642,3385,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
3051,625207,4,7,,103507642,3385,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3052,625208,5,5,,103507642,3385,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
3053,625209,4,7,,103507642,3385,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
3054,625210,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
3055,625211,1,6,,103507642,3385,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
3056,625212,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
3057,625213,4,7,,103507642,3385,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
3058,625214,1,9,,103507642,3385,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
3059,625215,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
3060,625216,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
3061,625217,4,7,,103507642,3385,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3062,625218,4,7,,103507642,3385,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
3063,625219,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
3064,625220,4,7,,103507642,3385,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
3065,625221,4,7,,103507642,3385,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
3066,625222,4,7,,103507642,3385,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
3067,625223,4,7,,103507642,3385,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
3068,625224,3,4,,103507642,3385,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
3069,625225,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
3070,625226,4,7,,103507642,3385,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
3071,625227,4,7,,103507642,3385,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
3072,625228,4,7,,103507642,3385,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
3073,625229,5,5,,103507642,3385,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
3074,625230,1,6,,103507642,3385,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
3075,625231,4,7,,103507642,3385,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
3076,625232,1,9,,103507642,3385,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
3077,625233,4,7,,103507642,3385,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
3078,625234,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
3079,625235,4,7,,103507642,3385,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
3080,625236,5,5,,103507642,3385,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
3081,625237,4,7,,103507642,3385,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
3082,625238,4,7,,103507642,3385,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
3083,625239,4,7,,103507642,3385,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
3084,625240,1,9,,103507642,3385,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
3085,625241,4,7,,103507642,3385,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
3086,625242,4,7,,103507642,3385,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
3087,625243,5,5,,103507642,3385,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3088,625244,5,5,,103507642,3385,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
3089,625245,5,5,,103507642,3385,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3090,625246,1,9,,103507642,3385,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
3091,625247,5,5,,103507642,3385,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3092,625248,5,5,,103507642,3385,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3093,625249,5,5,,103507642,3385,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3094,625250,5,5,,103507642,3385,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
3095,625251,5,5,,103507642,3385,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
3096,625252,4,7,,103507642,3385,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
3097,625253,4,7,,103507642,3385,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3098,625254,4,7,,103507642,3385,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3099,625255,4,7,,103507642,3385,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
3100,625256,4,7,,103507642,3385,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
3101,625257,4,7,,103507642,3385,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
3102,625258,4,7,,103507642,3385,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3103,625259,4,7,,103507642,3385,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
3104,625260,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
3105,625261,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
3106,625262,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
3107,625263,4,7,,103507642,3385,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
3108,625264,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
3109,625265,1,6,,103507642,3385,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
3110,625266,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
3111,625267,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
3112,625268,4,2,,103507642,3385,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3113,625268,4,2,,103507642,3385,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3114,625268,4,2,,103507642,3385,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3115,625268,4,2,,103507642,3385,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
3116,625269,4,7,,103507642,3385,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
3117,625270,4,7,,103507642,3385,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
3118,625271,5,5,,103507642,3385,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
3119,625272,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
3120,625273,4,6,,103507642,3385,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
3121,625274,1,6,,103507642,3385,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
3122,625275,3,4,,103507642,3385,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
3123,625279,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
3124,625280,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
3125,625281,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
3126,625282,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
3127,625283,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
3128,625284,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
3129,625285,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
3130,625286,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
3131,625287,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
3132,625288,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
3133,625289,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
3134,625290,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
3135,625291,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
3136,625292,1,3,,103507642,3385,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
3137,625524,3,2,,103507642,3385,Active,,,0.42,IC50,Cytotoxicity against human A549 cells after 3 days by MTT assay,Confirmatory,22000925.0,
3138,625525,3,2,,103507642,3385,Active,,,2.7,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,22000925.0,
3139,625526,3,3,,103507642,3385,Active,,,6.15,IC50,Cytotoxicity against human BCG823 cells after 3 days by MTT assay,Confirmatory,22000925.0,
3140,625527,3,3,,103507642,3385,Unspecified,,,72.9,IC50,Cytotoxicity against human BT474 cells after 3 days by MTT assay,Confirmatory,22000925.0,
3141,625608,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as G1-phase DNA content at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 40.71%),Other,22000925.0,
3142,625609,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as G1-phase DNA content at 2 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 40.71%),Other,22000925.0,
3143,625611,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as G2-phase DNA content at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 30.55 %),Other,22000925.0,
3144,625612,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as G2-phase DNA content at 2 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 30.55 %),Other,22000925.0,
3145,625614,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as S-phase DNA content at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 28.74 %),Other,22000925.0,
3146,625615,1,4,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HepG2 cells assessed as S-phase DNA content at 2 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 28.74 %),Other,22000925.0,
3147,627331,3,2,,103507642,3385,Active,,,0.49,IC50,Cytostatic activity against mouse L1210 cells,Confirmatory,21917363.0,
3148,627332,3,2,,103507642,3385,Active,,,18.0,IC50,Cytostatic activity against human CEM cells,Confirmatory,21917363.0,
3149,627333,3,2,,103507642,3385,Active,,,0.54,IC50,Cytostatic activity against human HeLa cells,Confirmatory,21917363.0,
3150,628879,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HEK293 cells assessed as cell survival at 30 uM after 48 hrs by MTT assay,Other,21644529.0,
3151,630275,1,5,,103507642,3385,Active,,,,,"Antitumor activity against mouse Ehrlich Ascitic tumor xenografted in BALB/c mouse assessed as reduction of tumor volume in paw at 10 mg/kg, ip administered every 3 days for 15 days measured on day 9 by plethysmograph analysis",Other,21944971.0,
3152,630393,3,2,,103507642,3385,Unspecified,,,110.01,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,21962523.0,
3153,630394,3,2,,103507642,3385,Unspecified,,,110.16,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,21962523.0,
3154,630395,3,3,,103507642,3385,Unspecified,,,95.17,IC50,Antiproliferative activity against human SW1116 cells after 48 hrs by MTT assay,Confirmatory,21962523.0,
3155,630396,3,3,,103507642,3385,Unspecified,,,100.02,IC50,Antiproliferative activity against human BGC823 cells after 48 hrs by MTT assay,Confirmatory,21962523.0,
3156,633704,3,2,,103507642,3385,Active,,,15.1,GI50,Growth inhibition of human leukemia cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3157,633705,3,2,,103507642,3385,Unspecified,,,100.0,GI50,Growth inhibition of human NSCLC cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3158,633706,3,2,,103507642,3385,Active,,,8.4,GI50,Growth inhibition of human colon cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3159,633707,3,2,,103507642,3385,Unspecified,,,72.1,GI50,Growth inhibition of human CNS cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3160,633708,3,2,,103507642,3385,Unspecified,,,70.6,GI50,Growth inhibition of human Melanoma cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3161,633709,3,2,,103507642,3385,Unspecified,,,61.4,GI50,Growth inhibition of human ovarian cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3162,633710,3,2,,103507642,3385,Active,,,45.6,GI50,Growth inhibition of human renal cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3163,633711,3,2,,103507642,3385,Active,,,22.7,GI50,Growth inhibition of human prostate cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3164,633788,3,2,,103507642,3385,Unspecified,,,76.4,GI50,Growth inhibition of human breast cancer cells after 48 hrs by coulter counter method,Confirmatory,22119151.0,
3165,634900,3,3,,103507642,3385,Unspecified,,,85.5,IC50,Cytotoxicity against human HO8910 cells after 2 days by alamar blue assay,Confirmatory,22093761.0,
3166,634901,3,3,,103507642,3385,Unspecified,,,76.0,IC50,Cytotoxicity against human SGC7901 cells after 2 days by alamar blue assay,Confirmatory,22093761.0,
3167,634902,3,2,,103507642,3385,Unspecified,,,76.7,IC50,Cytotoxicity against human HepG2 cells after 2 days by alamar blue assay,Confirmatory,22093761.0,
3168,634904,3,2,,103507642,3385,Active,,,42.9,IC50,Cytotoxicity against human HEK293 cells after 2 days by alamar blue assay,Confirmatory,22093761.0,
3169,635049,3,2,,103507642,3385,Active,,,9.85,IC50,Antiproliferative activity against human KB cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3170,635050,3,3,,103507642,3385,Active,,,17.2,IC50,Antiproliferative activity against human CNE2 cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3171,635051,3,4,,103507642,3385,Active,,,16.6,IC50,Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3172,635052,3,3,,103507642,3385,Active,,,15.5,IC50,Antiproliferative activity against human GLC82 cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3173,635053,3,2,,103507642,3385,Unspecified,,,50.0,IC50,Antiproliferative activity against human MDA-MB-453 cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3174,635054,3,2,,103507642,3385,Active,,,9.67,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22079378.0,
3175,635119,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human Caco2 cells at 20 uM after 48 hrs by SRB assay,Other,22071256.0,
3176,635122,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human THP1 cells at 20 uM after 48 hrs by SRB assay,Other,22071256.0,
3177,635699,3,3,,103507642,3385,Active,,,15.1,GI50,Cytotoxicity against human leukemia cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3178,635700,3,3,,103507642,3385,Active,,,8.4,GI50,Cytotoxicity against human colon cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3179,635701,3,3,,103507642,3385,Unspecified,,,72.1,GI50,Cytotoxicity against human CNS cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3180,635702,3,3,,103507642,3385,Unspecified,,,70.6,GI50,Cytotoxicity against human melanoma cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3181,635703,3,3,,103507642,3385,Active,,,45.6,GI50,Cytotoxicity against human renal cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3182,635704,3,3,,103507642,3385,Unspecified,,,61.4,GI50,Cytotoxicity against human ovarian cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3183,635705,3,3,,103507642,3385,Active,,,22.7,GI50,Cytotoxicity against human prostate cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3184,635706,3,3,,103507642,3385,Unspecified,,,76.4,GI50,Cytotoxicity against human breast cancer cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3185,635707,3,2,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against human NSCLC cells after 48 hrs by coulter counting,Confirmatory,22056277.0,
3186,635948,1,5,,103507642,3385,Unspecified,,,,,Growth inhibition of human IMR32 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3187,635949,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human SK-N-SH cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3188,635950,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human SiHa cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3189,635951,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human SW620 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3190,635952,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT15 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3191,635953,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human 502713 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3192,635957,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR5 cells at 10 uM by sulforhodamine B assay,Other,22047801.0,
3193,636970,3,2,,103507642,3385,Active,,,5.64,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
3194,636971,3,3,,103507642,3385,Active,,,14.3,IC50,Cytotoxicity against human QGY7701 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
3195,636972,3,2,,103507642,3385,Active,,,16.32,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
3196,636973,3,2,,103507642,3385,Active,,,15.71,IC50,Cytotoxicity against human SW480 cells after 24 hrs by MTT assay,Confirmatory,22182926.0,
3197,637246,3,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Other,22154835.0,
3198,637247,3,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Other,22154835.0,
3199,637448,3,2,,103507642,3385,Active,,,9.0,IC50,Cytotoxicity against human KB cells after 72 hrs ny MTT assay,Confirmatory,22200404.0,
3200,637449,3,3,,103507642,3385,Active,,,13.5,IC50,Cytotoxicity against human CNE2 cells after 72 hrs ny MTT assay,Confirmatory,22200404.0,
3201,637492,3,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay,Other,22204901.0,
3202,637493,3,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human WI38 cells after 96 hrs by MTT assay,Other,22204901.0,
3203,637494,3,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay,Other,22204901.0,
3204,637495,3,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Other,22204901.0,
3205,638251,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells by MTT assay,Other,22011319.0,
3206,638252,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells by MTT assay,Other,22011319.0,
3207,638253,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells by MTT assay,Other,22011319.0,
3208,638254,5,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells by MTT assay,Other,22011319.0,
3209,638255,5,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SMMC7721 cells by MTT assay,Other,22011319.0,
3210,638256,5,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MKN45 cells by MTT assay,Other,22011319.0,
3211,638412,1,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3212,638413,1,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3213,638414,1,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3214,638415,1,5,,103507642,3385,Unspecified,,,,,Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3215,638416,1,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3216,638417,1,4,,103507642,3385,Unspecified,,,,,Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay,Other,22123322.0,
3217,644045,3,2,,103507642,3385,Unspecified,,,68.3,IC50,Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay,Confirmatory,22244588.0,
3218,644046,3,2,,103507642,3385,Unspecified,,,54.8,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22244588.0,
3219,644047,3,2,,103507642,3385,Unspecified,,,82.2,IC50,Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay,Confirmatory,22244588.0,
3220,644048,3,2,,103507642,3385,Unspecified,,,218.0,IC50,Cytotoxicity against human SiHa cells after 48 hrs by MTT assay,Confirmatory,22244588.0,
3221,644096,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human A549 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3222,644097,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human PC3 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3223,644098,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR5 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3224,644099,1,5,,103507642,3385,Unspecified,,,,,Growth inhibition of human IMR32 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3225,644100,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human HeLa cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3226,644101,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human THP1 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3227,644122,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human DU145 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3228,644131,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT15 cells at 20 uM after 48 hrs by sulpharhodamine B assay,Other,22245048.0,
3229,644642,5,1,,103507642,3385,Active,,,0.0238,GI50,Cytotoxicity against human SR cells after 48 hrs by SRB assay,Confirmatory,22305543.0,
3230,644651,5,1,,103507642,3385,Active,,,7.28,GI50,Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay,Confirmatory,22305543.0,
3231,645581,3,2,,103507642,3385,Active,,,14.0,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22130132.0,
3232,645582,3,2,,103507642,3385,Active,,,4.0,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,22130132.0,
3233,645583,3,2,,103507642,3385,Active,,,3.0,IC50,Cytotoxicity against human H460 cells after 72 hrs by MTT assay,Confirmatory,22130132.0,
3234,648133,3,3,,103507642,3385,Active,,,7.9,IC50,Antiproliferative activity against human WHCO1 cells after 48 hrs by MTT assay,Confirmatory,22381354.0,
3235,648738,3,2,,103507642,3385,Unspecified,,,266.0,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22424614.0,
3236,648739,3,2,,103507642,3385,Active,,,2.1,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22424614.0,
3237,648740,3,2,,103507642,3385,Active,,,3.2,IC50,Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,22424614.0,
3238,651550,1,1,,8139872,3385,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
3239,651560,1,1,,8139872,3385,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
3240,651572,1,2,,8139872,3385,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
3241,651582,1,1,,8139872,3385,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
3242,651602,1,1,,8139872,3385,Active,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3243,651602,1,1,,8139872,3385,Active,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3244,651602,1,1,,8139872,3385,Active,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
3245,651631,4,1,,144203701,3385,Active,269849759.0,7157.0,4.2163,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3246,651631,4,1,,144209533,3385,Active,269849759.0,7157.0,3.5674,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3247,651631,4,1,,144210432,3385,Active,269849759.0,7157.0,1.5699,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
3248,651632,4,1,,144203701,3385,Active,296439460.0,79915.0,7.4978,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3249,651632,4,1,,144209533,3385,Active,296439460.0,79915.0,10.0542,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3250,651632,4,1,,144210432,3385,Inconclusive,296439460.0,79915.0,7.8684,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
3251,651633,4,1,,144203701,3385,Active,,,1.0591,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3252,651633,4,1,,144209533,3385,Inconclusive,,,0.3567,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3253,651633,4,1,,144210432,3385,Active,,,0.9906,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
3254,651634,4,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3255,651634,4,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3256,651634,4,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
3257,651635,1,3,,8139872,3385,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3258,651635,1,3,,90341469,3385,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
3259,651636,1,1,,8139872,3385,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
3260,651640,1,1,,8139872,3385,Inconclusive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
3261,651644,1,1,,8139872,3385,Inconclusive,28872817.0,155807.0,10.0,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
3262,651647,1,1,,8139872,3385,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
3263,651654,1,1,,8139872,3385,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3264,651654,1,1,,85148656,3385,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3265,651658,1,1,,8139872,3385,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3266,651660,1,1,,8139872,3385,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3267,651661,2,1,,8139872,3385,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3268,651687,1,1,,8139872,3385,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3269,651699,1,1,,8139872,3385,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3270,651699,1,1,,8139872,3385,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
3271,651702,1,2,,8139872,3385,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
3272,651704,2,1,,8139872,3385,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3273,651710,1,1,,8139872,3385,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3274,651711,2,1,,8139872,3385,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3275,651718,1,2,,8139872,3385,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
3276,651723,1,1,,8139872,3385,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
3277,651724,1,1,,8139872,3385,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
3278,651725,1,1,,8139872,3385,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
3279,651741,1,1,,17389875,3385,Inconclusive,20149576.0,4780.0,10.5909,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3280,651743,1,1,,17389875,3385,Active,269849759.0,7157.0,3.9811,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
3281,651749,1,1,,17389875,3385,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
3282,651751,1,1,,17389875,3385,Inactive,5702233.0,84385.0,56.2341,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
3283,651754,1,1,,17389875,3385,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
3284,651755,1,1,,17389875,3385,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
3285,651757,1,1,,17389875,3385,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
3286,651758,1,1,,17389875,3385,Inconclusive,186368.0,3576.0,66.8242,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
3287,651768,1,2,,8139872,3385,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3288,651777,1,1,,17389875,3385,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3289,651778,1,1,,17389875,3385,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3290,651800,1,1,,8139872,3385,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3291,651802,1,1,,17389875,3385,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3292,651819,1,1,,8139872,3385,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3293,651820,1,1,,8139872,3385,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3294,651821,2,4,,8139872,3385,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3295,651828,1,2,,92309160,3385,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3296,651828,1,2,,121361357,3385,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3297,651828,1,2,,121362603,3385,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3298,651838,1,1,,17389875,3385,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3299,651838,1,1,1.0,17389875,3385,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3300,651838,1,1,2.0,17389875,3385,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3301,651838,1,1,3.0,17389875,3385,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3302,651838,1,1,4.0,17389875,3385,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3303,651838,1,1,5.0,17389875,3385,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3304,651838,1,1,6.0,17389875,3385,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3305,651838,1,1,7.0,17389875,3385,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3306,651838,1,1,8.0,17389875,3385,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3307,651957,1,1,,8139872,3385,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3308,651958,1,1,,8139872,3385,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3309,651965,1,1,,8139872,3385,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3310,651982,1,1,,8139872,3385,Active,16130723.0,947287.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3311,651982,1,1,,8139872,3385,Active,16130724.0,947286.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3312,651982,1,1,,8139872,3385,Active,16130726.0,947294.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
3313,651983,1,1,,8139872,3385,Active,,,,,Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,Screening,,
3314,651984,1,1,,8139872,3385,Active,15645703.0,899625.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
3315,651984,1,1,,8139872,3385,Active,15646160.0,899738.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
3316,651999,1,1,,8139872,3385,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3317,652010,1,1,,8139872,3385,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3318,652017,1,1,,8139872,3385,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3319,652025,1,1,,8139872,3385,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3320,652039,1,1,,8139872,3385,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3321,652048,1,2,,8139872,3385,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3322,652048,1,2,,144203701,3385,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3323,652051,1,1,,8139872,3385,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3324,652051,1,1,,144203701,3385,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3325,652054,1,1,,8139872,3385,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3326,652067,1,4,,8139872,3385,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3327,652104,1,1,,8139872,3385,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3328,652105,1,1,,8139872,3385,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3329,652106,1,1,,8139872,3385,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3330,652106,1,1,,90341469,3385,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3331,652115,1,1,,8139872,3385,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3332,652126,1,3,,8139872,3385,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3333,652154,1,1,,8139872,3385,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3334,652162,2,1,,8139872,3385,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3335,652163,1,1,,8139872,3385,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3336,652163,1,1,,85148656,3385,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3337,652197,1,1,,8139872,3385,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3338,652257,1,1,,8139872,3385,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3339,652628,2,2,,103507642,3385,Active,,,25.0,LC50,Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay,Confirmatory,22381050.0,
3340,653267,2,2,,103507642,3385,Active,,,0.49,IC50,Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis,Confirmatory,22405290.0,
3341,653268,2,2,,103507642,3385,Active,,,18.0,IC50,Cytostatic activity against human CEM cells after 3 days by coulter counter analysis,Confirmatory,22405290.0,
3342,653269,2,2,,103507642,3385,Active,,,0.54,IC50,Cytostatic activity against human HeLa cells after 3 days by coulter counter analysis,Confirmatory,22405290.0,
3343,653270,2,2,,103507642,3385,Active,,,4.0,IC50,Cytostatic activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,22405290.0,
3344,653271,2,2,,103507642,3385,Active,,,15.0,IC50,Cytostatic activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22405290.0,
3345,653272,2,2,,103507642,3385,Active,,,3.0,IC50,Cytostatic activity against human NCI-H460 cells after 72 hrs by MTT assay,Confirmatory,22405290.0,
3346,653273,2,2,,103507642,3385,Active,,,0.3,IC50,Cytostatic activity against human HaCaT cells after 72 hrs by MTT assay,Confirmatory,22405290.0,
3347,653485,2,4,,103507642,3385,Active,,,3.42,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,22405648.0,
3348,653486,2,2,,103507642,3385,Active,,,5.33,IC50,Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay,Confirmatory,22405648.0,
3349,653487,2,3,,103507642,3385,Active,,,7.11,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,22405648.0,
3350,654074,2,2,,103507642,3385,Active,,,4.17,IC50,Cytotoxicity against human COLO205 cells,Confirmatory,22409967.0,
3351,654075,2,2,,103507642,3385,Active,,,13.5,IC50,Cytotoxicity against human HCC2998 cells,Confirmatory,22409967.0,
3352,654076,2,2,,103507642,3385,Active,,,8.51,IC50,Cytotoxicity against human HCT116 cells,Confirmatory,22409967.0,
3353,654077,2,2,,103507642,3385,Active,,,9.71,IC50,Cytotoxicity against human HCT15 cells,Confirmatory,22409967.0,
3354,654078,2,2,,103507642,3385,Active,,,10.2,IC50,Cytotoxicity against human HT-29 cells,Confirmatory,22409967.0,
3355,654079,2,2,,103507642,3385,Active,,,8.32,IC50,Cytotoxicity against human KM12 cells,Confirmatory,22409967.0,
3356,654080,2,2,,103507642,3385,Unspecified,,,380.0,IC50,Cytotoxicity against human SW620 cells,Confirmatory,22409967.0,
3357,654081,2,4,,103507642,3385,Unspecified,,,2512.0,IC50,Cytotoxicity against human HL-60(TB) cells,Confirmatory,22409967.0,
3358,654082,2,2,,103507642,3385,Active,,,2.4,IC50,Cytotoxicity against human K562 cells,Confirmatory,22409967.0,
3359,654560,2,2,,103507642,3385,Unspecified,,,108.0,IC50,Cytotoxicity against human HeLa cells,Confirmatory,22283451.0,
3360,654561,2,2,,103507642,3385,Unspecified,,,108.0,IC50,Cytotoxicity against human HepG2 cells,Confirmatory,22283451.0,
3361,654562,2,2,,103507642,3385,Active,,,31.0,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,22283451.0,
3362,654563,2,2,,103507642,3385,Unspecified,,,62.0,IC50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,22283451.0,
3363,654564,2,2,,103507642,3385,Active,,,8.0,IC50,Cytotoxicity against human NCI-H460 cells,Confirmatory,22283451.0,
3364,654565,2,3,,103507642,3385,Active,,,15.0,IC50,Cytotoxicity against human SMMC7721 cells,Confirmatory,22283451.0,
3365,654566,2,2,,103507642,3385,Unspecified,,,123.0,IC50,Cytotoxicity against human SW1990 cells,Confirmatory,22283451.0,
3366,654895,2,2,,103507642,3385,Active,,,33.0,IC50,Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3367,654896,2,2,,103507642,3385,Active,,,34.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3368,654897,2,2,,103507642,3385,Active,,,45.0,IC50,Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3369,654898,2,2,,103507642,3385,Active,,,43.0,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3370,654899,2,2,,103507642,3385,Active,,,29.0,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3371,654900,2,2,,103507642,3385,Active,,,35.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22304344.0,
3372,657128,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT116 cells at 20 uM after 48 hrs by SRB assay,Other,22472045.0,
3373,657129,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human THP1 cells at 20 uM after 48 hrs by SRB assay,Other,22472045.0,
3374,657320,2,2,,103507642,3385,Active,,,35.05,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22483608.0,
3375,657321,2,2,,103507642,3385,Active,,,31.72,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,22483608.0,
3376,657322,2,2,,103507642,3385,Active,,,46.31,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22483608.0,
3377,657323,2,3,,103507642,3385,Active,,,23.47,IC50,Cytotoxicity against human PC9 cells after 48 hrs by MTT assay,Confirmatory,22483608.0,
3378,657324,2,2,,103507642,3385,Active,,,46.55,IC50,Cytotoxicity against human A375 cells after 48 hrs by MTT assay,Confirmatory,22483608.0,
3379,658408,2,2,,103507642,3385,Active,,,4.7,IC50,Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 144 hrs by crystal violet staining method,Confirmatory,22450132.0,
3380,658409,2,2,,103507642,3385,Active,,,9.6,IC50,Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 144 hrs by crystal violet staining method,Confirmatory,22450132.0,
3381,658410,2,2,,103507642,3385,Active,,,7.3,IC50,Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 144 hrs by crystal violet staining method,Confirmatory,22450132.0,
3382,658513,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human HCT116 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3383,658514,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human HCT15 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3384,658515,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human DU145 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3385,658516,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human PC3 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3386,658979,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3387,658980,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human IGROV1 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3388,658981,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human OVCAR5 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3389,658983,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human SF295 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3390,658984,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human U251 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3391,658985,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3392,658986,2,4,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human DMS114 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3393,658987,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human NCI-H69 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3394,658988,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human H69AR cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3395,658989,2,4,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human HL-60(TB) cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3396,658990,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3397,658991,2,4,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3398,658992,2,4,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3399,658994,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of HUVEC cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3400,658995,2,3,,103507642,3385,Unspecified,,,,GI50,Growth inhibition of human MSC cells after 48 hrs by SRB assay,Confirmatory,22512908.0,
3401,659001,1,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as reduction in tumor volume at 17 mg/kg, ip twice a week",Other,22512908.0,
3402,659002,1,5,,103507642,3385,Unspecified,,,,,"Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as tumor weight at 17 mg/kg, ip twice a week (Rvb = 723 +/- 45 mg)",Other,22512908.0,
3403,663982,2,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
3404,663984,2,2,,103507642,3385,Active,,,6.8,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
3405,663985,2,3,,103507642,3385,Active,,,33.4,IC50,Cytotoxicity against human KB/VCR cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
3406,663986,2,3,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
3407,663987,2,2,,103507642,3385,Active,,,2.1,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,22537362.0,
3408,665010,2,2,,103507642,3385,Active,,,14.93,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3409,665011,2,2,,103507642,3385,Unspecified,,,66.91,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3410,665012,2,2,,103507642,3385,Unspecified,,,56.2,IC50,Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3411,665013,2,2,,103507642,3385,Active,,,6.68,IC50,Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3412,665014,2,2,,103507642,3385,Active,,,11.67,IC50,Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3413,665015,2,3,,103507642,3385,Active,,,24.66,IC50,Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay,Confirmatory,22555152.0,
3414,665491,2,3,,103507642,3385,Active,,,46.57,IC50,Cytotoxicity against human L02 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3415,665492,2,2,,103507642,3385,Active,,,5.64,IC50,Cytotoxicity against human A549 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3416,665493,2,2,,103507642,3385,Active,,,16.32,IC50,Cytotoxicity against human HeLa cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3417,665494,2,3,,103507642,3385,Active,,,14.3,IC50,Cytotoxicity against human QGY7701 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3418,665495,2,2,,103507642,3385,Active,,,15.71,IC50,Cytotoxicity against human SW480 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3419,665496,2,3,,103507642,3385,Active,,,6.04,IC50,Cytotoxicity against human SGC7901 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3420,665497,2,2,,103507642,3385,Active,,,13.65,IC50,Cytotoxicity against human MDA-MB-231 cells by after 48 hrs by MTT assay,Confirmatory,22579780.0,
3421,666653,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human HepG2 cells at 40 ug/ml after 72 hrs by MTT assay,Other,22727445.0,
3422,666654,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human SGC7901 cells at 40 ug/ml after 72 hrs by MTT assay,Other,22727445.0,
3423,666655,1,4,,103507642,3385,Unspecified,,,,,Growth inhibition of human BGC823 cells at 40 ug/ml after 72 hrs by MTT assay,Other,22727445.0,
3424,666656,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H460 cells at 40 ug/ml after 72 hrs by MTT assay,Other,22727445.0,
3425,666657,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human MCF7 cells at 40 ug/ml after 72 hrs by MTT assay,Other,22727445.0,
3426,666658,2,2,,103507642,3385,Active,,,4.8,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22727445.0,
3427,666659,2,3,,103507642,3385,Active,,,6.3,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,22727445.0,
3428,666660,2,3,,103507642,3385,Active,,,4.5,IC50,Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay,Confirmatory,22727445.0,
3429,666661,2,2,,103507642,3385,Active,,,2.4,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay,Confirmatory,22727445.0,
3430,666662,2,2,,103507642,3385,Active,,,12.5,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22727445.0,
3431,667221,2,2,,103507642,3385,Active,,,8.28,IC50,Cytotoxicity against human KB cells after 72 hrs by MTT assay,Confirmatory,22749192.0,
3432,667222,2,3,,103507642,3385,Active,,,15.1,IC50,Cytotoxicity against human CNE2 cells after 72 hrs by MTT assay,Confirmatory,22749192.0,
3433,667223,2,4,,103507642,3385,Active,,,18.5,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,22749192.0,
3434,667224,2,2,,103507642,3385,Active,,,14.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,22749192.0,
3435,667225,2,3,,103507642,3385,Active,,,17.4,IC50,Cytotoxicity against human GLC82 cells after 72 hrs by MTT assay,Confirmatory,22749192.0,
3436,667345,2,4,,103507642,3385,Active,,,30.7,IC50,Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3437,667346,2,2,,103507642,3385,Active,,,5.0,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3438,667347,2,2,,103507642,3385,Active,,,6.0,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3439,667348,2,2,,103507642,3385,Active,,,3.5,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3440,667466,2,3,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human Mahlavu cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3441,667467,2,3,,103507642,3385,Active,,,7.6,IC50,Cytotoxicity against human FOCUS cells after 72 hrs by SRB assay,Confirmatory,22409771.0,
3442,667623,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H69 cells after 3 days MTT assay,Other,22796042.0,
3443,667624,2,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PZ-HPV-7 cells after 3 days MTT assay,Other,22796042.0,
3444,667625,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 3 days MTT assay,Other,22796042.0,
3445,667626,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells after 3 days MTT assay,Other,22796042.0,
3446,667780,2,2,,103507642,3385,Unspecified,,,,,Toxicity in po dosed BDF-1 mouse,Other,22796042.0,
3447,667800,2,2,,103507642,3385,Active,,,46.83,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22809558.0,
3448,667801,2,2,,103507642,3385,Active,,,35.41,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22809558.0,
3449,667802,2,3,,103507642,3385,Active,,,22.63,IC50,Cytotoxicity against human PC3M cells after 48 hrs by MTT assay,Confirmatory,22809558.0,
3450,667803,2,3,,103507642,3385,Active,,,41.73,IC50,Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay,Confirmatory,22809558.0,
3451,670481,2,2,,103507642,3385,Active,,,12.32,IC50,Cytotoxicity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3452,670482,2,3,,103507642,3385,Active,,,14.49,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3453,670483,2,2,,103507642,3385,Active,,,8.83,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3454,670484,2,4,,103507642,3385,Active,,,1.09,IC50,Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3455,670485,2,2,,103507642,3385,Active,,,32.22,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3456,670486,2,2,,103507642,3385,Active,,,15.99,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3457,670487,2,2,,103507642,3385,Active,,,1.38,IC50,Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3458,670488,2,2,,103507642,3385,Unspecified,,,100.0,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,22687745.0,
3459,671700,2,2,,103507642,3385,Active,,,15.92,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22209486.0,
3460,671727,1,3,,103507642,3385,Unspecified,,,,,Antitumor activity against human MX1 cells xenografted in Balb/c-A JcL-nu mouse assessed as tumor volume at 15 mg/kg/day by continuous infusion for 14 days measured on day 15 (Rvb = 2048 +/- 693.7 mm3),Other,22339362.0,
3461,671728,1,3,,103507642,3385,Unspecified,,,,,Antitumor activity against human MX1 cells xenografted in Balb/c-A JcL-nu mouse assessed as tumor volume at 15 mg/kg/day by continuous infusion for 14 days measured on day 15 relative to control (Rvb = 11.4 +/- 3.74),Other,22339362.0,
3462,671729,1,3,,103507642,3385,Unspecified,,,,,Antitumor activity against human MX1 cells xenografted in Balb/c-A JcL-nu mouse assessed as tumor growth inhibition at 15 mg/kg/day by continuous infusion for 14 days measured on day 15 relative to control,Other,22339362.0,
3463,671864,2,2,,103507642,3385,Active,,,4.7,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet staining method,Confirmatory,22765897.0,
3464,671865,2,2,,103507642,3385,Active,,,9.6,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by crystal violet staining method,Confirmatory,22765897.0,
3465,671866,2,2,,103507642,3385,Active,,,7.3,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by crystal violet staining method,Confirmatory,22765897.0,
3466,673246,2,3,,103507642,3385,Active,,,24.58,IC50,Cytotoxicity against human Hep2 cells by MTT assay,Confirmatory,22801644.0,
3467,673247,2,3,,103507642,3385,Active,,,9.92,IC50,Cytotoxicity against human A375-S2 cells by MTT assay,Confirmatory,22801644.0,
3468,673248,2,2,,103507642,3385,Active,,,3.06,IC50,Cytotoxicity against human HT1080 cells by MTT assay,Confirmatory,22801644.0,
3469,673249,2,2,,103507642,3385,Active,,,31.52,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,22801644.0,
3470,673250,2,2,,103507642,3385,Active,,,10.45,IC50,Cytotoxicity against human HepG2 cells by MTT assay,Confirmatory,22801644.0,
3471,673251,2,2,,103507642,3385,Active,,,35.75,IC50,Cytotoxicity against human PC3 cells by MTT assay,Confirmatory,22801644.0,
3472,673252,2,3,,103507642,3385,Active,,,31.57,IC50,Cytotoxicity against human MDA231 cells by MTT assay,Confirmatory,22801644.0,
3473,673253,2,2,,103507642,3385,Active,,,24.58,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,22801644.0,
3474,673254,2,3,,103507642,3385,Active,,,15.65,IC50,Cytotoxicity against human BGC823 cells by MTT assay,Confirmatory,22801644.0,
3475,673255,2,2,,103507642,3385,Active,,,10.36,IC50,Cytotoxicity against human HeLa cells by MTT assay,Confirmatory,22801644.0,
3476,674744,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human THP1 cells at 20 uM after 48 hrs by SRB assay,Other,22818042.0,
3477,674745,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human Caco2 cells at 20 uM after 48 hrs by SRB assay,Other,22818042.0,
3478,675020,2,2,,103507642,3385,Active,,,16.2,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22840493.0,
3479,675021,2,2,,103507642,3385,Active,,,12.8,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22840493.0,
3480,675022,2,2,,103507642,3385,Active,,,3.3,IC50,Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay,Confirmatory,22840493.0,
3481,675023,2,3,,103507642,3385,Active,,,25.6,IC50,Antiproliferative activity against human IOSE-144 cells after 48 hrs by MTT assay,Confirmatory,22840493.0,
3482,675024,1,3,,103507642,3385,Unspecified,,,,,Antiproliferative activity against human MCF7 cells assessed as cell viability at 30 uM after 48 hrs by MTT assay,Other,22840493.0,
3483,681386,4,2,,103507642,3385,Unspecified,124015184.0,19879.0,0.0539,Km,TP_TRANSPORTER: uptake in mOat3-expressing oocytes,Confirmatory,15100168.0,
3484,682615,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse EAC after 2 hrs by trypan blue staining based hemocytometer analysis,Other,23022735.0,
3485,682616,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay,Other,23022735.0,
3486,682617,2,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human WI38 cells after 96 hrs by MTT assay,Other,23022735.0,
3487,682618,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against African green monkey Vero cells after 96 hrs by MTT assay,Other,23022735.0,
3488,682619,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay,Other,23022735.0,
3489,684452,2,2,,103507642,3385,Active,,,4.7,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by crystal violet staining,Confirmatory,22959205.0,
3490,684453,2,2,,103507642,3385,Active,,,9.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining,Confirmatory,22959205.0,
3491,684454,2,2,,103507642,3385,Active,,,7.3,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by crystal violet staining,Confirmatory,22959205.0,
3492,685092,2,2,,103507642,3385,Active,,,5.7,IC50,Cytotoxicity against human HepG2 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3493,685093,2,4,,103507642,3385,Active,,,30.7,IC50,Cytotoxicity against human HuH7 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3494,685094,2,3,,103507642,3385,Active,,,9.97,IC50,Cytotoxicity against human MV cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3495,685095,2,3,,103507642,3385,Active,,,7.69,IC50,Cytotoxicity against human FOCUS cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3496,685096,2,2,,103507642,3385,Active,,,18.7,IC50,Cytotoxicity against human HCT116 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3497,685097,2,2,,103507642,3385,Active,,,8.91,IC50,Cytotoxicity against human T47D cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3498,685098,2,2,,103507642,3385,Active,,,3.5,IC50,Cytotoxicity against human MCF7 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3499,685099,2,3,,103507642,3385,Active,,,47.3,IC50,Cytotoxicity against human BT20 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3500,685100,2,3,,103507642,3385,Active,,,1.28,IC50,Cytotoxicity against human CAMA1 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3501,685101,2,3,,103507642,3385,Active,,,30.68,IC50,Cytotoxicity against human MFE296 cells incubated for 72 hrs by SRB assay,Confirmatory,22867707.0,
3502,685154,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human A549 cells at 20 uM after 48 hrs by MTT assay,Other,22982123.0,
3503,685155,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT116 cells at 20 uM after 48 hrs by MTT assay,Other,22982123.0,
3504,686940,1,1,,8139872,3385,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3505,686964,1,1,,8139872,3385,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3506,686970,1,2,,8139872,3385,Inconclusive,49168486.0,3417.0,2.3109,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3507,686971,1,2,,8139872,3385,Inconclusive,,,8.1995,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3508,686978,1,1,,8139872,3385,Active,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3509,686978,1,1,,124880118,3385,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3510,686978,1,1,,144203701,3385,Active,79154014.0,55775.0,14.9631,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3511,686979,1,1,,8139872,3385,Active,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3512,686979,1,1,,124880118,3385,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3513,686979,1,1,,144203701,3385,Inconclusive,79154014.0,55775.0,33.4983,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3514,686992,2,1,,8139872,3385,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3515,686996,1,1,,8139872,3385,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3516,687014,1,1,,8139872,3385,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3517,687016,1,1,,8139872,3385,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3518,687035,1,1,,163564490,3385,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3519,687037,1,3,,163564490,3385,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3520,687169,1,2,,103507642,3385,Unspecified,,,,,Antitumor activity against human MX1 cells xenografted in Balb/cA JcL mouse at 15 mg/kg/day dosed as as continuous infusion measured on day 15,Other,22607122.0,
3521,687730,2,3,,103507642,3385,Active,,,12.5,IC50,Cytotoxicity against human COLO320 cells assessed as cell viability after 72 hrs by WST-1 assay,Confirmatory,22955095.0,
3522,687731,2,3,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human Calu3 cells assessed as cell viability after 72 hrs by WST-1 assay,Confirmatory,22955095.0,
3523,689263,4,1,,103507642,3385,Active,,,0.28,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,22959518.0,
3524,689264,4,1,,103507642,3385,Active,,,0.06,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,22959518.0,
3525,689265,4,1,,103507642,3385,Active,,,1.07,IC50,Cytotoxicity against human U937 cells after 72 hrs by MTT assay,Confirmatory,22959518.0,
3526,689266,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PBMC cells assessed as cell viability at 5 uM after 12 hrs by MTT assay,Other,22959518.0,
3527,689267,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PBMC cells assessed as cell viability at 5 uM after 24 hrs by MTT assay,Other,22959518.0,
3528,689268,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PBMC cells assessed as cell viability at 5 uM after 48 hrs by MTT assay,Other,22959518.0,
3529,689269,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PBMC cells assessed as cell viability at 5 uM after 72 hrs by MTT assay,Other,22959518.0,
3530,691598,2,3,,103507642,3385,Active,,,15.1,GI50,Antiproliferative activity against human leukemia cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3531,691599,2,2,,103507642,3385,Unspecified,,,100.0,GI50,Antiproliferative activity against human non-small cell lung cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3532,691600,2,3,,103507642,3385,Active,,,8.4,GI50,Antiproliferative activity against human colon cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3533,691601,2,3,,103507642,3385,Unspecified,,,72.1,GI50,Antiproliferative activity against human CNS cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3534,691602,2,3,,103507642,3385,Unspecified,,,70.6,GI50,Antiproliferative activity against human melanoma cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3535,691603,2,3,,103507642,3385,Unspecified,,,61.4,GI50,Antiproliferative activity against human ovarian cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3536,691604,2,3,,103507642,3385,Active,,,45.6,GI50,Antiproliferative activity against human renal cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3537,691605,2,2,,103507642,3385,Active,,,22.7,GI50,Antiproliferative activity against human prostate cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3538,691666,2,3,,103507642,3385,Unspecified,,,76.4,GI50,Antiproliferative activity against human breast cancer cells after 48 hrs by cell counting analysis,Confirmatory,22995621.0,
3539,691723,2,2,,103507642,3385,Active,,,9.5,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23002924.0,
3540,691778,2,3,,103507642,3385,Active,,,12.0,IC50,Cytotoxicity against human MNK45 cells after 48 hrs by MTT assay,Confirmatory,23002924.0,
3541,695570,2,2,,103507642,3385,Active,,,1.3,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT method,Confirmatory,23018096.0,
3542,695571,2,3,,103507642,3385,Active,,,2.41,IC50,Antiproliferative activity against human SW1116 cells after 48 hrs by MTT method,Confirmatory,23018096.0,
3543,695572,2,2,,103507642,3385,Active,,,3.25,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT method,Confirmatory,23018096.0,
3544,695573,2,3,,103507642,3385,Active,,,1.52,IC50,Antiproliferative activity against human BGC823 cells after 48 hrs by MTT method,Confirmatory,23018096.0,
3545,696880,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PANC1 cells grown in DMEM medium after 24 hrs by WST8 assay,Other,23092429.0,
3546,696881,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PANC1 cells grown in nutrient-deprived medium after 24 hrs by WST8 assay,Other,23092429.0,
3547,697313,2,2,,103507642,3385,Active,,,4.21,IC50,Cytotoxicity against human A549 cells assessed cell viability after 48 hrs by SRB assay,Confirmatory,23044370.0,
3548,698312,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against human MX1 cells xenografted in Balb/cA JcL-nu mouse assessed as tumor growth inhibition at 15 mg/kg/day, po for 14 days dosed as continuous infusion using osmotic pump and measured twice a week relative to untreated control",Other,22715973.0,
3549,704514,1,4,,103507642,3385,Unspecified,,,,,Stability of the compound in potassium phosphate buffer at pH 7.4 assessed as E.coli thymidine phosphorylase-mediated release of 5-FU after 5 mins by [19F] NMR spectroscopy,Other,21892829.0,
3550,704523,2,2,,103507642,3385,Active,,,0.54,IC50,Cytostatic activity against human HeLa cells after 72 hrs by cell counting,Confirmatory,21892829.0,
3551,704524,2,2,,103507642,3385,Active,,,0.23,IC50,Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting,Confirmatory,21892829.0,
3552,704525,2,2,,103507642,3385,Active,,,12.0,IC50,Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting,Confirmatory,21892829.0,
3553,704526,2,3,,103507642,3385,Active,,,18.0,IC50,Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting,Confirmatory,21892829.0,
3554,704528,2,2,,103507642,3385,Active,,,0.32,IC50,Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting,Confirmatory,21892829.0,
3555,709336,2,2,,103507642,3385,Active,,,4.5,IC50,Growth inhibition of african green monkey Vero cells by crystal violet assay,Confirmatory,23075414.0,
3556,709337,2,2,,103507642,3385,Active,,,5.1,IC50,Growth inhibition of human A2780 cells by crystal violet assay,Confirmatory,23075414.0,
3557,709338,2,2,,103507642,3385,Active,,,12.3,IC50,Growth inhibition of cDDP-resistant human A2780/CP70 cells by crystal violet assay,Confirmatory,23075414.0,
3558,709339,2,2,,103507642,3385,Active,,,8.5,IC50,Growth inhibition of cDDP-resistant human C13 cells by crystal violet assay,Confirmatory,23075414.0,
3559,709341,2,2,,103507642,3385,Active,,,4.2,IC50,Growth inhibition of human 2008 cells by crystal violet assay,Confirmatory,23075414.0,
3560,716412,2,2,,103507642,3385,Active,,,15.2,IC50,Cytotoxicity against human HT1080 cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3561,716413,2,2,,103507642,3385,Active,,,36.4,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3562,716414,2,2,,103507642,3385,Unspecified,,,51.5,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3563,716415,2,2,,103507642,3385,Unspecified,,,88.9,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3564,716416,2,2,,103507642,3385,Unspecified,,,78.6,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3565,716417,2,2,,103507642,3385,Unspecified,,,63.4,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23067549.0,
3566,716453,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay,Other,22647218.0,
3567,716454,2,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay,Other,22647218.0,
3568,716455,2,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Other,22647218.0,
3569,716456,2,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Other,22647218.0,
3570,717967,2,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as tumor growth inhibition at 35 mg/kg, ip administered twice a week for three cycles measured after 3 cycles relative to control",Other,23094992.0,
3571,717971,2,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against human BxPC3 cells xenografted in SCID mouse assessed as tumor growth inhibition at 17 mg/kg, ip administered twice a week for three cycles measured after 3 cycles relative to control",Other,23094992.0,
3572,718344,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human NHDF cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3573,718345,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human MSC cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3574,718346,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human HUVEC cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3575,718347,1,4,,103507642,3385,Active,,,,GI50,Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3576,718348,1,4,,103507642,3385,Active,,,,GI50,Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3577,718349,1,4,,103507642,3385,Active,,,,GI50,Growth inhibition of human HL-60(TB) cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3578,718350,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3579,718351,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human OVCAR5 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3580,718352,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human U251 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3581,718353,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human IGROV1 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3582,718354,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human PC3 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3583,718355,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human MCF7 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3584,718356,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human DU145 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3585,718357,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human HCT116 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3586,718358,1,3,,103507642,3385,Active,,,,GI50,Growth inhibition of human HCT15 cells after 48 hrs by SRB assay,Confirmatory,23094992.0,
3587,720504,1,1,,8139872,3385,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3588,720508,1,1,,8139872,3385,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3589,720509,1,1,,8139872,3385,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3590,720511,1,1,,8139872,3385,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3591,720516,2,1,,144203701,3385,Active,296439460.0,79915.0,7.4978,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3592,720516,2,1,,144209533,3385,Active,296439460.0,79915.0,10.0542,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3593,720516,2,1,,144210432,3385,Active,296439460.0,79915.0,3.9435300000000004,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3594,720532,1,1,,124880118,3385,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3595,720532,1,1,,124880121,3385,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3596,720532,1,1,,144203701,3385,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3597,720533,1,1,,124880118,3385,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3598,720533,1,1,,124880121,3385,Inconclusive,,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3599,720533,1,1,,144203701,3385,Inconclusive,,,17.7828,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3600,720538,1,2,,90341469,3385,Inconclusive,220983390.0,410.0,26.8545,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3601,720542,1,2,,8139872,3385,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3602,720543,1,1,,8139872,3385,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3603,720551,1,2,,8139872,3385,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3604,720552,2,1,,144203701,3385,Active,269849759.0,7157.0,4.21632,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3605,720552,2,1,,144209533,3385,Active,269849759.0,7157.0,4.321969999999999,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3606,720552,2,1,,144210432,3385,Active,269849759.0,7157.0,2.79181,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3607,720553,1,2,,8139872,3385,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3608,720554,1,3,,121362603,3385,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
3609,720559,1,2,,90341469,3385,Inactive,112927.0,351.0,18.3564,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3610,720572,1,2,,90341469,3385,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3611,720573,1,2,,90341469,3385,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3612,720579,2,1,,8139872,3385,Active,222762.0,3707576.0,5.6234,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3613,720579,2,1,,124880118,3385,Inconclusive,222762.0,3707576.0,6.3096,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3614,720580,1,1,,8139872,3385,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3615,720580,1,1,,124880118,3385,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3616,720582,1,1,,8139872,3385,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3617,720596,1,1,,8139872,3385,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3618,720634,2,1,,144203701,3385,Inactive,,,6.6824,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3619,720634,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3620,720634,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3621,720635,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3622,720635,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3623,720635,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3624,720636,1,1,,17389875,3385,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3625,720637,2,1,,144203701,3385,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3626,720637,2,1,,144209533,3385,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3627,720637,2,1,,144210432,3385,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3628,720641,1,2,,92307309,3385,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3629,720641,1,2,,92309160,3385,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3630,720647,1,2,,8139872,3385,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3631,720648,1,1,,8139872,3385,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3632,720652,1,1,,17389875,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3633,720653,1,1,,17389875,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3634,720659,1,1,,17389875,3385,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3635,720674,2,2,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3636,720674,2,2,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3637,720674,2,2,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3638,720675,2,2,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3639,720675,2,2,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3640,720675,2,2,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3641,720678,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3642,720678,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3643,720678,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3644,720679,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3645,720679,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3646,720679,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3647,720680,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3648,720680,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3649,720680,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3650,720681,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3651,720681,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3652,720681,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3653,720682,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3654,720682,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3655,720682,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3656,720683,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3657,720683,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3658,720683,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3659,720684,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3660,720684,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3661,720684,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3662,720685,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3663,720685,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3664,720685,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3665,720686,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3666,720686,2,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3667,720686,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3668,720687,2,2,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3669,720687,2,2,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3670,720687,2,2,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3671,720691,4,1,,144203701,3385,Inactive,311348376.0,2908.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3672,720691,4,1,,144209533,3385,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3673,720691,4,1,,144210432,3385,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3674,720692,3,1,,144203701,3385,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3675,720692,3,1,,144209533,3385,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3676,720692,3,1,,144210432,3385,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3677,720693,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3678,720693,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3679,720693,3,1,,144210432,3385,Inconclusive,,,22.3738,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3680,720700,1,4,,8139872,3385,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3681,720702,1,1,,8139872,3385,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3682,720704,1,4,,8139872,3385,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3683,720706,1,2,,8139872,3385,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3684,720707,1,2,,8139872,3385,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3685,720708,1,2,,8139872,3385,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3686,720709,1,2,,8139872,3385,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3687,720711,1,2,,8139872,3385,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3688,720717,1,3,,92124222,3385,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3689,720717,1,3,,92307309,3385,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3690,720717,1,3,,92309160,3385,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3691,720719,2,1,,144203701,3385,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3692,720719,2,1,,144209533,3385,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3693,720719,2,1,,144210432,3385,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3694,720725,2,1,,144203701,3385,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3695,720725,2,1,,144209533,3385,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3696,720725,2,1,,144210432,3385,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3697,721440,1,2,,103507642,3385,Unspecified,,,100.0,IC50,Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
3698,721441,1,2,,103507642,3385,Unspecified,,,100.0,IC50,Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
3699,721442,1,2,,103507642,3385,Active,,,14.78,IC50,Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay,Confirmatory,23313635.0,
3700,722073,3,1,,103507642,3385,Active,,,3.85,IC50,Cytotoxicity against human Bel7042 cells by MTT method,Confirmatory,23164710.0,
3701,722074,3,1,,103507642,3385,Active,,,7.12,IC50,Cytotoxicity against human NIH-H460 cells by MTT method,Confirmatory,23164710.0,
3702,722075,3,1,,103507642,3385,Active,,,5.4,IC50,Cytotoxicity against human A2780 cells by MTT method,Confirmatory,23164710.0,
3703,722076,3,2,,103507642,3385,Active,,,3.84,IC50,Cytotoxicity against human BGC823 cells by MTT method,Confirmatory,23164710.0,
3704,722077,3,1,,103507642,3385,Active,,,1.54,IC50,Cytotoxicity against human A549 cells by MTT method,Confirmatory,23164710.0,
3705,722078,3,2,,103507642,3385,Active,,,5.38,IC50,Cytotoxicity against human HCT8 cells by MTT method,Confirmatory,23164710.0,
3706,722914,1,2,,103507642,3385,Active,,,17.2,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23279864.0,
3707,722915,1,3,,103507642,3385,Active,,,28.5,IC50,Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay,Confirmatory,23279864.0,
3708,722916,1,2,,103507642,3385,Active,,,21.9,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,23279864.0,
3709,723245,3,1,,103507642,3385,Unspecified,,,114.5,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,23356786.0,
3710,723246,3,1,,103507642,3385,Unspecified,,,126.2,IC50,Cytotoxicity against human QGY cells after 48 hrs by MTT assay,Confirmatory,23356786.0,
3711,723247,3,1,,103507642,3385,Unspecified,,,158.2,IC50,Cytotoxicity against human SW480 cells after 48 hrs by MTT assay,Confirmatory,23356786.0,
3712,723248,3,1,,103507642,3385,Unspecified,,,142.6,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23356786.0,
3713,723249,3,1,,103507642,3385,Unspecified,,,56.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23356786.0,
3714,725041,1,3,,103507642,3385,Unspecified,,,110.0,IC50,Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3715,725042,1,3,,103507642,3385,Active,,,39.5,IC50,Cytotoxicity against human PA1 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3716,725043,1,2,,103507642,3385,Active,,,29.87,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3717,725044,1,2,,103507642,3385,Unspecified,,,56.76,IC50,Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3718,725045,1,3,,103507642,3385,Active,,,45.01,IC50,Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3719,725046,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
3720,725047,1,2,,103507642,3385,Unspecified,,,51.8,IC50,Cytotoxicity against human T47D cells after 24 hrs by MTT assay,Confirmatory,23202484.0,
3721,725048,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
3722,725049,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PA1 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
3723,725050,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H522 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
3724,725051,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human T47D cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay,Other,23202484.0,
3725,726451,1,3,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HCT116 cell proliferation inhibition to IC50 for human CRL1790 cell proliferation inhibition",Other,23305919.0,
3726,726462,1,4,,103507642,3385,Unspecified,,,,,Induction of ROS generation in human HCT116 cells measured as fold increase in fluorescence units at 3.51 uM by using dichlorodihydrofluorescein diacetate relative to negative control,Other,23305919.0,
3727,726466,1,4,,103507642,3385,Unspecified,,,25.0,IC50,Antiproliferative activity against human CRL1790 cells assessed as inhibition cell proliferation after 48 hrs by Sulforhodamine B assay,Confirmatory,23305919.0,
3728,726467,1,4,,103507642,3385,Active,,,3.56,IC50,Antiproliferative activity against human HCT116 cells assessed as inhibition cell proliferation after 48 hrs by Sulforhodamine B assay,Confirmatory,23305919.0,
3729,729740,1,3,,103507642,3385,Unspecified,,,50.0,IC50,Cytotoxicity against human PANC1 cells assessed as inhibition of cell viability after 6 days by MTT assay,Confirmatory,23360104.0,
3730,729847,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,23387901.0,
3731,729849,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human THP1 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,23387901.0,
3732,729851,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells at 20 uM after 48 hrs by sulforhodamine B assay,Other,23387901.0,
3733,730921,1,3,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse HepS cells allografted in Kunming mouse assessed as inhibition of tumor growth at 25 mg/kg, iv bid administered 2 days once for 4 times",Other,23167526.0,
3734,733315,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human HL60 cells at 10 uM after 48 hrs by MTT assay,Other,23419739.0,
3735,733316,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human PC3 cells at 10 uM after 48 hrs by MTT assay,Other,23419739.0,
3736,733588,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Other,23352638.0,
3737,733589,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human U937 cells after 24 hrs by MTT assay,Other,23352638.0,
3738,733590,1,4,,103507642,3385,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay,Other,23352638.0,
3739,733591,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human THP1 cells after 24 hrs by MTT assay,Other,23352638.0,
3740,734068,1,2,,103507642,3385,Active,,,5.64,IC50,Growth inhibition of human A549 cells after 48 hrs by MTT assay,Confirmatory,23353737.0,
3741,734069,1,2,,103507642,3385,Active,,,16.32,IC50,Growth inhibition of human HeLa cells after 48 hrs by MTT assay,Confirmatory,23353737.0,
3742,734070,1,2,,103507642,3385,Active,,,14.3,IC50,Growth inhibition of human QGY7701 cells after 48 hrs by MTT assay,Confirmatory,23353737.0,
3743,734071,1,4,,103507642,3385,Active,,,15.85,IC50,Growth inhibition of human HuH7 cells after 48 hrs by MTT assay,Confirmatory,23353737.0,
3744,734072,1,2,,103507642,3385,Active,,,46.57,IC50,Growth inhibition of human L02 cells after 48 hrs by MTT assay,Confirmatory,23353737.0,
3745,735003,1,3,,103507642,3385,Active,,,3.34,IC50,Cytotoxicity against human EC109 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23353743.0,
3746,735004,1,3,,103507642,3385,Active,,,27.07,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23353743.0,
3747,735005,1,2,,103507642,3385,Active,,,7.54,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23353743.0,
3748,735006,1,4,,103507642,3385,Active,,,7.01,IC50,Cytotoxicity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,23353743.0,
3749,735442,1,3,,103507642,3385,Active,,,46.35,IC50,Anticancer activity against human SGC7901 cells assessed as cell survival measured after 48 hrs by MTT assay,Confirmatory,23312949.0,
3750,735443,1,3,,103507642,3385,Active,,,21.41,IC50,Anticancer activity against mouse B16F10 cells assessed as cell survival measured after 48 hrs by MTT assay,Confirmatory,23312949.0,
3751,736815,1,2,,103507642,3385,Active,,,25.0,LC50,Cytotoxicity against HEK293 cells after 48 hrs by MTT assay,Confirmatory,23321564.0,
3752,740239,1,3,,103507642,3385,Active,,,28.9,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,23490159.0,
3753,740240,1,2,,103507642,3385,Active,,,16.7,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23490159.0,
3754,740241,1,2,,103507642,3385,Active,,,22.8,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23490159.0,
3755,743012,3,1,,144203701,3385,Active,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3756,743012,3,1,,144209533,3385,Inconclusive,,,7.9864,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3757,743012,3,1,,144210432,3385,Active,,,27.9181,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3758,743014,3,1,,144203701,3385,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3759,743014,3,1,,144209533,3385,Active,,,50.3905,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3760,743014,3,1,,144210432,3385,Active,,,27.9181,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3761,743015,3,1,,144203701,3385,Active,,,21.1317,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3762,743015,3,1,,144209533,3385,Active,,,40.0266,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3763,743015,3,1,,144210432,3385,Active,,,17.6151,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3764,743033,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3765,743033,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3766,743033,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3767,743035,2,1,,144203701,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3768,743035,2,1,,144209533,3385,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3769,743035,2,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3770,743036,2,1,,144203701,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3771,743036,2,1,,144209533,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3772,743036,2,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3773,743040,3,1,,144203701,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3774,743040,3,1,,144209533,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3775,743040,3,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3776,743041,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3777,743041,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3778,743041,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3779,743042,3,1,,144203701,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3780,743042,3,1,,144209533,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3781,743042,3,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3782,743053,2,1,,144203701,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3783,743053,2,1,,144209533,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3784,743053,2,1,,144210432,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3785,743054,2,1,,144203701,3385,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3786,743054,2,1,,144209533,3385,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3787,743054,2,1,,144210432,3385,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3788,743063,2,1,,144203701,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3789,743063,2,1,,144209533,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3790,743063,2,1,,144210432,3385,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3791,743064,3,1,,144203701,3385,Inconclusive,,,9.4392,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3792,743064,3,1,,144209533,3385,Active,,,20.0608,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3793,743064,3,1,,144210432,3385,Inconclusive,,,27.9181,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3794,743065,3,1,,144203701,3385,Active,399498506.0,24831.0,4.7308,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3795,743065,3,1,,144209533,3385,Active,399498506.0,24831.0,1.7879,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3796,743065,3,1,,144210432,3385,Active,399498506.0,24831.0,2.4882,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3797,743066,3,1,,144203701,3385,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3798,743066,3,1,,144209533,3385,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3799,743066,3,1,,144210432,3385,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3800,743067,2,1,,144203701,3385,Inconclusive,399498506.0,24831.0,4.5526800000000005,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3801,743067,2,1,,144209533,3385,Active,399498506.0,24831.0,1.8578700000000001,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3802,743067,2,1,,144210432,3385,Active,399498506.0,24831.0,1.83043,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3803,743069,2,1,,144203701,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3804,743069,2,1,,144209533,3385,Inconclusive,348019627.0,2099.0,35.9929,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3805,743069,2,1,,144210432,3385,Inconclusive,348019627.0,2099.0,44.6416,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3806,743074,2,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3807,743074,2,1,,144209533,3385,Inconclusive,,,22.71,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3808,743074,2,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3809,743075,2,1,,144203701,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3810,743075,2,1,,144209533,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3811,743075,2,1,,144210432,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3812,743077,2,1,,144203701,3385,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3813,743077,2,1,,144209533,3385,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3814,743077,2,1,,144210432,3385,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3815,743078,2,1,,144203701,3385,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3816,743078,2,1,,144209533,3385,Inconclusive,348019627.0,2099.0,41.9646,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3817,743078,2,1,,144210432,3385,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3818,743079,3,1,,144203701,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3819,743079,3,1,,144209533,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3820,743079,3,1,,144210432,3385,Inactive,348019627.0,2099.0,9.9057,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3821,743080,3,1,,144203701,3385,Inconclusive,348019627.0,2099.0,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3822,743080,3,1,,144209533,3385,Inconclusive,348019627.0,2099.0,35.6737,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3823,743080,3,1,,144210432,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3824,743081,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3825,743081,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3826,743081,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3827,743083,3,1,,144203701,3385,Inconclusive,119597822.0,1588.0,10.5909,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3828,743083,3,1,,144209533,3385,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3829,743083,3,1,,144210432,3385,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3830,743084,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3831,743084,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3832,743084,3,1,,144210432,3385,Inconclusive,,,62.5008,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3833,743085,3,1,,144203701,3385,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3834,743085,3,1,,144209533,3385,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3835,743085,3,1,,144210432,3385,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3836,743086,3,1,,144203701,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3837,743086,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3838,743086,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3839,743091,2,1,,144203701,3385,Inconclusive,348019627.0,2099.0,13.3332,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3840,743091,2,1,,144209533,3385,Inconclusive,348019627.0,2099.0,35.6737,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3841,743091,2,1,,144210432,3385,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3842,743094,3,1,,144203701,3385,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3843,743094,3,1,,144209533,3385,Inconclusive,216409692.0,5468.0,57.0449,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3844,743094,3,1,,144210432,3385,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3845,743122,2,1,,144203701,3385,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3846,743122,2,1,,144209533,3385,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3847,743122,2,1,,144210432,3385,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3848,743126,1,1,,8139872,3385,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3849,743139,2,1,,144203701,3385,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3850,743139,2,1,,144209533,3385,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3851,743139,2,1,,144210432,3385,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3852,743140,2,1,,144203701,3385,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3853,743140,2,1,,144209533,3385,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3854,743140,2,1,,144210432,3385,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3855,743191,3,1,,144209533,3385,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3856,743191,3,1,,144210432,3385,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3857,743191,3,1,,170464762,3385,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3858,743194,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3859,743194,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3860,743194,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3861,743199,2,1,,144209533,3385,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3862,743199,2,1,,144210432,3385,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3863,743199,2,1,,170464762,3385,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3864,743202,4,1,,144209533,3385,Inconclusive,20149576.0,4780.0,28.3367,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3865,743202,4,1,,144210432,3385,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3866,743202,4,1,,170464762,3385,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3867,743203,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3868,743203,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3869,743203,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3870,743205,1,1,,90341469,3385,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3871,743205,1,1,,90341469,3385,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3872,743206,1,1,,90341469,3385,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3873,743206,1,1,,90341469,3385,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3874,743207,1,1,,90341469,3385,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3875,743207,1,1,,90341469,3385,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3876,743209,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3877,743209,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3878,743209,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3879,743210,4,1,,144209533,3385,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3880,743210,4,1,,144210432,3385,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3881,743210,4,1,,170464762,3385,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3882,743211,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3883,743211,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3884,743211,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3885,743212,3,1,,144209533,3385,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3886,743212,3,1,,144210432,3385,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3887,743212,3,1,,170464762,3385,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3888,743213,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3889,743213,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3890,743213,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3891,743215,3,1,,144209533,3385,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3892,743215,3,1,,144210432,3385,Inconclusive,216409690.0,5467.0,19.9407,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3893,743215,3,1,,170464762,3385,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3894,743217,3,1,,144209533,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3895,743217,3,1,,144210432,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3896,743217,3,1,,170464762,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3897,743218,3,1,,144209533,3385,Inconclusive,,,0.5704,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3898,743218,3,1,,144210432,3385,Inconclusive,,,22.3738,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3899,743218,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3900,743219,3,1,,144209533,3385,Inconclusive,20149576.0,4780.0,11.9495,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3901,743219,3,1,,144210432,3385,Inconclusive,20149576.0,4780.0,62.5008,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3902,743219,3,1,,170464762,3385,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3903,743220,3,1,,144209533,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3904,743220,3,1,,144210432,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3905,743220,3,1,,170464762,3385,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3906,743221,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3907,743221,3,1,,144210432,3385,Inconclusive,,,0.7939,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3908,743221,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3909,743222,3,1,,144209533,3385,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3910,743222,3,1,,144210432,3385,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3911,743222,3,1,,170464762,3385,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3912,743223,3,1,,144209533,3385,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3913,743223,3,1,,144210432,3385,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3914,743223,3,1,,170464762,3385,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3915,743224,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3916,743224,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3917,743224,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3918,743225,3,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3919,743225,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3920,743225,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3921,743226,2,1,,144209533,3385,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3922,743226,2,1,,144210432,3385,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3923,743226,2,1,,170464762,3385,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3924,743227,2,1,,144209533,3385,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3925,743227,2,1,,144210432,3385,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3926,743227,2,1,,170464762,3385,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3927,743228,3,1,,144209533,3385,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3928,743228,3,1,,144210432,3385,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3929,743228,3,1,,170464762,3385,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3930,743238,1,1,,8139872,3385,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3931,743239,2,1,,144209533,3385,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3932,743239,2,1,,144210432,3385,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3933,743239,2,1,,170464762,3385,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3934,743240,2,1,,144209533,3385,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3935,743240,2,1,,144210432,3385,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3936,743240,2,1,,170464762,3385,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3937,743241,2,1,,144209533,3385,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3938,743241,2,1,,144210432,3385,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3939,743241,2,1,,170464762,3385,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3940,743242,2,1,,144209533,3385,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3941,743242,2,1,,144210432,3385,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3942,743242,2,1,,170464762,3385,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3943,743244,1,1,,90341469,3385,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3944,743244,1,1,,144203701,3385,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3945,743247,1,2,,8139872,3385,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3946,743255,1,1,,8139872,3385,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3947,743266,1,2,,8139872,3385,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3948,743268,1,1,,172080577,3385,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3949,743269,1,1,,8139872,3385,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3950,743269,1,1,,8139872,3385,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3951,743270,1,1,,172080577,3385,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3952,743271,1,1,,172080577,3385,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3953,743272,1,1,,172080577,3385,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3954,743279,1,2,,8139872,3385,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3955,743288,1,1,,17389875,3385,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3956,743292,1,1,,17389875,3385,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3957,743344,1,1,,174007005,3385,Inactive,,,6.678,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3958,743345,1,1,,174007005,3385,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3959,743346,1,1,,174007005,3385,Inactive,,,10.5839,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3960,743347,1,1,,174007005,3385,Inactive,,,9.4329,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3961,743397,1,1,,8139872,3385,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3962,743398,1,1,,8139872,3385,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3963,743750,1,2,,103507642,3385,Unspecified,,,76.4,GI50,Cytotoxicity against human breast cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3964,743751,1,2,,103507642,3385,Active,,,22.7,GI50,Cytotoxicity against human prostate cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3965,743752,1,2,,103507642,3385,Unspecified,,,61.4,GI50,Cytotoxicity against human ovarian cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3966,743753,1,2,,103507642,3385,Active,,,45.6,GI50,Cytotoxicity against human renal cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3967,743754,1,2,,103507642,3385,Unspecified,,,70.6,GI50,Cytotoxicity against human melanoma cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3968,743755,1,2,,103507642,3385,Unspecified,,,72.1,GI50,Cytotoxicity against human CNS cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3969,743756,1,2,,103507642,3385,Active,,,8.4,GI50,Cytotoxicity against human colon cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3970,743757,1,2,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against human non-small cell lung cancer cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3971,743758,1,2,,103507642,3385,Active,,,15.1,GI50,Cytotoxicity against human leukemia cells after 48 hrs by sulphorhodamine B assay,Confirmatory,23474899.0,
3972,743827,3,1,,103507642,3385,Unspecified,,,,,Toxicity against brine shrimp larvae assessed as mortality after 24 hrs by binocular microscopic analysis,Other,23474904.0,
3973,743828,1,1,,103507642,3385,Unspecified,,,,,Toxicity against brine shrimp larvae assessed as mortality at 10 ug/mL after 24 hrs by binocular microscopic analysis relative to control,Other,23474904.0,
3974,743829,1,1,,103507642,3385,Unspecified,,,,,Toxicity against brine shrimp larvae assessed as mortality at 100 ug/mL after 24 hrs by binocular microscopic analysis relative to control,Other,23474904.0,
3975,743830,1,1,,103507642,3385,Unspecified,,,,,Toxicity against brine shrimp larvae assessed as mortality at 500 ug/mL after 24 hrs by binocular microscopic analysis relative to control,Other,23474904.0,
3976,743831,1,1,,103507642,3385,Unspecified,,,,,Toxicity against brine shrimp larvae assessed as mortality at 1000 ug/mL after 24 hrs by binocular microscopic analysis relative to control,Other,23474904.0,
3977,744291,1,2,,103507642,3385,Active,,,4.5,IC50,Antiproliferative activity against human Hep2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
3978,744292,1,2,,103507642,3385,Active,,,4.9,IC50,Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
3979,744293,1,2,,103507642,3385,Active,,,1.0,IC50,Antiproliferative activity against human THP1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
3980,744295,1,2,,103507642,3385,Active,,,2.2,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23501113.0,
3981,744784,1,1,,103507642,3385,Active,,,32.0,IC50,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Confirmatory,23535322.0,
3982,744786,1,1,,103507642,3385,Active,,,28.0,IC50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,23535322.0,
3983,745185,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human ACHN cells after 24 hrs by MTT assay,Other,23548704.0,
3984,745186,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay,Other,23548704.0,
3985,745216,1,1,,103507642,3385,Active,,,23.55,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3986,745217,1,1,,103507642,3385,Active,,,23.93,IC50,Cytotoxicity against human U937 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3987,745218,1,1,,103507642,3385,Active,,,10.05,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3988,745219,1,2,,103507642,3385,Active,,,6.67,IC50,Cytotoxicity against human A375-S2 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3989,745220,1,1,,103507642,3385,Active,,,35.62,IC50,Cytotoxicity against human HT1080 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3990,745221,1,1,,103507642,3385,Active,,,27.76,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3991,745222,1,1,,103507642,3385,Active,,,44.05,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3992,745223,1,1,,103507642,3385,Active,,,40.34,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3993,745224,1,1,,103507642,3385,Active,,,7.34,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3994,745225,1,1,,103507642,3385,Active,,,11.5,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23558238.0,
3995,745412,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in Kunming mouse allografted with mouse H22 cells assessed as decrease in body weight at 20 mg/kg/day, ip measured every day for 8 days",Other,23597099.0,
3996,745413,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse H22 cells allografted in Kunming mouse assessed as decrease in weight of tumor mass at 20 mg/kg/day, ip administered 8 days measured after 10 days relative to control",Other,23597099.0,
3997,747046,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF295 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
3998,747047,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
3999,747048,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
4000,747050,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PC3 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
4001,747051,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
4002,747052,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human THP1 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
4003,747053,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HL60 cells at 20 uM after 48 hrs by SRB assay,Other,23584541.0,
4004,747508,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human MDA-MB-468 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4005,747509,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human BT549 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4006,747510,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human T47D cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4007,747511,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Hs578T cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4008,747512,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4009,747513,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4010,747514,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4011,747515,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UO31 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4012,747516,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PC3 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4013,747517,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human TK10 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4014,747518,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human RXF393 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4015,747519,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SN12C cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4016,747520,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Caki1 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4017,747521,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human ACHN cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4018,747522,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A498 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4019,747523,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human 786-0 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4020,747524,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SKOV3 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4021,747525,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI/ADR-RES cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4022,747526,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human OVCAR8 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4023,747527,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR5 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4024,747528,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR4 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4025,747529,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR3 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4026,747530,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human IGROV1 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4027,747531,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UACC62 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4028,747532,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UACC257 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4029,747533,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human SK-MEL-28 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4030,747534,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-MEL-5 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4031,747535,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4032,747536,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human M14 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4033,747537,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4034,747538,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MALME-3M cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4035,747539,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human U251 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4036,747540,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human LOXIMVI cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4037,747541,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SNB75 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4038,747542,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SNB19 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4039,747543,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF295 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4040,747544,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF539 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4041,747545,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF268 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4042,747546,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4043,747547,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human KM12 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4044,747548,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT-29 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4045,747549,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4046,747550,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT116 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4047,747551,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCC2998 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4048,747552,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human COLO205 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4049,747553,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H522 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4050,747554,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4051,747555,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H322M cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4052,747556,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H226 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4053,747557,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H23 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4054,747558,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HOP62 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4055,747559,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HOP92 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4056,747560,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human EKVX cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4057,747561,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4058,747562,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SR cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4059,747563,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MOLT4 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4060,747564,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human RPMI8226 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4061,747565,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human K562 cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4062,747566,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HL-60(TB) cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4063,747567,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human CCRF-CEM cells at 10 uM after 48 hrs by SRB assay,Other,23611732.0,
4064,747869,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PBMC at 40 to 80 uM after 24 to 48 hrs by MTT assay,Other,23647462.0,
4065,747880,1,1,,103507642,3385,Unspecified,,,70.8,IC50,Cytotoxicity against human HT1080 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,23647462.0,
4066,750517,1,1,,103507642,3385,Inactive,,,,,Induction of DNA damage in human HCT116 cells assessed as formation of marker ser-139 phosphorylated H2AX nuclear foci after 2 hrs by immunofluorescence assay,Other,23665106.0,
4067,750518,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at IC50 after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 11.54%),Other,23665106.0,
4068,750519,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at IC50 after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 25.39%),Other,23665106.0,
4069,750520,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at IC50 after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 63.07%),Other,23665106.0,
4070,750528,1,1,,103507642,3385,Active,,,5.53,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,23665106.0,
4071,750529,1,1,,103507642,3385,Active,,,24.5,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23665106.0,
4072,750532,1,1,,103507642,3385,Active,,,43.71,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,23665106.0,
4073,750534,1,1,,103507642,3385,Active,,,32.18,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23665106.0,
4074,750536,1,1,,103507642,3385,Active,,,3.52,IC50,Antiproliferative activity against human A549 cells after 72 hrs by MTT assay,Confirmatory,23665106.0,
4075,752884,1,2,,103507642,3385,Active,,,0.32,IC50,Cytotoxicity against human EC9706 cells after 72 hrs by MTT assay,Confirmatory,23644193.0,
4076,752885,1,1,,103507642,3385,Active,,,7.33,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23644193.0,
4077,752886,1,1,,103507642,3385,Active,,,26.71,IC50,Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay,Confirmatory,23644193.0,
4078,752887,1,3,,103507642,3385,Active,,,7.14,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,23644193.0,
4079,753179,1,1,,103507642,3385,Unspecified,,,,,Ratio of 5-fluorouracil IC50 to compound IC50 for human HT-29 cells after 48 hrs by sulforhodamine B assay,Other,23644215.0,
4080,753189,1,1,,103507642,3385,Active,,,6.35,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23644215.0,
4081,753191,1,1,,103507642,3385,Active,,,4.52,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23644215.0,
4082,753193,1,1,,103507642,3385,Unspecified,,,,,Ratio of 5-fluorouracil IC50 to compound IC50 for human HCT116 cells after 48 hrs by sulforhodamine B assay,Other,23644215.0,
4083,754023,1,1,,103507642,3385,Active,,,9.71,IC50,Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4084,754024,1,2,,103507642,3385,Active,,,0.97,IC50,Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4085,754025,1,1,,103507642,3385,Active,,,3.24,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4086,754026,1,1,,103507642,3385,Active,,,8.71,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4087,754027,1,1,,103507642,3385,Active,,,10.14,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4088,754028,1,1,,103507642,3385,Active,,,24.96,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,23685571.0,
4089,754548,1,3,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse H22 cells transfected in mouse assessed as inhibition of tumor growth at 153.8 umol/kg, ip after 14 days relative to vehicle-treated control",Other,23617697.0,
4090,754798,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4091,754799,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human T47D cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4092,754800,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human BT549 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4093,754801,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human Hs578T cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4094,754802,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4095,754803,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4096,754804,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4097,754805,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human PC3 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4098,754806,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UO31 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4099,754807,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SN12C cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4100,754808,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Caki1 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4101,754809,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human ACHN cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4102,754810,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SKOV3 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4103,754811,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human A498 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4104,754812,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-ADR-RES cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4105,754813,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human OVCAR8 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4106,754814,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR5 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4107,754815,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR4 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4108,754816,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human IGROV1 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4109,754817,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human OVCAR3 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4110,754818,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UACC62 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4111,754819,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human UACC257 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4112,754820,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human SK-MEL-5 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4113,754821,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-MEL-28 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4114,754822,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human M14 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4115,754823,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4116,754824,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MALME-3M cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4117,754825,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human LOXIMVI cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4118,754826,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human U251 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4119,754827,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SNB75 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4120,754828,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF295 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4121,754829,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human SF539 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4122,754830,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SF268 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4123,754831,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4124,754832,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT15 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4125,754833,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human KM12 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4126,754834,1,3,,103507642,3385,Active,,,,,Cytotoxicity against human HCC2998 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4127,754835,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT116 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4128,754836,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H522 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4129,754837,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H23 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4130,754838,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H322M cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4131,754839,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H226 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4132,754840,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HOP62 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4133,754841,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HOP92 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4134,754842,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4135,754843,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human RPMI8226 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4136,754844,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SR cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4137,754845,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MOLT4 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4138,754846,1,3,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HL-60(TB) cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4139,754847,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human K562 cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4140,754848,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition at 10 uM after 48 hrs by SRB assay relative to control,Other,23642480.0,
4141,755180,1,2,,103507642,3385,Active,,,15.1,GI50,Cytotoxicity against human leukemia cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4142,755181,1,2,,103507642,3385,Unspecified,,,76.4,GI50,Cytotoxicity against human breast cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4143,755182,1,2,,103507642,3385,Active,,,45.6,GI50,Cytotoxicity against human renal cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4144,755183,1,2,,103507642,3385,Active,,,22.7,GI50,Cytotoxicity against human prostate cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4145,755184,1,2,,103507642,3385,Unspecified,,,61.4,GI50,Cytotoxicity against human ovarian cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4146,755185,1,2,,103507642,3385,Unspecified,,,70.6,GI50,Cytotoxicity against human melanoma cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4147,755186,1,2,,103507642,3385,Unspecified,,,72.1,GI50,Cytotoxicity against human CNS cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4148,755187,1,2,,103507642,3385,Active,,,8.4,GI50,Cytotoxicity against human colon cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4149,755188,1,2,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against human non-small cell lung cancer cells after 48 hrs by coulter counter analysis,Confirmatory,23683592.0,
4150,757853,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay,Confirmatory,23735281.0,
4151,757855,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,23735281.0,
4152,757856,1,1,,103507642,3385,Active,,,31.44,IC50,Antiproliferative activity against human PC3 cells expressing PCDNA after 72 hrs by MTT assay,Confirmatory,23735281.0,
4153,757857,1,1,,103507642,3385,Active,,,27.07,IC50,Antiproliferative activity against human PC3 cells expressing SKP2 after 72 hrs by MTT assay,Confirmatory,23735281.0,
4154,761693,1,1,,103507642,3385,Active,,,,,Cell cycle arrest in human MCF7 cells assessed as increase in G0/G1-phase accumulation at IC50 after 24 hrs by FACs analysis,Other,23800391.0,
4155,761694,1,1,,103507642,3385,Active,,,,,Cell cycle arrest in human MCF7 cells assessed as reduction in S-phase accumulation at IC50 after 24 hrs by FACs analysis,Other,23800391.0,
4156,761695,1,1,,103507642,3385,Active,,,,,Cell cycle arrest in human MCF7 cells assessed as increase in pre-G apoptotic fraction at IC50 after 24 hrs by FACs analysis relative to untreated control,Other,23800391.0,
4157,761699,1,1,,103507642,3385,Active,,,10.0,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23800391.0,
4158,761700,1,1,,103507642,3385,Active,,,10.0,IC50,Antiproliferative activity against human WI38 cells after 48 hrs by MTT assay,Confirmatory,23800391.0,
4159,761701,1,1,,103507642,3385,Active,,,8.0,IC50,Antiproliferative activity against african green monkey Vero cells after 48 hrs by MTT assay,Confirmatory,23800391.0,
4160,761702,1,1,,103507642,3385,Active,,,5.0,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23800391.0,
4161,763700,1,1,,103507642,3385,Active,,,9.78,IC50,Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay,Confirmatory,23792764.0,
4162,763701,1,1,,103507642,3385,Active,,,7.54,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23792764.0,
4163,763702,1,1,,103507642,3385,Active,,,24.76,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,23792764.0,
4164,763703,1,3,,103507642,3385,Active,,,6.92,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,23792764.0,
4165,763704,1,2,,103507642,3385,Active,,,10.61,IC50,Cytotoxicity against human EC109 cells after 72 hrs by MTT assay,Confirmatory,23792764.0,
4166,763932,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT116 cells assessed as dead cells at 20 uM after 48 hrs by sulforhodamine-B assay relative to control,Other,23811086.0,
4167,763933,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human THP1 cells assessed as dead cells at 20 uM after 48 hrs by sulforhodamine-B assay relative to control,Other,23811086.0,
4168,763934,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human A549 cells assessed as dead cells at 20 uM after 48 hrs by sulforhodamine-B assay relative to control,Other,23811086.0,
4169,765432,1,2,,103507642,3385,Active,,,26.7,IC50,Cytotoxicity against human H460 cells after 48 hrs by MTT assay,Confirmatory,23867385.0,
4170,765436,1,1,,103507642,3385,Active,,,22.3,IC50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,23867385.0,
4171,766063,1,1,,103507642,3385,Active,,,8.12,GI50,Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4172,766064,1,1,,103507642,3385,Active,,,10.6,GI50,Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4173,766065,1,1,,103507642,3385,Active,,,9.77,GI50,Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4174,766066,1,1,,103507642,3385,Active,,,6.6,GI50,Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4175,766067,1,1,,103507642,3385,Active,,,0.36,GI50,Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4176,766068,1,1,,103507642,3385,Active,,,0.07,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4177,766069,1,1,,103507642,3385,Active,,,1.42,GI50,Growth inhibition of human UO31 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4178,766070,1,1,,103507642,3385,Active,,,2.36,GI50,Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4179,766071,1,1,,103507642,3385,Active,,,1.12,GI50,Growth inhibition of human TK10 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4180,766072,1,1,,103507642,3385,Active,,,2.61,GI50,Growth inhibition of human RXF393 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4181,766073,1,1,,103507642,3385,Active,,,0.49,GI50,Growth inhibition of human SN12C cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4182,766074,1,1,,103507642,3385,Active,,,0.07,GI50,Growth inhibition of human CAKI-1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4183,766075,1,1,,103507642,3385,Active,,,0.35,GI50,Growth inhibition of human A498 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4184,766076,1,1,,103507642,3385,Active,,,0.29,GI50,Growth inhibition of human ACHN cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4185,766077,1,1,,103507642,3385,Active,,,21.8,GI50,Growth inhibition of human SKOV3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4186,766078,1,1,,103507642,3385,Active,,,0.72,GI50,Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4187,766079,1,1,,103507642,3385,Active,,,0.31,GI50,Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4188,766080,1,1,,103507642,3385,Active,,,10.9,GI50,Growth inhibition of human OVCAR5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4189,766081,1,1,,103507642,3385,Active,,,1.74,GI50,Growth inhibition of human OVCAR8 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4190,766082,1,1,,103507642,3385,Active,,,4.43,GI50,Growth inhibition of human OVCAR4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4191,766083,1,1,,103507642,3385,Active,,,1.22,GI50,Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4192,766084,1,1,,103507642,3385,Active,,,0.01,GI50,Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4193,766085,1,1,,103507642,3385,Active,,,3.55,GI50,Growth inhibition of human UACC257 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4194,766086,1,1,,103507642,3385,Active,,,0.52,GI50,Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4195,766087,1,1,,103507642,3385,Active,,,0.46,GI50,Growth inhibition of human SK-MEL-5 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4196,766088,1,1,,103507642,3385,Unspecified,,,56.7,GI50,Growth inhibition of human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4197,766089,1,1,,103507642,3385,Active,,,1.03,GI50,Growth inhibition of human SK-MEL-28 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4198,766090,1,1,,103507642,3385,Active,,,0.98,GI50,Growth inhibition of human M14 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4199,766091,1,1,,103507642,3385,Active,,,0.07,GI50,Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4200,766092,1,1,,103507642,3385,Active,,,0.05,GI50,Growth inhibition of human MALME-3M cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4201,766093,1,1,,103507642,3385,Active,,,0.9,GI50,Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4202,766094,1,3,,103507642,3385,Active,,,0.24,GI50,Growth inhibition of human LOXIMVI cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4203,766095,1,1,,103507642,3385,Unspecified,,,78.7,GI50,Growth inhibition of human SNB75 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4204,766096,1,1,,103507642,3385,Active,,,3.81,GI50,Growth inhibition of human SNB19 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4205,766097,1,1,,103507642,3385,Active,,,0.06,GI50,Growth inhibition of human SF539 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4206,766098,1,1,,103507642,3385,Active,,,0.22,GI50,Growth inhibition of human SF295 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4207,766099,1,1,,103507642,3385,Active,,,0.92,GI50,Growth inhibition of human SW620 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4208,766100,1,1,,103507642,3385,Active,,,1.62,GI50,Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4209,766101,1,1,,103507642,3385,Active,,,0.17,GI50,Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4210,766102,1,1,,103507642,3385,Active,,,0.21,GI50,Growth inhibition of human KM12 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4211,766103,1,1,,103507642,3385,Active,,,0.22,GI50,Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4212,766104,1,1,,103507642,3385,Active,,,0.11,GI50,Growth inhibition of human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4213,766105,1,3,,103507642,3385,Active,,,0.15,GI50,Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4214,766106,1,1,,103507642,3385,Active,,,0.05,GI50,Growth inhibition of human HCC2998 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4215,766107,1,1,,103507642,3385,Active,,,7.27,GI50,Growth inhibition of human NCI-H522 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4216,766108,1,1,,103507642,3385,Active,,,0.05,GI50,Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4217,766109,1,1,,103507642,3385,Unspecified,,,54.7,GI50,Growth inhibition of human NCI-H226 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4218,766110,1,1,,103507642,3385,Active,,,0.33,GI50,Growth inhibition of human NCI-H23 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4219,766111,1,1,,103507642,3385,Active,,,0.39,GI50,Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4220,766112,1,1,,103507642,3385,Unspecified,,,77.9,GI50,Growth inhibition of human HOP92 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4221,766113,1,1,,103507642,3385,Active,,,0.18,GI50,Growth inhibition of human A549/ATCC cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4222,766114,1,1,,103507642,3385,Unspecified,,,61.8,GI50,Growth inhibition of human EKVX cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4223,766115,1,1,,103507642,3385,Active,,,0.02,GI50,Growth inhibition of human SR cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4224,766116,1,1,,103507642,3385,Active,,,0.04,GI50,Growth inhibition of human RPMI8226 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4225,766117,1,1,,103507642,3385,Active,,,0.35,GI50,Growth inhibition of human MOLT4 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4226,766118,1,1,,103507642,3385,Active,,,3.58,GI50,Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4227,766119,1,2,,103507642,3385,Active,,,2.3,GI50,Growth inhibition of human HL-60(TB) cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4228,766120,1,1,,103507642,3385,Active,,,,IC50,Growth inhibition of human CCRF-CEM cells after 48 hrs by sulforhodamine B assay,Confirmatory,23887055.0,
4229,767031,1,1,,103507642,3385,Active,,,15.71,IC50,Cytotoxicity against human SW480 cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4230,767032,1,1,,103507642,3385,Active,,,13.65,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4231,767033,1,1,,103507642,3385,Active,,,6.04,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4232,767034,1,2,,103507642,3385,Active,,,14.3,IC50,Cytotoxicity against human QGY7701 cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4233,767035,1,1,,103507642,3385,Active,,,5.62,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4234,767036,1,1,,103507642,3385,Active,,,16.52,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23920246.0,
4235,767737,1,1,,103507642,3385,Active,,,3.6,GI50,Cytotoxicity against human A549 cells after 72 hrs by SRB assay,Confirmatory,23964677.0,
4236,768054,1,1,,103507642,3385,Active,,,3.6,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4237,768055,1,1,,103507642,3385,Unspecified,,,128.7,IC50,Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4238,768056,1,2,,103507642,3385,Active,,,14.5,IC50,Cytotoxicity against human MDA-MB-435S cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4239,768057,1,1,,103507642,3385,Active,,,8.1,IC50,Cytotoxicity against human SW480 cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4240,768058,1,2,,103507642,3385,Active,,,18.6,IC50,Cytotoxicity against human LM7 cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4241,768059,1,1,,103507642,3385,Active,,,3.4,IC50,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,23792763.0,
4242,769137,1,4,,103507642,3385,Active,,,,IC50,Antitumor activity against mouse EAC cells by trypan blue exclusion assay,Confirmatory,,
4243,769614,1,1,,103507642,3385,Active,,,6.53,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay,Confirmatory,23867603.0,
4244,769615,1,3,,103507642,3385,Active,,,4.84,IC50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,23867603.0,
4245,769616,1,1,,103507642,3385,Active,,,6.23,IC50,Cytotoxicity against human HeLa cells after 72 hrs by SRB assay,Confirmatory,23867603.0,
4246,771405,1,2,,103507642,3385,Unspecified,,,76.4,GI50,Cytotoxicity against human breast cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4247,771406,1,2,,103507642,3385,Active,,,22.7,GI50,Cytotoxicity against human prostate cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4248,771407,1,2,,103507642,3385,Active,,,45.6,GI50,Cytotoxicity against human renal cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4249,771408,1,2,,103507642,3385,Unspecified,,,70.6,GI50,Cytotoxicity against human melanoma cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4250,771409,1,2,,103507642,3385,Unspecified,,,61.4,GI50,Cytotoxicity against human ovarian cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4251,771410,1,2,,103507642,3385,Unspecified,,,72.1,GI50,Cytotoxicity against human CNS cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4252,771411,1,2,,103507642,3385,Active,,,8.4,GI50,Cytotoxicity against human colon cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4253,771412,1,2,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against human non-small cell lung cancer cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4254,771413,1,1,,103507642,3385,Inconclusive,,,,,Growth inhibition of human MDA-MB-468 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4255,771414,1,2,,103507642,3385,Active,,,1.51,GI50,Cytotoxicity against human leukemia cells after 48 hrs by SRB assay,Confirmatory,23994328.0,
4256,771415,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human BT549 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4257,771416,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human T47D cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4258,771417,1,1,,103507642,3385,Active,,,,,Growth inhibition of human Hs578T cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4259,771418,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human MCF7 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4260,771419,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4261,771420,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human PC3 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4262,771421,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human DU145 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4263,771422,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human TK10 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4264,771423,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human UO31 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4265,771424,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human RXF393 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4266,771425,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SN12C cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4267,771426,1,1,,103507642,3385,Active,,,,,Growth inhibition of human A498 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4268,771427,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human ACHN cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4269,771428,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human Caki1 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4270,771429,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human 786-0 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4271,771430,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SKOV3 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4272,771431,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-ADR-RES cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4273,771432,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR5 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4274,771433,1,1,,103507642,3385,Inconclusive,,,,,Growth inhibition of human OVCAR8 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4275,771434,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR4 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4276,771435,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human OVCAR3 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4277,771436,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human IGROV1 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4278,771437,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human UACC62 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4279,771438,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SK-MEL-5 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4280,771439,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human UACC257 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4281,771440,1,1,,103507642,3385,Inconclusive,,,,,Growth inhibition of human SK-MEL-28 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4282,771441,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SK-MEL-2 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4283,771442,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human MDA-MB-435 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4284,771443,1,1,,103507642,3385,Inconclusive,,,,,Growth inhibition of human M14 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4285,771444,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human LOXIMVI cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4286,771445,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human MALME-3M cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4287,771446,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human U251 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4288,771447,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SNB19 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4289,771448,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SNB75 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4290,771449,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SF295 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4291,771450,1,1,,103507642,3385,Active,,,,,Growth inhibition of human SF539 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4292,771451,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SW620 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4293,771452,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SF268 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4294,771453,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HT-29 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4295,771454,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human KM12 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4296,771455,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT116 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4297,771456,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4298,771457,1,3,,103507642,3385,Unspecified,,,,,Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4299,771458,1,1,,103507642,3385,Active,,,,,Growth inhibition of human HCC2998 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4300,771459,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H522 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4301,771460,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H322M cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4302,771461,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H460 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4303,771462,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H226 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4304,771463,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human NCI-H23 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4305,771464,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HOP92 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4306,771465,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human EKVX cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4307,771466,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human HOP62 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4308,771467,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human MOLT4 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4309,771468,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human CCRF-CEM cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4310,771469,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of human HL-60(TB) cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4311,771470,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human K562 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4312,771471,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human SR cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4313,771472,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human A549 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4314,771473,1,1,,103507642,3385,Unspecified,,,,,Growth inhibition of human RPMI8226 cells at 10 uM after 48 hrs by SRB assay,Other,23994328.0,
4315,771501,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Other,23994872.0,
4316,771584,2,1,,103507642,3385,Unspecified,,,50.2,ED50,Cytotoxicity against human T47D cells after 3 hrs by Alamar Blue assay,Confirmatory,24020806.0,
4317,771585,2,1,,103507642,3385,Active,,,15.07,ED50,Cytotoxicity against human MOLT4 cells after 6 hrs by Alamar Blue assay,Confirmatory,24020806.0,
4318,771586,2,1,,103507642,3385,Active,,,16.22,ED50,Cytotoxicity against human K562 cells after 6 hrs by Alamar Blue assay,Confirmatory,24020806.0,
4319,771973,1,3,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,,
4320,771975,1,3,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,,
4321,771980,1,3,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,,
4322,771987,1,3,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay,Confirmatory,,
4323,773060,1,1,,103507642,3385,Active,,,7.34,IC50,Growth inhibition against human HeLa cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4324,773061,1,1,,103507642,3385,Active,,,11.5,IC50,Growth inhibition against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4325,773062,1,1,,103507642,3385,Active,,,40.34,IC50,Growth inhibition against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4326,773063,1,1,,103507642,3385,Active,,,44.05,IC50,Growth inhibition against human A549 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4327,773064,1,1,,103507642,3385,Active,,,27.76,IC50,Growth inhibition against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4328,773065,1,2,,103507642,3385,Active,,,6.67,IC50,Growth inhibition against human A375-S2 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4329,773066,1,1,,103507642,3385,Active,,,23.55,IC50,Growth inhibition against human K562 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4330,773067,1,1,,103507642,3385,Active,,,35.62,IC50,Growth inhibition against human HT1080 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4331,773068,1,1,,103507642,3385,Active,,,10.05,IC50,Growth inhibition against human HL60 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4332,773069,1,1,,103507642,3385,Active,,,23.93,IC50,Growth inhibition against human U937 cells after 48 hrs by MTT assay,Confirmatory,23999046.0,
4333,774414,2,1,,103507642,3385,Active,,,7.7,ED50,Cytotoxicity against human HT-29 cells by Alamar blue assay,Confirmatory,24128077.0,
4334,774415,2,1,,103507642,3385,Active,,,21.0,ED50,Cytotoxicity against human K562 cells by Alamar blue assay,Confirmatory,24128077.0,
4335,774416,2,1,,103507642,3385,Active,,,6.2,ED50,Cytotoxicity against mouse P388 cells by Alamar blue assay,Confirmatory,24128077.0,
4336,774417,2,1,,103507642,3385,Active,,,7.7,ED50,Cytotoxicity against human MOLT4 cells by Alamar blue assay,Confirmatory,24128077.0,
4337,774790,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at S phase at IC50 by propidium iodide staining-based FACS flow cytometric analysis relative to control,Other,23988357.0,
4338,774791,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G2 phase at IC50 by propidium iodide staining-based FACS flow cytometric analysis relative to control,Other,23988357.0,
4339,774792,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at G1 phase at IC50 by propidium iodide staining-based FACS flow cytometric analysis relative to control,Other,23988357.0,
4340,774796,1,1,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 45 uM after 24 hrs by Annexin V-FITC and propidium iodide staining-based FACS flow cytometric analysis (Rvb = 1.5%),Other,23988357.0,
4341,774797,1,1,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human NCI-H460 cells assessed as necrotic/late apoptotic cells at 45 uM after 24 hrs by Annexin V-FITC and propidium iodide staining-based FACS flow cytometric analysis (Rvb = 0.8%),Other,23988357.0,
4342,774802,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human NCI-H460 cells assessed as loss of mitochondria membrane potential at 45 uM after 24 hrs by JC-1 staining-based fluorescence microscopic analysis,Other,23988357.0,
4343,774807,1,1,,103507642,3385,Active,,,44.04,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,23988357.0,
4344,774808,1,1,,103507642,3385,Active,,,34.33,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23988357.0,
4345,774809,1,1,,103507642,3385,Active,,,29.98,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,23988357.0,
4346,774810,1,1,,103507642,3385,Active,,,24.43,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay,Confirmatory,23988357.0,
4347,774984,1,2,,103507642,3385,Active,,,0.6,IC50,Cytotoxicity against human QSG7701 cells after 48 hrs by CCK-8 assay,Confirmatory,24013415.0,
4348,774985,1,1,,103507642,3385,Active,,,14.55,IC50,Cytotoxicity against human SMMC7721 cells after 48 hrs by CCK-8 assay,Confirmatory,24013415.0,
4349,774986,1,1,,103507642,3385,Active,,,12.48,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by CCK-8 assay,Confirmatory,24013415.0,
4350,774987,1,2,,103507642,3385,Active,,,15.66,IC50,Cytotoxicity against human QGY7703 cells after 48 hrs by CCK-8 assay,Confirmatory,24013415.0,
4351,775017,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,24021891.0,
4352,775018,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Other,24021891.0,
4353,775720,1,2,,103507642,3385,Active,,,0.5,IC50,Cytotoxicity against human Hep cells after 48 hrs by SRB assay,Confirmatory,24056146.0,
4354,775722,1,1,,103507642,3385,Active,,,1.3,IC50,Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay,Confirmatory,24056146.0,
4355,775725,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against mouse Daltons ascitic lymphoma cells assessed as dead cells at 100 ug/ml after 3 hrs by trypan blue exclusion assay relative to control,Other,24056147.0,
4356,775738,1,1,,103507642,3385,Active,,,1.1,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,24060486.0,
4357,775739,1,1,,103507642,3385,Active,,,1.3,IC50,Cytotoxicity against human DU145 cells after 24 hrs by MTT assay,Confirmatory,24060486.0,
4358,775740,1,1,,103507642,3385,Active,,,1.2,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,24060486.0,
4359,775741,1,1,,103507642,3385,Active,,,1.1,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,24060486.0,
4360,775939,1,1,,103507642,3385,Active,,,7.54,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4361,775940,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4362,775941,1,1,,103507642,3385,Active,,,24.76,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4363,775942,1,3,,103507642,3385,Active,,,6.92,IC50,Cytotoxicity against human MGC803 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4364,775943,1,1,,103507642,3385,Active,,,9.78,IC50,Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4365,775944,1,2,,103507642,3385,Active,,,10.61,IC50,Cytotoxicity against human EC109 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,24077182.0,
4366,776384,1,1,,103507642,3385,Active,,,29.98,IC50,Cytotoxicity against human HepG2 cells after 3 days by MTT assay,Confirmatory,24095745.0,
4367,776385,1,1,,103507642,3385,Active,,,24.43,IC50,Cytotoxicity against human SKOV3 cells after 3 days by MTT assay,Confirmatory,24095745.0,
4368,776386,1,1,,103507642,3385,Active,,,44.04,IC50,Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay,Confirmatory,24095745.0,
4369,776387,1,1,,103507642,3385,Active,,,34.33,IC50,Cytotoxicity against human A549 cells after 3 days by MTT assay,Confirmatory,24095745.0,
4370,780741,1,1,,103507642,3385,Active,,,6.92,IC50,Antiproliferative activity against human HCT8 cells by MTT assay,Confirmatory,24095094.0,
4371,780742,1,1,,103507642,3385,Active,,,8.3,IC50,Antiproliferative activity against human Bel7402 cells by MTT assay,Confirmatory,24095094.0,
4372,780743,1,1,,103507642,3385,Active,,,8.92,IC50,Antiproliferative activity against human A549 cells by MTT assay,Confirmatory,24095094.0,
4373,780966,1,1,,103507642,3385,Inactive,,,,,Induction of vascular disrupting activity in HUVEC assessed as VEGF-induced tube formation at 1000 nM after 4 hrs by microscopic analysis,Other,24106982.0,
4374,930945,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021104,Other,,
4375,930946,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021104,Other,,
4376,930947,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021104,Other,,
4377,930948,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021104,Other,,
4378,930949,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021104,Other,,
4379,930950,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021104,Other,,
4380,930951,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021104,Other,,
4381,930952,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021104,Other,,
4382,930953,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021104",Other,,
4383,930954,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021104,Other,,
4384,930955,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021104,Other,,
4385,930956,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021104,Other,,
4386,930957,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021104,Other,,
4387,930958,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021104,Other,,
4388,930959,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021104,Other,,
4389,930960,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021104,Other,,
4390,930961,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021104,Other,,
4391,930962,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021104,Other,,
4392,930963,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021104,Other,,
4393,943149,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S021104,Other,,
4394,943150,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S021104,Other,,
4395,943151,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S021104,Other,,
4396,943152,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S021104,Other,,
4397,943153,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S021104,Other,,
4398,943154,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S021104,Other,,
4399,943155,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S021104,Other,,
4400,943156,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S021104,Other,,
4401,943157,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S021104,Other,,
4402,943158,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S021104,Other,,
4403,943159,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S021104,Other,,
4404,943160,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S021104,Other,,
4405,943161,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S021104,Other,,
4406,943162,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S021104,Other,,
4407,943163,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S021104,Other,,
4408,943164,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S021104,Other,,
4409,943165,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S021104",Other,,
4410,943796,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S021104,Other,,
4411,943797,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S021104,Other,,
4412,963041,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021104,Other,,
4413,963042,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021104,Other,,
4414,963043,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021104,Other,,
4415,963044,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021104,Other,,
4416,963045,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021104,Other,,
4417,964866,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021104,Other,,
4418,964867,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021104,Other,,
4419,964868,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021104,Other,,
4420,964869,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021104,Other,,
4421,964870,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021104,Other,,
4422,964871,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021104,Other,,
4423,964872,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021104,Other,,
4424,964873,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021104,Other,,
4425,964874,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021104,Other,,
4426,964875,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021104,Other,,
4427,964876,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021104,Other,,
4428,964877,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021104,Other,,
4429,964878,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021104,Other,,
4430,964879,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021104,Other,,
4431,970343,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S021104,Other,,
4432,970344,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S021104,Other,,
4433,972366,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S021104,Other,,
4434,972367,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S021104,Other,,
4435,972368,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S021104,Other,,
4436,972369,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S021104,Other,,
4437,972370,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S021104,Other,,
4438,972371,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S021104,Other,,
4439,972372,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S021104,Other,,
4440,972373,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S021104,Other,,
4441,972374,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S021104,Other,,
4442,972375,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S021104,Other,,
4443,972376,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S021104,Other,,
4444,972377,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S021104,Other,,
4445,972378,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S021104,Other,,
4446,972379,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S021104,Other,,
4447,972380,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S021104,Other,,
4448,972381,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S021104,Other,,
4449,972382,1,3,,103507642,3385,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S021104,Other,,
4450,977599,1,1,,103507642,3385,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4451,977602,1,2,,103507642,3385,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4452,977610,3,1,,46393324,3385,Active,5542499.0,,25.0,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,9628859.0,
4453,1006079,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4454,1006080,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4455,1006081,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S021104",Other,,
4456,1006082,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S021104",Other,,
4457,1006083,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4458,1006084,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S021104",Other,,
4459,1006085,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4460,1006086,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4461,1006087,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S021104",Other,,
4462,1006088,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S021104",Other,,
4463,1006667,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S021104",Other,,
4464,1006668,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S021104",Other,,
4465,1006669,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S021104",Other,,
4466,1006670,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4467,1006671,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4468,1008537,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S021104",Other,,
4469,1008538,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4470,1008539,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S021104",Other,,
4471,1008540,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S021104",Other,,
4472,1008541,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4473,1008542,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S021104",Other,,
4474,1008543,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4475,1008544,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4476,1008545,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S021104",Other,,
4477,1008546,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S021104",Other,,
4478,1008547,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S021104",Other,,
4479,1008548,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4480,1008549,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4481,1008550,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S021104",Other,,
4482,1008551,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S021104",Other,,
4483,1008552,1,3,,103507642,3385,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S021104",Other,,
4484,1053188,2,1,,8139872,3385,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
4485,1053197,1,1,,8139872,3385,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4486,1055559,1,1,,103507642,3385,Unspecified,,,264.0,IC50,Cytotoxicity against human UACC62 cells after 48 hrs by MTT assay,Confirmatory,24177365.0,
4487,1055561,1,1,,103507642,3385,Unspecified,,,1000.0,IC50,Cytotoxicity against human VH10 cells after 48 hrs by MTT assay,Confirmatory,24177365.0,
4488,1055759,1,2,,103507642,3385,Active,,,8.5,IC50,Cytotoxic activity against human NCI-H460 cells,Confirmatory,24195466.0,
4489,1055764,1,1,,103507642,3385,Active,,,3.4,IC50,Cytotoxic activity against human DU145 cells,Confirmatory,24195466.0,
4490,1058462,1,2,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at diploid S phase at IC50 after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 23.27%),Other,24211021.0,
4491,1058463,1,2,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at diploid G2 phase at IC50 after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 8.14%),Other,24211021.0,
4492,1058464,1,2,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human NCI-H460 cells assessed as accumulation at diploid G1 phase at IC50 after 48 hrs by propidium iodide staining-based FACS analysis (Rvb = 68.60%),Other,24211021.0,
4493,1058474,1,2,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 45 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.8%),Other,24211021.0,
4494,1058475,1,2,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 45 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 1.5%),Other,24211021.0,
4495,1058488,1,2,,103507642,3385,Active,,,15.32,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,24211021.0,
4496,1058489,1,2,,103507642,3385,Active,,,19.45,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,24211021.0,
4497,1058490,1,1,,103507642,3385,Active,,,8.32,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,24211021.0,
4498,1058491,1,2,,103507642,3385,Active,,,20.13,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,24211021.0,
4499,1058492,1,2,,103507642,3385,Active,,,23.32,IC50,Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay,Confirmatory,24211021.0,
4500,1060711,1,1,,103507642,3385,Active,,,7.48,IC50,Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay,Confirmatory,24286761.0,
4501,1060712,1,1,,103507642,3385,Active,,,5.26,IC50,Cytotoxicity against human SW1116 cells after 48 hrs by MTT assay,Confirmatory,24286761.0,
4502,1060713,1,2,,103507642,3385,Active,,,9.79,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24286761.0,
4503,1060714,1,2,,103507642,3385,Active,,,7.43,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24286761.0,
4504,1061795,1,2,,103507642,3385,Active,,,4.2,IC50,Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,24332497.0,
4505,1061796,1,1,,103507642,3385,Active,,,4.9,IC50,Cytotoxicity against human ME180 cells after 48 hrs by MTT assay,Confirmatory,24332497.0,
4506,1061797,1,2,,103507642,3385,Active,,,3.5,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24332497.0,
4507,1061799,1,2,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
4508,1061801,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
4509,1061804,1,2,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
4510,1061805,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human IMR32 cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
4511,1061807,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human prostate cancer cells assessed as growth inhibition at 10 uM by SRB assay,Other,24332623.0,
4512,1063361,1,1,,103507642,3385,Active,,,8.1,IC50,Cytotoxicity against human KB cells after 4 days by MTT assay,Confirmatory,24359303.0,
4513,1063362,1,1,,103507642,3385,Active,,,5.5,IC50,Cytotoxicity against human Bel7402 cells after 4 days by MTT assay,Confirmatory,24359303.0,
4514,1063363,1,2,,103507642,3385,Active,,,3.1,IC50,Cytotoxicity against human A549 cells after 4 days by MTT assay,Confirmatory,24359303.0,
4515,1064203,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 23.29%),Other,24378217.0,
4516,1064208,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human HCT116 cells assessed as change in mitochondrial membrane potential after 24 hrs by JC-1 staining,Other,24378217.0,
4517,1064215,1,2,,103507642,3385,Unspecified,,,56.0,IC50,Cytotoxicity against human HUVEC after 48 hrs by MTT assay,Confirmatory,24378217.0,
4518,1064216,1,1,,103507642,3385,Active,,,5.78,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,24378217.0,
4519,1064217,1,1,,103507642,3385,Active,,,42.2,IC50,Cytotoxicity against human SPCA2 cells after 48 hrs by MTT assay,Confirmatory,24378217.0,
4520,1064218,1,2,,103507642,3385,Active,,,35.34,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24378217.0,
4521,1064219,1,2,,103507642,3385,Active,,,40.21,IC50,Cytotoxicity against human CNE cells after 48 hrs by MTT assay,Confirmatory,24378217.0,
4522,1064222,1,2,,103507642,3385,Active,,,29.98,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24378217.0,
4523,1064233,1,1,,103507642,3385,Unspecified,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at G1 phase after 48 hrs using propidium iodide staining by FACS analysis (Rvb = 39.08%),Other,24378217.0,
4524,1065290,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
4525,1065294,1,1,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human MG63 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
4526,1065297,1,1,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
4527,1065300,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
4528,1065303,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,23792352.0,
4529,1066272,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay,Other,24342667.0,
4530,1066273,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Other,24342667.0,
4531,1066274,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay,Other,24342667.0,
4532,1066719,1,2,,103507642,3385,Active,,,2.3,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24547794.0,
4533,1066721,1,2,,103507642,3385,Active,,,7.6,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24547794.0,
4534,1067707,1,2,,103507642,3385,Active,,,5.58,IC50,Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay,Confirmatory,24119869.0,
4535,1067708,1,2,,103507642,3385,Active,,,4.35,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24119869.0,
4536,1067709,1,1,,103507642,3385,Active,,,7.37,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,24119869.0,
4537,1067710,1,2,,103507642,3385,Active,,,3.68,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,24119869.0,
4538,1070279,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human breast cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4539,1070280,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human prostate cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4540,1070281,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human renal cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4541,1070282,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human ovarian cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4542,1070283,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human melanoma cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4543,1070284,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human CNS cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4544,1070285,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human colon cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4545,1070286,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human leukemia cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4546,1070287,1,2,,103507642,3385,Unspecified,,,,GI50,Cytotoxicity against human non-small cell lung cancer cells at 10 uM after 48 hrs,Confirmatory,24469112.0,
4547,1075002,1,4,,103507642,3385,Inactive,136611.0,7298.0,,,Inhibition of thymidylate synthase in 13-fold cisplatin-resistant human C13 cells assessed as effect on thymidylate synthase mRNA level at 5 uM after 48 hrs by RT-PCR analysis,Other,24450514.0,
4548,1075003,1,4,,103507642,3385,Active,136611.0,7298.0,,,Inhibition of thymidylate synthase in human 2008 cells assessed as upregulation of thymidylate synthase mRNA level at 5 uM after 48 hrs by RT-PCR analysis,Other,24450514.0,
4549,1075006,1,1,,103507642,3385,Active,,,,,Upregulation of thymidylate synthase total protein level in 13-fold cisplatin-resistant human C13 cells at 5 uM after 48 hrs by Western blotting analysis,Other,24450514.0,
4550,1075007,1,2,,103507642,3385,Active,,,,,Upregulation of thymidylate synthase total protein level in human 2008 cells at 5 uM after 48 hrs by Western blotting analysis,Other,24450514.0,
4551,1075010,1,1,,103507642,3385,Active,,,,,Cytotoxicity against 10-fold cisplatin-resistant human A2780C/P cells cell survival at 10 uM after 72 hrs by crystal violet staining-based spectrophotometric analysis relative to control,Other,24450514.0,
4552,1075012,1,1,,103507642,3385,Active,,,,,Cytotoxicity against 13-fold cisplatin-resistant human C13 cells cell survival at 10 uM after 72 hrs by crystal violet staining-based spectrophotometric analysis relative to control,Other,24450514.0,
4553,1076319,1,1,,103507642,3385,Active,,,15.8,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by LDH release assay,Confirmatory,24534537.0,
4554,1076320,1,1,,103507642,3385,Active,,,15.7,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by MTT assay,Confirmatory,24534537.0,
4555,1076321,1,1,,103507642,3385,Active,,,14.3,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by trypan blue exclusion assay,Confirmatory,24534537.0,
4556,1076322,1,1,,103507642,3385,Active,,,14.3,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by MTT assay,Confirmatory,24534537.0,
4557,1076323,1,1,,103507642,3385,Active,,,16.3,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by LDH release assay,Confirmatory,24534537.0,
4558,1076324,1,1,,103507642,3385,Active,,,16.4,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by trypan blue exclusion assay,Confirmatory,24534537.0,
4559,1076716,1,1,,103507642,3385,Active,,,24.43,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4560,1076717,1,2,,103507642,3385,Unspecified,,,80.48,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4561,1076718,1,1,,103507642,3385,Active,,,26.8,IC50,Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4562,1076719,1,1,,103507642,3385,Active,,,24.43,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4563,1076720,1,2,,103507642,3385,Active,,,26.98,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4564,1076721,1,2,,103507642,3385,Active,,,36.04,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,24565905.0,
4565,1079931,1,1,,103507642,3385,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4566,1079932,1,1,,103507642,3385,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4567,1079933,1,1,,103507642,3385,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4568,1079934,1,1,,103507642,3385,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4569,1079935,1,1,,103507642,3385,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4570,1079936,1,1,,103507642,3385,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4571,1079937,1,1,,103507642,3385,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4572,1079938,1,1,,103507642,3385,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4573,1079939,1,1,,103507642,3385,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4574,1079940,1,1,,103507642,3385,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4575,1079941,1,1,,103507642,3385,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4576,1079942,1,1,,103507642,3385,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4577,1079943,1,1,,103507642,3385,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4578,1079944,1,1,,103507642,3385,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4579,1079945,1,1,,103507642,3385,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4580,1079946,1,1,,103507642,3385,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4581,1079947,1,1,,103507642,3385,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4582,1079948,1,1,,103507642,3385,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4583,1079949,1,1,,103507642,3385,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4584,1083982,1,2,,103507642,3385,Active,,,2.9,IC50,Cytotoxicity against Homo sapiens (human) COLO205 cells by SRB assay,Confirmatory,,
4585,1083983,1,2,,103507642,3385,Active,,,2.0,IC50,Cytotoxicity against Homo sapiens (human) Hep2 cells by SRB assay,Confirmatory,,
4586,1083984,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay,Confirmatory,,
4587,1083985,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay,Confirmatory,,
4588,1083986,1,2,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay,Confirmatory,,
4589,1083987,1,2,,103507642,3385,Active,,,2.9,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay,Confirmatory,,
4590,1084276,1,2,,103507642,3385,Active,,,29.19,IC50,Cytotoxicity against Homo sapiens (human) SGC7901 cells after 72 hr by MTT assay,Confirmatory,,
4591,1084277,1,2,,103507642,3385,Active,,,9.72,IC50,Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay,Confirmatory,,
4592,1084840,2,3,,103507642,3385,Active,67474691.0,,13.0,Ki,Inhibition of Escherichia coli K-12 MTCC 1302 UPRT activity by spectrophotometry,Confirmatory,,
4593,1085609,1,2,,103507642,3385,Active,,,4.7,IC50,Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay,Confirmatory,,
4594,1085610,1,2,,103507642,3385,Unspecified,,,266.0,IC50,Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay,Confirmatory,,
4595,1085655,1,2,,103507642,3385,Active,,,8.12831,GI50,Cytotoxicity against Homo sapiens (human) T47D cells after 48 hr by SRB assay,Confirmatory,,
4596,1085656,1,2,,103507642,3385,Active,,,10.7152,GI50,Cytotoxicity against Homo sapiens (human) BT549 cells after 48 hr by SRB assay,Confirmatory,,
4597,1085657,1,2,,103507642,3385,Active,,,9.77237,GI50,Cytotoxicity against Homo sapiens (human) Hs578T cells after 48 hr by SRB assay,Confirmatory,,
4598,1085658,1,2,,103507642,3385,Active,,,6.60693,GI50,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by SRB assay,Confirmatory,,
4599,1085659,1,2,,103507642,3385,Active,,,0.07943,GI50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
4600,1085660,1,2,,103507642,3385,Active,,,0.36308,GI50,Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by SRB assay,Confirmatory,,
4601,1085661,1,2,,103507642,3385,Active,,,2.34423,GI50,Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay,Confirmatory,,
4602,1085662,1,2,,103507642,3385,Active,,,1.12202,GI50,Cytotoxicity against Homo sapiens (human) TK10 cells after 48 hr by SRB assay,Confirmatory,,
4603,1085663,1,2,,103507642,3385,Active,,,1.41254,GI50,Cytotoxicity against Homo sapiens (human) UO31 cells after 48 hr by SRB assay,Confirmatory,,
4604,1085664,1,2,,103507642,3385,Active,,,0.5011899999999999,GI50,Cytotoxicity against Homo sapiens (human) SN12C cells after 48 hr by SRB assay,Confirmatory,,
4605,1085665,1,2,,103507642,3385,Active,,,2.63027,GI50,Cytotoxicity against Homo sapiens (human) RXF393 cells after 48 hr by SRB assay,Confirmatory,,
4606,1085666,1,2,,103507642,3385,Active,,,0.07244,GI50,Cytotoxicity against Homo sapiens (human) Caki1 cells after 48 hr by SRB assay,Confirmatory,,
4607,1085667,1,2,,103507642,3385,Active,,,0.29512,GI50,Cytotoxicity against Homo sapiens (human) ACHN cells after 48 hr by SRB assay,Confirmatory,,
4608,1085668,1,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Cytotoxicity against Homo sapiens (human) A498 cells after 48 hr by SRB assay,Confirmatory,,
4609,1085669,1,2,,103507642,3385,Active,,,0.72444,GI50,Cytotoxicity against Homo sapiens (human) 786-0 cells after 48 hr by SRB assay,Confirmatory,,
4610,1085670,1,2,,103507642,3385,Active,,,21.8776,GI50,Cytotoxicity against Homo sapiens (human) SKOV3 cells after 48 hr by SRB assay,Confirmatory,,
4611,1085671,1,2,,103507642,3385,Active,,,1.7378,GI50,Cytotoxicity against Homo sapiens (human) OVCAR8 cells after 48 hr by SRB assay,Confirmatory,,
4612,1085673,1,2,,103507642,3385,Active,,,10.9648,GI50,Cytotoxicity against Homo sapiens (human) OVCAR5 cells after 48 hr by SRB assay,Confirmatory,,
4613,1085674,1,2,,103507642,3385,Active,,,4.46684,GI50,Cytotoxicity against Homo sapiens (human) OVCAR4 cells after 48 hr by SRB assay,Confirmatory,,
4614,1085675,1,2,,103507642,3385,Active,,,0.01585,GI50,Cytotoxicity against Homo sapiens (human) OVCAR3 cells after 48 hr by SRB assay,Confirmatory,,
4615,1085676,1,2,,103507642,3385,Active,,,1.23027,GI50,Cytotoxicity against Homo sapiens (human) IGROV1 cells after 48 hr by SRB assay,Confirmatory,,
4616,1085677,1,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Cytotoxicity against Homo sapiens (human) UACC257 cells after 48 hr by SRB assay,Confirmatory,,
4617,1085678,1,2,,103507642,3385,Active,,,0.52481,GI50,Cytotoxicity against Homo sapiens (human) UACC62 cells after 48 hr by SRB assay,Confirmatory,,
4618,1085679,1,2,,103507642,3385,Active,,,1.02329,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-28 cells after 48 hr by SRB assay,Confirmatory,,
4619,1085680,1,2,,103507642,3385,Active,,,0.46774,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-5 cells after 48 hr by SRB assay,Confirmatory,,
4620,1085681,1,3,,103507642,3385,Unspecified,,,56.2341,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-2 cells after 48 hr by SRB assay,Confirmatory,,
4621,1085682,1,2,,103507642,3385,Active,,,0.97724,GI50,Cytotoxicity against Homo sapiens (human) M14 cells after 48 hr by SRB assay,Confirmatory,,
4622,1085684,1,2,,103507642,3385,Active,,,0.051289999999999995,GI50,Cytotoxicity against Homo sapiens (human) MALME-3M cells after 48 hr by SRB assay,Confirmatory,,
4623,1085685,1,2,,103507642,3385,Active,,,0.91201,GI50,Cytotoxicity against Homo sapiens (human) U251 cells after 48 hr by SRB assay,Confirmatory,,
4624,1085686,1,2,,103507642,3385,Active,,,0.24547,GI50,Cytotoxicity against Homo sapiens (human) LOXIMVI cells after 48 hr by SRB assay,Confirmatory,,
4625,1085687,1,2,,103507642,3385,Active,,,3.80189,GI50,Cytotoxicity against Homo sapiens (human) SNB19 cells after 48 hr by SRB assay,Confirmatory,,
4626,1085688,1,3,,103507642,3385,Unspecified,,,79.4328,GI50,Cytotoxicity against Homo sapiens (human) SNB75 cells after 48 hr by SRB assay,Confirmatory,,
4627,1085689,1,2,,103507642,3385,Active,,,0.0631,GI50,Cytotoxicity against Homo sapiens (human) SF539 cells after 48 hr by SRB assay,Confirmatory,,
4628,1085690,1,3,,103507642,3385,Active,,,1.58489,GI50,Cytotoxicity against Homo sapiens (human) SF268 cells after 48 hr by SRB assay,Confirmatory,,
4629,1085691,1,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Cytotoxicity against Homo sapiens (human) SF295 cells after 48 hr by SRB assay,Confirmatory,,
4630,1085692,1,2,,103507642,3385,Active,,,0.2138,GI50,Cytotoxicity against Homo sapiens (human) KM12 cells after 48 hr by SRB assay,Confirmatory,,
4631,1085693,1,2,,103507642,3385,Active,,,0.93325,GI50,Cytotoxicity against Homo sapiens (human) SW620 cells after 48 hr by SRB assay,Confirmatory,,
4632,1085694,1,2,,103507642,3385,Active,,,0.17783,GI50,Cytotoxicity against Homo sapiens (human) HT-29 cells after 48 hr by SRB assay,Confirmatory,,
4633,1085695,1,2,,103507642,3385,Active,,,0.22909000000000002,GI50,Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by SRB assay,Confirmatory,,
4634,1085696,1,2,,103507642,3385,Active,,,0.10965,GI50,Cytotoxicity against Homo sapiens (human) HCT15 cells after 48 hr by SRB assay,Confirmatory,,
4635,1085697,1,2,,103507642,3385,Active,,,0.05248,GI50,Cytotoxicity against Homo sapiens (human) HCC2998 cells after 48 hr by SRB assay,Confirmatory,,
4636,1085698,1,2,,103507642,3385,Active,,,0.15849000000000002,GI50,Cytotoxicity against Homo sapiens (human) COLO205 cells after 48 hr by SRB assay,Confirmatory,,
4637,1085699,1,2,,103507642,3385,Active,,,7.24436,GI50,Cytotoxicity against Homo sapiens (human) NCI-H522 cells after 48 hr by SRB assay,Confirmatory,,
4638,1085700,1,2,,103507642,3385,Active,,,0.17783,GI50,Cytotoxicity against Homo sapiens (human) NCI-H322M cells after 48 hr by SRB assay,Confirmatory,,
4639,1085701,1,2,,103507642,3385,Active,,,0.056229999999999995,GI50,Cytotoxicity against Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay,Confirmatory,,
4640,1085702,1,3,,103507642,3385,Unspecified,,,54.9541,GI50,Cytotoxicity against Homo sapiens (human) NCI-H226 cells after 48 hr by SRB assay,Confirmatory,,
4641,1085703,1,2,,103507642,3385,Active,,,0.33113000000000004,GI50,Cytotoxicity against Homo sapiens (human) NCI-H23 cells after 48 hr by SRB assay,Confirmatory,,
4642,1085704,1,2,,103507642,3385,Active,,,0.39810999999999996,GI50,Cytotoxicity against Homo sapiens (human) HOP62 cells after 48 hr by SRB assay,Confirmatory,,
4643,1085705,1,3,,103507642,3385,Unspecified,,,77.6247,GI50,Cytotoxicity against Homo sapiens (human) HOP92 cells after 48 hr by SRB assay,Confirmatory,,
4644,1085706,1,3,,103507642,3385,Unspecified,,,61.6595,GI50,Cytotoxicity against Homo sapiens (human) EKVX cells after 48 hr by SRB assay,Confirmatory,,
4645,1085707,1,2,,103507642,3385,Active,,,0.02399,GI50,Cytotoxicity against Homo sapiens (human) SR cells after 48 hr by SRB assay,Confirmatory,,
4646,1085708,1,2,,103507642,3385,Active,,,0.19055,GI50,Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay,Confirmatory,,
4647,1085709,1,2,,103507642,3385,Active,,,0.35481,GI50,Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay,Confirmatory,,
4648,1085710,1,2,,103507642,3385,Active,,,0.04467,GI50,Cytotoxicity against Homo sapiens (human) RPMI8226 cells after 48 hr by SRB assay,Confirmatory,,
4649,1085711,1,2,,103507642,3385,Active,,,3.5481300000000005,GI50,Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by SRB assay,Confirmatory,,
4650,1085712,1,2,,103507642,3385,Active,,,9.77237,GI50,Cytotoxicity against Homo sapiens (human) CCRF-CEM cells after 48 hr by SRB assay,Confirmatory,,
4651,1085713,1,3,,103507642,3385,Active,,,2.29087,GI50,Cytotoxicity against Homo sapiens (human) HL-60(TB) cells after 48 hr by SRB assay,Confirmatory,,
4652,1086297,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay,Other,,
4653,1086298,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay,Other,,
4654,1086299,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay,Other,,
4655,1086300,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay,Other,,
4656,1086301,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay,Other,,
4657,1086701,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) THP1 cells assessed as growth inhibition at 2 x 10'-5 mole after 48 hr by SRB assay,Other,,
4658,1086704,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) COLO205 cells assessed as growth inhibition at 2 x 10'-5 mole after 48 hr by SRB assay,Other,,
4659,1086917,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
4660,1086918,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
4661,1086919,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
4662,1086920,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
4663,1086921,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay,Other,,
4664,1086942,1,2,,103507642,3385,Unspecified,,,85113.8,IC50,Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay,Confirmatory,,
4665,1086943,1,2,,103507642,3385,Unspecified,,,9332.54,IC50,Cytotoxicity against Homo sapiens (human) DLD1 cells after 72 hr by MTT assay,Confirmatory,,
4666,1086944,1,2,,103507642,3385,Unspecified,,,45708.8,IC50,Cytotoxicity against Homo sapiens (human) HCT116 cells after 72 hr by MTT assay,Confirmatory,,
4667,1086945,1,2,,103507642,3385,Unspecified,,,21877.6,IC50,Cytotoxicity against Mus musculus (mouse) P388 cells after 72 hr by MTT assay,Confirmatory,,
4668,1094961,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HL60 cells by MTT assay,Other,,
4669,1094962,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay,Other,,
4670,1094963,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HT-29 cells by MTT assay,Other,,
4671,1094997,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus Swiss Albino (mouse) xenografted with Mus musculus (mouse) EAC assessed as increase in body weight at 20 mg/kg/day, ip measured on day 14",Other,,
4672,1094999,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus (mouse) assessed as normalization of hemoglobin level at 20 mg/kg/day, ip measured on day 14 (Rvb = 8.7 g/dl)",Other,,
4673,1095002,1,2,,103507642,3385,Active,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus (mouse) assessed as normalization of WBC level at 20 mg/kg/day, ip measured on day 14 relative to untreated control",Other,,
4674,1095003,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus (mouse) assessed as decrease in tumor number at 20 mg/kg/day, ip measured on day 14 by Giemsa staining (Rvb = 220 million/ml)",Other,,
4675,1095005,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus (mouse) assessed as increase in mean survival time at 20 mg/kg/day, ip after 9 days (Rvb = 9.1 days)",Other,,
4676,1095007,2,1,,103507642,3385,Unspecified,,,,ED50,Cytotoxicity against Mus musculus (mouse) EAC assessed as cell viability by trypan blue exclusion assay,Confirmatory,,
4677,1095008,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus (mouse) assessed as normalization of hematocrit at 20 mg/kg/day, ip measured on day 14 (Rvb = 35.5%)",Other,,
4678,1095921,1,2,,103507642,3385,Active,,,2.19,IC50,Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay,Confirmatory,,
4679,1095922,1,2,,103507642,3385,Active,,,2.95,IC50,Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay,Confirmatory,,
4680,1095923,1,2,,103507642,3385,Active,,,45.4,IC50,Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay,Confirmatory,,
4681,1095924,1,2,,103507642,3385,Active,,,9.7,IC50,Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay,Confirmatory,,
4682,1095925,1,2,,103507642,3385,Active,,,1.93,IC50,Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay,Confirmatory,,
4683,1096326,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus Swiss albino (mouse) assessed as increase in median life span at 20 mg/kg, ip qd for 7 days relative to control",Other,,
4684,1096327,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus Swiss albino (mouse) assessed as increase in average life span at 20 mg/kg, ip qd for 7 days relative to control",Other,,
4685,1096328,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus Swiss albino (mouse) assessed as non-viable cells at 20 mg/kg, ip qd for 7 days relative to control",Other,,
4686,1096329,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC xenografted in Mus musculus Swiss albino (mouse) assessed as viable cells at 20 mg/kg, ip qd for 7 days relative to control",Other,,
4687,1096704,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Mus musculus (mouse) EAC cells assessed as dead cell at ED25 ug/cm'3 after 2 hr by trypan blue assay,Other,,
4688,1096705,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Mus musculus (mouse) EAC cells assessed as dead cell at ED50 ug/cm'3 after 2 hr by trypan blue assay,Other,,
4689,1096706,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Mus musculus (mouse) EAC cells assessed as dead cell at ED100 ug/cm'3 after 2 hr by trypan blue assay,Other,,
4690,1103432,1,1,,103507642,3385,Unspecified,,,,,Antiproliferative activity against Homo sapiens (human) A431 cells at 5 uM measured after 72 hr by MTT assay,Other,16190646.0,
4691,1103433,1,1,,103507642,3385,Unspecified,,,,,Antiproliferative activity against Homo sapiens (human) PC3 cells at 5 uM measured after 72 hr by MTT assay,Other,16190646.0,
4692,1105877,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) THP1 cells assessed as growth inhibition at 20 uM after 48 hr by SRB assay,Other,,
4693,1105887,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) CV1 cells assessed as growth inhibition at 20 uM after 48 hr by SRB assay,Other,,
4694,1105896,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) Hep2 cells assessed as growth inhibition at 20 uM after 48 hr by SRB assay,Other,,
4695,1105897,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition at 20 uM after 48 hr by SRB assay,Other,,
4696,1106542,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) THP1 cells at 10 uM after 48 hr by SRB assay,Other,,
4697,1106544,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) IMR32 cells at 10 uM after 48 hr by SRB assay,Other,,
4698,1106545,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) A549 cells at 10 uM after 48 hr by SRB assay,Other,,
4699,1106546,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) SiHa cells at 10 uM after 48 hr by SRB assay,Other,,
4700,1106547,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HeLa cells at 10 uM after 48 hr by SRB assay,Other,,
4701,1106548,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) SW620 cells at 10 uM after 48 hr by SRB assay,Other,,
4702,1106549,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) COLO205 cells at 10 uM after 48 hr by SRB assay,Other,,
4703,1106609,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability at 20 ug/ml by trypan blue assay,Other,,
4704,1106610,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability at 20 ug/ml by trypan blue assay,Other,,
4705,1106611,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) WI38 cells assessed as cell viability at 20 ug/ml by trypan blue assay,Other,,
4706,1106612,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as cell viability at 20 ug/ml by trypan blue assay,Other,,
4707,1107265,1,2,,103507642,3385,Active,,,2.72,IC50,Cytotoxicity against Homo sapiens (human) MDA231 cells assessed as inhibition of cell growth after 48 hr by MTT assay,Confirmatory,,
4708,1107266,1,2,,103507642,3385,Active,,,3.24,IC50,Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as inhibition of cell growth after 48 hr by MTT assay,Confirmatory,,
4709,1110337,1,2,,103507642,3385,Active,,,,,Cytotoxicity against Spodoptera frugiperda (fall armyworm) Sf9 cells at 0.1 to 1 uM after 72 hr by trypan blue dye exclusion test,Other,,
4710,1110434,1,2,,103507642,3385,Inactive,,,,,Reduction of ATP level in Spodoptera frugiperda (fall armyworm) Sf9 cells at 10 uM after 6 to 24 hr by luminescent cell viability assay,Other,,
4711,1113421,1,2,,103507642,3385,Active,,,21.9,IC50,Cytotoxicity against Mus musculus (mouse) P388 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
4712,1113422,1,2,,103507642,3385,Active,,,46.2,IC50,Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
4713,1113424,1,2,,103507642,3385,Active,,,5.2,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 72 hr by MTT assay,Confirmatory,,
4714,1113558,3,1,,103507642,3385,Unspecified,,,79.4328,GI50,Cytotoxicity against Homo sapiens (human) T47D cells after 48 hr by SRB assay,Confirmatory,,
4715,1113559,1,3,,103507642,3385,Unspecified,,,251.18900000000002,GI50,Cytotoxicity against Homo sapiens (human) Hs 578T cells after 48 hr by SRB assay,Confirmatory,,
4716,1113560,3,1,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against Homo sapiens (human) BT549 cells after 48 hr by SRB assay,Confirmatory,,
4717,1113561,3,1,,103507642,3385,Unspecified,,,501.18699999999995,GI50,Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by SRB assay,Confirmatory,,
4718,1113562,3,1,,103507642,3385,Active,,,1.58489,GI50,Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay,Confirmatory,,
4719,1113563,3,1,,103507642,3385,Active,,,10.0,GI50,Cytotoxicity against Homo sapiens (human) DU145 cells after 48 hr by SRB assay,Confirmatory,,
4720,1113564,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay,Confirmatory,,
4721,1113565,3,1,,103507642,3385,Active,,,5.01187,GI50,Cytotoxicity against Homo sapiens (human) UO31 cells after 48 hr by SRB assay,Confirmatory,,
4722,1113566,3,1,,103507642,3385,Unspecified,,,125.89299999999999,GI50,Cytotoxicity against Homo sapiens (human) TK10 cells after 48 hr by SRB assay,Confirmatory,,
4723,1113567,3,1,,103507642,3385,Active,,,25.1189,GI50,Cytotoxicity against Homo sapiens (human) SN12C cells after 48 hr by SRB assay,Confirmatory,,
4724,1113568,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) RXF393 cells after 48 hr by SRB assay,Confirmatory,,
4725,1113569,3,1,,103507642,3385,Active,,,3.98107,GI50,Cytotoxicity against Homo sapiens (human) Caki1 cells after 48 hr by SRB assay,Confirmatory,,
4726,1113570,3,1,,103507642,3385,Active,,,10.0,GI50,Cytotoxicity against Homo sapiens (human) A498 cells after 48 hr by SRB assay,Confirmatory,,
4727,1113571,3,1,,103507642,3385,Active,,,10.0,GI50,Cytotoxicity against Homo sapiens (human) ACHN cells after 48 hr by SRB assay,Confirmatory,,
4728,1113572,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) 786-0 cells after 48 hr by SRB assay,Confirmatory,,
4729,1113573,3,1,,103507642,3385,Unspecified,,,158.489,GI50,Cytotoxicity against Homo sapiens (human) SKOV3 cells after 48 hr by SRB assay,Confirmatory,,
4730,1113575,3,1,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) OVCAR8 cells after 48 hr by SRB assay,Confirmatory,,
4731,1113576,3,1,,103507642,3385,Unspecified,,,63.0957,GI50,Cytotoxicity against Homo sapiens (human) OVCAR4 cells after 48 hr by SRB assay,Confirmatory,,
4732,1113577,3,1,,103507642,3385,Unspecified,,,158.489,GI50,Cytotoxicity against Homo sapiens (human) OVCAR5 cells after 48 hr by SRB assay,Confirmatory,,
4733,1113578,3,1,,103507642,3385,Active,,,25.1189,GI50,Cytotoxicity against Homo sapiens (human) OVCAR3 cells after 48 hr by SRB assay,Confirmatory,,
4734,1113579,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) IGROV1 cells after 48 hr by SRB assay,Confirmatory,,
4735,1113580,3,1,,103507642,3385,Unspecified,,,100.0,GI50,Cytotoxicity against Homo sapiens (human) UACC257 cells after 48 hr by SRB assay,Confirmatory,,
4736,1113581,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) UACC62 cells after 48 hr by SRB assay,Confirmatory,,
4737,1113582,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-5 cells after 48 hr by SRB assay,Confirmatory,,
4738,1113583,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-28 cells after 48 hr by SRB assay,Confirmatory,,
4739,1113585,3,1,,103507642,3385,Unspecified,,,398.10699999999997,GI50,Cytotoxicity against Homo sapiens (human) SK-MEL-2 cells after 48 hr by SRB assay,Confirmatory,,
4740,1113586,3,1,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) MALME-3M cells after 48 hr by SRB assay,Confirmatory,,
4741,1113587,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) M14 cells after 48 hr by SRB assay,Confirmatory,,
4742,1113588,3,1,,103507642,3385,Active,,,39.8107,GI50,Cytotoxicity against Homo sapiens (human) U251 cells after 48 hr by SRB assay,Confirmatory,,
4743,1113589,3,1,,103507642,3385,Active,,,6.30957,GI50,Cytotoxicity against Homo sapiens (human) LOXIMVI cells after 48 hr by SRB assay,Confirmatory,,
4744,1113590,3,1,,103507642,3385,Unspecified,,,125.89299999999999,GI50,Cytotoxicity against Homo sapiens (human) SNB19 cells after 48 hr by SRB assay,Confirmatory,,
4745,1113591,3,1,,103507642,3385,Unspecified,,,199.52599999999998,GI50,Cytotoxicity against Homo sapiens (human) SNB75 cells after 48 hr by SRB assay,Confirmatory,,
4746,1113592,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) SF295 cells after 48 hr by SRB assay,Confirmatory,,
4747,1113593,3,1,,103507642,3385,Active,,,1.2589299999999999,GI50,Cytotoxicity against Homo sapiens (human) SF539 cells after 48 hr by SRB assay,Confirmatory,,
4748,1113594,3,1,,103507642,3385,Active,,,25.1189,GI50,Cytotoxicity against Homo sapiens (human) SW620 cells after 48 hr by SRB assay,Confirmatory,,
4749,1113595,3,1,,103507642,3385,Unspecified,,,50.1187,GI50,Cytotoxicity against Homo sapiens (human) SF268 cells after 48 hr by SRB assay,Confirmatory,,
4750,1113596,3,1,,103507642,3385,Active,,,6.30957,GI50,Cytotoxicity against Homo sapiens (human) HT-29 cells after 48 hr by SRB assay,Confirmatory,,
4751,1113597,3,1,,103507642,3385,Active,,,10.0,GI50,Cytotoxicity against Homo sapiens (human) KM12 cells after 48 hr by SRB assay,Confirmatory,,
4752,1113598,3,1,,103507642,3385,Active,,,3.98107,GI50,Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by SRB assay,Confirmatory,,
4753,1113599,3,1,,103507642,3385,Active,,,6.30957,GI50,Cytotoxicity against Homo sapiens (human) HCT15 cells after 48 hr by SRB assay,Confirmatory,,
4754,1113600,3,1,,103507642,3385,Active,,,6.30957,GI50,Cytotoxicity against Homo sapiens (human) COLO205 cells after 48 hr by SRB assay,Confirmatory,,
4755,1113601,3,1,,103507642,3385,Active,,,1.58489,GI50,Cytotoxicity against Homo sapiens (human) HCC2998 cells after 48 hr by SRB assay,Confirmatory,,
4756,1113602,3,1,,103507642,3385,Active,,,1.0,GI50,Cytotoxicity against Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay,Confirmatory,,
4757,1113603,3,1,,103507642,3385,Active,,,39.8107,GI50,Cytotoxicity against Homo sapiens (human) NCI-H522 cells after 48 hr by SRB assay,Confirmatory,,
4758,1113604,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) NCI-H23 cells after 48 hr by SRB assay,Confirmatory,,
4759,1113605,3,1,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) NCI-H322M cells after 48 hr by SRB assay,Confirmatory,,
4760,1113606,3,1,,103507642,3385,Unspecified,,,251.18900000000002,GI50,Cytotoxicity against Homo sapiens (human) NCI-H226 cells after 48 hr by SRB assay,Confirmatory,,
4761,1113607,3,1,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) HOP62 cells after 48 hr by SRB assay,Confirmatory,,
4762,1113608,3,1,,103507642,3385,Unspecified,,,158.489,GI50,Cytotoxicity against Homo sapiens (human) HOP92 cells after 48 hr by SRB assay,Confirmatory,,
4763,1113610,3,1,,103507642,3385,Active,,,1.9952599999999998,GI50,Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay,Confirmatory,,
4764,1113611,3,1,,103507642,3385,Unspecified,,,316.228,GI50,Cytotoxicity against Homo sapiens (human) EKVX cells after 48 hr by SRB assay,Confirmatory,,
4765,1113612,3,1,,103507642,3385,Active,,,5.01187,GI50,Cytotoxicity against Homo sapiens (human) RPMI8226 cells after 48 hr by SRB assay,Confirmatory,,
4766,1113613,3,1,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by SRB assay,Confirmatory,,
4767,1113614,3,1,,103507642,3385,Active,,,12.5893,GI50,Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay,Confirmatory,,
4768,1113615,3,1,,103507642,3385,Active,,,31.6228,GI50,Cytotoxicity against Homo sapiens (human) CCRF-CEM cells after 48 hr by SRB assay,Confirmatory,,
4769,1113616,3,2,,103507642,3385,Active,,,19.9526,GI50,Cytotoxicity against Homo sapiens (human) HL-60(TB) cells after 48 hr by SRB assay,Confirmatory,,
4770,1113725,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Ehrlich ascites carcinoma cells xenografted in Swiss albino Mus musculus (mouse) assessed as increase in lifespan at 50 mg/kg, ip qd for 9 days administered at 24 hr after tumour cell inoculation",Other,,
4771,1113726,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Ehrlich ascites carcinoma cells xenografted in Swiss albino Mus musculus (mouse) assessed as mean survival time at 50 mg/kg, ip qd for 9 days administered at 24 hr after tumour cell inoculation (Rvb = 9.10/day)",Other,,
4772,1113727,1,2,,103507642,3385,Unspecified,,,,,"Decrease in number of WBC in Ehrlich ascites carcinoma xenografted Swiss albino Mus musculus (mouse) blood at 50 mg/kg, ip qd for 9 days administered at 24 hr after tumour cell inoculation measured on day 14 post-tumor cell implantation (Rvb = 38.60 x 10'3 cm)",Other,,
4773,1113728,1,2,,103507642,3385,Unspecified,,,,,"Increase in hematocrit content in Ehrlich ascites carcinoma xenografted Swiss albino Mus musculus (mouse) blood at 50 mg/kg, ip qd for 9 days administered at 24 hr after tumour cell inoculation measured on day 14 post-tumor cell implantation (Rvb = 35.50%)",Other,,
4774,1113729,1,2,,103507642,3385,Unspecified,,,,,"Increase in hemoglobin content in Ehrlich ascites carcinoma xenografted Swiss albino Mus musculus (mouse) blood at 50 mg/kg, ip qd for 9 days administered at 24 hr after tumour cell inoculation measured on day 14 post-tumor cell implantation (Rvb = 8.70 g/dl)",Other,,
4775,1113730,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Ehrlich ascites carcinoma cells xenografted in Swiss albino Mus musculus (mouse) assessed as carcinoma cell viability at 50 mg/kg, ip qd for 5 days administered at 24 hr after tumour cell inoculation by trypan blue assay (Rvb = 220x10'6/ml)",Other,,
4776,1113740,1,3,,103507642,3385,Unspecified,,,70.0,IC50,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell survival after 96 hr,Confirmatory,,
4777,1113741,1,2,,103507642,3385,Active,,,20.0,IC50,Cytotoxicity against Homo sapiens (human) WI38 cells assessed as inhibition of cell survival after 96 hr,Confirmatory,,
4778,1113742,1,3,,103507642,3385,Unspecified,,,50.0,IC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell survival after 96 hr,Confirmatory,,
4779,1113743,1,2,,103507642,3385,Active,,,20.0,IC50,Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell survival after 96 hr,Confirmatory,,
4780,1114112,1,2,,103507642,3385,Unspecified,,,,IC50,Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay,Confirmatory,,
4781,1114113,1,2,,103507642,3385,Unspecified,,,,IC50,Anticancer activity against Homo sapiens (human) HCT116 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay,Confirmatory,,
4782,1114392,1,2,,103507642,3385,Active,,,2.15,IC50,Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
4783,1114393,1,2,,103507642,3385,Active,,,1.25,IC50,Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
4784,1114394,1,2,,103507642,3385,Active,,,2.3,IC50,Anticancer activity against Homo sapiens (human) NCI lung cancer cell assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
4785,1114563,1,3,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4786,1114564,1,2,,103507642,3385,Active,,,19.2,IC50,Antitumor activity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4787,1114565,1,3,,103507642,3385,Inconclusive,,,,IC50,Antitumor activity against Homo sapiens (human) LN229 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4788,1114566,1,2,,103507642,3385,Active,,,2.95,IC50,Antitumor activity against Homo sapiens (human) DU145 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4789,1114567,1,3,,103507642,3385,Unspecified,,,100.0,IC50,Antitumor activity against Homo sapiens (human) A549 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4790,1114568,1,2,,103507642,3385,Active,,,1.93,IC50,Antitumor activity against Homo sapiens (human) HCT116 cells assessed as inhibition of cell viability after 72 hr by MTT assay,Confirmatory,,
4791,1115104,1,2,,103507642,3385,Unspecified,,,,,In vitro antitumor activity against Mus musculus (mouse) Ehrlich ascites cell assessed as dead tumor cells by trypan blue exclusion test,Other,,
4792,1115772,1,2,,103507642,3385,Unspecified,,,,,"Antineoplastic activity against Mus musculus (mouse) EACs transplanted in Swiss albino Mus musculus (mouse) assessed as decrease in WBC level at 5 mg/kg, ip administered 9 days measured on day 14 (Rvb = 38.6 10'3/mm3)",Other,,
4793,1115773,1,2,,103507642,3385,Unspecified,,,,,"Antineoplastic activity against Mus musculus (mouse) EACs transplanted in Swiss albino Mus musculus (mouse) assessed as increase in hematocritis level at 5 mg/kg, ip administered 9 days measured on day 14 (Rvb = 35.5 g%)",Other,,
4794,1115774,1,2,,103507642,3385,Unspecified,,,,,"Antineoplastic activity against Mus musculus (mouse) EACs transplanted in Swiss albino Mus musculus (mouse) assessed as increase in hemoglobin level at 5 mg/kg, ip administered 9 days measured on day 14 (Rvb = 8.7 g%)",Other,,
4795,1115776,1,2,,103507642,3385,Unspecified,,,,,"Antineoplastic activity against Mus musculus (mouse) EACs transplanted in Swiss albino mouse assessed as increase in life span at 20 mg/kg, ip after 9 days (Rvb = 9.1%)",Other,,
4796,1115868,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in cancer cell count measured 10'6 cells at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 2.76 +/- 0.33 ml)",Other,,
4797,1115870,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in body weight at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 7.6 +/- 0.94 g)",Other,,
4798,1115872,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as increase in life span at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 50%)",Other,,
4799,1115874,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in alkaline phosphatase level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 242.22 +/- 4.3 U/L)",Other,,
4800,1115876,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in alanine amino transferase level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 61.2 +/- 2.6 U/L)",Other,,
4801,1115878,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in aspartate amino transferase level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 85.6 +/- 2.72 U/L)",Other,,
4802,1115880,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in triglyceride level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 210.12 +/- 4.65 mg/dl)",Other,,
4803,1115882,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in cholesterol level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 140.86 +/- 4.6 mg/dl)",Other,,
4804,1115884,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as increase in platelet count at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 1.6 +/- 0.52 lakhs/mm3)",Other,,
4805,1115886,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in packed cell volume at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 30.55 +/- 3.52%)",Other,,
4806,1115888,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as increase in haemoglobin level at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 7.12 +/- 0.95 g/dl)",Other,,
4807,1115891,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as decrease in total WBC count measured 10'3 cells at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 14.40 +/- 2.5 ml)",Other,,
4808,1115892,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) DLA cells transplanted in Swiss albino mouse assessed as increase in RBC count at 20 mg/kg, ip qd administered 24 hr post tumor transplantation for 14 days measured on day 14 (Rvb = 2.46 +/- 0.45 million/mm3)",Other,,
4809,1116068,1,2,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay,Confirmatory,,
4810,1116069,1,2,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay,Confirmatory,,
4811,1116070,1,2,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay,Confirmatory,,
4812,1116071,1,2,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) Caco2 cells after 48 hr by SRB assay,Confirmatory,,
4813,1116277,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay,Other,,
4814,1116278,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay,Other,,
4815,1116279,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay,Other,,
4816,1116280,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay,Other,,
4817,1116281,1,2,,103507642,3385,Unspecified,,,,,Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay,Other,,
4818,1116282,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
4819,1116283,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
4820,1116284,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
4821,1116285,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
4822,1116286,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay,Other,,
4823,1116436,1,2,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay,Confirmatory,,
4824,1116608,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as effect on monocytes level at 20 mg/kg, ip measured on day 13 post tumor implantation (Rvb = 1.4 +/- 0.24%)",Other,,
4825,1116610,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as effect on neutrophils level at 20 mg/kg, ip measured on day 13 post tumor implantation (Rvb = 60.4 +/- 1.5%)",Other,,
4826,1116612,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as effect on lymphocytes level at 20 mg/kg, ip measured on day 13 post tumor implantation (Rvb = 35.8 +/- 1.15%)",Other,,
4827,1116614,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as effect on WBC level measured per 10'3 cells at 20 mg/kg, ip on day 13 post tumor implantation (Rvb = 19.49 +/- 0.26 mm3)",Other,,
4828,1116615,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as increase in hemoglobin level at 20 mg/kg, ip measured on day 13 post tumor implantation (Rvb = 7.5 +/- 0.01 g%)",Other,,
4829,1116619,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC cells transplanted in mouse assessed as increase in life span at 20 mg/kg, ip relative to vehicle-treated control",Other,,
4830,1116621,1,2,,103507642,3385,Unspecified,,,,,"Antitumor activity against Mus musculus (mouse) EAC cells transplanted in mouse assessed as decrease in body weight at 20 mg/kg, ip measured up to 11 days relative to vehicle-treated control",Other,,
4831,1116622,1,2,,103507642,3385,Unspecified,,,,,"Toxicity in Mus musculus (mouse) transplanted with mouse EAC cells assessed as effect on RBC level at 20 mg/kg, ip measured on day 13 post tumor implantation (Rvb = 3.95 +/- 0.32 million/mm3)",Other,,
4832,1117298,1,2,,170464762,3385,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4833,1117301,1,2,,170464762,3385,Inactive,,,2.2387,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
4834,1117302,1,2,,170464762,3385,Inactive,,,1.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
4835,1117303,1,2,,170464762,3385,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
4836,1117304,1,2,,170464762,3385,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4837,1117305,1,2,,170464762,3385,Inactive,,,14.1254,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4838,1117310,1,1,,170464762,3385,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4839,1117311,1,1,,170464762,3385,Inactive,,,2.2387200000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
4840,1117312,1,1,,170464762,3385,Inactive,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4841,1117314,1,1,,170464762,3385,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4842,1117315,1,1,,170464762,3385,Inactive,,,1.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
4843,1117318,1,1,,170464762,3385,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
4844,1117319,1,2,,8139872,3385,Inconclusive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4845,1117319,1,2,,8139872,3385,Inconclusive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
4846,1117322,1,1,,170464762,3385,Inactive,,,20.0,IC50,RKO viability from Cell TiterGlo-IC50,Confirmatory,,
4847,1117323,1,1,,170464762,3385,Inactive,,,20.0,IC50,SNU-C1 viability from Cell TiterGlo-IC50,Confirmatory,,
4848,1117324,1,1,,170464762,3385,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
4849,1117326,1,1,,170464762,3385,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4850,1117329,1,1,,170464762,3385,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4851,1117330,1,1,,170464762,3385,Inactive,,,20.0,IC50,HT-29 viability from Cell TiterGlo-IC50,Confirmatory,,
4852,1117332,1,1,,170464762,3385,Active,,,1.9627,IC50,HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
4853,1117334,1,1,,170464762,3385,Inactive,,,20.0,IC50,Colo320 viability from Cell TiterGlo-IC50,Confirmatory,,
4854,1117336,1,1,,170464762,3385,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4855,1117337,1,1,,170464762,3385,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
4856,1117338,1,1,,170464762,3385,Inactive,,,20.0,IC50,SW480 viability from Cell TiterGlo-IC50,Confirmatory,,
4857,1117339,1,1,,170464762,3385,Active,,,3.1613,IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
4858,1117340,1,1,,170464762,3385,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4859,1117341,1,1,,170464762,3385,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4860,1117342,1,1,,170464762,3385,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4861,1117343,1,1,,170464762,3385,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4862,1117346,1,1,,170464762,3385,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4863,1117347,1,1,,170464762,3385,Inactive,,,10.0,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
4864,1117348,1,1,,170464762,3385,Inactive,,,10.0,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
4865,1117349,1,1,,170464762,3385,Inactive,,,10.0,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
4866,1117350,1,1,,170464762,3385,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
4867,1117351,1,1,,170464762,3385,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
4868,1117352,1,1,,170464762,3385,Inactive,,,20.0,IC50,DLD-1 viability from Cell TiterGlo-IC50,Confirmatory,,
4869,1121629,1,1,,103507642,3385,Active,,,21.0,IC50,Cytotoxicity against human Caco2 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay,Confirmatory,,
4870,1124906,1,1,,103507642,3385,Active,,,0.33,IC50,Cytotoxicity against mouse L1210 cells assessed as reduction in cell number after 48 hrs by cell counting assay,Confirmatory,24631358.0,
4871,1124907,1,1,,103507642,3385,Active,,,18.0,IC50,Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell number after 72 hrs by cell counting assay,Confirmatory,24631358.0,
4872,1124908,1,1,,103507642,3385,Active,,,0.54,IC50,Cytotoxicity against human HeLa cells assessed as reduction in cell number after 72 hrs by cell counting assay,Confirmatory,24631358.0,
4873,1124909,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human HEL cells assessed as reduction in cell number by cell counting assay,Other,24631358.0,
4874,1124910,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against African green monkey Vero cells assessed as reduction in cell number,Other,24631358.0,
4875,1124911,1,1,,103507642,3385,Inconclusive,,,,,Cytotoxicity against human HeLa cells assessed as reduction in cell number,Other,24631358.0,
4876,1125361,1,1,,103507642,3385,Active,,,1.9,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24641975.0,
4877,1125362,1,2,,103507642,3385,Active,,,1.9,IC50,Cytotoxicity against human DU145 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24641975.0,
4878,1125363,1,1,,103507642,3385,Active,,,1.8,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24641975.0,
4879,1125364,1,1,,103507642,3385,Active,,,1.8,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 hrs by MTT assay,Confirmatory,24641975.0,
4880,1126735,1,1,,103507642,3385,Unspecified,,,86.87,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay,Confirmatory,24684840.0,
4881,1126736,1,1,,103507642,3385,Unspecified,,,67.65,IC50,Cytotoxicity against human BCG823 cells assessed as growth inhibition by MTT assay,Confirmatory,24684840.0,
4882,1126737,1,1,,103507642,3385,Unspecified,,,500.0,IC50,Cytotoxicity against human Bel7402 cells assessed as growth inhibition by MTT assay,Confirmatory,24684840.0,
4883,1126738,1,1,,103507642,3385,Unspecified,,,95.36,IC50,Cytotoxicity against human HL-7702 cells assessed as growth inhibition by MTT assay,Confirmatory,24684840.0,
4884,1127202,1,1,,103507642,3385,Active,,,0.98,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition measured at 48 hrs by SRB assay,Confirmatory,24727462.0,
4885,1130074,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against human HepG2 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 5 mg/kg, iv administered once every 2 days for 21 days measured every 3 days up to 35 days relative to control",Other,24629450.0,
4886,1130590,1,1,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose,Other,490545.0,
4887,1130627,1,1,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as once each 4 days for 3 total injection,Other,490545.0,
4888,1130628,1,1,,103507642,3385,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose,Other,490545.0,
4889,1130629,1,1,,103507642,3385,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as once each 4 days for 3 total injection,Other,490545.0,
4890,1130630,1,1,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose,Other,490545.0,
4891,1130631,1,1,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as once each 4 days for 3 total injection,Other,490545.0,
4892,1130632,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose",Other,490545.0,
4893,1130633,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as once each 4 days for 3 total injection",Other,490545.0,
4894,1132874,1,1,,103507642,3385,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as survival rate at 25 mg/kg relative to control,Other,671468.0,
4895,1132955,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as increase in survival rate at 25 mg/kg/day, ip administered for 2 weeks relative to control",Other,691008.0,
4896,1135817,1,1,,103507642,3385,Unspecified,,,,,Retention time of the compound by liquid chromatography,Other,214555.0,
4897,1136456,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as host survival on day 7 at 20 mg/kg, ip qd for 2 weeks",Other,316462.0,
4898,1136457,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as tumor growth inhibition at 20 mg/kg, ip qd for 2 weeks (Rvb = 100%)",Other,316462.0,
4899,1136542,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Aspergillus niger ATCC 1004 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum,Other,321785.0,
4900,1136544,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Aspergillus niger ATCC 1004 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum,Other,321785.0,
4901,1136546,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Aspergillus niger ATCC 1004 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum,Other,321785.0,
4902,1136548,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum,Other,321785.0,
4903,1136550,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum,Other,321785.0,
4904,1136552,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum,Other,321785.0,
4905,1136554,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Mucor mucedo ATCC 7941 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum,Other,321785.0,
4906,1136556,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum,Other,321785.0,
4907,1136558,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum,Other,321785.0,
4908,1136560,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum,Other,321785.0,
4909,1136562,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Trichophyton mentagrophytes ATCC 9129 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum,Other,321785.0,
4910,1136564,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum,Other,321785.0,
4911,1136566,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 at <100 ug/ml at pH 5.6 after 5 days in presence of 10% beef serum,Other,321785.0,
4912,1136568,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 at <100 ug/ml at pH 7 after 5 days in absence of 10% beef serum,Other,321785.0,
4913,1136570,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 at <100 ug/ml at pH 7 after 5 days in presence of 10% beef serum,Other,321785.0,
4914,1136572,1,1,,103507642,3385,Inactive,,,,,Antifungal activity against Aspergillus niger ATCC 1004 at <100 ug/ml at pH 5.6 after 5 days in absence of 10% beef serum,Other,321785.0,
4915,1136869,1,1,,103507642,3385,Unspecified,,,,,In-vivo antitumor activity against mouse L1210 cells at 20 mg/kg relative to control,Other,385879.0,
4916,1136870,1,1,,103507642,3385,Unspecified,,,,,Inhibition of cell cycle traverse in human HeLa cells assessed as mitotic index at 50 ug/ml after 16 hrs,Other,385879.0,
4917,1136871,1,1,,103507642,3385,Unspecified,,,,,Inhibition of cell cycle traverse in human HeLa cells assessed as mitotic index at 25 ug/ml after 16 hrs,Other,385879.0,
4918,1136872,1,1,,103507642,3385,Unspecified,,,,,Inhibition of cell cycle traverse in human HeLa cells assessed as mitotic index at 12.5 ug/ml after 16 hrs,Other,385879.0,
4919,1136877,1,1,,103507642,3385,Unspecified,,,,,Antiyeast activity against Saccharomyces cerevisiae 9763 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method,Other,385880.0,
4920,1136878,1,1,,103507642,3385,Unspecified,,,,,Antiyeast activity against Candida albicans clinical isolate 1-V assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method,Other,385880.0,
4921,1136879,1,1,,103507642,3385,Unspecified,,,,,Antiyeast activity against Candida albicans WD 18-4 assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method,Other,385880.0,
4922,1136880,1,1,,103507642,3385,Unspecified,,,,,Antiyeast activity against Candida krusei 1-T assessed as total inhibition of fungal growth after 24 to 48 hrs by microdilution-colorimetric method,Other,385880.0,
4923,1139889,1,1,,103507642,3385,Active,,,0.28,IC50,Cytotoxicity against mouse E0771 cells after 3 days by SRB assay,Confirmatory,24704691.0,
4924,1139890,1,1,,103507642,3385,Active,,,2.86,IC50,Cytotoxicity against human MCF7 cells after 3 days by SRB assay,Confirmatory,24704691.0,
4925,1139893,1,1,,103507642,3385,Active,,,18.12,IC50,Cytotoxicity against human MDA-MB-231 cells after 3 days by SRB assay,Confirmatory,24704691.0,
4926,1139894,1,1,,103507642,3385,Active,,,10.56,IC50,Cytotoxicity against human T47D cells after 3 days by SRB assay,Confirmatory,24704691.0,
4927,1139895,1,1,,103507642,3385,Active,,,8.06,IC50,Cytotoxicity against human MCF10A cells after 3 days by SRB assay,Confirmatory,24704691.0,
4928,1139896,1,1,,103507642,3385,Active,,,2.58,IC50,Cytotoxicity against human HT-29 cells after 3 days by SRB assay,Confirmatory,24704691.0,
4929,1139897,1,1,,103507642,3385,Active,,,4.39,IC50,Cytotoxicity against human RKO cells after 3 days by SRB assay,Confirmatory,24704691.0,
4930,1139898,1,1,,103507642,3385,Active,,,3.69,IC50,Cytotoxicity against human SW480 cells after 3 days by SRB assay,Confirmatory,24704691.0,
4931,1139899,1,1,,103507642,3385,Active,,,9.26,IC50,Cytotoxicity against human CCD-18Co cells after 3 days by SRB assay,Confirmatory,24704691.0,
4932,1139900,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MCF10A cells to IC50 for human MCF7 cells",Other,24704691.0,
4933,1139901,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MCF10A cells to IC50 for human MDA-MB-231 cells",Other,24704691.0,
4934,1139902,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MCF10A cells to IC50 for human T47D cells",Other,24704691.0,
4935,1139903,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human MCF10A cells to IC50 for mouse E0771 cells",Other,24704691.0,
4936,1139904,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CCD-18Co cells to IC50 for human T84 cells",Other,24704691.0,
4937,1139905,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CCD-18Co cells to IC50 for human HT-29 cells",Other,24704691.0,
4938,1139906,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CCD-18Co cells to IC50 for human RKO cells",Other,24704691.0,
4939,1139907,1,1,,103507642,3385,Unspecified,,,,,"Therapeutic index, ratio of IC50 for human CCD-18Co cells to IC50 for human SW480 cells",Other,24704691.0,
4940,1141830,1,1,,103507642,3385,Active,,,11.5,IC50,Cytotoxicity against human MCF7 cells after 2 days by MTT assay,Confirmatory,24767839.0,
4941,1141831,1,1,,103507642,3385,Active,,,44.05,IC50,Cytotoxicity against human A549 cells after 2 days by MTT assay,Confirmatory,24767839.0,
4942,1141832,1,1,,103507642,3385,Active,,,7.34,IC50,Cytotoxicity against human HeLa cells after 2 days by MTT assay,Confirmatory,24767839.0,
4943,1141833,1,1,,103507642,3385,Active,,,17.2,IC50,Cytotoxicity against human HT-29 cells after 2 days by MTT assay,Confirmatory,24767839.0,
4944,1143311,1,1,,103507642,3385,Active,,,7.08,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24819956.0,
4945,1143312,1,1,,103507642,3385,Active,,,10.54,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,24819956.0,
4946,1143313,1,1,,103507642,3385,Active,,,11.12,IC50,Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay,Confirmatory,24819956.0,
4947,1143432,1,1,,103507642,3385,Active,,,9.45,IC50,Antiproliferative activity against human EC9706 cells after 48 hrs by MTT assay,Confirmatory,24835817.0,
4948,1143433,1,2,,103507642,3385,Active,,,11.34,IC50,Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,24835817.0,
4949,1143434,1,1,,103507642,3385,Active,,,3.52,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,24835817.0,
4950,1146868,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4951,1146869,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Sarcina lutea ATCC 9341 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4952,1146870,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Micrococcus flavus ATCC 10240 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4953,1146871,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4954,1146872,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Escherichia coli NIHJ assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4955,1146873,1,1,,103507642,3385,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 10031 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4956,1146874,1,1,,103507642,3385,Active,,,,,Antibacterial activity against Proteus vulgaris IFO 3045 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4957,1146875,1,1,,103507642,3385,Unspecified,,,,,Antibacterial activity against Pseudomonas diminuta IAM 1513 assessed as growth inhibition after 24 hrs by plate dilution method,Other,338900.0,
4958,1146930,1,1,,103507642,3385,Unspecified,,,,,Toxicity in po dosed ddY mouse after 1 week by up and down method,Other,357721.0,
4959,1146931,1,1,,103507642,3385,Unspecified,,,,,Toxicity in po dosed ddY mouse after 2 weeks by up and down method,Other,357721.0,
4960,1146932,1,1,,103507642,3385,Unspecified,,,,,Toxicity in po dosed ddY mouse after 3 weeks by up and down method,Other,357721.0,
4961,1146935,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse Ehrlich carcinoma cells allografted in ddY mouse assessed as tumor inhibition at 0.08 mmol/kg, po qd for 7 days measured on day 10 relative to control",Other,357721.0,
4962,1146938,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse Sarcoma 180 cells allografted in ICR mouse assessed as tumor inhibition at 0.08 mmol/kg, po qd for 7 days measured on day 10 relative to control",Other,357721.0,
4963,1146941,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against rat Yoshida cells allografted in Donryu rat assessed as tumor inhibition at 0.08 mmol/kg, po qd for 7 days measured on day 10 relative to control",Other,357721.0,
4964,1146944,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against rat AH-130 cells allografted in Donryu rat assessed as tumor inhibition at 0.08 mmol/kg, po qd for 7 days measured on day 10 relative to control",Other,357721.0,
4965,1146947,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against rat Walker 256 cells allografted in Wistar rat assessed as tumor inhibition at 0.08 mmol/kg, po qd for 7 days measured on day 10 relative to control",Other,357721.0,
4966,1146950,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in Donryu rat allografted with rat AH-130 cells assessed as body weight change at 0.08 mmol/kg, po administered for 7 days measured on day 10 relative to control",Other,357721.0,
4967,1148057,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as animal survival days at 20 mg/kg/day, ip",Other,592323.0,
4968,1148058,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as tumor growth inhibition at 20 mg/kg/day, ip",Other,592323.0,
4969,1149714,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in DBA/2 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control",Other,874966.0,
4970,1149715,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in C57Bl/6 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control",Other,874966.0,
4971,1151278,1,1,,103507642,3385,Active,,,4.55,GI50,Growth inhibition of human A549 cells after 48 hrs by SRB assay,Confirmatory,24797798.0,
4972,1152384,1,2,,103507642,3385,Active,,,8.13,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,24798098.0,
4973,1152385,1,1,,103507642,3385,Active,,,7.76,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24798098.0,
4974,1152386,1,1,,103507642,3385,Active,,,24.14,IC50,Cytotoxicity against human EC109 cells after 72 hrs by MTT assay,Confirmatory,24798098.0,
4975,1152387,1,1,,103507642,3385,Active,,,4.68,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,24798098.0,
4976,1153401,1,1,,103507642,3385,Active,,,1.3,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,24835633.0,
4977,1153402,1,1,,103507642,3385,Active,,,1.4,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay,Confirmatory,24835633.0,
4978,1153403,1,2,,103507642,3385,Active,,,1.5,IC50,Cytotoxicity against human DU145 cells after 24 hrs by MTT assay,Confirmatory,24835633.0,
4979,1153404,1,1,,103507642,3385,Active,,,1.3,IC50,Cytotoxicity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,24835633.0,
4980,1155389,1,1,,103507642,3385,Active,,,2.2,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
4981,1155390,1,1,,103507642,3385,Active,,,4.5,IC50,Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
4982,1155391,1,1,,103507642,3385,Active,,,4.9,IC50,Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay,Confirmatory,24910974.0,
4983,1156029,1,1,,103507642,3385,Active,,,2.45,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
4984,1156030,1,1,,103507642,3385,Active,,,3.52,IC50,Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
4985,1156031,1,1,,103507642,3385,Active,,,2.78,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24941129.0,
4986,1156582,1,1,,103507642,3385,Active,,,4.21,IC50,Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24956552.0,
4987,1156583,1,1,,103507642,3385,Active,,,12.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,24956552.0,
4988,1156938,1,1,,103507642,3385,Active,,,1.65,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 24 to 48 hrs by sulforhodamine B assay,Confirmatory,24996138.0,
4989,1157143,1,1,,103507642,3385,Unspecified,,,,,"Hepatotoxicity in rat assessed as SGOT level at 0.12 mg/kg, po after 12 days (Rvb = 140.23 +/- 1.39 U/mL)",Other,25010935.0,
4990,1157144,1,1,,103507642,3385,Unspecified,,,,,"Hepatotoxicity in rat assessed as SGPT level at 0.12 mg/kg, po after 12 days (Rvb = 31.17 +/- 0.39 U/mL)",Other,25010935.0,
4991,1159183,1,1,,103507642,3385,Active,,,23.33,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4992,1159184,1,1,,103507642,3385,Active,,,45.1,IC50,Cytotoxicity against human CNE cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4993,1159185,1,1,,103507642,3385,Active,,,10.05,IC50,Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4994,1159186,1,2,,103507642,3385,Active,,,46.93,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4995,1159187,1,1,,103507642,3385,Active,,,45.14,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4996,1159188,1,1,,103507642,3385,Active,,,34.34,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4997,1159189,1,2,,103507642,3385,Active,,,1.23,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4998,1159190,1,1,,103507642,3385,Active,,,38.34,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24953029.0,
4999,1159191,1,1,,103507642,3385,Active,,,24.12,IC50,Cytotoxicity against HUVEC after 48 hrs by MTT assay,Confirmatory,24953029.0,
5000,1159509,1,1,,144209533,3385,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
5001,1159509,1,1,,144210432,3385,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
5002,1159509,1,1,,170464762,3385,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
5003,1159515,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
5004,1159515,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
5005,1159515,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
5006,1159516,1,1,,144209533,3385,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
5007,1159516,1,1,,144210432,3385,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
5008,1159516,1,1,,170464762,3385,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
5009,1159517,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
5010,1159517,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
5011,1159517,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
5012,1159518,1,1,,144209533,3385,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
5013,1159518,1,1,,144210432,3385,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
5014,1159518,1,1,,170464762,3385,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
5015,1159519,1,1,,144209533,3385,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
5016,1159519,1,1,,144210432,3385,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
5017,1159519,1,1,,170464762,3385,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
5018,1159520,1,1,,144209533,3385,Inconclusive,,,63.4379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
5019,1159520,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
5020,1159520,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
5021,1159521,1,1,,144209533,3385,Active,15928672.0,19885.0,4.4911,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
5022,1159521,1,1,,144210432,3385,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
5023,1159521,1,1,,170464762,3385,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
5024,1159523,1,1,,144209533,3385,Inconclusive,15928672.0,19885.0,4.49106,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
5025,1159523,1,1,,144210432,3385,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
5026,1159523,1,1,,170464762,3385,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
5027,1159524,1,1,,8139872,3385,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
5028,1159524,1,1,,124880118,3385,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
5029,1159525,1,1,,144209533,3385,Inconclusive,,,35.9929,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
5030,1159525,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
5031,1159525,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
5032,1159526,1,1,,144209533,3385,Inconclusive,119627033.0,3725.0,16.0774,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
5033,1159526,1,1,,144210432,3385,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
5034,1159526,1,1,,170464762,3385,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
5035,1159527,1,1,,144209533,3385,Inconclusive,325495497.0,6256.0,14.329,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
5036,1159527,1,1,,144210432,3385,Active,325495497.0,6256.0,28.1669,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
5037,1159527,1,1,,170464762,3385,Inconclusive,325495497.0,6256.0,1.8996,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
5038,1159528,1,1,,144209533,3385,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
5039,1159528,1,1,,144210432,3385,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
5040,1159528,1,1,,170464762,3385,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
5041,1159529,1,1,,144209533,3385,Active,,,45.3124,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
5042,1159529,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
5043,1159529,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
5044,1159531,1,1,,144209533,3385,Inconclusive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
5045,1159531,1,1,,144210432,3385,Active,325495497.0,6256.0,28.1669,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
5046,1159531,1,1,,170464762,3385,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
5047,1159550,3,1,,252401391,3385,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
5048,1159551,1,1,,144209533,3385,Inconclusive,,,63.4379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
5049,1159551,1,1,,144210432,3385,Inconclusive,,,9.9057,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
5050,1159551,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
5051,1159552,1,1,,144209533,3385,Active,325495463.0,5914.0,6.3438,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5052,1159552,1,1,,144210432,3385,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5053,1159552,1,1,,170464762,3385,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5054,1159553,2,1,,144209533,3385,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5055,1159553,2,1,,144210432,3385,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5056,1159553,2,1,,170464762,3385,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
5057,1159555,1,1,,144209533,3385,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5058,1159555,1,1,,144210432,3385,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5059,1159555,1,1,,170464762,3385,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
5060,1159580,2,1,,268734552,3385,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
5061,1159580,2,1,,273002822,3385,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
5062,1159606,1,1,,8139872,3385,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
5063,1159607,2,1,,312310296,3385,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
5064,1159614,1,2,,170464762,3385,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
5065,1159620,1,1,,103507642,3385,Active,,,,,Summary of drug indications.,Other,,
5066,1161321,1,2,,103507642,3385,Active,,,46.93,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5067,1161322,1,1,,103507642,3385,Active,,,44.04,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5068,1161323,1,1,,103507642,3385,Active,,,29.98,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5069,1161324,1,1,,103507642,3385,Active,,,35.34,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5070,1161325,1,1,,103507642,3385,Active,,,40.21,IC50,Cytotoxicity against human SMMC-7404 cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5071,1161326,1,1,,103507642,3385,Unspecified,,,56.0,IC50,Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay,Confirmatory,25151580.0,
5072,1161833,1,1,,103507642,3385,Unspecified,,,67.7,IC50,Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5073,1161834,1,1,,103507642,3385,Active,,,17.85,IC50,Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5074,1161835,1,1,,103507642,3385,Unspecified,,,59.9,IC50,Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5075,1161836,1,1,,103507642,3385,Unspecified,,,51.64,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5076,1161837,1,2,,103507642,3385,Unspecified,,,53.52,IC50,Antiproliferative activity against human KB cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5077,1161838,1,1,,103507642,3385,Active,,,27.01,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,25164762.0,
5078,1162264,1,1,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
5079,1162265,1,1,,103507642,3385,Active,,,1.3,IC50,Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
5080,1162266,1,1,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
5081,1162267,1,1,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
5082,1162268,1,1,,103507642,3385,Active,,,0.5,IC50,Cytotoxicity against human Hep cells after 48 hrs by SRB assay,Confirmatory,25176329.0,
5083,1162426,1,1,,103507642,3385,Active,,,10.81,IC50,Cytotoxicity against human EC109 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25180925.0,
5084,1162427,1,1,,103507642,3385,Active,,,8.93,IC50,Cytotoxicity against human MCF7 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25180925.0,
5085,1162428,1,2,,103507642,3385,Active,,,7.69,IC50,Cytotoxicity against human MGC803 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25180925.0,
5086,1162429,1,1,,103507642,3385,Active,,,0.87,IC50,Cytotoxicity against mouse B16F10 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25180925.0,
5087,1163065,1,2,,103507642,3385,Unspecified,,,50.0,EC50,Antiproliferative activity against human SW620 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5088,1163066,1,1,,103507642,3385,Active,,,16.3,EC50,Antiproliferative activity against human DLD1 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5089,1163067,1,1,,103507642,3385,Unspecified,,,50.0,EC50,Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5090,1163068,1,1,,103507642,3385,Active,,,38.06,EC50,Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5091,1163069,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against african green monkey Vero cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5092,1163070,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5093,1163071,1,1,,103507642,3385,Active,,,48.7,IC50,Antiproliferative activity against HEK293 cells after 24 hrs by MTT assay,Confirmatory,25198997.0,
5094,1163077,1,1,,103507642,3385,Unspecified,,,,,"Safety index, ratio of IC50 for human MCF10A cells to EC50 for human SW620 cells",Other,25198997.0,
5095,1163078,1,1,,103507642,3385,Unspecified,,,,,"Safety index, ratio of IC50 for human MCF10A cells to EC50 for human DLD1 cells",Other,25198997.0,
5096,1163079,1,1,,103507642,3385,Unspecified,,,,,"Safety index, ratio of IC50 for human MCF10A cells to EC50 for human HCT116 cells",Other,25198997.0,
5097,1163080,1,1,,103507642,3385,Unspecified,,,,,"Safety index, ratio of IC50 for human MCF10A cells to EC50 for human COLO205 cells",Other,25198997.0,
5098,1163406,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HCT8 cells assessed as growth inhibition rate at 0.1 to 100 umol/L after 96 hrs by MTT assay,Other,25203783.0,
5099,1163407,1,1,,103507642,3385,Active,,,3.54,IC50,Cytotoxicity against human HCT8 cells assessed as growth inhibition rate after 96 hrs by MTT assay,Confirmatory,25203783.0,
5100,1163408,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human A549 cells assessed as growth inhibition rate at 0.1 to 100 umol/L after 96 hrs by MTT assay,Other,25203783.0,
5101,1163409,1,1,,103507642,3385,Active,,,6.69,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition rate after 96 hrs by MTT assay,Confirmatory,25203783.0,
5102,1163410,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Bel7402 cells assessed as growth inhibition rate at 0.1 to 100 umol/L after 96 hrs by MTT assay,Other,25203783.0,
5103,1163411,1,1,,103507642,3385,Active,,,2.23,IC50,Cytotoxicity against human Bel7402 cells assessed as growth inhibition rate after 96 hrs by MTT assay,Confirmatory,25203783.0,
5104,1163412,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human C33A cells assessed as growth inhibition rate at 0.1 to 100 umol/L after 96 hrs by MTT assay,Other,25203783.0,
5105,1163414,1,1,,103507642,3385,Active,,,4.61,IC50,Cytotoxicity against human C33A cells assessed as growth inhibition rate after 96 hrs by MTT assay,Confirmatory,25203783.0,
5106,1165767,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse B16 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post tumor transplantation",Other,25247772.0,
5107,1165773,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse B6 cells transplanted ICR mouse assessed as mouse survival at 30 mg/kg, iv administered 7 days post tumor transplantation",Other,25247772.0,
5108,1165775,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse B6 cells transplanted ICR mouse assessed as mouse body weight at 30 mg/kg, iv administered 7 days post tumor transplantation (Rvb = 18.2 +/- 0.5g)",Other,25247772.0,
5109,1166321,1,2,,103507642,3385,Active,,,0.04,IC50,Cytotoxicity against human THP1 cells after 48 hrs by SRB assay,Confirmatory,25259515.0,
5110,1166322,1,1,,103507642,3385,Active,,,0.01,IC50,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,Confirmatory,25259515.0,
5111,1166476,1,1,,103507642,3385,Active,,,14.6,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by trypan blue dye exclusion method,Confirmatory,25261825.0,
5112,1166477,1,1,,103507642,3385,Active,,,16.3,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by MTT method,Confirmatory,25261825.0,
5113,1166478,1,1,,103507642,3385,Active,,,15.4,IC50,Cytotoxicity against mouse EAC cells after 48 hrs by LDH release assay,Confirmatory,25261825.0,
5114,1166479,1,1,,103507642,3385,Active,,,15.3,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by trypan blue dye exclusion method,Confirmatory,25261825.0,
5115,1166480,1,1,,103507642,3385,Active,,,15.6,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by MTT method,Confirmatory,25261825.0,
5116,1166481,1,1,,103507642,3385,Active,,,16.8,IC50,Cytotoxicity against mouse DLA cells after 48 hrs by LDH release assay,Confirmatory,25261825.0,
5117,1170106,1,1,,103507642,3385,Active,,,,,Growth inhibition of cisplatin-resistant human C13 cells at 5 uM after 72 hrs by flow-cytometric analysis,Other,25353379.0,
5118,1170107,1,1,,103507642,3385,Active,,,,,Cytotoxicity against cisplatin-resistant human C13 cells assessed as reduction in cell survival at 1 to 5 uM after 72 hrs by crystal violet assay relative to untreated control,Other,25353379.0,
5119,1172109,1,1,,103507642,3385,Active,,,0.33,IC50,Cytostatic activity against mouse L1210 cells after 48 hrs by Coulter counting,Confirmatory,25435471.0,
5120,1172110,1,1,,103507642,3385,Active,,,18.0,IC50,Cytostatic activity against human CEM cells after 72 hrs by Coulter counting,Confirmatory,25435471.0,
5121,1172111,1,1,,103507642,3385,Active,,,2.6,IC50,Cytostatic activity against human HeLa cells after 72 hrs by Coulter counting,Confirmatory,25435471.0,
5122,1172636,1,1,,103507642,3385,Active,,,5.62,IC50,Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell proliferation by CCK8 assay,Confirmatory,25442303.0,
5123,1172637,1,1,,103507642,3385,Active,,,14.26,IC50,Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation by CCK8 assay,Confirmatory,25442303.0,
5124,1172638,1,1,,103507642,3385,Active,,,8.13,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation by CCK8 assay,Confirmatory,25442303.0,
5125,1172944,1,1,,103507642,3385,Active,,,35.6,IC50,Antiproliferative activity against human BGC823 cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5126,1172945,1,1,,103507642,3385,Active,,,18.1,IC50,Antiproliferative activity against human HeLa cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5127,1172946,1,1,,103507642,3385,Active,,,16.3,IC50,Antiproliferative activity against human MCF7 cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5128,1172947,1,1,,103507642,3385,Active,,,38.2,IC50,Antiproliferative activity against human U87 cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5129,1172948,1,1,,103507642,3385,Active,,,36.2,IC50,Antiproliferative activity against human HCT116 cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5130,1172949,1,1,,103507642,3385,Active,,,12.7,IC50,Antiproliferative activity against human LoVo cells assessed as cell-growth inhibition after 48 hrs by MTT assay,Confirmatory,25453794.0,
5131,1174408,1,1,,103507642,3385,Active,,,36.53,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25462253.0,
5132,1174409,1,1,,103507642,3385,Active,,,36.04,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay,Confirmatory,25462253.0,
5133,1174410,1,2,,103507642,3385,Active,,,30.45,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,25462253.0,
5134,1174411,1,1,,103507642,3385,Inconclusive,,,,IC50,Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay,Confirmatory,25462253.0,
5135,1174572,1,1,,103507642,3385,Active,,,26.9,IC50,Anticancer activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
5136,1174573,1,1,,103507642,3385,Active,,,31.6,IC50,Anticancer activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
5137,1174574,1,1,,103507642,3385,Active,,,30.9,IC50,Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay,Confirmatory,25462264.0,
5138,1174603,1,1,,103507642,3385,Unspecified,,,,,Induction of cytochrome c release in human MCF7 cells incubated for 2 hrs by ELISA method (Rvb = 364.2 +/- 20.5 ng),Other,25462264.0,
5139,1174604,1,1,,103507642,3385,Unspecified,,,,,Induction of cytochrome c release in extracellular region of human MCF7 cells incubated for 2 hrs by ELISA method (Rvb = 15.7 +/- 0.77 ng),Other,25462264.0,
5140,1174605,1,1,,103507642,3385,Unspecified,,,,,Induction of cytochrome c release in cytoplasm of human MCF7 cells incubated for 2 hrs by ELISA method (Rvb = 44.1 +/- 2.7 ng),Other,25462264.0,
5141,1174606,1,1,,103507642,3385,Unspecified,,,,,Induction of cytochrome c release in mitochondria of human MCF7 cells incubated for 2 hrs by ELISA method (Rvb = 347.8 +/- 14.5 ng),Other,25462264.0,
5142,1174817,1,1,,103507642,3385,Active,,,30.7,IC50,Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay,Confirmatory,25462277.0,
5143,1174818,1,1,,103507642,3385,Active,,,6.0,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay,Confirmatory,25462277.0,
5144,1174819,1,1,,103507642,3385,Active,,,7.9,IC50,Cytotoxicity against human T47D cells after 72 hrs by SRB assay,Confirmatory,25462277.0,
5145,1176274,1,1,,103507642,3385,Active,,,13.45,IC50,Cytotoxicity against human HeLa cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25506718.0,
5146,1176275,1,1,,103507642,3385,Active,,,9.67,IC50,Cytotoxicity against human MKN28 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25506718.0,
5147,1176276,1,1,,103507642,3385,Active,,,7.64,IC50,Cytotoxicity against mouse B16 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25506718.0,
5148,1176850,1,1,,103507642,3385,Active,,,10.52,IC50,Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
5149,1176851,1,1,,103507642,3385,Active,,,9.09,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
5150,1176852,1,1,,103507642,3385,Active,,,9.34,IC50,Antiproliferative activity against human SF763 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
5151,1176853,1,1,,103507642,3385,Active,,,10.45,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
5152,1176854,1,1,,103507642,3385,Active,,,11.78,IC50,Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay,Confirmatory,25529742.0,
5153,1176857,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post inoculation measured at day 25 of tumor transplantation",Other,25529742.0,
5154,1177464,1,1,,103507642,3385,Active,,,0.5,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay,Confirmatory,25066282.0,
5155,1177465,1,2,,103507642,3385,Active,,,5.3,IC50,Cytotoxicity against human SW620 cells after 72 hrs by MTS assay,Confirmatory,25066282.0,
5156,1177466,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human HCT116 cells assessed as cell death at IC50 after 72 hrs by LDH release assay relative to control,Other,25066282.0,
5157,1177467,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human HCT116 cells assessed as cell death at 2 times IC50 after 72 hrs by LDH release assay relative to control,Other,25066282.0,
5158,1177468,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells assessed as cell death at IC50 after 72 hrs by LDH release assay relative to control,Other,25066282.0,
5159,1177469,1,2,,103507642,3385,Unspecified,,,,,Cytotoxicity against human SW620 cells assessed as cell death at 2 times IC50 after 72 hrs by LDH release assay relative to control,Other,25066282.0,
5160,1177470,1,1,,103507642,3385,Active,,,,,Induction of cell death in human HCT116 cells at IC50 after 72 hrs by Guava ViaCount assay relative to control,Other,25066282.0,
5161,1177471,1,2,,103507642,3385,Active,,,,,Induction of cell death in human SW620 cells at IC50 after 72 hrs by Guava ViaCount assay relative to control,Other,25066282.0,
5162,1177472,1,1,,103507642,3385,Active,,,,,Induction of cell death in human HCT116 cells at 2 times IC50 after 72 hrs by Guava ViaCount assay relative to control,Other,25066282.0,
5163,1177473,1,2,,103507642,3385,Active,,,,,Induction of cell death in human SW620 cells at 2 times IC50 after 72 hrs by Guava ViaCount assay relative to control,Other,25066282.0,
5164,1177476,1,1,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human HCT116 cells assessed as change in nuclear morphology at 2 times IC50 after 24 hrs by fluorescent microscopy relative to control,Other,25066282.0,
5165,1177477,1,2,,103507642,3385,Unspecified,,,,,Induction of apoptosis in human SW620 cells assessed as change in nuclear morphology at 2 times IC50 after 24 hrs by fluorescent microscopy relative to control,Other,25066282.0,
5166,1177865,1,1,,103507642,3385,Active,,,24.87,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay,Confirmatory,24583355.0,
5167,1177870,1,1,,103507642,3385,Active,,,11.64,IC50,Cytotoxicity against human H3347 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay,Confirmatory,24583355.0,
5168,1177871,1,1,,103507642,3385,Active,,,29.14,IC50,Cytotoxicity against human DLD1 cells assessed as growth inhibition after 72 hrs by Alamar Blue assay,Confirmatory,24583355.0,
5169,1178006,1,1,,103507642,3385,Active,,,29.5,IC50,Cytotoxicity against human NCI60 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5170,1178007,1,2,,103507642,3385,Active,,,3.39,IC50,Cytotoxicity against human COLO205 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5171,1178008,1,2,,103507642,3385,Active,,,5.75,IC50,Cytotoxicity against human HCC2998 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5172,1178009,1,1,,103507642,3385,Active,,,6.61,IC50,Cytotoxicity against human HCT15 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5173,1178010,1,1,,103507642,3385,Active,,,7.94,IC50,Cytotoxicity against human KM12 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5174,1178011,1,2,,103507642,3385,Active,,,18.6,IC50,Cytotoxicity against human SW620 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5175,1178012,1,2,,103507642,3385,Unspecified,,,85.1,IC50,Antileukemic activity against human HL-60(TB) cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5176,1178013,1,1,,103507642,3385,Unspecified,,,126.0,IC50,Antileukemic activity against human K562 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5177,1178014,1,1,,103507642,3385,Active,,,3.55,IC50,Antileukemic activity against human RPMI8226 cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5178,1178015,1,1,,103507642,3385,Unspecified,,,60.3,IC50,Antileukemic activity against human SR cells assessed as inhibition of tumor growth after 24 hrs,Confirmatory,24657568.0,
5179,1179385,1,1,,103507642,3385,Active,,,18.0,IC50,Cytostatic activity against human CEM cells assessed as inhibition of proliferation after 72 hrs by Coulter cell counting method,Confirmatory,24906510.0,
5180,1179386,1,1,,103507642,3385,Active,,,0.33,IC50,Cytostatic activity against mouse L1210 cells assessed as inhibition of proliferation after 48 hrs by Coulter cell counting method,Confirmatory,24906510.0,
5181,1179387,1,1,,103507642,3385,Active,,,0.54,IC50,Cytostatic activity against human HeLa cells assessed as inhibition of proliferation after 72 hrs by Coulter cell counting method,Confirmatory,24906510.0,
5182,1179980,1,1,,103507642,3385,Active,,,30.21,GI50,Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay,Confirmatory,24934992.0,
5183,1179981,1,1,,103507642,3385,Active,,,28.76,GI50,Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay,Confirmatory,24934992.0,
5184,1182436,1,1,,103507642,3385,Active,,,15.08,IC50,Anticancer activity against human SSMC-7721 cells after 72 hrs by MTT assay,Confirmatory,25001482.0,
5185,1182438,1,1,,103507642,3385,Active,,,8.07,IC50,Anticancer activity against human EC9706 cells after 72 hrs by MTT assay,Confirmatory,25001482.0,
5186,1182439,1,2,,103507642,3385,Active,,,3.45,IC50,Anticancer activity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,25001482.0,
5187,1182440,1,1,,103507642,3385,Active,,,7.12,IC50,Anticancer activity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25001482.0,
5188,1183279,1,1,,103507642,3385,Active,,,46.83,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25016234.0,
5189,1183280,1,1,,103507642,3385,Active,,,35.41,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25016234.0,
5190,1183281,1,1,,103507642,3385,Active,,,24.6,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,25016234.0,
5191,1183282,1,1,,103507642,3385,Active,,,39.88,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25016234.0,
5192,1183476,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25017036.0,
5193,1183477,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25017036.0,
5194,1183478,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25017036.0,
5195,1183479,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25017036.0,
5196,1183480,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against mouse LL/2 cells assessed as growth inhibition after 48 hrs by MTT assay,Other,25017036.0,
5197,1184529,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against human HCT116 cells xenografted in SCID mouse assessed as tumor growth inhibition at 15 mg/kg, ip qd for 5 days",Other,25043312.0,
5198,1186152,1,1,,103507642,3385,Active,,,25.0,LC50,Cytotoxicity against HEK293 cells after 48 hrs by MTT assay,Confirmatory,25078313.0,
5199,1186445,1,2,,103507642,3385,Active,,,10.0,IC50,Anticancer activity against human MGC803 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25086915.0,
5200,1186446,1,1,,103507642,3385,Active,,,4.7,IC50,Anticancer activity against human EC9706 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25086915.0,
5201,1186447,1,1,,103507642,3385,Active,,,12.0,IC50,Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25086915.0,
5202,1186448,1,1,,103507642,3385,Active,,,4.6,IC50,Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25086915.0,
5203,1187274,1,1,,103507642,3385,Active,,,15.07,IC50,Antiproliferative activity against human CNE cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,25113877.0,
5204,1187275,1,1,,103507642,3385,Active,,,19.84,IC50,Antiproliferative activity against human Bel7402 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,25113877.0,
5205,1187276,1,2,,103507642,3385,Active,,,7.76,IC50,Antiproliferative activity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,25113877.0,
5206,1187277,1,1,,103507642,3385,Active,,,7.62,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay,Confirmatory,25113877.0,
5207,1187637,1,1,,103507642,3385,Unspecified,,,50.0,IC50,Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay,Confirmatory,25124114.0,
5208,1191288,1,1,,103507642,3385,Active,,,21.68,TC50,Cytotoxicity against human HepG2(2.2.15) cells assessed as decrease in cell viability after 72 hrs by MTS assay,Confirmatory,25461891.0,
5209,1191405,1,1,,103507642,3385,Active,,,6.56,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay,Confirmatory,25554922.0,
5210,1191406,1,2,,103507642,3385,Active,,,3.71,IC50,Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay,Confirmatory,25554922.0,
5211,1191407,1,1,,103507642,3385,Active,,,5.18,IC50,Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay,Confirmatory,25554922.0,
5212,1192821,1,1,,103507642,3385,Active,,,11.61,IC50,Anticancer activity against human EC109 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25655718.0,
5213,1192822,1,1,,103507642,3385,Active,,,9.12,IC50,Anticancer activity against human MCF7 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25655718.0,
5214,1192823,1,2,,103507642,3385,Active,,,8.43,IC50,Anticancer activity against human MGC803 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25655718.0,
5215,1192824,1,1,,103507642,3385,Active,,,1.43,IC50,Anticancer activity against mouse B16F10 cells assessed as inhibition of proliferation after 72 hrs by MTT assay,Confirmatory,25655718.0,
5216,1195208,1,1,,103507642,3385,Active,,,5.82,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay,Confirmatory,25870131.0,
5217,1195209,1,1,,103507642,3385,Active,,,7.51,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25870131.0,
5218,1195210,1,2,,103507642,3385,Active,,,6.37,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25870131.0,
5219,1197449,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HepG2(2.2.15) cells,Other,25600408.0,
5220,1199977,1,1,,103507642,3385,Active,,,22.54,IC50,Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25644674.0,
5221,1199978,1,1,,103507642,3385,Active,,,21.15,IC50,Antiproliferative activity against human vincristine-resistant HL60/Vinc cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25644674.0,
5222,1199979,1,1,,103507642,3385,Active,,,4.69,IC50,Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5223,1199980,1,1,,103507642,3385,Active,,,6.0,IC50,Antiproliferative activity against human doxorubicin-resistant LoVo/DX cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5224,1199981,1,1,,103507642,3385,Active,,,25.08,IC50,Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5225,1199982,1,1,,103507642,3385,Active,,,38.92,IC50,Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5226,1199983,1,1,,103507642,3385,Active,,,20.46,IC50,Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5227,1199984,1,1,,103507642,3385,Active,,,3.23,IC50,Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method,Confirmatory,25644674.0,
5228,1199985,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60 cells",Other,25644674.0,
5229,1199986,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HL60/Vinc cells",Other,25644674.0,
5230,1199987,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo cells",Other,25644674.0,
5231,1199988,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LoVo/DX cells",Other,25644674.0,
5232,1199989,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human HT-29 cells",Other,25644674.0,
5233,1199990,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human LS180 cells",Other,25644674.0,
5234,1199991,1,1,,103507642,3385,Unspecified,,,,,"Selectivity index, ratio of IC50 for mouse BALB/3T3 cells to IC50 for human SW707 cells",Other,25644674.0,
5235,1199992,1,1,,103507642,3385,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/Vinc cells to IC50 for human HL60 cells",Other,25644674.0,
5236,1199993,1,1,,103507642,3385,Unspecified,,,,,"Resistance index, ratio of IC50 for human LoVo/DX cells to IC50 for human LoVo cells",Other,25644674.0,
5237,1199994,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus aureus ACTC 4163 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5238,1199995,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5239,1199996,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 6538 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5240,1199997,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 29213 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5241,1199998,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5242,1199999,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against Staphylococcus epidermidis ATCC 35984 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5243,1200000,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 452/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5244,1200001,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 456/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5245,1200002,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 462/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5246,1200003,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 514/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5247,1200004,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 522/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5248,1200005,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 537/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5249,1200006,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 572/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5250,1200007,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 573/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5251,1200008,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 585/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5252,1200009,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus 586/12 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5253,1200010,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 459/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5254,1200011,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 460/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5255,1200012,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 461/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5256,1200013,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 466/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5257,1200014,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 467/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5258,1200015,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 468/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5259,1200016,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 469/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5260,1200017,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 470/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5261,1200018,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 488/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5262,1200019,1,1,,103507642,3385,Active,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 489/11 after 18 hrs by two-fold serial microdilution method,Other,25644674.0,
5263,1200344,1,1,,103507642,3385,Active,,,0.91,IC50,Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25675144.0,
5264,1200345,1,1,,103507642,3385,Active,,,36.638000000000005,IC50,Antiproliferative activity against 5-FU resistant human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,25675144.0,
5265,1200791,1,2,,103507642,3385,Active,,,10.72,IC50,Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay,Confirmatory,25707012.0,
5266,1200792,1,1,,103507642,3385,Active,,,12.24,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,25707012.0,
5267,1200793,1,1,,103507642,3385,Active,,,15.67,IC50,Cytotoxicity against human EC9706 cells after 72 hrs by MTT assay,Confirmatory,25707012.0,
5268,1200794,1,2,,103507642,3385,Active,,,20.4,IC50,Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay,Confirmatory,25707012.0,
5269,1201096,1,1,,103507642,3385,Inconclusive,,,,GI50,Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5270,1201097,1,1,,103507642,3385,Active,,,5.5,GI50,Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5271,1201098,1,1,,103507642,3385,Active,,,4.3,GI50,Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5272,1201099,1,1,,103507642,3385,Active,,,15.0,GI50,Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5273,1201100,1,1,,103507642,3385,Active,,,47.0,GI50,Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5274,1201101,1,1,,103507642,3385,Active,,,49.0,GI50,Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay,Confirmatory,25752525.0,
5275,1201761,1,1,,103507642,3385,Active,,,6.12,IC50,Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
5276,1201762,1,1,,103507642,3385,Active,,,4.87,IC50,Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
5277,1201763,1,2,,103507642,3385,Active,,,3.58,IC50,Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
5278,1201764,1,1,,103507642,3385,Active,,,5.86,IC50,Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay,Confirmatory,25812966.0,
5279,1202045,1,1,,103507642,3385,Active,,,38.23,IC50,Cytotoxicity against human A549 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5280,1202046,1,2,,103507642,3385,Active,,,47.39,IC50,Cytotoxicity against human MGC803 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5281,1202047,1,1,,103507642,3385,Active,,,31.98,IC50,Cytotoxicity against human HepG2 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5282,1202048,1,1,,103507642,3385,Active,,,40.57,IC50,Cytotoxicity against human T24 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5283,1202049,1,1,,103507642,3385,Active,,,44.1,IC50,Cytotoxicity against human SPCA2 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5284,1202050,1,1,,103507642,3385,Active,,,46.15,IC50,Cytotoxicity against human NCI-H460 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5285,1202051,1,1,,103507642,3385,Active,,,27.34,IC50,Cytotoxicity against human SKOV3 cells after 2 days by MTT assay,Confirmatory,25841196.0,
5286,1202052,1,1,,103507642,3385,Unspecified,,,56.37,IC50,Cytotoxicity against human HUVEC cells after 2 days by MTT assay,Confirmatory,25841196.0,
5287,1202121,1,2,,103507642,3385,Active,,,40.94,IC50,Cytotoxicity against human MGC803 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5288,1202122,1,1,,103507642,3385,Active,,,29.58,IC50,Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5289,1202123,1,1,,103507642,3385,Active,,,37.56,IC50,Cytotoxicity against human T24 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5290,1202124,1,1,,103507642,3385,Active,,,30.79,IC50,Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5291,1202125,1,1,,103507642,3385,Active,,,36.34,IC50,Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5292,1202126,1,1,,103507642,3385,Unspecified,,,58.74,IC50,Cytotoxicity against human HL7702 cells assessed as cell viability after 48 hrs by MTT assay,Confirmatory,25841199.0,
5293,1203724,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 solid tumor cells implanted in Swiss albino mouse assessed as tumor growth inhibition at 22 mg/kg, ip measured on day 13",Other,25825934.0,
5294,1203727,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse S180 solid tumor cells implanted Swiss albino mouse assessed as mouse mortality at 22 mg/kg, ip measured on day 13",Other,25825934.0,
5295,1203730,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse S180 ascites cells implanted in Swiss albino mouse assessed as tumor growth inhibition at 22 mg/kg, ip measured on day 12",Other,25825934.0,
5296,1203733,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse S180 ascites cells implanted Swiss albino mouse assessed as mouse mortality at 22 mg/kg, ip measured on day 13",Other,25825934.0,
5297,1204376,1,1,,103507642,3385,Active,,,8.0,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25969171.0,
5298,1204816,1,1,,103507642,3385,Unspecified,,,,,"In vivo antitumor activity against mouse B16 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation",Other,25984840.0,
5299,1204818,1,1,,103507642,3385,Unspecified,,,,,"Toxicity against mouse xenografted with mouse B16 cells assessed as body weight at 30 mg/kg, ip administered after 7 days of tumor transplantation (Rvb = 18.2 to 18.3 gms)",Other,25984840.0,
5300,1207028,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against mouse HepS allografted in mouse assessed as tumor growth inhibition at 25 mg/kg, iv bid administered for 8 days relative to control",Other,25958244.0,
5301,1207032,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse allografted with mouse HepS cells assessed as vascular irritation at 25 mg/kg, iv bid administered for 8 days",Other,25958244.0,
5302,1207036,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in mouse allografted with mouse HepS cells assessed as body weight at 25 mg/kg, iv bid administered for 8 days (Rvb = 25.25 to 26.4 g)",Other,25958244.0,
5303,1207074,1,1,,103507642,3385,Active,,,22.36,IC50,Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay,Confirmatory,25959813.0,
5304,1207075,1,1,,103507642,3385,Active,,,40.38,IC50,Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay,Confirmatory,25959813.0,
5305,1207076,1,1,,103507642,3385,Active,,,19.91,IC50,Antiproliferative activity against human Bel7402 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay,Confirmatory,25959813.0,
5306,1207077,1,1,,103507642,3385,Active,,,8.93,IC50,Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay,Confirmatory,25959813.0,
5307,1207078,1,1,,103507642,3385,Active,,,9.56,IC50,Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay,Confirmatory,25959813.0,
5308,1216028,1,1,,103507642,3385,Active,,,33.2,IC50,Cytotoxicity against human 5-FU-resistant Patu-T cells by crystal violet staining,Confirmatory,20930123.0,
5309,1216029,1,1,,103507642,3385,Inactive,,,,,Induction of thymidylate synthase expression in human Patu-T cells after 6 months by RT-PCR analysis relative to control,Other,20930123.0,
5310,1216030,1,1,,103507642,3385,Inactive,,,,,Induction of BCRP expression in human Patu-T cells after 6 months by RT-PCR analysis relative to control,Other,20930123.0,
5311,1216031,1,1,,103507642,3385,Unspecified,,,,,Induction of MRP5 expression in human MRP5 vector transfected Colo-357 cells by RT-PCR analysis relative to control,Other,20930123.0,
5312,1216032,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells assessed as cell killing at 1 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5313,1216033,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells assessed as cell killing at 3 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5314,1216034,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells assessed as cell killing at 10 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5315,1216035,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells assessed as cell killing at 33 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5316,1216036,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells expressing MRP5 assessed as cell killing at 1 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5317,1216037,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells expressing MRP5 assessed as cell killing at 3 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5318,1216038,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells expressing MRP5 assessed as cell killing at 10 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5319,1216039,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Colo-357 cells expressing MRP5 assessed as cell killing at 33 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5320,1216040,1,1,,103507642,3385,Inactive,,,,,Cytotoxicity against human Colo-357 cells expressing MRP5 assessed as cell killing after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5321,1216041,1,2,,103507642,3385,Unspecified,8928547.0,10057.0,,,Activity at MRP5 in human Colo-357 cells assessed as decrease of drug accumulation after 2 hrs relative to wild type cells,Other,20930123.0,
5322,1216042,1,2,,103507642,3385,Unspecified,8928547.0,10057.0,,,Activity at MRP5 in human Colo-357 cells assessed as increase of drug efflux after 60 mins relative to wild type cells,Other,20930123.0,
5323,1216045,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MRP5 knockdown Patu-02 cells assessed as increase of cell death at 3.3 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5324,1216046,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MRP5 knockdown Patu-02 cells assessed as increase of cell death at 10 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5325,1216047,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MRP5 knockdown Patu-02 cells assessed as increase of cell death at 33 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5326,1216048,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MRP5 knockdown Patu-02 cells assessed as increase of cell death at 100 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5327,1216049,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Patu-02 cells assessed as increase of cell death at 3.3 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5328,1216050,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Patu-02 cells assessed as increase of cell death at 10 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5329,1216051,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Patu-02 cells assessed as increase of cell death at 33 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5330,1216052,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human Patu-02 cells assessed as increase of cell death at 100 uM after 48 hrs using propidium iodide staining by cytofluorometric analysis,Other,20930123.0,
5331,1216053,1,1,,103507642,3385,Active,,,0.33,IC50,Cytotoxicity against human T3M4 cells by crystal violet staining,Confirmatory,20930123.0,
5332,1216054,1,1,,103507642,3385,Active,,,2.05,IC50,Cytotoxicity against human Colo-357 cells by crystal violet staining,Confirmatory,20930123.0,
5333,1216055,1,1,,103507642,3385,Active,,,2.08,IC50,Cytotoxicity against human Patu-T cells by crystal violet staining,Confirmatory,20930123.0,
5334,1216056,1,1,,103507642,3385,Active,,,2.93,IC50,Cytotoxicity against human Patu-S cells by crystal violet staining,Confirmatory,20930123.0,
5335,1216057,1,1,,103507642,3385,Active,,,2.97,IC50,Cytotoxicity against human Aspc-1 cells by crystal violet staining,Confirmatory,20930123.0,
5336,1216058,1,1,,103507642,3385,Active,,,3.94,IC50,Cytotoxicity against human PANC1 cells by crystal violet staining,Confirmatory,20930123.0,
5337,1216059,1,1,,103507642,3385,Active,,,3.95,IC50,Cytotoxicity against human Patu-02 cells by crystal violet staining,Confirmatory,20930123.0,
5338,1216060,1,1,,103507642,3385,Active,,,4.38,IC50,Cytotoxicity against human DAN-G cells by crystal violet staining,Confirmatory,20930123.0,
5339,1216061,1,1,,103507642,3385,Unspecified,,,,,Induction of MRP4 expression in human Patu-T cells after 6 months by RT-PCR analysis relative to control,Other,20930123.0,
5340,1216062,1,1,,103507642,3385,Unspecified,,,,,Induction of MRP5 expression in human Patu-T cells after 6 months by RT-PCR analysis relative to control,Other,20930123.0,
5341,1224818,1,1,,312344661,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
5342,1224819,1,1,,312344661,3385,Inconclusive,325495545.0,2101.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5343,1224820,1,1,,312344661,3385,Inactive,325495545.0,2101.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5344,1224821,1,1,,312344661,3385,Inactive,325495545.0,2101.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5345,1224822,1,1,,312344661,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
5346,1224823,1,1,,312344661,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5347,1224824,1,1,,174007005,3385,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
5348,1224825,1,1,,174007005,3385,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
5349,1224834,3,1,,144209533,3385,Active,,,31.7943,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5350,1224834,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5351,1224834,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5352,1224835,1,1,,144209533,3385,Active,160794.0,,41.4502,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5353,1224835,1,1,,144210432,3385,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5354,1224835,1,1,,170464762,3385,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5355,1224836,1,1,,144209533,3385,Active,,,17.8792,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5356,1224836,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5357,1224836,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5358,1224837,1,1,,144209533,3385,Active,,,20.0608,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5359,1224837,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5360,1224837,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5361,1224838,1,1,,144209533,3385,Active,66775687.0,9970.0,10.0542,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5362,1224838,1,1,,144210432,3385,Active,66775687.0,9970.0,4.4247,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5363,1224838,1,1,,170464762,3385,Inconclusive,66775687.0,9970.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5364,1224839,1,1,,144209533,3385,Inactive,66775687.0,9970.0,31.7943,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5365,1224839,1,1,,144210432,3385,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5366,1224839,1,1,,170464762,3385,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5367,1224840,3,1,,144209533,3385,Active,,,44.9106,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5368,1224840,3,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5369,1224840,3,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5370,1224841,3,1,,144209533,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5371,1224841,3,1,,144210432,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5372,1224841,3,1,,170464762,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5373,1224842,3,1,,144209533,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5374,1224842,3,1,,144210432,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5375,1224842,3,1,,170464762,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5376,1224843,1,1,,144209533,3385,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5377,1224843,1,1,,144210432,3385,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5378,1224843,1,1,,170464762,3385,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5379,1224844,1,1,,144209533,3385,Active,,,10.1442,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5380,1224844,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5381,1224844,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5382,1224845,1,1,,144209533,3385,Inconclusive,344243002.0,100757539.0,74.0472,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5383,1224845,1,1,,144210432,3385,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5384,1224845,1,1,,170464762,3385,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5385,1224846,1,1,,144209533,3385,Inconclusive,11995455.0,3091.0,11.3819,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5386,1224846,1,1,,144210432,3385,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5387,1224846,1,1,,170464762,3385,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5388,1224847,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5389,1224847,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5390,1224847,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5391,1224848,3,1,,144209533,3385,Active,325495545.0,2101.0,22.5086,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5392,1224848,3,1,,144210432,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5393,1224848,3,1,,170464762,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5394,1224849,3,1,,144209533,3385,Inactive,325495545.0,2101.0,22.5086,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5395,1224849,3,1,,144210432,3385,Inactive,325495545.0,2101.0,62.5008,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5396,1224849,3,1,,170464762,3385,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5397,1224857,2,1,,170464762,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5398,1224857,2,1,,174007005,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5399,1224857,2,1,,312344661,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5400,1224859,2,1,,90341469,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5401,1224859,2,1,,170464762,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5402,1224859,2,1,,174007005,3385,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5403,1224863,1,1,,176484362,3385,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5404,1224863,1,1,,176484960,3385,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5405,1224863,1,1,,316920305,3385,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5406,1224864,1,2,,316933677,3385,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
5407,1224865,1,2,,8139872,3385,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
5408,1224867,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5409,1224867,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5410,1224867,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5411,1224868,1,1,,144209533,3385,Inconclusive,,,57.0449,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5412,1224868,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5413,1224868,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5414,1224869,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5415,1224869,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5416,1224869,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5417,1224870,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5418,1224870,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5419,1224870,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5420,1224871,1,1,,144209533,3385,Active,,,50.8413,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5421,1224871,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5422,1224871,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5423,1224872,1,1,,144209533,3385,Inconclusive,,,7.1815,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5424,1224872,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5425,1224872,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5426,1224873,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5427,1224873,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5428,1224873,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5429,1224874,1,1,,144209533,3385,Inconclusive,,,57.0449,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5430,1224874,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5431,1224874,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5432,1224875,1,1,,144209533,3385,Inconclusive,,,40.3847,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5433,1224875,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5434,1224875,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5435,1224876,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5436,1224876,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5437,1224876,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5438,1224877,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5439,1224877,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5440,1224877,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5441,1224878,1,1,,144209533,3385,Inconclusive,,,57.0449,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5442,1224878,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5443,1224878,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5444,1224879,1,1,,144209533,3385,Active,,,45.3124,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5445,1224879,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5446,1224879,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5447,1224880,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5448,1224880,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5449,1224880,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5450,1224881,1,1,,144209533,3385,Active,,,50.8413,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5451,1224881,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5452,1224881,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5453,1224882,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5454,1224882,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5455,1224882,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5456,1224883,1,1,,144209533,3385,Active,,,45.3124,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5457,1224883,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5458,1224883,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5459,1224884,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5460,1224884,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5461,1224884,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5462,1224885,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5463,1224885,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5464,1224885,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5465,1224886,1,1,,144209533,3385,Inconclusive,,,64.0054,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5466,1224886,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5467,1224886,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5468,1224887,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5469,1224887,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5470,1224887,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5471,1224888,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5472,1224888,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5473,1224888,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5474,1224889,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5475,1224889,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5476,1224889,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5477,1224890,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5478,1224890,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5479,1224890,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5480,1224892,1,1,,144209533,3385,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5481,1224892,1,1,,144210432,3385,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5482,1224892,1,1,,170464762,3385,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5483,1224893,1,1,,144209533,3385,Active,66775687.0,9970.0,5.236190000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5484,1224893,1,1,,144210432,3385,Active,66775687.0,9970.0,4.7777,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5485,1224893,1,1,,170464762,3385,Active,66775687.0,9970.0,9.43918,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5486,1224894,1,1,,144209533,3385,Inconclusive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5487,1224894,1,1,,144210432,3385,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5488,1224894,1,1,,170464762,3385,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5489,1224895,1,1,,144209533,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5490,1224895,1,1,,144210432,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5491,1224895,1,1,,170464762,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5492,1224896,1,1,,144209533,3385,Active,344243002.0,100757539.0,31.2254,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5493,1224896,1,1,,144210432,3385,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5494,1224896,1,1,,170464762,3385,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5495,1224905,2,1,,92309160,3385,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5496,1224905,2,1,,92309160,3385,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5497,1224905,2,1,,121361357,3385,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5498,1224905,2,1,,121361357,3385,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5499,1227848,1,1,,103507642,3385,Unspecified,,,77.28,IC50,Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by WST-1 assay,Confirmatory,25466196.0,
5500,1227850,1,1,,103507642,3385,Active,,,38.88,IC50,Cytotoxicity against human SKBR3 cells overexpressing HER2 assessed as cell growth inhibition after 48 hrs by WST-1 assay,Confirmatory,25466196.0,
5501,1227851,1,1,,103507642,3385,Active,,,34.48,IC50,Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by WST-1 assay,Confirmatory,25466196.0,
5502,1228628,1,1,,103507642,3385,Active,,,8.4,IC50,Antiproliferative activity against human TIG3 cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5503,1228629,1,1,,103507642,3385,Active,,,2.8,IC50,Antiproliferative activity against human A549 cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5504,1228630,1,1,,103507642,3385,Active,,,5.8,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5505,1228631,1,1,,103507642,3385,Active,,,3.7,IC50,Antiproliferative activity against human PANC1 cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5506,1228632,1,1,,103507642,3385,Active,,,4.4,IC50,Antiproliferative activity against human PSN1 cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5507,1228633,1,1,,103507642,3385,Active,,,5.2,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by WST8 assay,Confirmatory,25919052.0,
5508,1230120,1,1,,103507642,3385,Active,,,0.33,IC50,Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation,Confirmatory,26001344.0,
5509,1230121,1,1,,103507642,3385,Active,,,18.0,IC50,Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation,Confirmatory,26001344.0,
5510,1230122,1,1,,103507642,3385,Active,,,0.54,IC50,Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation,Confirmatory,26001344.0,
5511,1236353,1,1,,103507642,3385,Active,,,4.9,IC50,Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
5512,1236354,1,1,,103507642,3385,Active,,,4.71,IC50,Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
5513,1236355,1,1,,103507642,3385,Active,,,0.86,IC50,Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay,Confirmatory,,
5514,1236690,1,1,,103507642,3385,Unspecified,,,,,"Antitumor activity against human HCT116 cells xenografted in Balb/c athymic nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered daily after 42 days",Other,25937236.0,
5515,1236693,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in Balb/c athymic nude mouse xenografted with human HCT116 cells assessed as loss in body weight at 10 mg/kg, ip administered daily",Other,25937236.0,
5516,1236694,1,1,,103507642,3385,Unspecified,,,,,"Toxicity in Balb/c athymic nude mouse xenografted with human SKOV3 cells assessed as loss in body weight at 10 mg/kg, ip administered daily",Other,25937236.0,
5517,1240174,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human HCT116 cells assessed as reduction in cell viability at 5 to 50 uM after 72 hrs by MTS assay,Other,26169128.0,
5518,1240175,1,1,,103507642,3385,Active,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM after 72 hrs by MTS assay,Other,26169128.0,
5519,1240180,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human HCT116 cells at 5 to 50 uM after 72 hrs by Guava ViaCount flow cytometric analysis,Other,26169128.0,
5520,1240181,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human HepG2 cells at 5 to 50 uM after 72 hrs by Guava ViaCount flow cytometric analysis,Other,26169128.0,
5521,1240186,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human HCT116 cells assessed as change in nuclear morphology at 25 to 50 uM after 24 hrs by Hoechst staining-based fluorescence microscopic analysis,Other,26169128.0,
5522,1240187,1,1,,103507642,3385,Active,,,,,Induction of apoptosis in human HepG2 cells assessed as change in nuclear morphology at 25 to 50 uM after 24 hrs by Hoechst staining-based fluorescence microscopic analysis,Other,26169128.0,
5523,1242904,1,1,,103507642,3385,Active,,,10.07,IC50,Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay,Confirmatory,26227777.0,
5524,1242905,1,1,,103507642,3385,Active,,,16.42,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,26227777.0,
5525,1242906,1,1,,103507642,3385,Active,,,6.3,IC50,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Confirmatory,26227777.0,
5526,1242907,1,1,,103507642,3385,Active,,,14.15,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,26227777.0,
5527,1244475,1,1,,103507642,3385,Active,,,2.2,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay,Confirmatory,26222449.0,
5528,1244477,1,1,,103507642,3385,Active,,,4.9,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay,Confirmatory,26222449.0,
5529,1244478,1,1,,103507642,3385,Active,,,4.5,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay,Confirmatory,26222449.0,
5530,1244540,1,1,,103507642,3385,Active,,,2.13,IC50,Anticancer activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay,Confirmatory,26231080.0,
5531,1244541,1,1,,103507642,3385,Active,,,2.36,IC50,Anticancer activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay,Confirmatory,26231080.0,
5532,1244542,1,1,,103507642,3385,Active,,,4.6,IC50,Anticancer activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay,Confirmatory,26231080.0,
5533,1244543,1,1,,103507642,3385,Active,,,15.26,IC50,Cytotoxic activity against human HaCaT cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay,Confirmatory,26231080.0,
5534,1244895,1,1,,103507642,3385,Active,,,44.05,IC50,Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay,Confirmatory,26259802.0,
5535,1244896,1,1,,103507642,3385,Active,,,40.34,IC50,Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay,Confirmatory,26259802.0,
5536,1244897,1,1,,103507642,3385,Active,,,1.5,IC50,Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay,Confirmatory,26259802.0,
5537,1244898,1,1,,103507642,3385,Active,,,5.58,IC50,Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay,Confirmatory,26259802.0,
5538,1244899,1,1,,103507642,3385,Active,,,11.5,IC50,Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay,Confirmatory,26259802.0,
5539,1245986,1,1,,103507642,3385,Active,,,30.7,IC50,Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation by sulforhodamine B assay,Confirmatory,,
5540,1245987,1,1,,103507642,3385,Active,,,10.0,IC50,Cytotoxicity against human MV cells assessed as inhibition of cell proliferation by sulforhodamine B assay,Confirmatory,,
5541,1247276,1,1,,103507642,3385,Active,,,5.012,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
5542,1247277,1,1,,103507642,3385,Active,,,7.244,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
5543,1247278,1,1,,103507642,3385,Active,,,8.317,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
5544,1247279,1,1,,103507642,3385,Active,,,6.072,IC50,Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,26301558.0,
5545,1247416,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human HepG2 cells at 40 ug/ml after 72 hrs by MTT assay,Other,26312434.0,
5546,1247417,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human MCF7 cells at 40 ug/ml after 72 hrs by MTT assay,Other,26312434.0,
5547,1247792,1,1,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,26320625.0,
5548,1247793,1,1,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,26320625.0,
5549,1247794,1,1,,103507642,3385,Unspecified,,,,IC50,Cytotoxicity against human A875 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,26320625.0,
5550,1247795,1,1,,103507642,3385,Unspecified,,,700.0,IC50,Cytotoxicity against 5-fluorouracil-resistant human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,26320625.0,
5551,1251229,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human HuH7 cells assessed as inhibition of cell growth at 10 uM incubated for 4 days by CCK8 assay,Other,26364944.0,
5552,1251230,1,1,,103507642,3385,Unspecified,,,,,Anticancer activity against human A549 cells assessed as inhibition of cell growth at 10 uM incubated for 4 days by CCK8 assay,Other,26364944.0,
5553,1252388,1,1,,103507642,3385,Unspecified,,,66.5,IC50,Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5554,1252389,1,1,,103507642,3385,Active,,,0.79,IC50,Antiproliferative activity against human SW620 cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5555,1252390,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against mouse L1210/0 cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5556,1252391,1,1,,103507642,3385,Inconclusive,,,,IC50,Antiproliferative activity against human CEM/0 cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5557,1252392,1,1,,103507642,3385,Active,,,11.67,IC50,Antiproliferative activity against human MIAPaCa2 cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5558,1252393,1,1,,103507642,3385,Unspecified,,,55.2,IC50,Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5559,1252394,1,1,,103507642,3385,Active,,,28.3,IC50,Cytotoxicity against mouse 3T3 cells assessed as growth inhibition incubated for 72 hrs by MTT assay,Confirmatory,26291038.0,
5560,1254937,1,1,,103507642,3385,Active,,,22.63,IC50,Cytotoxicity against human PC3 cells after 48 hrs by MTT assay,Confirmatory,26363869.0,
5561,1254938,1,1,,103507642,3385,Active,,,46.83,IC50,Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,26363869.0,
5562,1254939,1,1,,103507642,3385,Active,,,22.28,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,26363869.0,
5563,1254940,1,1,,103507642,3385,Active,,,19.39,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,26363869.0,
5564,1255044,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human H460 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5565,1255045,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HuTu 80 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5566,1255046,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5567,1255047,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5568,1255048,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human M14 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5569,1255049,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5570,1255050,1,1,,103507642,3385,Unspecified,,,,,Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by SRB assay method,Other,26383125.0,
5571,1255663,1,1,,103507642,3385,Active,,,15.83,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by WST-1 assay,Confirmatory,26413725.0,
5572,1259241,1,1,,144209533,3385,Active,,,22.5086,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5573,1259241,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5574,1259241,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5575,1259242,1,1,,144209533,3385,Inconclusive,,,44.9106,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5576,1259242,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5577,1259242,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5578,1259243,1,1,,144209533,3385,Active,124375976.0,367.0,22.5086,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5579,1259243,1,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5580,1259243,1,1,,170464762,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5581,1259244,1,1,,144209533,3385,Active,348019627.0,2099.0,12.6575,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5582,1259244,1,1,,144210432,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5583,1259244,1,1,,170464762,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5584,1259247,1,1,,144209533,3385,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5585,1259247,1,1,,144210432,3385,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5586,1259247,1,1,,170464762,3385,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5587,1259248,1,1,,144209533,3385,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5588,1259248,1,1,,144210432,3385,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5589,1259248,1,1,,170464762,3385,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5590,1259252,1,1,,174007005,3385,Active,169655958.0,,5.2576,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
5591,1259253,1,1,,174007005,3385,Inconclusive,169655958.0,,5.8992,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
5592,1259255,1,1,,174007005,3385,Inconclusive,169655958.0,,7.4266,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
5593,1259256,1,1,,174007005,3385,Active,169655958.0,,9.3495,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
5594,1259310,1,1,,104169952,3385,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5595,1259310,1,1,,321942514,3385,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5596,1259310,1,1,,332950198,3385,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5597,1259310,1,1,,332950324,3385,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5598,1259313,1,1,,8139872,3385,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
5599,1259318,1,1,,8139872,3385,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
5600,1259325,1,2,,336956219,3385,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
5601,1259344,1,1,,144203701,3385,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5602,1259354,1,1,,348427236,3385,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
5603,1259355,1,1,,17389875,3385,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
5604,1259356,1,1,,144203701,3385,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
5605,1259364,1,1,,144209533,3385,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5606,1259364,1,1,,144210432,3385,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5607,1259364,1,1,,170464762,3385,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5608,1259365,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5609,1259365,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5610,1259365,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5611,1259366,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5612,1259366,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5613,1259366,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5614,1259367,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5615,1259367,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5616,1259367,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5617,1259368,1,1,,144209533,3385,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5618,1259368,1,1,,144210432,3385,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5619,1259368,1,1,,170464762,3385,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5620,1259369,1,1,,144209533,3385,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5621,1259369,1,1,,144210432,3385,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5622,1259369,1,1,,170464762,3385,Inconclusive,109731339.0,2737.0,3.7578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5623,1259370,2,2,,124637704,3385,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5624,1259370,2,2,,124637704,3385,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5625,1259370,2,2,,124637704,3385,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5626,1259377,1,1,,144209533,3385,Inconclusive,54288833.0,2100.0,14.202,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5627,1259377,1,1,,144210432,3385,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5628,1259377,1,1,,170464762,3385,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5629,1259378,1,1,,144209533,3385,Inconclusive,54288833.0,2100.0,17.8792,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5630,1259378,1,1,,144210432,3385,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5631,1259378,1,1,,170464762,3385,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5632,1259379,1,1,,144209533,3385,Inconclusive,,,63.4379,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5633,1259379,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5634,1259379,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5635,1259380,1,1,,144209533,3385,Active,,,10.0542,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5636,1259380,1,1,,144210432,3385,Active,,,12.4705,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5637,1259380,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5638,1259381,1,1,,144209533,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5639,1259381,1,1,,144210432,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5640,1259381,1,1,,170464762,3385,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5641,1259382,1,1,,144209533,3385,Active,,,14.202,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5642,1259382,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5643,1259382,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5644,1259383,1,1,,144209533,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5645,1259383,1,1,,144210432,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5646,1259383,1,1,,170464762,3385,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5647,1259384,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5648,1259384,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5649,1259384,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5650,1259385,1,1,,144209533,3385,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5651,1259385,1,1,,144210432,3385,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5652,1259385,1,1,,170464762,3385,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5653,1259386,1,1,,144209533,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5654,1259386,1,1,,144210432,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5655,1259386,1,1,,170464762,3385,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5656,1259387,1,1,,144209533,3385,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5657,1259387,1,1,,144210432,3385,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5658,1259387,1,1,,170464762,3385,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5659,1259388,1,1,,144209533,3385,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5660,1259388,1,1,,144210432,3385,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5661,1259388,1,1,,170464762,3385,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5662,1259389,1,1,,124637704,3385,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
5663,1259390,1,1,,144209533,3385,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5664,1259390,1,1,,144210432,3385,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5665,1259390,1,1,,170464762,3385,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5666,1259391,1,1,,144209533,3385,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5667,1259391,1,1,,144210432,3385,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5668,1259391,1,1,,170464762,3385,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5669,1259392,1,1,,144209533,3385,Inconclusive,109731339.0,2737.0,4.7571699999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5670,1259392,1,1,,144210432,3385,Inconclusive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5671,1259392,1,1,,170464762,3385,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5672,1259393,1,1,,144209533,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5673,1259393,1,1,,144210432,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5674,1259393,1,1,,170464762,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5675,1259394,1,1,,144209533,3385,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5676,1259394,1,1,,144210432,3385,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5677,1259394,1,1,,170464762,3385,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5678,1259395,1,1,,144209533,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5679,1259395,1,1,,144210432,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5680,1259395,1,1,,170464762,3385,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5681,1259396,1,1,,144209533,3385,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5682,1259396,1,1,,144210432,3385,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5683,1259396,1,1,,170464762,3385,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5684,1259400,1,1,,170464762,3385,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
5685,1259401,1,1,,144209533,3385,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5686,1259401,1,1,,144210432,3385,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5687,1259401,1,1,,170464762,3385,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5688,1259402,1,1,,144209533,3385,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5689,1259402,1,1,,144210432,3385,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5690,1259402,1,1,,170464762,3385,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5691,1259403,1,1,,144209533,3385,Active,325495545.0,2101.0,18.9386,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5692,1259403,1,1,,144210432,3385,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5693,1259403,1,1,,170464762,3385,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5694,1259404,1,1,,144209533,3385,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5695,1259404,1,1,,144210432,3385,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5696,1259404,1,1,,170464762,3385,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5697,1259406,1,1,,363920464,3385,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
5698,1259406,1,1,1.0,363920464,3385,Inactive,26638650.0,3778.0,-0.0333731,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
5699,1259406,1,1,2.0,363920464,3385,Inactive,4758626.0,3779.0,0.0119213,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5700,1259406,1,1,3.0,363920464,3385,Inactive,5031823.0,10242.0,-0.061260699999999994,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5701,1259406,1,1,4.0,363920464,3385,Inactive,26051275.0,27345.0,-0.0443767,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5702,1259406,1,1,5.0,363920464,3385,Inactive,160410009.0,389816.0,-0.0275842,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5703,1259406,1,1,6.0,363920464,3385,Inactive,26638650.0,3778.0,-0.049223,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
5704,1259406,1,1,7.0,363920464,3385,Inactive,4758626.0,3779.0,0.0261899,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
5705,1259406,1,1,8.0,363920464,3385,Inactive,5031823.0,10242.0,-0.0331372,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
5706,1259406,1,1,9.0,363920464,3385,Inactive,26051275.0,27345.0,-0.08763660000000001,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
5707,1259406,1,1,10.0,363920464,3385,Inactive,5031823.0,10242.0,0.0574683,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
5708,1259407,1,1,,363900532,3385,Inactive,,,,,CCRIS mutagenicity studies,Other,,
5709,1259408,1,1,,363894782,3385,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
5710,1259411,1,1,,363900532,3385,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
5711,1259413,1,2,,104169952,3385,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
5712,1259415,1,1,,8139872,3385,Inconclusive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
5713,1259416,1,2,,85148656,3385,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5714,1259416,1,2,,340079948,3385,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5715,1259416,1,2,,375178131,3385,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5716,1259421,1,1,,340079948,3385,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5717,1259421,1,1,,375178131,3385,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5718,1259423,1,2,,354793909,3385,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5719,1259423,1,2,,354933416,3385,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5720,1259423,1,2,,354960903,3385,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
